

ESSENTIAL HYPERTENSION

AN INTERNATIONAL SYMPOSIUM

BERNE, JUNE 7th 10th 1960
SPONSORED BY CIBA

CHAIRMAN
F C REUBI
BERNE

EDITED BY
K D BOCK
BASEL

P T COTTIER
BERNE

WITH 81 FIGURES




SPRINGER VERLAG
BERLIN GÖTTINGEN HEIDELBERG
1960

This book has also been published in German under the title
ESSENTIELLE HYPERTONIE
Ein internationales Symposium

All rights especially that of translation into foreign languages reserved
It is also forbidden to reproduce this book either whole or in part by photomechanical means
(photostat microfilm and/or microcard) without express permission from the Publishers

© by Springer Verlag OHG
Berlin Göttingen Heidelberg 1960
Printed in Germany



The reproduction of general descriptive names trade names trade marks etc in this
publication even when there is no special identification mark is not to be taken as a
sign that such names as understood by the Trade Marks and Merchandise Marks Law
may accordingly be freely used by anyone

Printed by Brühl & Co Universitätsdruckerei in Gießen

Contents

Opening remarks (F C PERCI)	VII
The mosaic theory of hypertension (I H PAGE)	1
Inheritance of high blood pressure (C W PICKERING)	30
The nature of essential hypertension (P PLATT)	39
Discussion Brod Govaerts Grollman, Pearl Pickering Platt Peubi Sarre Schroeder Taquini Wilson	4
Possible role of salt intake in the development of essential hypertension (L H DEMP)	3
Renal hemodynamics water and electrolyte excretion in essential hyper- tension (P T COTTIER)	66
Discussion Brod Cottier Dahl Freis Hilden Hoobler Hood Machi Platt Peubi, Schroeder Taquini	63
Adrenocortical function and renal pressor mechanisms in experimental hypertension (F GROSS)	8
Possible relationship between salt metabolism and the angiotensin system (W S PERART)	11
Discussion Bock Brod, Cottier Grollman Gross Pearl Pickering, Peubi, Wilson	121
Adrenocortical function in essential hypertension (J GENEST W NO WACZYNSKI F KOTW T SANDOR, and P BIRON)	121
The significance of hyperaldosteronuria in hypertension (J WALTER J SCHWARTZ and P BLOCH)	147
Discussion Brod Dahl Genest Gross Muller Pearl Peubi Schroeder Schwartz Wilson	153
Therapeutic aspects of salt restriction (A C ROLLMAN)	169
Mechanism of hypotensive action of osuretics (F D FREIS)	180
Discussion Bock Cottier Ferrero Freis Grollman Gross Hoobler Hood Plummer Peubi Sarre Schottler Schmil Schroeder Ta- quini, Wilson	193
The natural history of benign hypertension (P BECHGAARD)	193
The natural course of malignant hypertension (P MILLIEZ, P TCHERDA KOFF P SAMARQ and L P PEY)	214
Discussion Bechgaard Brod Govaerts Hamburger Hilden Milliez Page Pickering Platt Peubi Sarre Schroeder Wilson	231
Pharmacology of new hypotensive drugs (A J ILLMER)	40
Effect of guanethidine (clinical results) (T HILDEN)	261
Combined drug therapy of hypertension (S W HOOBLER and P LAWERS)	280

<i>Effects of the administration of saluretic drugs in the treatment of arterial hypertension</i> (C BARTORELLI)	283
Discussion Bartorelli Brod I Reis C enest Cross Hilden Hoobler Hood Page Peart Reubi Schroeder Wilson	296
<i>Survival rates in severe hypertension intensively treated with hydralazine and ganglionic blockade</i> (H A SCHROEDER and H V PERRY jr)	307
<i>The late effects of hypotensive drug therapy on renal functions of patients with essential hypertension</i> (F C REUBI)	317
<i>Late results of surgical therapy (sympathectomy and adrenalectomy)</i> (H SARRE)	332
Discussion Arnold Dahl Ferrero Freis Hilden Hoobler Hood Imhof Milhez Peart Pickering Platt Reubi Sarre Schroeder Schwartz	347
<i>Hypertension and its associated vascular diseases</i> (P IMHOF I H PACER and H DUSTAN)	354
<i>Prevention and treatment of atheromatous complications of hypertension</i> (G SCHETTLE)	360
Discussion Cottet Hoobler Hood Imhof Schettler Steinmann	380
Closing remarks (F C REUBI)	383
List of authors	387
Subject index	388

Participants in the Symposium 'ESSENTIAL HYPERTENSION'

Terne 1th - 10th June 1960

- Arnold O H Medizinische Klinik der Städtischen Krankenanstalten Essen (Germany)
- Bartorelli C Università di Siena Istituto di Patologia Speciale Medica e Metodologia Clinica Siena (Italy)
- Bechgaard I Medicinsk afdeling Aarhus Universitet Aarhus (Denmark)
- Bock H D CIBA Aktiengesellschaft Basel (Switzerland)
- Brod J Ústav pro Choroby Oběhu Krveního Praha 4rc (Czechoslovakia)
- Cottet J Médecin consultant Paris and Evry (France)
- Cottier P T Medizinische Universitäts-Poliklinik Bern (Switzerland)
- Dahl L H Brookhaven National Laboratory Associated Universities Upton N Y (USA)
- Ferrero C Centre de Cardiologie Hôpital Cantonal Genève (Switzerland)
- Freis E D Veterans Administration Hospital Washington D C (USA)
- Frey W Oberhofen am Thunersee (Switzerland)
- Genest J Département de recherches cliniques Hôpital Dieu de Montréal Montréal (Canada)
- Govaert P Fondation Médicale Reine Elisabeth Bruxelles (Belgium)
- Cröllman A University of Texas Dallas (USA)
- Gross F CIBA Aktiengesellschaft Basel (Switzerland)
- Hadorn W Medizinische Klinik der Universität Bern (Switzerland)
- Hamburger J Hôpital Necker Paris (France)
- Hilden T Diakonissestiftelsen København (Denmark)
- Hoobler S W University of Michigan Ann Arbor (USA)
- Hood B Göteborgs Universitet Medicinska Kliniken I Göteborg (Sweden)
- Imhof P Lory Spital Bern (Switzerland)
- Mach P S Hôpital Cantonal Clinique Universitaire de Thérapeutique Genève (Switzerland)
- Milhez P Faculté de Médecine Paris (France)
- Müller A F Hôpital Cantonal Clinique Universitaire de Thérapeutique Genève (Switzerland)
- Lage I H Cleveland Clinic Foundation Cleveland Ohio (USA)
- Peart W S St Mary's Hospital London (Great Britain)
- Pickering Sir George University of Oxford Oxford (Great Britain)
- Platt Sir Robert The Royal Infirmary Manchester (Great Britain)
- Plummer A J CIBA Pharmaceutical Products Inc Summit N J (USA)

VI Participants in the Symposium ESSENTIAL HYPERTENSION

Reubi F C Medizinische Universitäts Poliklinik Bern (Switzerland)

Sarre H Medizinische Universitäts Poliklinik Freiburg i Br (Germany)

Schettler G Krankenhaus Bad Cannstatt Inner Klinik Stuttgart
(Germany)

Schmid A Bern (Switzerland)

Schroeder H A West Brattleboro Vermont (USA)

Schwartz J Faculté de Médecine Strasbourg (France)

Steinmann B Lory Spital Bern (Switzerland)

Taquini A C Universidad de Buenos Aires Buenos Aires (Argentina)

Wilson C The London Hospital London (Great Britain)

Opening remarks

By

F C REUM

It is a great honour for me to open this symposium and I should like to extend to you a most cordial welcome and to thank you for accepting our invitation. I am sure you will all wish me on your behalf to express our sincere gratitude to CIBA Basle for financing this undertaking.

Although the question of arterial hypertension has commanded the attention of research workers ever since its existence was first discovered, we still seem to be a very long way from having solved the problem. On the other hand, while it was once true to say that medical research was confined to only a few countries, we can derive satisfaction from the knowledge that today a great deal of work has been accomplished during the past few years in both the old and the new world, in the East and in the West. For this very reason it is becoming more and more important to ensure that results should be compared, opinions exchanged and trends of research defined periodically on an international plane. The more widely differing the concepts presented, the more fruitful we can expect the resultant clash of ideas to prove. As men of science we have no need to concern ourselves with the battles being waged in the field of international politics. Let us therefore ignore such matters and seek to reconcile our views here in a spirit of understanding and open-mindedness. Let us banish all preconceived notions and beware of allowing ourselves to be blinded by questions of dogma, prestige and personal pride.

Attending this symposium are some forty specialists from 12 different countries. The number of participants has deliberately been limited and the discussions will be held in private. You will all know yourselves from experience that an atmosphere conducive to a frank exchange of views — views that are sometimes diametrically opposed — can only be established if the speakers cut themselves off from the outside world. We have however made allowance on the programme for two sessions in public. In today's public session we shall hear three lectures in which the problem of the pathogenesis of hypertension will be dealt with from the general

VI Participants in the Symposium ESSENTIAL HYPERTENSION

- Reubi F C Medizinische Universitäts Poliklinik Bern (Switzerland)
Sarre H Medizinische Universitäts Poliklinik Freiburg i Br (Germany)
Schettler G Krankenhaus Bad Cannstatt Innere Klinik Stuttgart
(Germany)
Schmid A Bern (Switzerland)
Schroeder H A West Brattleboro Vermont (USA)
Schwartz J Faculté de Médecine Strasbourg (France)
Steinmann B Lory Spital Bern (Switzerland)
Taquini A C Universidad de Buenos Aires Buenos Aires (Argentina)
Wilson C The London Hospital London (Great Britain)

The mosaic theory of hypertension

By

J H PAGE

It has been some years now since I proposed the mosaic theory of hypertension and it is time I think to review where it stands today. Has it proved useful and is it likely to continue to do so?

The mosaic theory had its background in the fact that thirty years ago thinking in the field of infectious disease mostly prevailed not only in its own field but in others as well. The search was often limited to the finding of a single causative agent. If the typhoid bacillus was isolated and cultured this was the cause of the disease and its elimination was the treatment. So those of us who worked in other fields tried to find the cause of hypertension and the cause of atherosclerosis. As a result of repeated failures as many theories sprang up as there were investigators. The chief contender for the cause of hypertension in those days was the kidney. Many felt that after GOLDBLATT work the kidney was the true and only cause of essential hypertension. The fate of this view is an interesting story but it is diverting.

As time passed it slowly became evident that the problems of cardiovascular disease and cancer were not likely to yield to an attack on one front. It seemed unlikely that all types of hypertension and arteriosclerosis would be explained by single mechanisms. And it seems to me that reflection on the nature of the circulation gives a clue as to why this is so. Arterial blood pressure is one of the components of the system used to perfuse tissues with blood. The problem of getting the right amount of blood to the right part of the body at the right time is an amazingly complicated and difficult one. To know where blood is available and from where it can safely be withdrawn is a major problem in itself. It is not surprising then that the body has developed a highly complex system for carrying out this task efficiently. We shall again put this wonderful mechanism to the test when gravitation has become but a memory in our exploration of outer space. It is my guess that man is more likely to have trouble with his cardiovascular responses to weightlessness than with his control over his actions by his brain which is certainly a change.

aspect. The second public session — to be held at the end of the week in connection with the Annual Meeting of the Swiss Society for Internal Medicine — will take the form of a panel discussion on the treatment of hypertension. The symposium itself will be entirely devoted to the study of two specific questions: the first being the problem of the possible relationships between so-called essential hypertension and salt and water metabolism, and the second the long term effects of anti-hypertensive therapy as regards the clinical course of hypertensive disease. We are convinced that rather than attempt to cover the whole subject of essential hypertension it is a sound procedure to concentrate our attention on certain particular aspects of this vast problem. Perhaps this approach will enable us to get closer to our objective and finally to reach agreement on a certain number of points — in which case we shall be in a better position to offer some practical recommendations when we come to our second public session.

You may possibly wonder why we chose these two topics for discussion in preference to others. As regards the connections between hypertension and salt and water metabolism we have the impression that this problem has become of great current interest since the salt diuretics were introduced in the treatment of hypertension and that the whole question deserves to be reconsidered in the light of recent endocrinological findings. As for the long term effects of purely hypotensive therapy on the course of the disease the time that has elapsed since effective anti-hypertensive agents were first introduced should now be sufficient to enable us to make a preliminary assessment of the value of such treatment. Since this is a matter of major practical importance we should certainly not wait too long before undertaking a critical analysis of the results obtained to date.

Let us hope that this symposium will prove of great help in enriching our knowledge.

inant on one patient it does not mean that the endocrine cardiovascular and renal systems have quit their participation. It is just that they participate to a lesser degree.

Primitive and sophisticated control

I like to think of the circulation as having two levels of operation the one primitive and largely chemically controlled the other a more highly integrated one and nervously controlled. The prolonged slow changes in pressure and/or perfusion may be chiefly set in motion by humoral mechanisms and the fine quick changes by the autonomic and in part voluntary nervous system. In fact the two systems must be closely integrated themselves to be the effective unit they actually constitute.

Even within the humoral and neurogenic mechanisms themselves there are degrees of primitiveness. For example I have suggested that serotonin is in some ways a primitive norepinephrine. In invertebrates it seems to be able to act as a neurotransmitter a function largely replaced by norepinephrine in vertebrates. The endocrine secretory function of some neurones in insects is an example of the more primitive function of the nerve cell which may not be as highly developed in man. Yet there may well be important functional vestiges in higher animals which have so far been overlooked. I think until very recently we were inclined to relegate the pineal body to oblivion. Whatever its function it is quite apparent that things of importance transpire within its orbit. I have often suspected that the pressor material cerebrotonin which TAYLOR and I (2) showed coming from the stimulated brain might have represented endocrine secretion of neurones. Of course this is just a guess which is at least better than a bad experiment.

Arterial blood pressure and tissue perfusion

Arterial blood pressure is only one of the components of the mechanism of tissue perfusion. But before I turn to consideration of some of these varied facets I would like to mention the discussion going on between those who believe that the increase in peripheral resistance which occurs in hypertension is due chiefly to humoral and neurogenic mechanisms and those who look upon it as principally anatomical and biophysical due to the swelling and overgrowth of the arteriolar wall or to the inherent physical properties of vascular smooth muscle. Probably all are involved. The question rather is how much of each.

I have suggested in the mosaic theory that the varied facets which compose blood pressure control are in equilibrium with one another and the final pressure level is determined by the equilibrium point. Thus if blood volume changes neurogenic vasomotor tone changes to keep the blood pressure at a constant level. While one facet may temporarily play a dominant role in determining the level this does not mean that all the other facets cease functioning. Just so in the hypertensive patient one facet may be dominant but the secondary facets are in equilibrium with it and, with the passage of time may themselves become primary.




Fig 1 The mosaic theory of hypertension showing the equilibration of the various facets of pressure control to provide for controlled tissue perfusion

This seems a simple concept indeed with which no one should quarrel but few physicians truly understand it. For instance it explains why there are so many possible points at which the mechanisms of blood pressure control can be blocked for therapeutic reasons. It explains why the clinical picture of hypertension is so variable. Not the least of its virtues is that it makes thinking about the disease orderly.

Beyond the physiological processes which I have included in the octagon I have further divided and grouped what seem to be primary mechanisms of a variety of hypertension. These groups are 1 nervous 2 endocrine 3 cardiovascular and 4 renal. Again it must be recognized that while the nervous system may be predom-

want on one patient it does not mean that the endocrine cardiovascular and renal systems have quit their participation. It is just that they participate to a lesser degree.

Primitive and sophisticated control

I like to think of the circulation as having two levels of operation: the one primitive and largely chemically controlled, the other a more highly integrated one and nervously controlled. The prolonged slow changes in pressure and/or perfusion may be chiefly set in motion by humoral mechanisms and the fine quick changes by the autonomic and in part voluntary nervous system. In fact the two systems must be closely integrated themselves to be the effective unit they actually constitute.

Even within the humoral and neurogenic mechanisms themselves there are degrees of primitiveness. For example, I have suggested that serotonin is in some ways a primitive norepinephrine. In invertebrates it seems to be able to act as a neurotransmitter, a function largely replaced by norepinephrine in vertebrates. The endocrine secretory function of some neurones in insects is an example of the more primitive function of the nerve cell which may not be as highly developed in man. Yet there may well be important functional vestiges in higher animals which have so far been overlooked. I think until very recently we were inclined to relegate the pineal body to oblivion. Whatever its function it is quite apparent that things of importance transpire within its orbit. I have often suspected that the precursor material, cerebrotonin, which FARLOP and I (1) showed coming from the stimulated brain might have represented endocrine secretion of neurones. Of course this is just a guess which is at least better than a bad experiment.

Arterial blood pressure and tissue perfusion

Arterial blood pressure is only one of the components of the mechanism of tissue perfusion. But before I turn to consideration of some of these varied facets I would like to mention the discussion going on between those who believe that the increase in peripheral resistance which occurs in hypertension is due chiefly to humoral and neurogenic mechanisms and those who look upon it as principally anatomical and biophysical due to the swelling and overgrowth of the arteriolar wall or to the inherent physical properties of vascular smooth muscle. Probably all are involved. The question rather is how much of each.

We assume that if the sympathetic nerves are cut this removes all tonic vasomotor impulses. What vascular tone remains must then be due to blood borne vasoconstrictors or to the anatomy of the blood vessels. It has been further assumed that complete relaxation of the blood vessels may be achieved with such drugs as acetylcholine, ATP or nitrites. The degree to which various vascular areas are under sympathetic control varies enormously as CFLANDER and FOLKOW (2) have shown. The relative importance of the composition of the bathing medium for the tone of denervated blood vessels has not, so far as I know, been adequately studied. In this composition I would include both the usual constituents of the blood and any humoral agents that may be secreted into it. Such an experimental demonstration is difficult because of the subtlety of the possible compositional changes as well as the length of time required for such changes to be reflected in the tone of the blood vessels.

From the days of COHNHEIM and GULL and SUTTON the notion has existed that thickening of the blood vessel wall preceded the hypertension and was the cause of it. The arguments for and against this concept are too well known to this audience to waste their time repeating them. Some elaboration has recently occurred in that thickening as a result of electrolyte changes in the vessel wall has been added to thickening due to hypertrophy and hyperplasia.

One more factor concerned with peripheral resistance is inherent in the vascular wall itself. Automaticity or vasomotion of the smooth muscle is considered one of the factors. The distending force of the blood pressure creates in smooth muscle a tendency to rebound and thereby induces some degree of vascular tone.

Applying this type of thinking to the hypertensive is no more satisfying than it is in the normotensive. Theoretically it is clearly of importance but so far little objective measurement of the separate components of this complex mechanism of maintenance of vascular tone is possible in patients or indeed in intact animals.

Whether vascular resistance when smooth muscle is completely relaxed is the same in hypertensives as in normotensives would depend at least on the stage of the disease. Early it may well be the same but with time development of vascular disease could scarcely help increasing it. The impressive thing to me is the extensive anatomical change that can occur in hypertensives and yet maintain their ability to vasodilate. FOLKOW (3) stresses the fact that it takes only a small decrease in the internal diameter of the

maximally dilated blood vessel to cause a pronounced effect on the resistance to flow a five percent decrease causing the resistance to be raised something of the order of 25%. Further it can be calculated that for any given shortening of the smooth muscle the resistance of a hypertrophied vessel would be increased proportionately more than in normal vessels because a larger tissue volume intrudes on the vascular lumen. At the same degree of smooth muscle tension the hypertrophied vessel for purely mechanical reasons exhibits a greater vasoconstrictor action than normal (4).

FOLKOW, GRIMBY and THULESSON (5) tested this hypothesis by measuring forearm blood flow in normo and hypertensive subjects in whom an attempt was made to elicit maximum vasodilatation by ischemia and work. Dilatation was further facilitated by heat. If in fact these measures yield maximal dilatation then in some well established essential hypertensives resistance remained moderately raised. They point out that there are serious technical difficulties with this method and that the results can only be looked upon as suggestive.

Experience with the antihypertensive drugs has done much to dispel a firmly fixed notion as to the so-called fixed hypertensive. It is relatively rare in my experience to see a patient in whom the supine blood pressure cannot be reduced to normal and when it is normal to exhibit symptoms or signs of ischemia. This is not proof that some residue of structural change in the resistance vessels is not still present but it indicates that stronger proof of its paramount importance must be forthcoming. I would like to venture the opinion that increases in peripheral resistance as a result of structural vascular change may be important in certain specific areas such as the renal, myocardial and cerebral vessels but that a generalized increase in resistance due to structural change is less significant comes late in the course of the disease and is commonly to some degree reversible.

Distribution of blood according to local need

Surely it is the need of organs which determines the distribution of blood. Organs undoubtedly can store blood in amounts above their need but lack of blood is a condition essential organs do not tolerate. I say essential because it is well recognized that some vascular areas may be almost closed down during periods of great need in other areas. But when the heart, the brain, some endocrine gland is and the kidneys need blood they usually get it.

The mechanism by which this is accomplished must be more than mere passive dilatation from local axon reflexes or locally formed metabolites allowing more blood to drain into the dilated area. I should suppose that the need is signaled by neurones and humoral messages indicating need and that after integration the appropriate afferent messages go to those vascular areas where blood can be spared.

In keeping with what I have said before for quick changes in blood distribution I would expect nerve mechanisms to be chiefly involved but for prolonged changes humoral mechanisms. Are there then such physiological mechanisms demonstrable?

The kidneys demonstrate the humoral mechanisms admirably though I must admit that the demonstration is not rigorously proved (28). I shall not discuss the mechanism at this point but simply say that when the kidneys do not receive enough blood or there is a change in the pulsatile character of the blood received a reaction is set up which raises blood pressure which may aid in overcoming blood deficit. The nerve bundles supplying the kidneys have always been a puzzle and like those supplying the brain seem to have only mild vasoconstrictor action and do not appear to take an important part in circulatory control except possibly under conditions of great stress. McCUBBIN and I (6) found some evidence of nervous connections with the adrenal glands which could be stimulated by the ganglion stimulating agent Dmpp but the actual function of such connections is purely conjectural.

The brain in respect to its control of its circulation is a good deal like the kidneys. It is highly dependent on the height of the systemic blood pressure, partially on humoral agents and with relatively little dependence on vasomotor control. On the other hand vasoconstriction and dilatation within the brain can importantly influence vasomotor reflexes such as the reflex pressor response to occlusion of the common carotid artery. HANEKO, McCUBBIN and I (7) found that several vasoconstrictor drugs given into the cerebral lateral ventricles as well as cooling of the cerebrospinal fluid inhibited this reflex. The effect was opposed by central administration of vasodilator drugs or heating the cerebrospinal fluid. Vasoconstriction in the cerebral vessel was associated with a fall in systemic arterial pressure and slowing of the heart rate while local vasodilatation opposed these central inhibitory effects. I shall discuss this phenomenon later but I want to use it now to illustrate the thesis that the blood flow to an organ can influence systemic blood pressure to an important degree. The brain unlike the kidney seems to exert its influence largely on the cardio

vascular system by changes in neural control. But even the brain seems to have some modicum of direct chemical control if the pressor substance tentatively called *cerebrotonin* can be more closely identified and characterized. At one stage in its evolution the brain exhibited relatively highly developed endocrine function which may not have been wholly lost.

The control of blood to the myocardium seems to combine the neural and humoral mechanisms to give each clear importance. When the heart lacks blood it cries out for more during the familiar *angina pectoris*. Its afferent control is highly responsive. The efferent control affects both inotropic and chronotropic characteristics of the muscle but it is less clear how effective the vasomotor response may be. The same may be said for the control by the blood-borne vasoactive agents although again it is clear that both have important effects even though their quantitative relationships are not defined. We know too little of the meaning of the storage of catecholamines and other vasoactive agents in the myocardium and blood vessels to speculate profitably.

Each organ could be considered in similar fashion but enough has been discussed. I believe to illustrate the thesis that the local need for blood is one of the critical determinants of systemic blood pressure. From this it follows that disturbances in the level of blood pressure may result from disturbances in the need for blood in single and multiple organs. The dominant mechanism employed by an organ to control its own perfusion may under some circumstances assume a primary role in controlling systemic blood pressure levels. However the dominance of one mechanism does not insure the abrogation of all other controlling mechanisms. It is for this reason that arterial blood pressure may be affected by agents acting on such different facets of the blood pressure controlling mechanism.

1 Neurogenic participation

Clinical	Experimental
Polio myelitis of brain stem	Cerebral ischemia
Porphyria chronic	Cushing's experiment
Increased intracranial pressure	Resection of sinus and aortic depressor nerves
Sclerosis of carotid sinus	
Resection of glossopharyngeal nerve	Hypertension from audiogenic stimulus
Emotion	



The mechanism by which this is accomplished must be more than mere passive dilatation from local axon reflexes or locally formed metabolites allowing more blood to drain into the dilated area. I should suppose that the need is signaled by neurones and humoral messages indicating need and that after integration the appropriate afferent messages go to those vascular areas where blood can be spared.

In keeping with what I have said before for quick changes in blood distribution I would expect nerve mechanisms to be chiefly involved but for prolonged changes humoral mechanisms. Are there then such physiological mechanisms demonstrable?

The kidneys demonstrate the humoral mechanisms admirably though I must admit that the demonstration is not rigorously proved (58). I shall not discuss the mechanism at this point but simply say that when the kidneys do not receive enough blood or there is a change in the pulsatile character of the blood received a reaction is set up which raises blood pressure which may aid in overcoming blood deficit. The nerve bundles supplying the kidneys have always been a puzzle and like those supplying the brain seem to have only mild vasoconstrictor action and do not appear to take an important part in circulatory control except possibly under conditions of great stress. McCUBBIN and I (6) found some evidence of nervous connections with the adrenal glands which could be stimulated by the ganglion stimulating agent Dmpp but the actual function of such connections is purely conjectural.

The brain in respect to its control of its circulation is a good deal like the kidneys. It is highly dependent on the height of the systemic blood pressure partially on humoral agents and with relatively little dependence on vasomotor control. On the other hand vasoconstriction and dilatation within the brain can importantly influence vasomotor reflexes such as the reflex pressor response to occlusion of the common carotid artery. KANEKO, McCUBBIN and I (7) found that several vasoconstrictor drugs given into the cerebral lateral ventricles as well as cooling of the cerebrospinal fluid inhibited this reflex. The effect was opposed by central administration of vasodilator drugs or heating the cerebrospinal fluid. Vasoconstriction in the cerebral vessel was associated with a fall in systemic arterial pressure and slowing of the heart rate while local vasodilatation opposed these central inhibitory effects. I shall discuss this phenomenon later but I want to use it now to illustrate the thesis that the blood flow to an organ can influence systemic blood pressure to an important degree. The brain unlike the kidney seems to exert its influence largely on the cardio

For example it may explain why nephrectomy lowers pressure in the acute stage of renal hypertension but not in the chronic. It might be a factor in the occasional patient in whom the hypertension persists after removal of a pheochromocytoma and in



The Patient with malignant hypertension treated successfully with hydralazine. The drug was withdrawn blood pressure did not rise. Blood pressure was kept at 110/70 mmHg by the use of 4 mg hydralazine daily for 10 weeks. Triangles represent a change from 1 to 2 patient. While hydralazine was given on a 2-4 mg daily basis of the blocking of the Dibenamine to lower arterial pressure is shown at arrow 1.

the group of patients we have found to become normotensive after years of antihypertensive therapy. An example of such a patient is shown in Fig. 2.

The Carotid sinus mechanism is only one of several nervous mechanisms which can control blood pressure in a discriminative fashion. Much work has shown the highly selective action of

As I promised I shall touch only superficially on a few topics of special interest to illustrate my thesis there will be no marshalling of evidence to show the important participation of the nervous system in the mechanisms of hypertension. We have already done this in outline form recently (59). I shall first consider the problem of the resetting of the carotid sinus and similar buffer mechanisms when renal hypertension develops merely as an example of the behavior of the nervous system under the changed conditions of hypertension.

Blood pressure regulatory mechanisms and the level of their "set"

Physicians have been puzzled for many years because of the fact that pressure on the carotid sinus area elicited the same circulatory response in hypertensive subjects as in normotensive ones. It had been taught that the sinus mechanism was one of the most powerful modulators of blood pressure levels. When blood pressure is raised by injection of pressor drugs baroreceptors are stimulated and reflexly diminish or eliminate neurogenic vasoconstriction from the vasomotor centers in an effort to lower blood pressure. But when the pressure rises during the course of essential or malignant hypertension the sinus mechanism seems to fail. Indeed it seems to operate to maintain the elevated pressure.

MCCUBBIN, GREEN and I (8) studied this problem using electro-neurographic techniques to measure baroreceptor activity in normotensive states and then after production of acute and chronic renal hypertension. The observation that in chronically hypertensive dogs baroreceptors fire intermittently at supernormal pressure levels — which elicits continuous firing in normotensive animals — indicates that the regulating mechanism has been set to buffer arterial pressure at higher levels. The carotid sinus buffer mechanism has shifted its threshold and range of response upward so that it perceives so to speak the hypertensive levels as normal ones. The regulator has been reset upwards. After the resetting it naturally acts to maintain arterial pressure at the higher level rather than normal ones.

Clearly even hypertension of primarily renal origin has an important neurogenic component and it is in my opinion the reason that patients with such hypertension respond to neuroleptic drugs in many cases as well as patients with central hypertension in whom the renal component is less clearly defined. The resetting phenomenon can be used as an explanation for many of the pharmacological and clinical phenomena associated with hypertension.

system. Reserpine is an excellent example. It is known to have a strong central cardiovascular action but the mechanism is not known. Recently Drs McCUBBIN, KAREKO and I (9) studied this problem in dogs. Both serotonin and norepinephrine are released from the bound to free form in the brain by reserpine. Both inhibit central synaptic transmission. It is therefore possible that the central effects of reserpine on vasomotor activity depend upon release of these two amines and it should be possible to reproduce these effects by injecting them directly into the cerebrospinal fluid since reserpine is effective when given in this way. We tested both serotonin and norepinephrine and their respective precursors.

All of these substances had qualitatively the same effects in that they lowered arterial pressure, usually caused bradycardia despite prior vagus nerve section and caused marked inhibition of the pressor response to occlusion of the common carotid arteries. The same result was obtained in anesthetized and unanesthetized dogs. These results are all consistent with the premise that the acute cardiovascular effects of reserpine are mediated centrally by serotonin and/or norepinephrine either released from a bound and inactive to a free and active form or formed by decarboxylation of their respective amino acids.

But how might they do this? We found that not only reserpine but several vasoconstrictor drugs given into the cerebral ventricles inhibited the carotid occlusion pressor reflex. This effect was opposed by central administration of vasodilator drugs. Cooling of the cerebrospinal fluid which presumably caused local vasoconstriction also caused inhibition of the carotid reflex, hypotension and bradycardia — effects counteracted by central injection of vasodilator drugs. Warming the cerebrospinal fluid did just the opposite. It would appear then that these effects on vasomotor activity depend upon changes in local blood flow. It follows that the cardiovascular effects of reserpine are probably due to local increase in tissue perfusion caused by release of serotonin, norepinephrine or other vasoconstrictor agents.

From this and the example taken from the resetting phenomenon in the carotid sinus mechanism one begins to feel the power and complexity of the nervous control of arterial blood pressure and tissue perfusion.

² Cardiovascular participation

Clinical

Clotting of aorta
Heart failure
Arteriovenous fistula
Arteriosclerosis

Experimental

Clamping of aorta above renal vessels

concentration of circulating red blood cells and plasma proteins) diastolic hypertension is inevitable. Hypertension, then, can be considered a form of generalized vasospasm, a variant of normal responses to circulatory stresses, characterized by healthy blood and heart and by its chronic nature. Any one of several of the mechanisms which produce vasospasm can be involved in causing hypertension, new mechanisms can also arise at a time long after the organism would be dead or recovered from shock, had that been the initiating cause.

While we do not know the exact causes of generalized vasospasm, we do know a great deal about the mechanisms which produce it. The causes themselves lie in biochemical alterations in blood vessels, nervous tissue and organs of high metabolic activity. It is not enough to say that we do not know and therefore we must not try to know. For there are not many areas which have been so well studied, and there is little need to invoke esoteric mechanisms to the neglect of known ones. If one asked any physiologist what influences he would think could raise diastolic blood pressure on the basis of experimental data he would choose autonomic nerves, kidneys and endocrine organs. He would not choose liver, thyroid, spleen or pancreas, however, but consider sympathetic nerves and their origins, renal blood flow and adrenal glands.

Clinical Chronic Hypertension We can transfer these thoughts of our physiologist immediately to our own clinical experiences, viewing each case in their light. Let us take some typical ones.

1. A woman of 25 was found on routine examination to have a blood pressure of 152/88 mm Hg which after a rest fell to 138/82. Her mother had hypertension without sequelae. She had no symptoms, but her physician noticed that her heart rate was a little rapid and that she

III 55 At autopsy were found cerebral hemorrhage massive arteriosclerosis moderate of aorta renal arteries coronary arteries marked of circle of Willis with rupture arteriolar nephrosclerosis moderate cardiac hypertrophy (460 Gm) Her adrenal glands were normal

This sequence of events leading to early death can be reconstructed in the light of what is known. For many years this woman reacted to stressful situations by neurogenic vasospasm. Slowly the reversibility of this alteration became less and less some gradually increasing factor being added which maintained a basal blood pressure at higher and higher levels upon which was engrafted a widely fluctuating neurogenic component. This added factor was what killed her. Perhaps she would not have died so early were it not for another disease atherosclerosis which began probably after her menopause and affected her cerebral arteries to such an extent that one ruptured under the high pressure.

2 A man of 25 was found to have a slightly elevated blood pressure and tachycardia when examined for the draft. His mother was hypertensive and his father had died of a coronary occlusion at the age of 51. Enuresis until the age of 8 had occurred but he was free of further urinary symptoms and his urine showed no albumin. He went to his family doctor who found a few bacteria in his urine with about 10 white blood cells per high power field in the centrifuged sediment. repeated cultures showed non hemolytic streptococcus of the colon group in large numbers. He was given phenobarbital and was accepted for duty in the Army. He had a creditable career and won several decorations for bravery. His discharge physical examination showed a blood pressure of 160/100 mm. Not until the age of 33 did he consult a physician for severe headaches and blurring of vision which had appeared a month earlier. His blood pressure was 236/160

every 4 hours, it was normal during sleep (140/90) and dropped to 122/88 when tetra-ethyl ammonium chloride was injected intravenously. She was given phenobarbital but was never the same. Investigative studies on the renal clearance of para aminohippurate and inulin revealed reduction of renal plasma flow and relatively increased glomerular filtration rate. The profile of efferent arteriolar spasm.

Emotionally induced vasospasm had added to it another factor. In the first place the neurogenic influence had increased. Secondly the reversibility of the vasospasm had lessened.

She had her menopause at 45. By the age of 48, she was suffering from headaches every morning, anxiety increased, nervous tension and an inner sense of excitement. Her blood pressure was now constantly over 200 mm systolic in spite of sedatives but fell with rest to 160/110 fluctuating widely. During sleep induced by heavy sedation it did not fall to normal. Her fundi now showed some sclerotic tortuous arteries, her electrocardiogram indicated enlargement of the left ventricle, seen also in x-ray photographs. Occasionally she had a trace of albumin in her urine but she excreted 30 per cent of intravenously injected phenol red (PSP) in 15 minutes and her kidneys were able to concentrate urine to a specific gravity of 1.025. The blushing became more pronounced.

Now had appeared an irreversible component to the vasospasm, in that sleep did not completely abolish it. Signs of organic damage were developing. Rest, reassurance, sedatives, superficial psychotherapy and laying on of hands could not interrupt the vicious cycle.

She suffered her first stroke of apoplexy, a mild one, at 51 and recovered with little residual other than a limp. Hypertension persisted unabated and she died of another

kidney and cardiac hypertrophy (520 Gm) and dilatation His brain was edematous his adrenals normal

This man suffered from the 'accelerated phase' or what is more exactly and descriptively called malignant hypertension and died young He had the constitutional make up of the hypertensive person to which was added chronic low-grade smouldering pyelonephritis with an organism which does not produce pus but causes scar tissue These two factors operating together shortened his life By the time he died there was little evidence left of the primary renal disease in the kidney distorted by nephrosclerosis

3 An older man had a slightly elevated blood pressure at times of stress which had been normal on regular examinations all of his life At 49 however he was refused life insurance because of a blood pressure of 170/110 mm Hg He had no symptoms except nervousness but he was a tense dynamic individual with excessive drive and ambition somewhat of a perfectionist Examination in hospital revealed no significant abnormalities except minimal left ventricular enlargement studies on his renal plasma flow showed slight reduction with the calculated increased renal vascular resistance on the afferent side of the glomerulus His blood pressure varied moderately but did not fall to normal levels during sleep or the injection of tetraethyl ammonium chloride Renal "function" was normal He was well working hard and taking few vacations until he was suddenly seized at age 54 with a severe retrosternal pain and was admitted to hospital with an acute coronary occlusion Other than minimal *cardiac* enlargement a tortuous aorta and the usual signs of infarction there were no abnormalities He recovered slowly but his blood pressure normal or low during his illness became elevated again to 180/110 mm during rest and as high as 220/120 during activity In spite of rearranging his life he remained hypertensive until his second infarction at 57 from which

mm there was 3 plus proteinuria and microscopic hematuria, the ocular fundi showed early papilledema and soft cotton wool exudates but no hemorrhages, and his heart was slightly enlarged. He was able to concentrate urine to a specific gravity of only 1.019 and excrete only 15 per cent of the intravenously injected dose of phenol red in 15 minutes. Culture of the urine showed nonhemolytic staphylococcus, considered a contaminant but intravenous pyelography revealed blunting of one upper calyx in the right kidney. His blood pressure altered little during deep sleep and when tertiary ethyl ammonium ion was injected, his diastolic pressure fell from 158 to 145 mm Hg.

This man, unlike his predecessor, had rapidly reached an irreversible stage of vasospasm. His blood pressure was 'fixed' and his course was presumed to be rapidly progressive. Some organic renal component could be inferred from the earlier urinary findings and the pyelographic evidence, but this was asymptomatic. His family and early history suggested that he might be one of those persons who react to stress by vasospasm, added to this component was a chronically diseased kidney.

He refused admission to hospital but was examined frequently during the next year and took the new Rauwolfia drugs continuously without effect on his slowly rising blood pressure and deteriorating condition. Finally he was forced to seek help because of increasing dyspnea, but by that time the nonprotein nitrogen in his blood was 132 mg per cent, his diastolic pressure 160 mm Hg or more; he had suffered one attack of pulmonary edema and his ocular fundi showed many hemorrhages, hard exudates, soft exudates and papilledema. After a stormy downhill course he died of uremia complicated by congestive heart failure. At autopsy there was moderate generalized arteriosclerosis, advanced arteriolar nephrosclerosis with necrosis, a few depressed scars on the cortices of one

The curious thing about her obesity was its distribution over the trunk upper arms and thighs Her lower legs and arms were not obese at all There was a "buffalo hump" and her face resembled those seen after overdoses of cortisone Measurements of the sodium and chloride in her sweat showed values of 10 mEq/L or less levels found in Cushing's syndrome She bruised easily and her ankles had a tendency to swell in the evenings She had a distinct mustache Serum sodium was 145 chloride 101 CO_2 32.4 and potassium 2.8 mEq/L

She did well but remained hypertensive at home as it was impossible for her to restrict her salt intake and her appetite Not until she was 45 did her first episode of congestive heart failure bring her back into hospital She died 2 years later a cardiac cripple in the interim At autopsy were found arteriolar nephrosclerosis slight to none moderate generalized arteriosclerosis marked cardiac hypertrophy and dilatation (640 Gm.) There was a 1 x 1.2 cm adenoma in the left adrenal cortex.

In her case a functioning adenoma in her adrenal cortex was affecting both her salt and fat metabolism the former influencing her hypertension Better diagnostic methods would have allowed surgical removal

These four cases are illustrative of distinct types of arterial hypertension encountered clinically In actual practice one sees wide variations in their courses and some times bizarre mixtures If the first patient had contracted glomerulonephritis in childhood or pyelonephritis during her pregnancy or had by chance had a link in her ureteropelvic junction due to an aberrant renal artery with stasis and infection she probably would have exhibited more severe hypertension at an earlier age If the second had not contracted pyelonephritis in childhood he might have lived to become hypertensive in his 50's and died of heart failure or apoplexy in his 60's If the renal arterial

he died At autopsy there was found *cardiac enlargement* with focal myocardial fibrosis a new infarct arteriolar nephrosclerosis slight, and generalized arteriosclerosis Careful cross sectioning of the mouths of the renal arteries revealed some encroachment of their lumina by atherosclerotic plaques

This man also probably had the constitution for hypertension When he developed atherosclerosis, the slight narrowing of his renal arteries interfered enough with renal hemodynamics to cause a moderate hypertension The elevated pressure worsened the atherosclerotic process, which in his case was lethal because it involved his coronary arteries Hypertension itself did little direct but much indirect harm for he died before his time

4 A woman of normal weight began to gain rapidly after her second pregnancy at age 22 Within 2 years her weight increased from 110 to 190 pounds and slowly increased thereafter At 35 she weighed 252 but on dietary restriction lost 23 pounds Her menses had always been somewhat irregular and frequent but in her 30's periods of amenorrhea for 3 to 6 months appeared She was found to exhibit hypertension at age 31 using the large (18 cm) cuff her blood pressure was 160/102 and using the normal (12 cm) cuff 186/122 Subsequently hypertension was moderate blood pressure seldom exceeding 200/130 mm and usually being about 200/120 Fundal changes were minimal Studied in hospital there was little evidence of vascular damage other than an enlarged heart Periods of decreased urinary output followed by polyuria were noticed when her fluid balance was measured Renal plasma flow and glomerular filtration rate were normal Weight was lost very slowly on severe dietary restriction of calories, but restriction of salt promptly lowered blood pressure to normal levels Her mother and one of three sisters were fat hirsute and hypertensive

The curious thing about her obesity was its distribution over the trunk upper arms and thighs Her lower legs and arms were not obese at all There was a "buffalo hump" and her face resembled those seen after overdoses of cortisone Measurements of the sodium and chloride in her sweat showed values of 10 mEq/L or less levels found in Cushing's syndrome She bruised easily and her ankles had a tendency to swell in the evenings She had a distinct mustache Serum sodium was 145 chloride 103 CO_2 32.4 and potassium 2.8 mEq/L

She did well but remained hypertensive at home as it was impossible for her to restrict her salt intake and her appetite Not until she was 45 did her first episode of congestive heart failure bring her back into hospital She died 2 years later a cardiac cripple in the interim At autopsy were found arteriolar nephrosclerosis slight to none moderate generalized arteriosclerosis marked cardiac hypertrophy and dilatation (640 Gm) There was a 1 x 1.2 cm adenoma in the left adrenal cortex.

In her case a functioning adenoma in her adrenal cortex was affecting both her salt and fat metabolism the former influencing her hypertension Better diagnostic methods would have allowed surgical removal

These four cases are illustrative of distinct types of arterial hypertension encountered clinically In actual practice one sees wide variations in their courses and sometimes bizarre mixtures If the first patient had contracted glomerulonephritis in childhood or pyelonephritis during her pregnancy or had by chance had a kink in her ureteropelvic junction due to an aberrant renal artery with stasis and infection she probably would have exhibited more severe hypertension at an earlier age If the second had not contracted pyelonephritis in childhood he might have lived to become hypertensive in his 50's and died of heart failure or apoplexy in his 60's If the renal arterial

atheromata in the third had piled up enough to cause serious encroachment on the lumina, he might have entered the malignant stage, unless heart or brain gave out first. If the fourth had contracted pyelonephritis as well as her tumor, her course would have been shortened. Renal disease of any nature to interfere with blood flow, when combined with the "hypertensive diathesis," can increase the severity and shorten the course. The fact that hypertension is absent before azotemia in approximately 30 to 40 per cent of patients with renal diseases, points up the necessity for the presence of another factor to explain pathogenesis.

Pathologic Alterations Dead house pathology does not always explain physiologic and biochemical alterations in disease. But it cannot be neglected. There are very few anatomic changes in hypertension, but they are characteristic.

1 Renal arteriolar and arteriosclerosis are almost universal in this disorder (2). Cases similar to our fourth are a notable exception (3, 4). The thickening, scarring and hyalinization of the afferent arterioles vary from slight to marked, with complete or almost complete occlusion of their lumina. Only in azotemia, and then only in half the cases, are the necrotizing arteriolar lesions seen (5, 6). These are called "malignant nephrosclerosis, a term which has little to do with non azotemic malignant hypertension." What has been little described are the earliest changes seen in hypertension: a thickening of the basement membrane of the glomerulus, later an increase in ground substance of the tuft, well followed in dogs (7) and observed in man. This change may be the result of increased intraglomerular pressure which must occur when efferent arterioles are constricted more than afferent ones.

2 Cardiac hypertrophy, and often dilatation, are almost

universal although we have rarely seen normal sized hearts after sustained hypertension. This change is probably a work hypertrophy resulting from the increased cardiac work necessitated by the hypertension. It can be modified by associated atherosclerosis of the coronary arteries.

3 Generalized atherosclerosis is almost universal in this country although cases without it are common in China (8)

Sequence of Development of Arteriolar Nephrosclerosis
This basic lesion which by its very nature can cause renal ischemia and hypertension, is a result of hypertension. In other words the altered hemodynamics of hypertension can lead to a pathologic change which further alters renal and therefore peripheral hemodynamics. The evidence is clear on this point, in rats rabbits dogs and man (Chapter V). Therefore at some point in two of our cases renal vascular disease appeared after hypertension had become well established. Whether or not this secondary disease is responsible for the loss of reversibility of vasospasm is not known, but presumably it is not wholly accountable.

Comment All biological phenomena can eventually be understood in terms of physics and chemistry. The remainder of this monograph is concerned largely with an examination of the biochemical alterations possibly operating to cause this disease which is so eventually fatal as a rule and which is so common to Western Civilization.

MECHANISMS OF SOME OF THE EFFECTS OF CHRONIC ARTERIAL HYPERTENSION

Degree of Peripheral Vasospasm in Chronic Hypertension
The vasospasm can be very intense in chronic arterial hypertension. In fact, it must be so in order to maintain the diastolic pressure at high levels. One can estimate the intensity of the vasospasm by measuring the pressure

atheromata in the third had piled up enough to cause serious encroachment on the lumina, he might have entered the malignant stage, unless heart or brain gave out first. If the fourth had contracted pyelonephritis as well as her tumor, her course would have been shortened. Renal disease of any nature to interfere with blood flow, when combined with the "hypertensive diathesis," can increase the severity and shorten the course. The fact that hypertension is absent before azotemia in approximately 30 to 40 per cent of patients with renal diseases points up the necessity for the presence of another factor to explain pathogenesis.

Pathologic Alterations Dead house pathology does not always explain physiologic and biochemical alterations in disease. But it cannot be neglected. There are very few anatomic changes in hypertension, but they are characteristic.

1. Renal arteriolar and arteriosclerosis are almost universal in this disorder (2). Cases similar to our fourth are a notable exception (3, 4). The thickening, scarring and hyalinization of the afferent arterioles vary from slight to marked, with complete or almost complete occlusion of their lumina. Only in azotemia, and then only in half the cases, are the necrotizing arteriolar lesions seen (5, 6). These are called "malignant nephrosclerosis," a term which has little to do with non azotemic "malignant hypertension." What has been little described are the earliest changes seen in hypertension, a thickening of the basement membrane of the glomerulus, later an increase in ground substance of the tuft, well followed in dogs (7) and observed in man. This change may be the result of increased intraglomerular pressure which must occur when efferent arterioles are constricted more than afferent ones.

2. Cardiac hypertrophy, and often dilatation, are almost

universal although we have rarely seen normal sized hearts after sustained hypertension. This change is probably a work hypertrophy resulting from the increased cardiac work necessitated by the hypertension. It can be modified by associated atherosclerosis of the coronary arteries.

3 Generalized atherosclerosis is almost universal in this country although cases without it are common in China (8).

Sequence of Development of Arteriolar Nephrosclerosis
This basic lesion which by its very nature can cause renal ischemia and hypertension is a result of hypertension. In other words the altered hemodynamics of hypertension can lead to a pathologic change which further alters renal and therefore peripheral hemodynamics. The evidence is clear on this point in rats rabbits dogs and man (Chapter V). Therefore at some point in two of our cases renal vascular disease appeared after hypertension had become well established. Whether or not this secondary disease is responsible for the loss of reversibility of vasospasm is not known but presumably it is not wholly accountable.

Comment: All biological phenomena can eventually be understood in terms of physics and chemistry. The remainder of this monograph is concerned largely with an examination of the biochemical alterations possibly operating to cause this disease which is so eventually fatal as a rule and which is so common to Western Civilization.

MECHANISMS OF SOME OF THE EFFECTS OF CHRONIC ARTERIAL HYPERTENSION

Degree of Peripheral Vasospasm in Chronic Hypertension
The vasospasm can be very intense in chronic arterial hypertension. In fact, it must be so in order to maintain the diastolic pressure at high levels. One can estimate the intensity of the vasospasm by measuring the pressure

in an artery peripheral to complete intermittent mechanical occlusion (9 11) In man only the brachial bed offers a convenient means of doing this In Figure 1 are shown 'asystolic arterial pressure gradients' in various types of hypertension Persons with diastolic pressures from 100 to 200 mm Hg have shown asystolic brachial pressures 18




FIG 1 Brachial asystolic arterial pressure gradient in man (9 10) A needle connected to a recording manometer was inserted into the brachial artery and a sphygmomanometer cuff placed about the upper arm After rapid occlusion of the cuff the fall of pressure in the distal segment (the forearm) was measured The level of pressure with no circulation is a measure of the degree of vasoconstriction opposing arterial run off Curves were obtained from a 46-year old normotensive woman a 54 year-old arteriosclerotic man without much diastolic hypertension a 56 year old severely hypertensive man treated with ganglionic blocking agents and hydralazine and a 37 year-old woman with untreated malignant hypertension The curves are a function of diastolic pressure (11)

seconds after occlusion from 30 to 122 mm Hg (average 65.8 normotension being 15 to 40 average 28.7 mm) a finding surprising on the surface but expected when due consideration is given to hypertensive hemodynamics. The smooth muscle of all arteries and arterioles must therefore be in a state of chronic spasm otherwise hyperemia would occur in those which are not.

Pathogenesis of Hemorrhagic and Exudative Retinitis

The lesions found in the fundi oculi when the diastolic pressure is high are those of edema, hemorrhage, deposits of proteinaceous or lipid material and scarring. Many ophthalmologists consider that hemorrhagic and exudative retinitis is due to localized ischemia of the retina secondary to excessive vasospasm. From a hemodynamic anatomic and physiologic viewpoint this concept is hardly tenable since a) ischemia of a part does not usually cause edema without infarction b) ischemia does not lead to hemorrhage c) the retinal arteries and arterioles have rather thin muscular coats and d) the lesions appear when the diastolic pressure is high, regress when it is lowered (sometimes to the point of producing retinal ischemia) and occur as a manifestation of a sudden worsening of the hypertension. A more logical explanation is that of plethora or excessive hyperemia. If the artery supplying an area of the retina were diseased so that it could not contract and 'healthy' vessels in the remainder of the body were made to constrict hyperemia through that diseased vessel would result. Excessive flow and pressure would be transmitted to the capillary bed supplied by that artery. When venous outflow became insufficient to carry off the increased load water then plasma and finally red blood cells would be forced through the capillary wall. This concept explains what we find: edema, cotton wool, exudates and hemorrhages. The hard

in an artery peripheral to complete intermittent mechanical occlusion (9 11) In man, only the brachial bed offers a convenient means of doing this In Figure 1 are shown 'asystolic arterial pressure gradients' in various types of hypertension Persons with diastolic pressures from 100 to 200 mm Hg have shown asystolic brachial pressures 18




FIG 1 Brachial asystolic arterial pressure gradient in man (9 10) A needle connected to a recording manometer was inserted into the brachial artery and a sphygmomanometer cuff placed about the upper arm After rapid occlusion of the cuff the fall of pressure in the distal segment (the forearm) was measured The level of pressure with no circulation is a measure of the degree of vasoconstriction opposing arterial run-off Curves were obtained from a 46-year old normotensive woman a 54 year-old arteriosclerotic man without much diastolic hypertension a 56 year old severely hypertensive man treated with ganglionic blocking agents and hydralazine and a 57 year old woman with untreated malignant hypertension The curves are a function of diastolic pressure (11)

Comment The secondary effects of hypertension are relatively unimportant to this discussion but they are of the utmost importance to the patient and to his therapy for it is by them that hypertension becomes a fatal disease. A further and often fatal effect is discussed in Chapter VII.

exudates may be the scars of old hemorrhages and the protein and lipid remnants of exudation of plasma

Since the arteries of the retina and brain are thin walled, weak structures compared to those in the remainder of the body, being in a media of higher external pressure, fairly generalized exudation and hemorrhage would be expected when systemic diastolic pressure rose to very high levels. It is probable that focal hemorrhages in the kidney, and perhaps in the gut, are the result of a high diastolic pressure through an artery or arteriole which is so diseased that it cannot constrict as much as the rest of the vascular bed. Therefore, many of the hemorrhagic and exudative lesions found in malignant hypertension are probably caused, not by excessive spasm proximal to the lesion but lack of enough spasm to compensate for that of the rest of the vascular bed.

Pathogenesis of Necrotizing Arteriolar Lesions In man, we find necrotizing lesions of the arteries and arterioles usually of the kidney only in nitrogen retention (5). Two influences are necessary, azotemia and a high diastolic pressure. Azotemia alone will not produce the lesions, for example, in uremia without much hypertension. On the other hand, hypertension alone will not usually cause the lesions in dogs (6) or in man. It is difficult to discover more than isolated cases in experimental animals without uremia (12). Both kidney (6) and a section of the small intestine can be protected from their occurrence by partial constriction of the main artery even in severely uremic animals (13). Necrotizing fibrinous arterial degeneration however has been caused by the injection of organ, notably renal, extracts into nephrectomized dogs (14, 15). Therefore both pressure and severe renal disease seem to be required for their occurrence.

This form of reacting to stress may be common to some human beings in many environments and of many races although adequate studies have not been made. The old idea that a part of the population is sympathotonic and part parasympathotonic or vagotonic may have some basis of fact. Different species of animals show different types of reaction to stress rats cats guinea pigs and rabbits not only exhibit opposite types but respond in aberrant ways to known pressor and depressor agents. There are at least two kinds of dogs nervous overactive breeds which are hypertensive on the first and many subsequent examinations and more or less phlegmatic breeds or cross-breeds which exhibit normal blood pressures and bradycardia (21). There is little reason to believe that the human organism differs radically in its fundamental reactions from those of higher animals.

Sympathotonic people are supposed to be subject to vasomotor phenomena tachycardia and cardiovascular diseases especially hypertension. Parasympathotonic people are supposed to be subject to bradycardia a low blood pressure and gastrointestinal disorders especially peptic ulcer. Another type of individual develops allergic reactions. In any population all varieties and degrees of reactive ability can be expected depending probably on the amount of imbalance between sympathetic and parasympathetic nervous function and the amount of external stress to which individuals are exposed. There may be several different constitutional types we have not observed true extrinsic asthma in a hypertensive person and such allergic states as hay fever and urticaria are much less common than in the general population. duodenal ulcer is unusual in hypertension although it exists (4). Rheumatoid arthritis and most malignant tumors are seldom encountered in a hypertensive population (22).

Chapter II

BASIC OR CONSTITUTIONAL FACTORS

THE BASIC factors in arterial hypertension are those broad and ill defined influences which cause a human being to become predisposed to the development of the disease. By arbitrarily separating basic traits from factors operating after the disease has become established one can outline the areas of therapeutic approach and predict, with some success, efficacy of various forms of therapy.

Reaction to Stress by Vasospasm The basic defect in persons predisposed to hypertension appears to be a reaction to stress by vasospasm or through vasomotor phenomena. Thus Levy, Stroud, White and Hillman (15, 18) found in Army Officers that transient hypertension, transient tachycardia and overweight each predisposed to the later development of hypertension, the last factor being the least significant. Long prior to these studies Hines found that when the stress of the first examination resulted in transient elevation of the systolic pressure to more than 140 mm Hg, 63 per cent of the patients would develop hypertension 20 years later; if more than 150, 78 per cent would exhibit it (19). Critical predisposing diastolic levels were above 85 mm. Furthermore, Hines has shown that persons reacting by vasospasm to pain (cold pressor test) later usually develop hypertension (20). This manner of reacting therefore probably constitutes the underlying etiology, which lies in the constitution of the individual and is described but not understood.

This form of reacting to stress may be common to some human beings in many environments and of many races although adequate studies have not been made. The old idea that a part of the population is sympathotonic and part parasympathotonic or vagotonic may have some basis of fact. Different species of animals show different types of reaction to stress: rats, cats, guinea pigs and rabbits not only exhibit opposite types but respond in aberrant ways to known pressor and depressor agents. There are at least two kinds of dogs: nervous overactive breeds which are hypertensive on the first and many subsequent examinations and more or less phlegmatic breeds or cross breeds which exhibit normal blood pressures and bradycardia (21). There is little reason to believe that the human organism differs radically in its fundamental reactions from those of higher animals.

Sympathotonic people are supposed to be subject to vasomotor phenomena: tachycardia and cardiovascular diseases especially hypertension. Parasympathotonic people are supposed to be subject to bradycardia, a low blood pressure and gastrointestinal disorders especially peptic ulcer. Another type of individual develops allergic reactions. In any population all varieties and degrees of reactive ability can be expected depending probably on the amount of imbalance between sympathetic and parasympathetic nervous function and the amount of external stress to which individuals are exposed. There may be several different constitutional types: we have not observed true extrinsic asthma in a hypertensive person and such allergic states as hay fever and urticaria are much less common than in the general population. duodenal ulcer is unusual in hypertension although it exists (4). rheumatoid arthritis and most malignant tumors are seldom encountered in a hypertensive population (22).

The ability, or habit, of reacting to stress by vasospasm does not cause hypertension. It merely predisposes those individuals so constituted to the slow development of the disease. Other influences are probably operative which change reversible into irreversible vasospasm.

HEREDITY AND ENVIRONMENT

Heredity The manner of reacting to stress by vasospasm is apparently an inherited characteristic. Hines has shown clearly that persons who so react have parents who are either hypertensive or react likewise to painful stimuli (23). The gross hereditary nature of chronic hypertension is well established, although Pickering disagrees with this idea (24). What makes up this predisposition has been little understood.

Thomas has clearly shown that cardiovascular disease is an inherited trait in the United States (25).

Personality Patients suffering from chronic arterial hypertension in all stages of severity supposedly exhibit certain defects of personality, the qualities of which go to make mature and well integrated individuals. The deficiencies have been considered as a subnormal level of assertiveness and tendencies towards obsessive-compulsive traits (26, 4). Anxiety which may precede, or be a result of the illness, is also common (27). Whether these alterations are similar in the major psychosomatic disorders which result in irreversible organic changes (peptic ulcer, asthma) or are specific for one disorder, has not yet been clearly established. Likewise the effects of abnormal renal metabolites (primary amines and other substances) upon cerebral metabolism, which might enhance relatively minor functional derangements, are not known (Chapter III).

Environment Without stimuli to cause a reaction the reaction would not occur. The stresses, or stimuli, which

are a product of the environment and the attitude of the individual toward it can be considered as initiating factors in the reaction. These influences vary widely from one person to another involving the many faceted aspects of existence and adjustment to a prevailing social order. It is probable that the more complex society becomes the greater are the environmental stresses consequent to adjustment to that society and therefore the stimuli to somatic reaction increase.

Pickering lately summed up his concepts on the relation of hereditary constitution and environment in hypertension (28). To get these conclusions in perspective it may be said that in its mode of inheritance blood pressure resembles height but that the size of the genetic factor is greater in the case of height. However the regression coefficient certainly underestimates the size of the genetic factor since we have been unable to allow for the day-to-day variability of blood pressure and we have had to allow for the effects of age by a device which is probably valid when it is applied to large numbers but not so accurate for individuals. By contrast, height shows quite insignificant variations from day to day and for a considerable span of adult existence is uninfluenced by age. The difference between the size of the genetic factor in blood pressure and height is probably less than regression coefficients suggest. Even so it would seem justifiable to conclude that environmental factors are more important than hereditary factors in the pathogenesis of hypertension.

These considerations lead to one further idea which is so revolutionary that I merely lay it before you knowing that your minds must instinctively reject it namely that the current concept of essential hypertension as a specific disease entity is largely an artefact. I venture to suggest that a restatement of the facts would define essen

tial hypertensives as that group of the population with arterial pressures exceeding a certain value arbitrarily selected and in whom no specific cause can be detected to account for the high pressure. It is suggested that the factors causing it are factors operating generally on the population. Of these factors the contributions of age, sex and inheritance can be defined approximately. The influence of environmental factors which would seem by exclusion to be of great importance, remains to be explored.

We do not believe that this idea is so revolutionary, having entertained it for many years (29, 31, 4). In Chapters V and VI will be discussed the factors operating generally on the population. In Chapter III this curious, ill defined but well known vasomotor manner of reacting which varies from individual to individual. These factors can now be examined separately.

CLINICAL IMPLICATIONS

Since persons predisposed to hypertension emotionally react to environmental stresses through somatic pathways by vasospasm, in the very earliest stages of the disorder some reversal of the somatic response can be expected if reversal of one or more of the psychic components could be accomplished. Many attempts to do so have been made. Psychotherapy has been extensively employed in young individuals without organic disease it may teach the person either to avoid emotional stresses to sidetrack the reactions thereto along other pathways or to resolve them without somatic reaction by means of logic and insight. In patients of older ages, with somewhat more advanced hypertension or with organic changes, however little in the way of therapy can be expected. By analogy, while psychotherapy of peptic ulcer is useful to promote healing and to prevent further attacks it is useless in relieving

pyloric obstruction with scarring secondary to repeated attacks. These defects of personality however are probably so deep-seated and fundamental to the growth of the individual that complete rebuilding becomes most difficult except in young people. In our experience psychotherapy has failed to modify the course of severe hypertension sufficiently to allow us even to suspect some beneficial somatic effect and we have often watched patients deteriorate to eventual death in spite of the most vigorous forms available (an analyst reanalyzed by an analyst).

An environment considered unfavorable by the individual may be altered by moving to a new one. Temporary effects upon the course of moderate and mild stages have been observed. The familiar fall in blood pressure when patients enter the hospital is an example. How permanent this change can be is not known. Minor adjustments in adverse environments especially those caused by other individuals with whom the patient is in close contact may for a time alter emotionally induced stresses (Figure 2).

Drugs especially sedatives have been employed for many years for the purpose of suppressing the emotional tension and lowering the threshold of reactions to stress. As a general rule the more severe the hypertension the less effective are sedative drugs and other such influences upon the disease. Contrariwise the milder the hypertension the more effective are measures aimed at the psyche and the emotional disturbance.

The effects upon the course of hypertension of any one or combinations of the above approaches is directly proportional to the relative influence of these factors in the total picture. Psychosomatic diseases may start as functional derangements mediated through autonomic nerves and end as organic conditions causing death. Therefore while the beginning may lie in the psyche as exemplified by the

word, constitution, that factor becomes increasingly less important as somatic changes occur. In reversible early and very mild stages the disease may be controlled, as its somatic ravages progress less and less can be expected from attacks upon these etiological factors. Alterations of




FIG. 2 Typical rapid fall of blood pressure after hospitalization. E. E. was a 39 year-old woman who was first discovered to have an elevated blood pressure six years previously at the time of pregnancy complicated by pycelonephritis. During the intervening years her blood pressure was always elevated in a physician's office. Six months and one month prior to admission she suffered two attacks of severe headaches, numbness and weakness of one side of her body and loss of consciousness for one to three hours with gradual recovery during the following week. Her blood pressure was said to have varied between 230/130 and 210/110 mm. Hg for 2 years. She complained of dyspnea on exertion and dizziness. On examination there was one small retinal hemorrhage. Blood pressure was 238/136. Her heart was enlarged to the left in x-ray photographs. Renal function was excellent. No cause for the attacks was discovered on careful neurologic examination. The first pressure shown (230/130 mm. Hg) was measured by both the intern and assistant resident the night of admission; subsequent ones were measured by nurses beginning the following morning. (From Schroeder H. A. and Perry H. M. Jr. *Am Heart J*, 51:776, 1956.)

disturbed emotional and nervous functions cannot be expected to dissolve scar tissue

Although Bays and Scrimshaw disagree (32) from all the evidence available we can be fairly certain that hypertension not secondary to renal disease is a disorder fairly well confined to persons exposed to the influences of Western Civilization (4) For example it is unusual in parts of Africa (33) and China (8) very prevalent in American Negroes but rare in American Indians in the Southwest (34) In Uganda only 2.6 per cent of autopsied cases of heart failure were due to essential hypertension the same percentage to atheromatosis and none to coronary thrombosis renal hypertension however, accounted for 16 per cent (35) Surely one is led to conclude that environmental influences are of the greatest importance for in this country probably half the cases of heart failure are hypertensive in origin When viewed from this outlook many discrepancies in the geographic incidence of hypertension fall into line

Comment There are three apparent facts upon which one can speculate

- 1 The predisposition to hypertension is inherited
- 2 There is an emotional overlay in the disease which may be either primary or secondary
- 3 The disease is confined more or less to civilized or partly civilized people without any particular ethnic cultural or social pattern suggesting that environmental factors such as food habits or contact with industrialized society plays an initiating role

Chapter III

NEUROGENIC EFFECTOR MECHANISMS

INTRODUCTION

WHILE yet unproven it seems clear that the sympathetic nervous system is somehow relatively or absolutely overactive in prehypertensive and hypertensive states, especially when there is no demonstrable organic renal component. The indirect evidence, suggesting rapid alterations in the nervous control of blood vessels is as follows:

1 The blood pressure is labile and widely variable (Fig 3)

2 Traube Hering and respiratory variations in blood pressure are often marked (36-37) (Fig 4)

3 The vasospastic response to painful stimuli and to emotion is often exaggerated (20-38-41)

4 The pressor effects of central vasomotor stimuli such as inhalation of carbon dioxide and holding the breath is often increased (42-44)

5 Blocking sympathetic nerves by drugs or surgery abolishes many of these exaggerated vasospastic responses to pain and emotion (45, 46)

6 Drugs acting partly on the central nervous system lower the blood pressure more or less (*vide infra*)

7 Sustained hypertension can be produced in certain animals by interfering with sympathetic and cerebral nervous mechanisms (47-50)




Fig. 9 Daily and nightly fluctuations of supine blood pressure in an 18-year-old man in the prehypertensive phase. His kidneys and heart were normal by all tests. Note that the rise in pressure occurs only during the day. The divisions between each 24-hour period are at midnight.

The evidence against neurogenic effector mechanisms operating in sustained human neurogenic hypertension is poor and usually explicable by an analysis of the cases employed for experimentation or by an understanding of the processes concerned in neurogenic vasoconstriction. At present no one doubts the existence of neurogenically induced vasospasm in man. We must emphasize, however, that in chronic human arterial hypertension the relative parts played by neurogenic and other mechanisms vary considerably from patient to patient (Chapter IV). The contrary evidence follows.

1. Little or no increase in urinary catechol amines is usually found (11). Norepinephrine, however, is liberated at nerve endings and metabolized or conjugated *in situ* before its products reach the blood stream. Therefore overproduction must be great enough to saturate oxidative and conjugative enzymes in order to allow enough to spill

Chapter III

NEUROGENIC EFFECTOR MECHANISMS

INTRODUCTION

WHILE yet unproven it seems clear that the sympathetic nervous system is somehow relatively or absolutely overactive in prehypertensive and hypertensive states especially when there is no demonstrable organic renal component. The indirect evidence suggesting rapid alterations in the nervous control of blood vessels is as follows:

1 The blood pressure is labile and widely variable (Fig 3)

2 Traube-Hering and respiratory variations in blood pressure are often marked (36, 37) (Fig 4)

3 The vasospastic response to painful stimuli and to emotion is often exaggerated (20, 38, 41)

4 The pressor effects of central vasomotor stimuli such as inhalation of carbon dioxide and holding the breath is often increased (42-44)

5 Blocking sympathetic nerves by drugs or surgery abolishes many of these exaggerated vasospastic responses to pain and emotion (45, 46)

6 Drugs acting partly on the central nervous system lower the blood pressure more or less (*vide infra*)

7 Sustained hypertension can be produced in certain animals by interfering with sympathetic and cerebral nervous mechanisms (47-50)








FIG. 4 Spontaneous variations in blood pressure measured photokymographically by direct arterial puncture W D F normal and normotensive variation 9.6 mm Hg F T normotensive convalescent from severe acute poliomyelitis with probable slight involvement of the hypothalamus or medulla giving rise to neurogenic vasomotor instability variation 41/20 mm Hg W D fairly severe neurogenic hypertension variation 13/12 mm Hg I H severe neurogenic hypertension variation 32/20 mm Hg W D (repeat after several days rest) variation 7.5 mm Hg C O mild neurogenic hypertension variation 49/95 mm Hg B indirect measurement C O = systolic pressure when taken by a white coated physician varied from 180 to 240 mm and her diastolic from 150 to 100 mm nurses always obtained readings 20 to 30 mm lower. The wide fairly regular tracings are those of respiration the smaller ones of a plethysmograph on the finger. Camera speeds 120 mm and 20 mm per second.



FT ♂



Several influences arising in the brain can cause experimental hypertension such as noise (54) internal hydrocephalus (46) puncture of the third ventricle (55) tying off the arterial supply (49) all of which may interfere with blood flow or nervous function in a regulatory area. Similarly in man increased intracranial pressure certain brain lesions of viral vascular or traumatic origin (fractures of the base of the skull encephalitis poliomyelitis) certain tumors and hypothalamic injury can lead to chronic neurogenic hypertension or its acute equivalent (56)

There are four possibilities to explain the cerebral role in human hypertension 1 The nervous temperament of the hypertensive person with the frequent finding of anxiety and frustration may initiate repetitive discharges through the sympathetic nervous system Subnormal assertiveness obsessive-compulsive traits and anxiety are said to be common to the hypertensive personality (26 27) This hypothesis has always been an attractive one but is unproven and most difficult to investigate with the tools at hand

2 The peripheral metabolic abnormalities associated with hypertension may cause stimulation of cerebral metabolism It is known that many primary amines cause central excitatory effects Amphetamine (Benzedrine) is a good example In fact Mann and Quastel (57) suggested that the central stimulant action of *dl* phenylisopropylamine (Amphetamine) is related to its inhibition of tyramine oxidation by amine oxidase in brain On this basis Fellows and Bernheim (58) examined a large number of structurally related salts in rats and found in many instances good correlations between central stimulation and cerebral amine oxidase inhibition Clinically the excitatory actions of epinephrine and a number of derivatives are well known we have observed profound and

over into blood and be excreted in urine. Actually some patients do have moderately increased amounts in their urines (51b) about a third.

2. No increase in circulating catechol amines can be detected (38).

3. Many patients do not show all of the typical exaggerated pressor responses nor the marked depression of blood pressure induced by drugs or surgery (52). The logical explanation is that another vasospastic process is largely operative in such individuals.

"Although neurogenic pathways effecting vasoconstriction are intimately connected it is necessary to examine each component of the sympathetic nervous system in the light of its role and of specific effector substances and chemotherapeutic agents. Some of these are known, some must be postulated. The brain and its appendages exert a profound effect upon normal vasomotor tone and are probably involved in many forms of generalized vasospasm." As Starling said (53): "No pathology will be adequate which does not take into account the sensitiveness of the vasomotor centers to the changes in the circulation." Considerable information on pathogenetic factors can be learned from the actions of specific drugs, more perhaps than by direct experiments.

CEREBRAL MECHANISMS

The areas within the brain initiating or transmitting sympathetic discharges or regulating vasomotor tone are three: the cortex, the hypothalamus, and the vasomotor center. Just how these areas are involved in the hypertensive process is not known. What is known, however, is that certain drugs modify their activities and partly affect the amount of peripheral vasospasm neurogenically induced.

the hypothalamus or vasomotor center may initiate somatic sustained neurogenic pressor responses. While such lesions have been found in some cases (64) and may account for the hypertension of some older persons, there is no uniform correlation with all cases and this idea remains merely an attractive hypothesis.

SPECIFIC DRUGS

Whatever the cause of the increased nervous excitability of hypertensive patients, many agents have been used to counteract it and thus produce variable effects upon blood pressure depending upon a) the relative part played by the brain, b) the effectiveness of the drug, and c) the ability of the patient to tolerate side effects. Sedatives have been used for many years in an attempt to allay tension and anxiety. They will not be discussed since their employment is wide.

Serotonin Antagonists Reserpine causes depletion of cerebral serotonin in the experimental animal (65-66); platelet serotonin is also reduced to a low level. The net effect of this agent, a chemical analogue of yohimbine, is to produce an effect the equivalent of a prefrontal lobotomy (67). Its locus of action appears to be prehypothalamic and subcortical, the posterior hypothalamus wherein lie the sympathetic centers, is partially blocked (68). The effect of the drug is cumulative, requiring a week or two for oral doses to act maximally, although rapidly excreted; the drug itself leaves serotonin receptors in the brain blocked for long periods. Aside from its tranquilizing action, the net somatic effect is that of relative parasympathetic overactivity (Table I). Diarrhea and gastric hyperacidity can result; peptic ulcer has appeared de novo or become activated in one of our cases; chronic ulcerative colitis has developed (69). Various cerebral symptoms are

uncontrollable anxiety induced by intravenous isoamyl amine in laboratory workers, for example. Therefore, some circulating primary amines may induce cerebral stimulation. Fast diffuse dysrhythmias in the electroencephalograms are common in human neurogenic hypertension (4). This picture can be produced by certain amines (59). Thus, a vicious circle could be established, from periphery to brain to periphery, the initiating organ not being known.

Serotonin, a derivative of tryptophane, has received the greatest interest in this regard, since its isolation from platelets. This primary amine occurs in brain and may have a definite function in nervous tissue (60), as may other similar substances. It is interesting and perhaps more than coincidental, that malignant carcinoid of the appendix, a serotonin producing tumor, apparently causes a peculiar flushing phenomenon which is similar to the diencephalic blush which we associate with neurogenic hypertension (61, 62). Injection of serotonin in man causes a variety of subjective symptoms not apparently associated with anxiety but similar in some respects to those seen following other substituted primary amines (63). The role of several tertiary and quaternary nitrogenous compounds on nerve conduction and synaptic transmission is barely beginning to be appreciated.

3. There is either excessive production of stimulating substances *in situ* or generalized inhibition of those enzymes concerned with metabolizing such substances. For example, if every sympathetic nerve ending contained a molecule inhibitory to amine oxidase or to the enzyme conjugating norepinephrine, the normal tone of sympathetic nerves would be enhanced. There are no proofs of this theory.

4. Local vascular lesions of an arteriosclerotic nature in

TABLE 1—(continued)

	Reserpine (123 subjects)	Chlorpromazine (137 subjects)
Epistaxis	24	0
Blurred Vision	0	15
Dry Mouth	0	15
Heart Burn	0	15
Edema	73	51
Pruritus	16	15
Dermatitis	0	95
Jaundice	0	51
Hepatomegaly	0	22

also induced among them vivid dreams and nightmares. One of the most interesting of its actions is to cause, in a sizeable percentage of people nervousness, insomnia, agitated depressions and suicidal tendencies (70). Used to treat these symptoms in psychotic individuals it can backfire and produce them. Truly this most interesting drug has begun to open up a wide field in our understanding of mental illness.

Chlorpromazine is also an antagonist to serotonin (73). Its locus of action has been presumed to lie subtentorially, probably in the medulla. Tranquilizing effects are seen as well and hypothalamic action has been postulated (74). While it can cause some depression of the sympathetic nervous system it can also produce symptoms of stimulation in some individuals (Table I) with hypertension and tachycardia. Likewise its antiemetic action may be reversed in other subjects.

Other antimetabolites to serotonin are not used in hypertension: yohimbine because of its nephrotoxicity and diisergic acid diethylamide which produces schizophrenic-like states (63-66). The most interesting are the nitroindoles which are true competitive antagonists blocking

TABLE I
RESERPINE AND CHLORPROMAZINE
INCIDENCE OF SIDE REACTIONS AND TOXIC EFFECTS IN
NORMOTENSIVE PATIENTS

	<i>Reserpine</i> (123 subjects)	<i>Chlorpromazine</i> (137 subjects)
<i>Sympathetic N S Inhibition</i>		
Hypotension	31.6	14.6
Bradycardia	17.0	3.7
Diaphoresis	1.6	0
Chilliness	3.3	0
Nausea	5.7	7.3
Vomiting	2.4	5.1
Diarrhea	7.3	0.7
Exacerbation of Peptic Ulcer	0*	0.7
<i>Sympathetic N S Stimulation</i>		
Hypertension	0	6.6
Tachycardia	0	8.8
Hyperthermia	0	3.7
<i>Cerebral Symptoms</i>		
Excessive Flushing	9.0	0
Dizziness	5.7	5.1
Fatigue weakness	9.7	2.2
Syncope	1.6	0.7
Excessive Drowsiness	17.8	12.4
Tremulousness	15.4	0.7
Myalgia	3.3	0
Ataxia	5.7	0
Parkinsonism	1.6	0.7
Vivid Dreams	2.4†	2.2
Agitated Depressive Psychosis	±5‡	
<i>Other</i>		
Nasal Stuffiness	27.6	1.5

* We have seen 4 cases

† Higher in our experience

‡ Author's series

(From Zeller W W Graffagnino P W Cullen C F and Reitman H J Use of chlorpromazine and reserpine in the treatment of emotional disorders *J A M A* 160 179 1956)




FIG 1 Metabolism of serotonin, modified from Sjoerdsma et al (61)

phane and its decarboxylation (Fig 5). The hydroxylase has not been discovered but the renal decarboxylase (71) contains a pyridoxal metal complex as a coenzyme (72) like many other amino acid decarboxylases. Serotonin is metabolized by monamine oxidase (Chapter IV) an enzyme requiring oxygen and sensitive to oxygen tension. Therefore renal ischemia could allow the formation of serotonin by anaerobic decarboxylation but prevent deamination *in situ* due to oxygen lack. Serotonin would then escape into the blood and be deaminated either in the lungs or on arterial smooth muscle. While it is doubt

the action of serotonin on smooth muscle, they have not been employed more than sporadically with little effects

A newer sedative, 2 methyl 2 n propyl 1,3 propanediol dicarbamate (meproamate) apparently selectively blocks interneurons primarily on the thalamus and caudate nucleus (75) There is little or no effect upon the autonomic nervous system This drug should therefore prove a tool for controlling anxiety in mildly hypertensive patients and thus estimating the role which nervous tension *per se* plays in minor elevations of blood pressure

Comment None of these agents are more than mild antihypertensive drugs One or another may control moderate or intermittent elevations of blood pressure, especially when associated with emotional tension, but they are relatively valueless, except as adjuncts, in more severe cases Obviously the sustaining mechanism for severe hypertension lies elsewhere than in the brain, although initiating mechanisms may be there, in cerebral edema, however, a large neurogenic influence may be exerted The most potent and specifically acting drug can do no more than inhibit the relatively minor role which the brain contributes to the process of generalized vasospasm Even after destruction of much of the brain by atherosclerotic disease, to the point of causing a vegetative existence, established hypertension may not disappear

Serotonin is one of the newest agents discovered to be involved in cerebral interneurone transmission Of great interest is the fact that this primary amine apparently has a specific affinity for cortical pathways to the posterior and lateral hypothalamus (Too much could stimulate and cause emotional tension a normal amount interest, initiative and drive, while too little could result in mental depression) Serotonin is found in quite primitive marine organisms, it is formed by the hydroxylation of trypto-




Fig. 11 Metabolism of serotonin modified from Sjoerdama *et al* (61)

phane and its decarboxylation (Fig 5). The hydroxylase has not been discovered but the renal decarboxylase (71) contains a pyridoxal metal complex as a coenzyme (72) like many other amino acid decarboxylases. Serotonin is metabolized by monamine oxidase (Chapter IV) an enzyme requiring oxygen and sensitive to oxygen tension. Therefore renal ischemia could allow the formation of serotonin by anaerobic decarboxylation but prevent deamination *in situ* due to oxygen lack. Serotonin would then escape into the blood and be deaminated either in the lungs or on arterial smooth muscle. While it is doubt

ful that serotonin is concerned directly in hypertension, injections into hypertensive, but not normotensive animals and man are moderately pressor, and this interesting substance in slightly increased amounts could represent an abnormal metabolite causing some symptoms and a small portion of the vasospasm

CAROTID SINUS MECHANISMS

There is no good evidence that the carotid sinus mechanism is underactive in the usual case of hypertension. Chronic sustained hypertension can be produced in dogs however, by ablation of the carotid sinus and aortic depressor nerves (76) while this state is true neurogenic hypertension, after several years the renal lesions of arteriolar nephrosclerosis develop (7). In our experience, this form of hypertension is not dependant solely upon increased cardiac output as there is intense peripheral vasoconstriction under anaesthesia (10). A clinical counterpart may be suspected in patients with atherosclerotic narrowing of the mouths of the innominate and left common carotid arteries. That an appreciable degree of narrowing is uncommon may be suspected from the clinical observations that symptoms of severe cerebral ischemia do not usually follow reduction of elevated blood pressure to normal that some degree of obstruction may occasionally be found as suggested by the vague discomfort accompanying normotension seen in many atherosclerotic hypertensive individuals (While hardening of the carotid sinus wall and local atherosclerotic narrowing have been suggested (77) these lesions are unproven as causes of chronic hypertension).

Specific Drugs There is a group of drugs from plants of the *veratrum* family which do affect the carotid sinus sensitizing the pressor receptors and thus increasing the activity of the depressor mechanism (78). Protoveratrine

A and B are the most purified alkaloids usually found in a mixture and most difficult to separate. They cause depression of blood pressure and bradycardia, nausea and vomiting may result from vagal stimulation (79). The pathway is through the glossopharyngeal nerve to the vasomotor center (78). When doses are adjusted properly, intermittent normotension can result from the careful use of protoveratrine and its impure derivatives (80). Apparently tolerance is quick to appear and disappear, so that sustained normotension will not result unless adjuncts operating on other mechanisms are used. Whether or not this drug is a true antihypertensive agent affecting the basic process is unclear, although the hemodynamic response is quite favorable (Table II).

Baroreceptor Changes McCubbin, Green and Page (81) have recently shown that the carotid sinus and aortic depressor mechanisms are set at a higher level of pressure in renal hypertensive dogs than in normotensive dogs. They propose (the ingenious theory that this higher setting maintains the hypertension) even when the initiating mechanism (renal ischemia, pheochromocytoma, toxemia of pregnancy) is removed. Thus (renal hypertension slowly becomes neurogenic) buffer nerve hypertension, as Ogden has suspected in rats (82). If this were so in man, one would expect that late chronic hypertension would respond to the use of drugs or surgery acting on nerves better than would early hypertension. Clinically, the opposite holds true; therefore, this attractive hypothesis necessarily can be discarded as applying to most human cases.

SYMPATHETIC NERVOUS MECHANISMS THROUGH GANGLIA

All autonomic nerves after emergence from the spinal cord pass through ganglia. In general, sympathetic nerves

TABLE II

CARDIOVASCULAR EFFECTS OF PROTOVERATRINE AND GANGLIONIC BLOCKING AGENTS IN MAN

	Normal		Hypertensive	
	Epinephrine	Norepinephrine	Protoneratrine	Gan- glionic Blockade
<i>Cardiac</i>				
Heart Rate	+	-	-	-
Stroke Volume	+	+	+	-
Cardiac Output	+	0	0	-
Coronary Blood Flow	+	+	?	?
<i>Blood Pressure</i>				
Systolic Arterial	+	+	-	-
Mean Arterial	+	+	-	-
Diastolic Arterial	-	+	-	-
Mean Pulmonary	+	+	?	-
<i>Peripheral Circulation</i>				
Total Peripheral Resistance	-	+	-	-
Cerebral Blood Flow	+	0-	0	0
Muscle Blood Flow	+	0-	+	+
Cutaneous Blood Flow	-	+	?	+
Renal Blood Flow	-	-	0	-*
Splanchnic Blood Flow	+	0	?	-

* Transient

thetic nerves end in ganglia at more peripheral (organ) areas. The adrenal medulla receives preganglionic fibres which cause discharges of epinephrine, a sympathetic effector substance, into the circulation; therefore it may be considered a ganglion in the broadest sense of the term.

The chemical mediator of ganglionic transmission is a quaternary ammonium compound, acetylcholine. Whether or not other compounds containing tetravalent nitrogen

or choline esters can act as transmitters is not known. Acetyl choline (or its derivatives) apparently is essential for synaptic transmission in all ganglia both sympathetic and parasympathetic. Nicotine in small doses is a stimulant.

The ganglion itself governs the integrity of the postganglionic fibres much as the spinal nuclei control the integrity of their neurons. Removal of a ganglion is probably followed by degeneration of the nerve after a few days sensitivity of the nerve ending to circulating vasoconstrictor substances develops. Therefore in order to perform an adequate sympathectomy preganglionic fibres must be cut.

Specific Drugs Chemical ganglionic blocking agents usually contain quaternary ammonium stabilized tetra covalent nitrogen competing with acetyl choline or other more labile nitrogenous substances. Numbers of such compounds exist. The simplest one of the group is tetraethyl ammonium ion known for many years as a vasodilating drug of short action. Longer action is achieved by lengthening the carbon chain and doubling the nitrogen group (pentamethonium pendiomide hexamethonium) or by adding cumbersome ring structures (pentolinium chlorisondamine). All act in a similar manner differing only in duration of action and degree of gastrointestinal absorption. A new blocking agent mecamylamine (Inversine) differs considerably in structure being a complex spatial molecule with trivalent nitrogen as a secondary amine. It has the advantage of virtually complete absorption from the gastrointestinal tract (83). Comparative doses are shown in Table III (Fig 6).

Since acetyl choline also mediates nerve transmission to striated muscle it may appear strange that curariform

paralysis does not result from ganglionic blocking agents. Some anatomical or chemical differences between ganglia and motor end plates undoubtedly exist, for hexame



Tetraethyl Ammonium (TEA)





Pentamethonium (C_5)Hexamethonium (C_6)

FIG. 1 Structural formulae of ions of some ganglionic blocking agents. The salts are not shown. The last known as Arfonad is only used intravenously. Note the quaternary or tetravalent nitrogen groups which are the active ones and the camphane structure of those with trivalent nitrogen.

TABLE III
COMPARATIVE DOSES OF GANGLIONIC BLOCKING AGENTS (SEVERE ADULT HYPERTENSION)

Ion	Usual Effective Oral Dose		Maximum Tolerated Oral Dose		Duration of Action of Oral Drug hrs	Usual Effective Parenteral Dose†
	Single Dose mg	Daily Dose mg	Single Dose mg	Daily Dose mg		
Tetraethyl Ammonium	†	†	†	†	1-1	500
Pentamethonium	500	2500	?	?	3	25
Hexamethonium	500	2500	1000	6000	4	25
Pentolinium (Ansoless)	100	500	800	4000	4-5	25
Chlorisondamine (Ecolid)	50	250	200	1000	4-6	15
Mecamylamine (Inversine)	10	50	25	150	4-8	10

* When combined with hydralazine

† Sublingual doses effective oral not

‡ Initial dose much smaller Wide variation as tolerance develops

thonium ion in large doses can exhibit curare like actions. Lengthening of the carbon chain to 10 atoms results in a curariform drug, decamethonium. Curare itself contains tetravalent nitrogen, and succinyl choline has a similar action (84). The longer the chain from 5 to 10 carbon atoms, the greater is the paralytic effect.

The cardiovascular effects of ganglionic blockade are summarized in Table II. Thus, ganglionic blockade while lowering blood pressure, does not act primarily upon all of the functions disturbed in hypertension. Furthermore, sympathetic nervous inhibition at the ganglionic level is also associated with parasympathetic nervous inhibition. Renal and splanchnic blood flow are altered in the wrong direction. Continuation of these disturbances could cause serious consequences, were it not for some unknown readjustments which take place within the organism counteracting the changes. While the effects of these agents in opposing the hypertensive process are real and offer evidence for the role of the sympathetic nervous system in pathogenesis, they are not all to be desired. Presumably they differ from the effects of surgical sympathectomy. The subject of the specificity of these drugs on the basic processes concerned in vasospasm is open and arguments pro and con the question of whether or not the observed effects are truly antihypertensive have validity on both sides.

SYMPATHETIC NERVE ENDINGS

The chemical effector substance of the sympathetic nerves is norepinephrine. On stimulation of a nerve, this primary amine is released at the junction of nerve and organ or smooth muscle fibre. Infusion of norepinephrine intravenously mimics the cardiovascular profile seen in sustained arterial hypertension (Table II) and a similar

"picture is caused by norepinephrine secreting pheochromocytomata. Therefore the neurogenic component of hypertension can be considered to be mediated by this substance."

Norepinephrine is derived either from dihydroxyphenylserine by decarboxylation or from tyramine by hydroxylation of the benzene ring and the β -carbon. The first appears the most facile method for the nerve ending to make this substance rapidly. It is inactivated either through conjugation through oxidation of the amine nitrogen by monamine oxidase or by rearrangement of its molecule to form an indole nucleus through oxidation by polyphenol oxidase, a copper enzyme.


The ideal agent for counteracting norepinephrine has not been found. There are a number of sympatholytic drugs which inhibit its action on nerve endings and which are effective for short or longer periods in experimental animals. We list them only as directions for research. These may be grouped roughly as derivatives of benzylamine or phenethylamine or ergot or benzodioxane and of imidazole (Table IV see page 48). All contain tertiary substituted nitrogen.

Derivatives of Benzylamine. Dibenzamine, a complex structure remotely related to norepinephrine, forms tight bonds at sympathetic nerve endings, preventing the action of this constrictor substance, probably by competitive inhibition. The action is prolonged for many hours. It is moderately effective by mouth, much more so intravenously. There are many side effects in man, especially on the brain. Dibenzamine and its relatives are the most effective sympatholytic agents known at present, but their value in hypertension remains to be proven.


Derivatives of Phenethylamine. We had an opportunity of testing a group of primary amines in rats for sympath

olytic qualities, some of which were given intravenously in man


Those blocking norepinephrine in the rat had the following formulae




SKF 1298 A



SKF 669 C




Mer 11




Norepinephrine


The nitrogen in these compounds was completely substituted all being tertiary amines. There was, however, no consistency in the results for the following gave no blocking action







SKF 690 A



SKF 1222





Renal hypertensive dogs responded by a lower diastolic pressure only when SKF 1298-A was given * SKF 690 A was a powerful epinephrine like substance in man causing vasodilatation and an increased cardiac output with fall in diastolic pressure SKF 1298-A caused symptoms suggestive of cholinergic stimulation two others were without effect

The experiments of Furchgott are of interest Using the spirally cut rabbit's aorta as a source of smooth muscle he was able to show on this simple system how certain agents such as dibenamine block all constrictor amines others block some and others block only a few (85) Therefore it is likely that very specific agents can be found which will pick out one primary amine and not others for inhibition

None of these substances specifically depressed elevated blood pressure in the anesthetized renal hypertensive rat without affecting normotensive rats.

TABLE IV

ACTIONS OF ADRENERGIC BLOCKING AGENTS IN MAN*

Function	Dihydrogenated Ergot Alkaloids		Phenolamine and Tolazoline		Ben odioxanes
	Diben- zyl- amine	Epinephrine	Both	Epinephrine	Epinephrine
Principal Action on Epi or Norepinephrine	Both	Unchanged or Decreased	Unchanged	Decreased?	Decreased?
Cardiovascular	Unchanged	Increased	Increased	Unchanged	Unchanged ?
Cardiac Output	Unchanged	Decreased	Decreased	Decreased transiently	?
Blood Flow—Femoral	Unchanged	Unchanged	Unchanged	Decreased	Constricted
—Mesenteric	Unchanged	Constricted	Constricted	Dilated	Variable
—Renal	Unchanged Dilated ?	Decreased	Decreased ?		
—Cerebral	Decreased				
Coronary arteries					
Peripheral Resistance					
Principal Adverse Effects					
Central Nervous Stimulant	+	+	+	0	+
Tachycardia	+	+	+	0	+
Tissue injury local	+	+	+	0	0
Nausea and Vomiting	+	+	+	0	0
Duration of Action	Days	Hours	Minutes	Minutes	Minutes

* After Goodman and Gilman (84)

Derivatives of Ergot The dihydrogenated ergot alkaloids have the ability of blocking adrenergic impulses but their action is greater on epinephrine than on norepinephrine. Toxic effects limit the tolerable dose so that useful blockade is rarely produced. They must be given sublingually or parenterally; their effects in hypertension vary but are usually inconsistent.

Derivatives of Imidazole Tolazoline (Priscoline) and Phentolamine (Regitine) are two short acting moderately effective adrenergic blocking agents containing both benzene and imidazole rings. Phentolamine while opposing the actions of both epinephrine and norepinephrine is useful for the most part only as a test substance for circulating catechol amines. It usually causes a transient fall of blood pressure in hypertensive patients suggesting that some sympathetic tone is present. In azotemia the effect may be prolonged and profound. Cardiac stimulation is the rule. Tolazoline is readily absorbed and excreted unchanged in the urine. Phentolamine is apparently metabolized up to 90 per cent of the dose. The short durations of action limit their use.

The Benzodioxanes Piperoxan (Benodaine) and pro-sympal first synthesized by Fourneau act transiently usually by vasoconstriction. They do oppose however the action of epinephrine probably by competitive inhibition. Norepinephrine is blocked only by toxic doses. Side effects are many especially smooth muscle stimulation and limit their use except in epinephrine producing pheochromocytomas.

Comment All of the known adrenergic blocking agents fail to block cardiac accelerator mechanisms. Tachycardia and increase in cardiac output of reflex origin limit their clinical uses. In all cases blockade of injected or circulating

vasoconstrictor amines is greater than is the blockade of nerve impulses, dibenamine has less differential activity in this respect. The ideal agent for chemical sympathectomy is one which prolongedly blocks norepinephrine at all vascular nervous endings including especially those in the heart. This agent has not been found, if it can be it should prove the best agent for controlling the neurogenic factor in human hypertension.

Other Effector Substances While the role of other sympathomimetic amines in hypertension is not established they are probably present in excessive amounts and may contribute to symptoms if not to vasospasm. Decarboxylation of amino acids by kidney is an anaerobic process (86, 87) while deamination is an aerobic one (88) the enzymes monamine oxidase and possibly diamine oxidase being sensitive to oxygen lack (89). Under these conditions any amino acid decarboxylated by the kidney could form amines by partial interrupted metabolism, altering the locus of deamination from kidney to peripheral smooth muscle or liver. The level of primary amines in hypertensive blood is usually high (4, 90, 91). This error of metabolism will be discussed at length in Chapter IV.

CLINICAL IMPLICATIONS

In the absence of a good specific adrenergic blocking agent which also blocks the cardiac sympathetics we are forced to use combinations of drugs depend upon ganglionic blockade or affect the carotid sinus mechanism. Combinations of adrenergic blocking agents such as dibenamine derivatives and protoveratrine have been advocated the former to block nerve endings and the latter to slow the heart. In fact one such preparation also contains reserpine, which tends to cause bradycardia. Such

pousse café combinations are to be avoided all drugs give reactions and side effects and it would be difficult to assess the vomiting induced by dibenamine and that by protoveratrine in such a mixture

The toxic or side reactions of reserpine and chlorpromazine have been given in Table I The most serious late toxic reactions of reserpine are those of agitated depressive psychosis which are often accompanied by suicidal tendencies and may lead therefore to death Of chlorpromazine there are hepatic disease and granulocytopenia some 17 deaths have resulted (92) Chronic administration of any drug given to control not cure a chronic disease may back fire Furthermore in severe hypertension the use of mild drugs is potentially dangerous giving the physician a sense of security while the disease continues relentlessly on its ravaging course

There are no known late toxic reactions to protoveratrine Immediate side effects are those attributable to vagal stimulation i.e. nausea and vomiting The rapid development of partial tolerance in a few hours with restoration of sensitivity after a few hours rest is unexplained

Ganglionic blocking agents show many side effects most of them the result of parasympatholysis or sympatholysis (Table V) Only two serious ones of this nature have been encountered The first occurs when partial often asymptomatic obstruction to a hollow organ has been present Complete obstruction may result The second is concerned with the mode of excretion Absorbed blocking agents are excreted in the urine If severe renal disease is present ganglionic blockade may cause hypotension and anuria as the drug is then retained hypotension and anuria persist To set one pharmacologic thief to catch another pharmacologic offender is undesirable in modern chemotherapy

but sometimes it becomes necessary. The activity of cholinergic drugs is enhanced when ganglia are blocked, thus, urecholine and prostigmine provide useful tools in abating unwanted parasympatholysis (98). Likewise norepinephrine infusions combat the hypotension quite effectively.

TABLE V
SIDE EFFECTS OF GANGLIONIC BLOCKADE

Carotid Sinus Reflex	Decreased
Cardioaccelerator nerves	Blocked
Cardiovascular reflexes (cold pres or etc.)	Blocked
Venous pressure	Decreased
Eye—Pupil	Fixed in mid position
—Accommodation	Fixed at normal resting point
Ptoxis	Slight or absent
Ear—Eustachian Tube	Paralyzed?
Salivary secretion	Decreased
Gastric juice acidity and volume	Decreased
Gastrointestinal motility	Decreased
Gastric tone	Decreased
Colonic tone	Decreased
Defecatory Reflex	Decreased
Urinary Bladder tone	Decreased
Sweating	Decreased
Sexual potency (male)	Inhibited
Response to injected norepinephrine	Increased
Response to injected cholinergic drugs	Increased

Mecamylamine intoxication occurs in azotemic individuals and in others with poor renal function. It is characterized by gross, generalized coarse muscle tremor, increased with activity, disappearing with sleep, by nervous tension and sometimes by visual hallucinations. The state resembles delirium tremens. The flapping tremor, which involves all voluntary muscles in advanced stages, is not associated with cog wheel rigidity and only moderate hy

perreflexia is found. The tremor usually remains for many days after discontinuation of the offending drug even as long as two weeks. Severe hyperpyrexia without infection leading to death was observed once. Dilantin may partly ameliorate the condition. It is probable that this secondary amine of a camphor nature affects the central nervous system; camphor itself is convulsant and high doses of mecamylamine cause gross tremors in dogs. We have observed fine tremors occasionally when hexamethonium ion was used. Meprobamate can cause leucopenia.

Ganglionic blockade disease occurs in poorly treated malignant hypertension (93-94-5). It is characterized by excessive tachypnea worsened in the sitting or standing position, diffuse or patchy roentgenologic changes in the lungs with few physical signs and interstitial pulmonary fibrosis at autopsy. Almost all cases have exhibited azotemia (5); the microscopic findings are indistinguishable from uremic pneumonitis. One patient recovered after the use of cortisone; the remainder died.

All of the antihypertensive agents with powerful actions can induce cardiovascular accidents due to the nature of the arterial disease (atherosclerosis) often encountered and too sudden alteration of hemodynamics. Arterial thrombosis is the most serious although it is rare. Such reactions are not true side effects of the drugs themselves but are inherent dangers in their overenthusiastic and careless use.

Summary Because drugs acting specifically on the autonomic nervous system may affect the elevated blood pressure in human hypertension, we may assume that there can be a profound neurogenic component in some cases. This component probably is mediated via sympathetic nerves. Although the ideal counteracting agent is not avail-

able, certain tools can be used with varying results on the course of the primary disorder. All have side effects and most, late toxic reactions, which usually do not preclude their use provided careful attention is paid to the patient and his personal reactions.

Chapter IV

NEPHROGENIC EFFECTOR MECHANISMS

EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

THIS point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence, the following clinical observations are pertinent:

1. Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension little or not at all.

2. Extensive surgical sympathectomy, either lumbodorsal or subtotal, still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degrees.

3. Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many; and no appreciable effects (other than postural ones) in the more severe forms of hypertension.

able, certain tools can be used with varying results on the course of the primary disorder. All have side effects and most, late toxic reactions, which usually do not preclude their use provided careful attention is paid to the patient and his personal reactions.

NEPHROGENIC EFFECTOR MECHANISMS

EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

TO THIS point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence the following clinical observations are pertinent:

- 1 Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension little or not at all.

- 2 Extensive surgical sympathectomy either lumbodorsal or subtotal still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degrees.

- 3 Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many; and no appreciable effects (other than postural ones) in the more severe forms of hypertension.

NEPHROGENIC EFFECTOR MECHANISMS

EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

THIS point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence, the following clinical observations are pertinent:

1. Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension little or not at all.

2. Extensive surgical sympathectomy, either lumbar or subtotal, still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degrees.

3. Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many; and no appreciable effects (other than postural ones) in the more severe forms of hypertension.

4 Injection of tetra ethyl ammonium ion causes transient falls of blood pressure to a floor, this level being low in milder cases and rising as the disease progresses into severe stages. Only in cerebral edema does the floor fall (95)

5 Injections of hexamethonium ion in full doses cause variable responses the estimate of the neurogenic component affected by the drug ranging from 100 to 15 per cent of the total elevation of blood pressure above normal. The less the fall after hexamethonium ion, the higher is the final blood pressure. There is a reciprocal relationship between neurogenic and humoral factors in maintaining the blood pressure high (53) (see Table XIX, p. 110)

THE NATURE OF THE OTHER MECHANISMS

Two processes can be hypothecated to explain these findings

1 The arteries and arterioles become so sclerotic that a mechanical increase in peripheral resistance accounts for the sustained hypertension in the absence of neurogenic mechanisms. This explanation is incompatible with the anatomic and pharmacologic facts. While hypertension causes vascular lesions, they vary in intensity and degree throughout the body. Only late hypertension is associated with these lesions. Reduction in blood pressure of a degree sufficient to cause local ischemia in areas of severe vascular disease usually can be accomplished without such ischemic manifestations.

2 The arteries and arterioles are in a state of spasm which is not mediated through nervous mechanisms. This is the only tenable hypothesis. If so several causes of the spasm must be examined

a) Some organ is forming and discharging into the circulation abnormal substances, which either are strong

vasoconstrictors themselves or which inhibit the destruction of normally circulating pressor substances

b) Some organ is not destroying or excreting pressor substances normally present, so that they accumulate in form a new homeostatic level

c) Some organ is sensitizing the blood vessels to normally circulating pressor substances

d) For some reason the arterial and arteriolar walls become edematous thereby increasing peripheral resistance.

Probably all of these mechanisms can operate under different clinical circumstances

The vast experimental and large clinical experience with hypertension induced by renal ischemia focuses attention upon the kidney as a mediating mechanism for that component of elevated arterial pressure which is not neurogenic in origin. The posterior pituitary however forms a pressor substance and the adrenal cortex can sensitize blood vessels to vasoconstriction therefore endocrine mechanisms must also be considered (Chapter V) In this section we are concerned however with nephrogenic mechanisms

First the effects of sympathetic nervous discharges upon the renal circulation must be examined. Both emotional tension and catechol amines cause renal vasoconstriction abolished in the case of the former by sympathectomy. Curiously enough norepinephrine constricts in so far as is known only the renal circulation to a greater extent than other vascular beds. The hemodynamic profile is similar to that seen in hypertension with efferent arteriolar constriction being dominant. Epinephrine produces the same renal profile. Therefore increased neurogenic sympathetic tone can cause relative renal ischemia but ischemia of no other known organ.

4 Injection of tetra ethyl ammonium ion causes transient falls of blood pressure to a floor, this level being low in milder cases and rising as the disease progresses into severe stages. Only in cerebral edema does the floor fall (95)

5 Injections of hexamethonium ion in full doses cause variable responses the estimate of the neurogenic component affected by the drug ranging from 100 to 15 per cent of the total elevation of blood pressure above normal. The less the fall after hexamethonium ion, the higher is the final blood pressure. There is a reciprocal relationship between neurogenic and 'humoral' factors in maintaining the blood pressure high (53) (see Table XIX, p. 110)

THE NATURE OF THE OTHER MECHANISMS

Two processes can be hypothecated to explain these findings

1 The arteries and arterioles become so sclerotic that a mechanical increase in peripheral resistance accounts for the sustained hypertension in the absence of neurogenic mechanisms. This explanation is incompatible with the anatomic and pharmacologic facts. While hypertension causes vascular lesions they vary in intensity and degree throughout the body. Only late hypertension is associated with these lesions. Reduction in blood pressure of a degree sufficient to cause local ischemia in areas of severe vascular disease usually can be accomplished without such ischemic manifestations.

2 The arteries and arterioles are in a state of spasm which is not mediated through nervous mechanisms. This is the only tenable hypothesis. If so several causes of the spasm must be examined

a) Some organ is forming and discharging into the circulation abnormal substances which either are strong

4 No renin or angiotonin can be found after several weeks of hypertension although the enzyme is present at first VEM in blood however increases with time to a plateau (103)

5 The oxygen consumption of the kidney may be reduced (104)

In kidneys removed from hypertensive rats and dogs the following enzymatic alterations have been demonstrated

1 Amino acid oxidation is reduced (104 105) suggesting a general inhibition of oxidative enzymes

2 Transamination is reduced in the presence of adequate pyridoxal phosphate (104) suggesting a depletion from renal tissue of apotransaminase

3 Deamination of amines is reduced (104) suggesting depletion of monamine oxidase

4 Succinic dehydrogenase and possibly cytochrome oxidase are reduced (105) All of these enzymatic alterations can be explained by loss of renal tissue consequent to prolonged ischemia

✓ In man the following changes have been measured

1 Renal oxygen consumption is usually reduced (106 107) reflecting the ischemia

2 The urine is usually acid (108) reflecting perhaps the acidity of the cortex in ischemia

3 There is a tendency for renal loss of sodium and some chloride (109 110 4) caused in the case of sodium possibly by the acidity producing loss of base

4 The ratio of ammonia to titrable acid is lower than normal influencing possibly the sodium losing tendency of hypertensive kidneys (111)

5 Primary amines in arterial blood are usually elevated (90 91 112) a result perhaps of insufficient deamination from oxygen lack

Removal of one ischemic kidney before hypertension

Second, what metabolic abnormalities are present in renal ischemia? This subject is little understood and alterations little measured. We know of some functional changes in experimental animals. Certain urinary abnormalities occur, reflecting what appear to be minor renal derangements. The cause is reduced blood flow, but whether it is mediated through oxygen lack or through some other mechanism concerned with flow remains to be discovered. In anaesthetized experimental animals the following occur after acute mechanical constriction of a renal artery:

- 1 Cortical oxygen tension falls only to rise again without changing the constriction (96) suggesting intrarenal vasodilatation

- 2 The same changes in blood flow take place. At this point the renal vascular bed becomes sensitive to injected epinephrine (97)

- 3 The cortex becomes acid (96)

- 4 Renin, the renal proteolytic enzyme, is released into renal venous blood where it reacts with a globulin to form hypertensin or angiotonin, a constrictor peptide (99). Likewise, a vaso excitator material (VEM) appears in blood (100). Angiotonin produced by the ischemic kidney, can constrict the vessels of the kidney making it more ischemic (101).

- 5 After several hours blood pressure may rise in the experimental animal (97), probably due to the release of renin and/or pressor amines.

In the dog made hypertensive by partial constriction of a renal artery the following changes have been seen:

- 1 Renal blood flow may be unchanged or decreased (102), but all of the increased resistance is not provided by the mechanical clamp; there is a component of intrarenal vasoconstriction as well, be it neurogenic or humoral (9).

- 2 Oxygen tension is lower than normal (96)

- 3 The cortex is acid (96)

This is more than an academic point. If hypertension were the result of chronic inhibition of a renal enzyme removal of the enzyme or removal of the kidneys would accomplish the same result. The next question is whether a precursor is altered by ischemic kidney into a pressor

G. J. W.




FIG 7 Azotemic hypertension with reversal when azotemia regressed. Patient was a 45-year-old woman with abdominal lymphosarcoma which had involved both ureters causing bilateral hydronephrosis. It was impossible to pass a urethral catheter through the left. Radiotherapy was instituted, resulting in a shrinkage of the tumor, a return of renal function toward normal and a fall of blood pressure occasionally to hypotensive levels.

substance or whether normal kidney inactivates a pressor substance found normally in blood. This question cannot be answered except by reference to the hypertension existing in the presence of one ischemic and one normal kidney. The hypotheses of best fit include both processes: retention of hypertension developing with azotemia and

has persisted for long often relieves the elevated blood pressure. Such experiments suggest that the ischemic kidney was making something new, a pressor substance. At this point there are two apparently diametrically opposing viewpoints. Grollman's experiments show that totally nephrectomized dogs develop chronic hypertension when maintained by peritoneal dialysis or the artificial kidney. He therefore believes that healthy kidneys are necessary to maintain normotension (113). In other words the kidney destroys normally circulating pressor substances, and on its removal (or in ischemic states) these substances arising elsewhere accumulate. The other viewpoint is that the ischemic kidney makes pressor substances not normally present from precursors adding something new. These two opposing theories can be resolved by moving to a more fundamental level.

The kidneys can make vasoactive amines from the proper amino acids. Perhaps by decarboxylation, without deamination, vasoactive peptides can be formed. Obviously nephrectomized dogs cannot make these substances. In azotemia or in the absence of the kidneys however, vasoactive amines are probably formed elsewhere and retained. The humoral substances produced by renal ischemia and those accumulating in the absence of the kidneys are different although both are pressor. The latter are mainly catechol amines for increased quantities have been found in uremic blood and heart muscle. Urinary concentrations are low and regitine and benzo-dioxane lower elevated blood pressure (as in pheochromocytoma) (38). A clinical counterpart is seen in cases of azotemic hypertension where the blood pressure rises only with the blood nonprotein and falls when azotemia is relieved (Fig. 7). Prostatic obstruction is the most common example.

TABLE VI
AMINO ACIDS CAPABLE OF FORMING URINARY AMMONIA*

Amino Acid	Renal Amino Acid Oxidase Present	Renal Diaminase Present	(Dog and Rat)	
			Renal Decar boxylase Present	Renal Amino Oxidase Present
Glycine	+			0
L-Alanine	+			+
L-Leucine			+	+
L-Cysteine			+	?
L-Methionine			?	?
L-Aspartic Acid	?		?	?
L-Asparagine				
L-Glutamine		+		
L-Histidine			+	+
Oxygen required for enzyme	+	0	0	+
No ammonia formed by glutamic acid lyase or arginine				

After Meister (432)

or diamine oxidase which also acts on other diamines such as cadaverine. The remainder are oxidized by monamine oxidase.

Both of these enzymes are found widespread throughout many tissues. The liver is a rich source. Smooth muscle and gut contain them. Their ubiquitous nature is all out of proportion to their known metabolic functions.

The most interesting aspect of monamine oxidase in reference to renal ischemia is its sensitivity to oxygen lack (Fig. 8). Small decrements of oxygen tension inhibit enzymatic activity considerably which is not always the case for other oxidases (89). If this relationship holds in

production of hypertension of the ordinary renal or essential variety

How are these often subtle changes made? What are the enzyme systems concerned? Very little is known, but speculation is rewarding

The Amine Oxidase Theory The kidney is an organ of high metabolic activity with one of the largest oxygen consumptions and blood flows of any in the body. Filtration is a passive process, tubular transport usually an active one. The kidney makes some ammonia from glutamine, thereby providing a base conserving mechanism. Other amino acids undoubtedly contribute their nitrogen groups as well, probably by transamination or deamination*. There are many enzymes in kidney. Of them, decarboxylases of certain amino acids have been described of tyrosine, histidine, dihydroxyphenylalanine (DOPA), tryptophane, leucine and 5 hydroxytryptophane. Decarboxylation is an anaerobic process liberating carbon dioxide from the amino acid and leaving the amine residue.

We do not know for certain that amino acid metabolism takes place in the kidney primarily through decarboxylation (Table VI). The enzymes are found, however, and presumably must act. If they do, they can provide bicarbonate for tubular transport. Interestingly enough, most known decarboxylases are pyridoxal enzymes.

The amine residues of these amino acids are the vasoactive substances: tyramine, histamine, dihydroxyphenyl ethylamine, tryptamine, isoamylamine and serotonin. Histamine is deaminated by a special enzyme, histaminase

* There is little or no L amino acid oxidase in mammalian kidney. Glycine oxidase is found, but for other amino acids to donate ammonia requires either transamination to form glutamine or the two phase reaction: anaerobic decarboxylation and then oxidative deamination by monoamine oxidase.

that passed would be distributed to all vascular organs and tissues including brain splanchnic bed and liver. In so doing they would be expected to show 1) vasoactivity before being deaminated and 2) some stimulatory or depressant actions on cerebral metabolism.

Bacteria in the colon have the proper decarboxylating enzymes for these amino acids and for several others. The resultant amines should theoretically act on the vascular system and brain in a similar manner if absorbed. That they do not usually so act can be explained by their destruction by amine oxidase in intestinal wall and in liver. For it is well known that primary amines and even epinephrine can be ingested in large quantities without systemic effects, adding one or more methyl groups to their side chains as in amphetamine or ephedrine however prevents oxidation by hepatic and intestinal amine oxidase allowing the drug to pass unchanged through liver and act on brain or blood vessels. No orally active amine vasoconstricting agent lacks this side chain. It is possible however that when bacterial flora are selectively inhibited by antibiotics products of intestinal putrefaction can be absorbed into the circulation from the lower colon and cause symptoms especially when the liver is damaged.

The fact that extracts of arterial hypertensive blood usually contain more primary amines than those of normotensive blood (90-91) and that certain new or abnormal amines appear in some hypertensive urine (114-115) lends support to the idea that renal amine oxidase is inhibited in most cases of severe hypertension. Presumably other renal ischemic states such as shock and congestive heart failure would be associated with the same metabolic abnormality.

This attractive theory first propounded by Holtz (87) has received considerable attention from our group.

the living animal, we may readily conceive of the consequences of renal oxygen lack.

The amino acids decarboxylated by kidney would continue to be so metabolized. Oxidation of the amine res




FIG 8 Relative rate of oxidation as a function of oxygen tension. Dotted circles are for tyramine or monamine oxidase; solid for xanthine oxidase. A reduction in oxygen tension of 50 per cent reduces the activity of the enzyme by about 50 per cent. Thus monamine oxidase as opposed to xanthine oxidase is extremely sensitive to oxygen lack. (From Kohn H I. Tyramine oxidase. *Biochem J* 31:1693, 1937.)

idues would be diminished in proportion to the oxygen lack. Presumably these amines would reenter the circulation through the renal vein and be deaminated by monamine oxidase at other sites where there is adequate oxygen. First, the lung would take some of them out, those

amines (which is theoretically possible) a minor vicious circle could be induced. The result would be minor degrees of fluctuating neurogenic hypertension and many of the symptoms of the neurogenic hypertensive state.

✓ Since we are concerned primarily with the killing factor in hypertension and not with mild neurogenic vasospastic states, it is well to examine the properties of this enzyme system further. There are two which are of help in implicating a disturbance of amine oxidation. First of all amine oxidase acts on hypertensin or angiotonin (4, 112). This pressor amine is a complex polypeptide (119). Second, the enzyme acts on pherentasin. This pressor amine is probably a polypeptide (120). If the enzyme can act on terminal amines of peptides, it is possible that the formation of such peptidic amines occurs through decarboxylation and destruction by terminal amine oxidation. Therefore we cannot exclude monamine oxidase in any theory of pathogenesis.

This enzyme probably needs vanadium as a cofactor. Vanadium occurs in three valence states and is therefore a good metal for oxidation-reduction reactions, being used as such by certain ascidia which concentrate it from sea water. While not shown to be an essential trace element for man, vanadium is found in tissues of mammals and occupies a place in the periodic table where essentiality might be inferred. This subject will be discussed further in Chapter VI.

Possible Role of the Lungs. In order to cover other conceivable mechanisms of vasospasm induced by humoral pressor substances, we cannot neglect the pulmonary circulation. Any vasoactive material formed in an organ and discharged into the venous circulation must pass through the lungs before entering the area of action, the peripheral arterial bed. The lungs destroy at least one vasoactive

Partly purified but still crude amine oxidase, injected into rats, prevents the pressor action of both renin and pherentasin (*vide infra*). Furthermore, hypertensin or angiotonin is a good substrate for the enzyme (112, 116) indicating the presence of a primary amine group necessary for activity, for the reaction mixture is vascularly inert or depressor. Renal hypertensive dogs can be maintained normotensive on daily injections of the active enzyme (117, 112). All naturally occurring pressor substances are amines. Why, then, does not this enzymatic disturbance account fully for the establishment and maintenance of hypertension?

Perhaps it does, but not through the mediation of the substances listed. For all of them are relatively weak pressor amines when compared to norepinephrine. Very large quantities would be required to cause hypertension—amounts readily detectable in blood. Furthermore, a mixture of these amines would be expected to produce a peripheral circulatory profile different from that seen in hypertension—in so far as is known—for many of them have selective actions on different vascular beds (112), although all, including histamine, constrict the vessels of the kidneys (118). Therefore, circulating primary amines from simple amino acids cannot be implicated as direct causes of generalized vasospasm. They can be concerned, however, with some of the minor manifestations of hypertension, such as headaches, anxiety, tension, nervousness, insomnia, the diencephalic blush, flushing, sweating, and the like. If they can cause nervous and emotional tension (which some of them can) and if nervous tension can cause peripheral vasoconstriction through sympathetic nervous discharges (which it can) and if sympathetic discharges can cause neurogenic renal ischemia (which it can), and if renal ischemia can produce circulating primary

ably is associated with renal abnormalities (90 91 120 124)
As far as is known it is the only pressor substance found
so far in hypertensive blood but not in normotensive blood
There is more in arterial than in venous blood

Pherentasin has a prolonged pressor action in rats
especially those with renal hypertension (91) It also con-
stricts the smooth muscle of the isolated rabbit aorta (120)
Because of its strong pressor action and the small quantities
present isolation and identification has been most difficult.
Much of what is known of its nature comes from inactiva-
tion studies by known agents

Pherentasin probably contains a trace metal essential
for activity the nature of which is unknown It is inacti-
vated by many antihypertensive agents not acting on
sympathetic nerves (Table VII) and disappears from the
blood when hypertension is controlled No one knows how
it is formed.

Renin Now largely discarded the mechanism for the
formation of renin by ischemic kidneys supplied an attrac-
tive hypothesis to explain chronic renal hypertension
When the kidney is made ischemic renin is released into
renal venous blood from parenchymal tissues possibly the
juxta-glomerular apparatus (125) This proteolytic enzyme
acts on an α_2 -globulin made in liver partially hydrolyzing
it to hypertensin or angiotonin * a vasoactive polypeptide
As with most other more simple substances this pressor
amine does not produce the peripheral circulatory profile
of the hypertensive state as does norepinephrine (126 127)
Unfortunately for the theory renin and its effector sub-
stances have not been found in renal venous blood of dogs
or human beings with chronic hypertension They do
appear however in the acute vasospastic states of acute

* Hypertensin and angiotonin are used interchangeably except when
reference is made to a specific preparation One term should be dropped.

material, serotonin, and probably others, for over a hundred years physiologists have taken advantage of this property to free shed blood of "spatgift" and "fruhgift" constrictor and dilator substances in preparation for perfusion experiments. Presumably monamine oxidase is the enzyme which deaminates constrictor primary amines in the pulmonary circuit.

Let us for a moment consider what might happen if all pulmonary monamine oxidase were inhibited. A portion of the pressor amines formed normally by kidney or tissues would be transported unchanged from venous to arterial circulations and would act on the peripheral blood vessels, the blood pressure would rise unless cardiac output were depressed. The remainder would constrict the pulmonary vascular bed, causing pulmonary hypertension. If *extra* quantities of primary amines were formed by kidney (or liver) and pulmonary monamine oxidase were inhibited or saturated beyond its capacity to oxidize them, further vasoconstriction would result. Therefore, the pulmonary circulation could play a part in hypertension.

In this respect it is interesting that the lungs were the only organs in which Tipton detected vanadium the possible cofactor of monamine oxidase. The pulmonary circulation responds to hypoxia by constriction. The lungs contain many abnormal trace elements notably aluminum and titanium, a known enzyme inhibitor. This hypothesis to our knowledge has not been explored.

SPECIFIC EFFECTOR SUBSTANCES

Pherentasin. Although pherentasin has never been proven to come only from the kidney, this pressor amine of probable peptide nature is found in increasing quantities in the blood of patients with severe hypertension, is difficult or impossible to detect in mild stages has been obtained from the renal vein of two patients and presum-

TABLE VIII

COMPARISON OF PROPERTIES OF ANIMAL HYPERTENSIN AND
HUMAN PHERENTASIN

Inactivation by	<i>Hypertensin</i> (1)	<i>Pherentasin</i> (2)	Method and Remarks
Drying	0	+	(1) can be lyophilized
Heat at pH 8.8	+	+	
Heat at pH 2.0	0	0	
Nitrous acid	+	+	
Ninhydrin	+	+	
Semicarbazide	?	±	(2) alters to a rapid reactant
Hydroxylamine	?	±	(2) alters to a rapid reactant
Amine Oxidase	+	+	
Tyrosinase	+	0	
Papain + cysteine	+	+	
Chymotrypsin	+	0	
Carboxypeptidase	+	0	
Trypsin	+	0	
Pepsin	+	0	
Mg ⁺⁺	0	0	
Mn ⁺⁺	+	+	(1) rapid (2) slow
Cr ⁺⁺	?	0	
Co ⁺⁺	+	±	(1) rapid (2) partial
Fe ⁺⁺	0	0	
V ⁺⁺⁺	-	-	Both enhanced
Cu ⁺⁺	0	0	
Zn ⁺⁺	0	0	
Hydralazine	+	+	(1) more sensitive
NaSCN	+	+	
8-Hydroxyquinoline	+	+	(1) slow (2) more rapid
EDTA Na ₂ H ₂	0	±	(1) 50% in 22 hours (2) 50-100% in 3-6 hours
Na ₂ S ₂ O ₄	+	+	
Na ₂ Fe(CN) ₆ NO	+	+	Rapid for both
1 benzyl 2 methyl 5 methoxy tryptamine	+	+	Serotonin antagonist

NOTE While distinct differences between these two substances are obvious the hypertensin used was probably principally hypertensin I (angiotensin) obtained from hog resin and serum Pherentasin may be hypertensin II of human origin with a slightly different structure since there is no reason to believe that the α_1 globulins of pig and man are identical.

TABLE VII

INACTIVATION OF PHERENTASIN BY METAL IONS AND METAL BINDING AGENTS (120)

Estimated Activity Per Cent of Control Values

Substance	Immediate	4-5 hr	24 hr	Boiled after 24 hr	Color Developed
Mg ⁺⁺	91	130	61	0	0
Cr ⁺⁺	187	180	12	0	0
Mn ⁺⁺	45	17	0	—	Pink cloudy
Fe ⁺⁺	70	134	38	0	0
Co ⁺⁺	59	50	50	0	Faint pink
Cu ⁺⁺	96	107	27	0	0
Zn ⁺⁺	84	137	54	27	0
Hg ⁺⁺	168	51	115	0	0
None	100	100	100	80	0
Hydralazine	46	20 (2)*	0 (18)		Deep blue
NaSCN	110	0 (1½)			Yellow-orange
Na Fe(CN) ₆ NO	110	0 (2)			0
NaN ₃	89	0 (2)			0
8 Hydroxyquinoline	35	0 (1)			Pale green
NaH ₂ EDTA	100	0 (3)			0
Cysteine	100		100 (120)		0

All metals were added to the active material in 0.01 M concentrations giving a final concentration in the 20 ml bath of 0.0005 M. The binding agents were added in 2-5 mg amounts per ml extract. None of the metal ions alone affected the test system at 0.0005 M concentrations. The test method was that of Furchgott (85).

Figures in italics represent more than 50% inhibition.

* The figures in parentheses indicate the number of hours of incubation at room temperature when different from that shown at the top of the column.

renal ischemia, toxemia of pregnancy, shock, acute nephritis and congestive heart failure (128-131).

The validity of the renin mechanism is unquestioned as a defense reaction to acute and subacute circulatory changes. When these become chronic, renin is replaced by another vasospastic mechanism, probably that of pherentasin.

Pherentasin may be a form of hypertensin, for there are similarities between the two substances. There are also dissimilarities. The known properties of the two are listed in Table VIII. It is possible that metabolic alterations

animals to normal levels (132) It is not renin As a protein it probably acts enzymatically Possibly sustained pressor principle is a precursor of pherentasin or represents another renal pressor mechanism

Vasoexcitor Material This unidentified substance has the property of sensitizing blood vessels to epinephrine when the latter is topically applied It comes from ischemic kidney and is active in minute amounts Larger quantities appear in chronic hypertension and congestive heart failure (100) Other substances such as renin pherentasin sustained pressor principle and some primary amines also have this property which may be nonspecific

Others A great many vasoactive substances have been found in urine and blood most of them eventually showing up as primary amines or more complex structures They may represent metabolic by products of the basic renal abnormality No good case for any has been proven as directly concerned in chronic generalized vasospasm (133-135 112 4)

Comment When many different substances are discovered or suspected to cause a single recognized abnormality time usually leads to the abandonment of all but one as causative factors Let us attempt to gather all of these different substances together and fit them into one unified scheme To do so we must speculate

1 Renin may be involved in experimental renal hypertension The evidence for this statement is indirect in that anti renin prepared by immunization reduces the hypertension of renal hypertensive dogs (136) Anti hog renin neutralizes hog and dog renin and canine hypertension anti monkey renin neutralizes monkey and human renin and simian hypertension (137) These anti renins are therefore species specific to some degree

2 If anti monkey renin is found to affect human hyper

occurring with time from the former from the latter, or that both have a common precursor. Hypertensin appears to require a metal as an activator.

Posterior Pituitary Factor A pressor substance of polypeptide nature which has received some serious attention in hypertension is vasopressin. While a smooth muscle stimulant in small doses, it also has such antidiuretic properties that little speculation concerning its role in hypertension has been aroused. The direct relationship of the hypothalamus and the stalk of the pituitary, the known but minor electrolyte imbalances found and the peptide nature of the substance make it not inconceivable as an effector substance, provided some minor alteration in its molecule negates its antidiuretic properties. While not a nephrogenic substance, one of its actions is on the kidney, if pressor, its release by the pituitary might be expected to cause widespread vascular constriction. The antidiuretic dose, however, is very small compared to the pressor dose. In our experience even large amounts do not constrict the smooth muscle of the isolated rabbit aorta, as pherentasin and hypertensin do. Although it is possible that pherentasin may be a renal metabolic product of vasopressin, there is no proof or disproof of this idea. Interestingly enough, however, pitressin has been used to treat hypertension, with most variable and inconclusive results.*

Sustained Pressor Principle A protein obtained from ischemic renal tissue or blood of animals in shock has the property of restoring the low blood pressure of pitied

* Pitressin or vasopressin may require an activator for commercial preparations are inactive on the rabbit aortic strip. It exists in a ring form with an S-S linkage (435). We have attempted to activate it by adding copper, cobalt, ferrous iron, zinc, manganese, nickel and mercury without success save for an equivocal slight activation with copper. Oxytocin or pituitrin is also inactive in this system.

contain a terminal amine group necessary for activity. Both can act as a VEM. Renin is inactivated *in vivo* by crude monamine oxidase (112).

6 Alterations may occur by two mechanisms: decarboxylation of a terminal carboxyl leaving a peptide amine or preferably peptide splitting leaving a terminal amine.

7 The substrates as well as the renins from different species are obviously different in composition. Human and primate renin will react with the substrates from all mammals tested, while animal renin will not react with α -globulins from primates. The exhibition of pressor activity of all hypertensins does not in any way mean that they are identical in chemical composition, but only that they have in common an active group, probably a terminal primary amine. Pepsin acting on casein produces a pressor peptide, pepsitensin, identical in action to hypertensin. There are thus many variables in species, the source of a renin, the source of serum α -globulins which almost certainly differ in composition from one species of animal to another, and perhaps the nature of the plasma enzyme converting the inactive peptide into its vasoactive form. The different amino acids found by various workers can be perhaps explained by the different sources from which the renin and its substrate were obtained (Table IX). Since human renin is unique to primates and since human globulins are unique to man, human hypertensin can be expected to be unique in its composition of amino acids. Therefore human hypertensin may have only a moderate resemblance to that obtained from horses, dogs, pigs, and cows, and could well be pherentasin.

8 There is no good evidence that renin or pepsin break down their protein substrates into substances having a terminal primary amine. Activation most likely occurs

tension, one can assume that renin or some similar protein is involved in human nephrogenic hypertension. But renin is found in renal venous blood only in acute vasospastic states and not in chronic hypertension, either experimental or clinical. Therefore, it must remain in the kidney, a highly speculative point.

3 Hypertensin or angiotonin is found only in acute vasospastic states. It has two forms, hypertensin I, inactive on isolated smooth muscle but active in blood,* and hypertensin II, a much more highly constrictor and pressor substance (138, 139). An enzyme in plasma converts I to II (141). Apparently this is a metalloenzyme, requiring chloride and another metal which is tightly bound. Perhaps this enzyme is, or acts like, sustained pressor principle.

4 Pherentasin is found only in chronic vasospastic states. Perhaps pherentasin is a form of hypertensin or angiotonin, altered either by a slightly changed renin or by a slightly different protein substrate, or by a new enzyme developing in chronic vasospasm, such as a peptide decarboxylase attacking the terminal carboxyl group.

5 Both of these substances are peptides inactivated by metal binding antihypertensive drugs and therefore probably contain a metal necessary for activity. Both are inactivated by monamine oxidase and therefore probably

* Hypertensin I obtained from the action of hog renin on horse serum contains the single amino acids aspartic proline valine isoleucine leucine tyrosine phenylalanine arginine and two molecules of histidine (139). Peart using hypertensin from rabbit renin and beef serum disagrees slightly in that there was no isoleucine and two molecules of valine (142). Obviously tyrosinase inactivates both through the tyrosine portion of the molecule. amine oxidase attacks the terminal primary amine probably on aspartic acid. Manganese inactivates by pseudopeptidase activity (140). The sequence of amino acids in Peart's hypertensin is Asp Arg Val Tyr Val His Pro Phe His Leu (142b).

through a manganous peptidase (295). Thus, we can postulate several theoretical alternate reactions based on all the evidence (Fig 9 the active materials are in italics)

Reaction A would thus occur in acute vasospastic states while reactions B, C, or D might take place in chronic states. Pherentasin needs no serum for activity that it has at least six amino acids as based upon the findings of the active material showing six spots in chromatograms. A more unitary hypothesis is that pherentasin is actually hypertensin II, a matter on which we have no evidence as yet.

Comment: The pieces of the picture puzzle are falling into place but there is need for much work to be done before the outlines are clear.

Locus of Action of Pressor Substances. While not directly established, it is reasonable to assume that all vascular smooth muscle is constructed by the pressor sub-




Fig 9

TABLE IX

Amino Acid	AMINO ACIDS IN VASOACTIVE PEPTIDES					Common to All
	Hypertension	Vaso- pressin (435)	Oxytocin (435)	Pepsitensin (434)		
	(142)*	(139)†	(436)			
Histidine	2	2	+			Aspartic acid
Arginine	1	1		1	+	Proline
Aspartic acid	1	1	+	1	+	
Proline	1	1	+		+	
Valine	2	1	+		+	Leucine
Lysine	1	1	+		+	
Leucine	1	1		1	+	
Isoleucine	1	1		1	+	
Phenylalanine	1	1			+	
Tyrosine				1	+	
Alanine				1	+	
Serine				1	+	
Glutamic acid				2	+	
Glycine				2	+	
Threonine				9	10+?	
Cysteine				11		
Methionine	10	10				
No amino acids						

NOTE The differences in hypertension may be due to the sources of the aa globulins from different species hog beef and horse Vasopressin from hogs differs from that of beef in that leucine replaces arginine (435) Pepsitensin was obtained from casein (434)

* Rabbit renin + beef serum

† 11log renin + horse serum

to do more than detect the grosser lesions. A disease causing renal ischemia which then influences hypertension is often unsuspected because the cardiovascular manifestations of the elevated blood pressure may mask the underlying renal abnormality.

Organic Parenchymal Renal Disease The most common diseases of the kidney producing ischemia are pyelonephritis and glomerulonephritis. The former is often a low grade smouldering fibrosing disorder without systemic manifestations and often without obvious urinary changes (143). The latter may be masked insofar as the urinary sediment is concerned by the superimposed hypertension. To list the other more unusual renal diseases, congenital or acquired, is hardly within the province of this discussion; most are often but not always associated with hypertension (144, 4).

Organic Extra-renal Arterial Disease Atherosclerosis of the months of the renal arteries is common in generalized and in aortic atherosclerosis. The mechanism for the deposition of lipid in plaques about the orifices of bifurcating arteries is not known. Undoubtedly pressure changes play a part, possibly the presence of increased numbers of vasa vasorum at such bifurcations influence the lesions. Therefore when atherosclerosis involves the renal arteries, partial renal ischemia may result with subsequent elevation of the blood pressure in predisposed individuals. With aortography becoming more common, such lesions are more frequently demonstrated. According to Blackman, they are the usual findings in hypertensive patients (145). It is possible that they represent the most common form of the disease in individuals beginning to be hypertensive over the age of 50. They are difficult to demonstrate at necropsy (146, 147).

Because the existence of these lesions has not been

stance (or substances) responsible for the humoral component of sustained hypertension. If this is so, the following physiological alterations in vascular volume can be expected

1 An increase in aortic volume, for the aorta is predominantly an elastic and not a muscular organ. As elastic limits are approached with increasing pressures the rate of increase of volume lessens

2 A decrease in the volume of blood in muscular arteries

3 If veins also took part in the process, venous volume in the smaller muscular veins should be decreased without, however, change in central venous pressure

It is often difficult to detect the high pulse pressure in hypertension by feeling the *dorsalis pedis* arteries or even the radials. When blood pressure is lowered by hydralazine, the pulses in these smaller arteries become full. Thus, as pulse pressure falls the detectable pulsations in muscular arteries increase. This seeming paradox is easily explicable on the basis that the muscles of these arteries are constricted in hypertension and that their volumes are diminished.

The high pulse pressure seen in most patients with hypertension is probably due to a relative loss of aortic elasticity because of stretching under pressure. Thus, the aorta becomes physiologically 'hardened'. In children and young adults we see low pulse pressures with diastolic hypertension probably because their aortas are more elastic than are those of older people.

ANATOMICAL CAUSES OF RENAL ISCHEMIA

A variety of mechanisms and lesions can account for renal ischemia in man, many with experimental counterparts. Unfortunately our diagnostic methods are too crude

in the two groups Yuile (158) recently reviewed the literature on the relation of obstructive lesions of the main renal artery and hypertension and concluded that such a relationship does exist in certain cases. This author pointed out the desirability of closer anatomical and physiologic correlation.

Organic Intra renal Arterial and Arteriolar Disease The almost universal lesion found in the kidneys of patients with hypertension at necropsy is renal arterial and arteriolar sclerosis. This lesion is not the cause of the hypertension however but is the result. And a late result at that. About 50 per cent of patients having renal biopsies done during the operation of lumbodorsal sympathectomy had little or no arterial or arteriolar sclerosis (159). This lesion has been shown to result from hypertension produced by a variety of causes in rats (160-163) rabbits (164) and dogs (165-7). Serial renal biopsies in dogs over a seven year period have demonstrated the gradual development of the lesions only after 2 to 4 years of both neurogenic and unilateral renal hypertension the first sign being a thickening of the glomerular capsule and later an increase in material in the glomerular tuft staining with periodic acid (7).

None of these renal diseases alone can be said to cause hypertension in man until azotemia develops. Hypertension is absent in 30 to 50 per cent of patients with the first two types in non azotemic stages. The third type of course is the result of hypertension. They do however influence it profoundly and may often alter its course to a progressive and severe one. That quality which we call the ability to react to stress by vasospasm must apparently be present first and in conjunction in order for severe sustained hypertension to develop in patients with organic renal ischemia.

Why then are there no more cures of hypertension

emphasized in the recent literature, we quote from Braun Menendez *et al* in 1946 (148) "Goldblatt (149) was the first to show that hypertension was associated in some cases with sclerosis and narrowing of the orifice or of the lumen of the main renal artery Leister (150) somewhat later described a case of chronic hypertension associated with complete arteriosclerotic occlusion of the left renal artery and incomplete occlusion of the right Freeman and Hartley (151) almost simultaneously reported hypertension in a patient who was nephrectomized because of an accident At autopsy an atheromatous plaque was found to obstruct the mouth of the renal artery Similar cases were described later by Blackman (145), Stewart (152) Saphir and Ballinger (153) and Laas (154) The importance of unilateral narrowing has been emphasized by Oppenheimer, Klemperer and Moschkowitz (146) who showed that in 18 cases who anatomically showed unilateral narrowing of the renal artery, 15 had hypertension Blackman (145) found a narrowing of the renal artery at or near its mouth in 86 per cent of cases with hypertension Richardson (155) recently reported stenosis of one or both renal arteries by arteriosclerotic plaques in 25 of 32 hypertensive patients studied at autopsy

Kahn and Lipply (147) observed a high incidence of bilateral arteriosclerosis in 1 000 hypertensive patients studied pathologically Friedman Moschkowitz and Marrus (156) observed arteriosclerosis of the renal vessels in 23 of 28 hypertensive patients who were nephrectomized

Lisa, Eckstein and Solomon (157) reported that in 100 consecutive cases coming to autopsy in which blood pressure readings were available, hypertension was present in 56 while 44 were nonhypertensive No appreciable difference in the average diameter of the renal artery was found

matter of fact many effective drugs bind metals in one way or another (Chapter VI) This common property immediately focuses attention on metalloenzymes in kidney and vascular smooth muscle It also stimulates considerable thought about the role of trace metals in pathogenesis of severe hypertension in which the neurogenic component has become of minor consequence

The agents used in man are hydralazine and its derivatives thiocyanate ion sodium nitroprusside ■ 3-dimer captopropanol (BAL) sodium azide and ethylenediamine tetra acetate Of practical interest for continuous use are only the first three the effects of the other three being short lived (Table X)

HYDRALAZINE AND OTHER CHELATING AGENTS

Hydralazine and its derivatives are unique drugs No other agents known produce the same actions on vascular smooth muscle Understanding of their mode of action is the key to understanding of pathogenesis and possibly etiology of severe hypertension While imperfectly understood a consideration of their pharmacological chemical and enzymatic actions is necessary

Chemical Reactions Hydralazine like other hydrazides is a strong chelating agent. It will form a complex with iron copper tin vanadium, manganese nickel silver and mercury The possible structure is



making a five sided ring with nitrogen a most stable chelate This property is shared by isonicotinic acid hydrazide (isoniazid) and probably its isopropyl derivative

in cases of unilateral renal diseases subjected to nephrectomy? The answer is obvious. If hypertension once long established, can cause bilateral renal arteriolar sclerosis removal of the one primarily affected kidney will not remove *all* of the ischemic renal tissue. On the other hand, nephrectomy done in time may result in temporary or semi permanent cure (166, 167). Experimental counterparts of this situation are known in rabbits, which get permanent hypertension after removal of an ischemic kidney which has been in place for three months or more (164), two of our unilateral renal ischemic dogs suffered autonephrectomy, without influencing their long established hypertension.

Comment These three types of organic renal disease can be considered as accessory factors in pathogenesis but not primary ones. They probably do not cause hypertension in themselves without the neurogenic factor being present.

DRUGS ACTING ON NEPHROGENIC MECHANISMS

We can learn something about nephrogenic mechanisms from the actions of specific drugs, although the effective agents are few and have several actions. In experimental hypertension however, there are broader leads. Three types of agents are active: metal binding agents, hydralazine and some other hydrazides (also metal binding agents) and pyrogens. The latter apparently dilate the renal vascular bed in some unknown manner allowing greater blood flow and therefore counteracting renal ischemia.

Metal Binding Agents All of the antihypertensive drugs used in man which do not apparently affect neurogenic pathways, have in common the ability to bind trace metals. There are no known exceptions to this statement. As a

(iproniazid) whose pyridine bases in themselves weakly bind metals without the hydrazide group (Table VI). Distinct specificities for metals are exhibited however.

Hydralazine is also a carbonyl reagent as are some other hydrazides phenyl hydrazine for example which forms an ozonone with glucose. It will bind pyruvate acetate and acetaldehyde (168). Hydralazine has specific reactions in that no ozonone is formed with glucose or lactic acid. It does not combine with any of the steroids tested (168). It is 1 hydrazinophthalazine (Apresoline).

This agent also complexes with the sulfhydryl groups on cysteine glutathione 2,3-dimercaptopropanol (BAL) and other simple mercaptans. The complex can be dissociated readily by arsenic.

TABLE XI A
ISONIAZID * HYDRALAZINE AND METALS

	Isoniazid		Binding of Hydral- azine† + Me ⁺⁺	Similarities
	Destruction by Me ⁺⁺ Auto- claving %	Destruction by Me ⁺⁺ H ₂ O ₂ %		
Mg ⁺⁺	0	5	0	+
Ca ⁺⁺	0	5	0	+
Mn ⁺⁺	100	100	87	+Greatest at pH 6.5-7.0
Fe ⁺⁺	50	80	22	
Fe ⁺⁺⁺	10	95	100	+
Co ⁺⁺	40	35	0	
Ni ⁺⁺	10	15	48	
Cu ⁺⁺	100	100	100	+Greatest at pH 9.5-10.0
Zn ⁺⁺	15	15	0	+

Lewin E. and Hirsch J. G. Studies on the stability of isoniazid. *Am. Rev. Tuberc. & Pulm. Dis.* 71:732 1955

†Perry H. M. Jr. and Schroeder H. A. Studies on the control of hypertension by Hyphex. III Pharmacological and chemical observations on 1 hydrazinophthalazine. *Am. J. M. Sc.* 228:396 1954

TABLE X
SUBSTANCES WITH METAL BINDING PROPERTIES SELECTIVELY AFFECTING ARTERIAL HYPERTENSION (312)

Substances	Rat	Dog	Man	Metals Bound	Reference	Remarks
Thiocyanate		+	+	Many	173	Used in industry soluble CuSCN in
Nitroprusside		+	+	Many	174	Zinc Reagent
Azide*	+	+	±	Many	175	Reactant
2 3-dimercaptopropanol (BAL)*	+	+	+	See Text	182	Chelator
Hydralazine and other hydrazines	+	+	+	See Text	168	Reactant
Tetrasodium pyrophosphate†	±	+		Many	4	Detergent and Reactant
9 mercaptans**	+	+		Many	182	Sulphydryl binding
6 sulfur compounds	+	+		Several	182	SCNH most active
8-hydroxyquinoline	+	+		Many	183	Chelator
Perma Kleer	+	+		Many	183	Polyamino carboxylic resin
Ca++ EDTA	+	+	±	Many	180 183	Slight effect in man
Cr++ EDTA	+	+			183	But not chelates of Fe++ Zn++ Ni++ Cu++, Fe+++
Mn++ EDTA	+	+			183	
Co++ EDTA	+	+			183	

* Short acting

† Large doses Only active phosphate of 11 tested

** Ten others inactive 5 nonspecific

TABLE XII

INHIBITION OF HISTAMINASE BY HYDRAZIDES

Substance	Concentration Producing 50% Inhibition (molar)	Antihyper- tensive Effect
Guanidine HCl	10^{-3}	0
Thiosemicarbazide	10^{-4}	+
Semicarbazide HCl	5×10^{-4}	?
Hydrazine SO_4	8×10^{-4}	?
Aminoguanidine HCO_3	5×10^{-4}	0
1-4 dihydrazinophthalazine	2.3×10^{-4}	+
1 hydrazino-4 methylphthalazine	2.5×10^{-4}	+
1 hydrazinophthalazine	6×10^{-4}	+

Gross F Schuler W Tripod J and Meier R Inhibition of diaminoxidase (histaminase) by phthalazine derivatives *Experientia* 8 229 1952

Schuler W Inhibition of diaminoxidase (histaminase) *Experientia* 8 230 1952

It binds strongly to arterial mash serum proteins egg albumin and some polypeptides possibly through carbonyl or sulfhydryl linkages. It does not bind with casein nor with mixed amino acids.

Enzymatic Reactions Hydralazine is also an anti-enzyme for several known systems. It and its derivatives are strong antihistaminases theoretically preventing histamine formed from histidine from being destroyed rapidly but not necessarily causing release of histamine from histidine (Table XII). Histamine can come from the action of histidine decarboxylase believed to be a pyridoxal enzyme if so inhibition by hydralazine might be suspected. Hydralazine is a potent inhibitor of DOPA decarboxylase in small concentrations also a vitamin B₆ enzyme (Table XIII). There is some evidence that histaminase itself may be a pyridoxal enzyme (169).

TABLE XI B
EFFECT OF METALS AND BINDING AGENTS ON HISTAMINASE (437)
(Substrate Cadaverine)
Inhibition of Reaction %

Concentration	No Drug			Hydralazine			Isoniazid			Ba 12 630		
	10 ⁻³	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁷	10 ⁻⁸	10 ⁻⁹	10 ⁻¹⁰	10 ⁻¹¹	10 ⁻¹²	10 ⁻¹³	10 ⁻¹⁴
Mn ⁺⁺	8	0		0				50		0		
Fe ⁺⁺⁺		0		0			0			0		
Co ⁺⁺	0				50		0					
Ni ⁺⁺	0	0		50			20		0			
Cu ⁺⁺		25	7	50						33	50	50

Schuler W and Meier R. Releasing action of metals on the hydrazine inhibited enzymatic oxidation of cadaverine
Arch Exper Path 223 169 1954

NOTE. The enzyme is inhibited by hydralazine isoniazid and Ba 12 630. 2,4-di hydrazinoquinazoline. The metals alone had little effect on the enzyme but inhibition of the enzymatic reaction by both hydralazine and Ba 12 630 was prevented by Co⁺⁺ and Ni⁺⁺ that by hydralazine by Cu⁺⁺ that by isoniazid only by Mn⁺⁺ and none by Fe⁺⁺⁺. The reaction between drug and enzyme was irreversible once it had occurred. These results offer indirect evidence for metal binding capacities of the three agents although histaminase (diamine oxidase) is not known to require a metal for activity.

TABLE VIII—(continued)

Substance	DOPA Decarboxylase Mallimolarity of agent				Monamine Oxidase (Substrate tryptamine) Mallimolarity of agent			
	10	1	0.1	0.01	10	1	0.1	0.01
Isoniazid	41	84	99	100	75	98	103	101
Iproniazid	108	—	—	—	14	52	91	101
Pyridoxal Isoniazid	100	114	92	91 (90)	96	101	101	101
1,5 diphensyl 3 thiocarbonyl hydrazide	100	97	—	—	—	—	—	—
8-hydroxyquinoline sulfonic acid	102	—	—	—	105	—	—	—
Reserpine	102	90	92	94	—	111	115	—
β -Mercaptopropionic acid	81	98	100	97	123	—	103	95
Tetrasodium pyrophosphate	86	101	97	—	95	98	95	97
Sodium cyanide	66	85	98	97	45	—	—	—
Sodium thiocyanate	100	98	100	110	100	116	98	94
Sodium azide*	91	94	—	—	115	104	101	101
Choline azide	100	—	—	—	112	98	101	100
Sodium Nitroprusside*	63	71	76	91	129	—	—	—

Italicized figures represent 20% change at 1.0 millimolar concentrations or less considered significant.

Those in parentheses show further dilutions by 10.

* Antihypertensive in man. Note that some of these tend to depress one enzyme and enhance the other.

TABLE XIII
EFFECT OF METAL-BINDING AND ANTIHYPERTENSIVE AGENTS UPON TWO RENAL
ENZYME SYSTEMS (GUINEA PIG)
(% Activity)

Substance	DOPA Decarboxylase Millimolarity of agent				Monamine Oxidase (Substrate tryptamine) Millimolarity of agent			
	10	1	0.1	0.01	10	1	0.1	0.01
1 hydrazinophthalazine								
C 5968* (H ₃ dralazine)	12	23	59	88 (99)	163	159	118	103
1-4 dihydrazinophthalazine								
C 7441* (Nepresol)	5	21	21	66 (83) (100)	144	156	118	103
3 hydrazine 6-phenyl diazine								
C 6084*	4	39	74	87 (89) (90)	87	118	95	93
1-4 dihydrazinopyridazine								
C 13504*	20	33	61	102	25	82	98	84
Phthalazine								
C-7182	87	—	99	98	61	103	101	96
1 hydrazino isouquinoline HCl								
C 7406	20	42	76	97	49	103	98	102

TABLE XIV B

EFFECT OF ADMINISTRATION OF HYDRALAZINE ON URINARY
EXCRETION OF 4-PYRIDOXIC ACID (MG) (111)

	No S. hydrs	No Tests	Mean Before	No Tests	Mean Dur. 2	Dose of Hydral- azine
Began on Hydralazine	4	9	24.5 (17.3-33.5)	14	15.5 (11.2-23.2)	150-600
On Hydralazine for 1-3 Years	6			28	13.8 (5.5-19.7)	200-600
O EDTA†	3	10	22.1	13	24.0 (22.0-26.0)	
On EDTA and hydral- azine	6			22	12.7 (4.4-18.8)	200-600
Normal	5	22	21.8			
Atherosclerosis	4	22	27.4			

Per 4 hours after 0 mg. orally 1 pyridoxal hydrochloride

† Calcium d sod um ethylenediamine tetraacetate intravenously

The ranges for each group shown in italics are the mean excretion rates of each patient

chelate trace metals. The antituberculous hydrazides are not antihypertensive however with the possible exception of isoniazid. The key to antihypertensive activity lies in the specificity of the hydralazines for a reaction not exhibited by other hydrazides and similar agents.

The known actions of hydralazine are listed in Table XV. The actions of a large number of similar substances are shown in Table XIII as regards the two enzyme systems considered here.

Other Metal Finding Agents Thiocyanate ion is used in industry for making soluble salts of a number of metals. In man according to Sollmann (173) it hastened the elimination of metals perhaps by rendering the metal protein compounds more soluble. In Table XVI is a partial list of the soluble metallic salts of thiocyanate. Symptoms

Whether or not hydralazine causes excretion or deficiency of vitamin B₆ is not known. It does seem to interfere with the conversion of pyridoxal to its metabolite 4 pyridoxic acid (Table XIV). A relative, isoniazid (isonicotinic acid hydrazide), promotes the excretion of a pyridoxal isoniazid complex in urine and can cause peripheral neuritis in patients taking large amounts for tuberculosis; presumably the neuritis is due to vitamin B₆ deficiency (170). Isoniazid is a good inhibitor of DOPA decarboxylase and a poor one of monamine oxidase (Table XIII). Its derivative iproniazid (isonicotinic isopropyl hydrazide) does not affect DOPA decarboxylase but is a strong inhibitor of monamine oxidase. Both inhibit histaminase (171, 172). The latter cannot be used clinically because of its 'benzedrine like' reactions of euphoria and cerebral stimulation, believed to be due to cerebral and peripheral inhibition of this oxidase, thus allowing natural primary amines to circulate.

We are discussing these related hydrazides because of their similarities of structure, their antienzymatic activities, their affinities for vitamin B₆, and their abilities to

TABLE XIV A

EFFECT OF REPEATED ADMINISTRATION OF PYRIDOXAL HYDROCHLORIDE UPON EXCRETION OF 4 PYRIDOXYLIC ACID (MG) (111)

Subjects	No	Mean Total Dose Vitamin B ₆ (mg)	Mean Days Given	Amount Excreted on Last Test	
				Mean	Range
Normal	5	250	5	22.3	9.8-27.8
Atherosclerosis	4	250	5	27.8	21.8-32.4
Patients on EDTA†	3	1470	18	21.0	18.0-24.2
Patients on Hydralazine	11	700	12	11.3	2.6-20.5

TABLE XIV B

EFFECT OF ADMINISTRATION OF HYDRALAZINE ON URINARY
EXCRETION OF 4 PYRIDOIC ACID (MG) (111)

	No Subjects	No Tests	Mean Before	No Tests	Mean During	Dose of Hydral- azine
Began on Hydralazine	4	9	24.5 (17.5-33.5)	18	15.5 (11.2-23.2)	150-600
On Hydralazine for 1-3 years	6			28	12.8 (5.5-18.7)	200-600
On EDTA†	3	10	22.1	18	24.0 (2.0-26.0)	
On EDTA and hydral- azine	4			22	12.7 (4.4-18.8)	200-600
Normal	5	22	21.8			
Atherosclerosis	4	22	27.4			

* Per 4 hours after 100 mg orally of pyridoxal hydrochloride.

† Calcium disodium ethylenediamine tetraacetate intravenously.

The ranges for each group shown in italics are the mean excretion rates of each patient.

chelate trace metals. The antituberculous hydrazides are not antihypertensive, however, with the possible exception of isoniazid. The key to antihypertensive activity lies in the specificity of the hydralazines for a reaction not exhibited by other hydrazides and similar agents.

The known actions of hydralazine are listed in Table XV. The actions of a large number of similar substances are shown in Table VIII as regards the two enzyme systems considered here.

Other Metal Binding Agents Thiocyanate ion is used in industry for making soluble salts of a number of metals. In man, according to Sollmann (173), it hastened the elimination of metals, perhaps by rendering the metal protein compounds more soluble. In Table XVI is a partial list of the soluble metallic salts of thiocyanate. Symptoms

TABLE XV
SUMMARY OF PROPERTIES OF HYDRALAZINE OTHER
THAN CARDIOVASCULAR

<i>Basic Chemical Reactions In Vitro</i>	<i>Reference</i>
Metal binding	
complete for Fe ²⁺ , Cu ²⁺ , Sn ²⁺ , V ²⁺	(168)
partial for Mn ²⁺ , Fe ³⁺ , V ³⁺ , Ni ²⁺ , Ag, Hg	
none for Na, K, Be ²⁺ , Mg ²⁺ , Ca ²⁺ , Zn ²⁺ , Co ²⁺ , Cr ³⁺ , Cd ²⁺ , Al ³⁺ , As ³⁺ , Pb ²⁺	
Carbonyl reagent	
with pyruvate, acetaldehyde, acetate	(168)
not with glucose, lactic acid	
Complex with SH	
with cysteine, glutathione, BAL and other simple mercaptans	(168)
Protein binding	
with serum, arterial mash, egg albumin, polypeptides	(436)
not with casein, mixed amino acids	
Enhances	
monamine oxidase (10 ⁻⁴)	(Table XIII)
Anti-enzyme	
for histaminase (10 ⁻⁶) stronger than guanidine thiosemicarbazide, weaker than hydrazine, amino-guanidine equal to semicarbazide	(172)
for DOPA decarboxylase moderate (10 ⁻⁴)	(Table XIII)
for succinic dehydrogenase, cholinesterase, polyphenol oxidase none	(111)
Combination with	
no primary amines or simple amino acids	
lyophilized angiotonin	(168)
<i>Blocking Actions In Vivo</i>	
Weak for epinephrine, norepinephrine, arterenone, tyramine, isocamylamine, angiotonin	(168)
Strong for pherentasin, pervanadyl, cadmium, barium, pitressin	(168, 438)
Variable for serotonin according to species (weak in rat and dog, strong in cat)	(168, 63)
<i>Blocking Actions on Rabbit's Arterial Strip</i>	
Strong for pherentasin, angiotonin	(120)
Weak for norepinephrine and other primary amines	(120)

TABLE XV—(continued)

<i>Vascular Reactions in Animals</i>	<i>References</i>
Dilates constricted vessels renal femoral coronary acts for many hours	(438)
Does not dilate dilated vessels further (as in spinal animal)	(438)
Abolishes constriction caused by Ba pitressin ephed rine ergotamine histamine Privine	(438)
<i>Reactions in Man</i>	
Lowering of plasma cholesterol	(180)
? lowering of blood pyruvate or total carbonyl	(168)
Apparent loss of Ti in urine	
Mild anemia	(168)
? Histamine release	(172)
Increases cardiac output tachycardia	(425)
Increases renal plasma flow	(426 427)

and side effects due to this ion are variable but resemble in some respects those induced by hydralazine because of the dissimilarity of the chemical structures of the two

TABLE XVI
SOLUBLE COMPLEXES OF THIOCYANATES IN WATER

<i>Soluble</i>	<i>Partly Soluble</i>	<i>Insoluble</i>
Mn	Pb	Cu
Fe	Hg	Ti ?
Co	Ag	Si
Zn		
Mo		
Ca		
Sr		
Ba		

Hodgman C B ed *Handbook of Chemistry and Physics* 33rd Ed
Cleveland Chemical Rubber Publishing Co 1951

TABLE XV

SUMMARY OF PROPERTIES OF HYDRALAZINE OTHER THAN CARDIOVASCULAR

<i>Basic Chemical Reactions In Vitro</i>	<i>Reference</i>
Metal binding complete for Fe ³⁺ Cu ²⁺ Sn ²⁺ V ⁵⁺ partial for Mn ²⁺ Fe ²⁺ V ³⁺ Ni ²⁺ Ag Hg none for Na K Be ²⁺ Mg ²⁺ Ca ²⁺ Zn ²⁺ Co ²⁺ Cr ³⁺ Cd ²⁺ Al ³⁺ As ³⁺ Pb ²⁺	(168)
Carbonyl reagent with pyruvate acetaldehyde acetate not with glucose lactic acid	(168)
Complex with SH with cysteine glutathione B4L and other simple mercaptans	(168)
Protein binding with serum arterial mash egg albumin polypeptides not with casein mixed amino acids	(436)
Enhances monamine oxidase (10 ⁻⁶)	(Table VIII)
Anti enzyme for histaminase (10 ⁻⁶) stronger than guanidine thio semicarbazide weaker than hydrazine amino- guanidine equal to semicarbazide for DOPA decarboxylase moderate (10 ⁻⁶) for succinic dehydrogenase cholinesterase poly phenol oxidase none	(172) (Table XIII) (111)
Combination with no primary amines or simple amino acids lyophilized angiotonin	(168)
<i>Blocking Actions In Vivo</i> Weak for epinephrine norepinephrine arterenone tyra mine isoamylamine angiotonin	(168)
Strong for pherentasin pervanadyl cadmium, barium pitressin	(168 438)
Variable for serotonin according to species (weak in rat and dog strong in cat)	(168 63)
<i>Blocking Actions on Rabbit's Arterial Strip</i> Strong for pherentasin angiotonin Weak for norepinephrine and other primary amines	(120) (120)

Sodium azide which has a strong affinity for metals is a rather transient vasodilator, as is its relative choline azide producing sharp reductions in blood pressure. It is said to show differential actions in normotensive and hypertensive rats not depressing blood pressure in the former (175). We have been unable to confirm claims for chronic effects in man.

British Anti Lewisite (2,3-dimercaptopropanol BAL) is used clinically to remove trace metals from the body. Much is known of its actions (176, 177, 178) which do not include affinities for all metals. It is a disulfide chelating agent. In our hands it has proven effective in causing lowering of blood pressure in American hypertensive patients for periods of a few hours. On the other hand British patients have responded with a rise. It is prolongedly pressor in normotensive subjects (177) but was depressor in one American hypertensive patient in the hands of others (176). BAL has little clinical use at present in hypertension. In cadmium poisoning it will mobilize the metal but binding is weaker than is that of kidney for the metal is deposited and cadmium nephritis results (179). Many other heavy metals are mobilized and removed in the urine.

Ethylenediamine tetra acetate is a mild antihypertensive agent in man. Given intravenously as the disodium calcium complex it either lowers elevated blood pressure or reduces the patient's requirement for ganglionic blocking agents (180). Not a strong chelating agent for many metals it has little clinical use at present. Prolonged oral use has led to no toxicity; intravenous use has produced signs of zinc deficiency (181) which resembles that of vitamin B₆.

Experimental Compounds In anaesthetized rats and other animals a number of compounds having the capacity for binding or chelating trace metals lower hypertensive

agents, a common denominator must be present in the actions of both (Table XVII). Little interest in its mode of action has been aroused. It can inhibit a number of enzymes, such as zinc-containing carbonic anhydrase and amino acid oxidase (173b). It is antithyroid, all antithyroid agents except those which act by competitive inhibition bind metals.

Sodium nitroprusside is an antihypertensive agent of considerable potency when given intravenously, alterations in the course of the disease have been described (174). A zinc reagent, it is a strong metal binder. Its chronic toxicity is not known but should become apparent with continued use.

TABLE XVII

SIDE EFFECTS OF TWO METAL BINDING ANTIHYPERTENSIVE DRUGS (84-108)

	<i>NaSCN</i>	<i>Hydralazine</i>
Action		
in normotension	0	±
in renal hypertension	+	+
enhanced by sympathectomy	+	+
Arthralgia	+	+
Lupus like syndrome		+
Cholesterolemia	+	+
Rhinitis	+	+
Conjunctivitis	+	+
Anti thyroid	+	0
Peripheral neuritis	+	+
Paraesthesia	+	+
Skin lesions	+	+
Headache	+	+
Flushing	0	+

both types of animals D Lowering of blood pressure in both types of rats and depression of the pressor action of norepinephrine E Lowering of the blood pressure of both normotensive and hypertensive rats without greater effect on the latter and without altering the pressor action of norepinephrine (Fig 11)

Mercaptan compounds which showed specific antihypertensive but not sympatholytic effects (Type A) in the rat were




Thioglycolic acid



β mercaptoethylamine

Procaine Salt of β mercapto-
propionic acid



Methyl tris (β mercaptoethyl)
ammonium chloride



2 Mercaptoethanol



Ethyl β mercaptopropionate



Thiomalic acid
(Mercaptosuccinic acid)



1-ethyl 2 mercaptimidazole

Compounds showing both antihypertensive and norepinephrine blockade (Type C) were



β -mercaptopropionic acid



Reduced glutathione



and to a less extent



mercaptopyruvic acid
(ammonium salt)

blood pressure but do not affect or raise normal blood pressure

Theoretically there are five types of sustained depressor responses of the blood pressure of hypertensive and normotensive rats to the intravenous injection of various active compounds. A Little or no effect on normotensive rats with specific lowering of the blood pressure of renal hypertensive rats, while the pressor action of norepinephrine is unaltered or little affected (Fig 10). B Little effect on blood pressure with depression of the pressor action of norepinephrine in both types of rats. C Effect of type A with depression of the pressor action of norepinephrine in






FIG 10 Effect of intravenous EDTA on diastolic blood pressure of anaesthetized rats. Note that the normotensive pressure varies little while the renal hypertensive falls with smaller doses. Typical type A response

Certain mercaptans were depressor in both types of animals (Type E) although the last two showed significant differential activities

6-amino- α mercaptobenzothiazole2,3-dimercaptopropanol (BAL)
(Fig. 12)


Only four mercaptans were sympatholytic (Type B) without depressor effects the last to a lesser degree



Acetyl mercaptan



1 thio-2 hydroxy propane


Sodium 2 mercapto-5 benzothiazole
sulfonate

Tri-decyl mercaptan

Five were inactive or pressor the last having a short lived differential action



Cysteine

2 mercaptoethyl hydrogen
(carboxymethylmercapto) succinate

Mercaptosalicylic acid



Tapazole



Pantetheine




Fig 11 Effect of intravenous sulphydryl compounds on the diastolic pressures of anaesthetized rats A Cysteine 50 mg Only hypertensive pressure is depressed (Type A) B α -Mercaptopropionic acid Both types of pressures are depressed (Type E) β -Mercaptopropionic acid gave a type A response The dotted lines denote the rises after 0.3 μ norepinephrine The dose of cysteamine at 0 minutes was 0 mg

A group of sulfur-containing compounds were similarly divided. Type A activity was demonstrated by





FIG 12 A. Transient effect of 2,3-dimercaptopropanol (BAL) on systolic pressure of renal hypertensive rat. Blood pressure was measured by the foot cuff method using a photoelectric cell. The open circles are measurements made 2, 3, and 4 hours after the injection; the closed circles 11 hours later. Note increasing tolerance."


B. Effect of BAL on blood pressure of a 59-year-old patient receiving hydralazine (5968) and hexamethonium chloride (C) in too low doses to produce normotension. Doses are indicated at the top. BAL, 50 mg every four hours intramuscularly was given for four doses. At the bottom urinary excretion of hexamethonium ion and hydralazine are shown. The solid black areas represent free urinary hydralazine; the open areas that bound to sulfhydryl. All excreted hydralazine was bound after BAL was given. (From Perry H. M. Jr, Schroeder H. A. and Morrow J. D. *Am J Med Sci* 228:405, 1954.)

BAL IN CHRONIC RAT



A


L.H. #



B

FIG 12 (See facing page for description)

There was no activity exhibited by oxidized glutathione nor by




One compound of interest contained three ethyl mercaptans on a quaternary ammonium nitrogen it was made on the possibility that ganglionic blockade as well as mercaptan effect might result. However it acutely raised the mean diastolic pressures of normal and hypertensive rats 36 and 15 mm Hg respectively producing the usual differential mercaptan effect of a depression of 11 and 32 mm respectively at the end of 2 hours. Another of special interest had the basic structure of hexamethonium ion with an ethyl thiopseudourea group on each quaternary nitrogen. Although listed as Type E it depressed the mean diastolic pressure of 5 normal rats 36 mm Hg and that of 5 hypertensive rats 86 mm in doses of 10 to 15 mg. Possibly ganglionic blockade was combined with another action on the renal pressor mechanism.




Examination of the structures reveals that antihypertensive or depressor activity was confined to those aliphatic compounds having a terminal sulphydryl group or SCNH in the molecule unencumbered by a heavy salt. Aromatic compounds containing SCN were likewise active. Such compounds usually bind metals, sulfur-nitrogen binding being strongest with Cu, Ni, Ag, Cd and contiguous heavier elements in the periodic table. These results suggest that possibly some copper enzyme was altered or inactivated causing the pharmacological activities of the compounds (182).

If this surmise be true the next step was obviously to test known chelating agents in the same system preferably those not metabolized. If they were active obviously a metalloenzyme was altered.



Type C activity was shown by only one




Partial sympatholytic with good antihypertensive activity was exhibited by



Type E activity occurred after the following the last two showing differential effects



2 Benzyl 2 thiopseudourea hydrochloride



In order further to control the studies various pyridoxylidene metal amino complexes were subjected to the same test. Selective Type A effects were observed with the copper tyrosine nickel arginine aluminum phenylalanine and possibly the cobalt phenylalanine complexes. No ef

DIVALENT METAL DISODIUM ETHYLENE DIAMINE TETRA ACETATE





FIG 19 The effects of a series of increasingly tightly bound metal ethylene-diamine tetra acetates on the diastolic pressures of groups of hypertensive (upper bars) and normotensive (lower bars) anesthetized rats. The first bar for each metal complex represents the change 20 to 30 minutes after one intravenous injection of 5 mg. the second and third changes a like interval after subsequent injections. Mean changes are shown each group representing at least 3 and usually 4 or more rats. All complexes were dihydrogen metal except for ferric as shown on the right. Note the comparable differences in hypertensive (mean diastolic pressure 119 mm. Hg) and normotensive animals (mean diastolic pressure 77 mm Hg) as well as the small effects with sodium and magnesium complexes which can alter calcium levels in blood, and the decreased effects with nickel copper zinc and trivalent iron. Metals are listed in order of atomic number. The ferrous was probably partly ferric. (From Schroeder H. A. and Perry H. M. Jr. *J. Lab. & Clin. Med.* 46:416 1955)

Activities of Type A were shown by the strong chelating compounds



and Perma Klear a polyaminocarboxylic acid resin with chelating qualities. Pressor activity was exhibited by the weaker chelating agent, 1,6-tolylbiguanide. Therefore one or more metals must have been removed presumably from metalloenzymes, since EDTA, at least, is not metabolized.

In order to ascertain which metal or groups of metals might be chelated, advantage was taken of the different stability constants of EDTA and various metals of the first transitional series. Figure 13 shows the results and Table XVIII the stability constants. Any metal removed from tissues must have displaced one with a lower stability constant. Aside from the ferrous chelate which readily oxidizes to ferric in solution, it is evident that those with higher constants than 16.1 (for cobalt) are not active; these included the nickel, zinc, and copper chelates. Since nickel has no known function, it is reasonable to assume that ferric iron, zinc, or copper was displaced from tissues by the chelating compound.

In order to determine whether or not the metal ions themselves showed activity, small amounts of the chlorides were injected (Fig. 14). Only ferrous, cobaltous, cupric, and zinc were active. Cobalt is a known vasodilator and zinc salts cause flocculation of plasma proteins which may have accounted for the obscured effects. Suspicion therefore rests upon copper or zinc as being involved in the maintenance of renal hypertension in the rat.

pressure of 4 hypertensive patients monothio glycerol was apparently inactive a trithione (SKF 1717) given orally appeared inert BAL, however exhibited depressor activity in 6 hypertensive patients when given every 4 hours in doses up to 50 mg per kg the effects were relatively short lived (2 to 4 hours) We did not observe a pressor effect after this material was given (183)

Comment This common denominator of the antihyper




FIG 14 The effects of a series of metal ions on the diastolic pressures of groups of hypertensive (mean diastolic pressure 121 mm. Hg) and normotensive (mean diastolic pressure 81 mm Hg) anesthetized rats similarly treated. Doses were 0.2 mg. For obvious reasons sodium and calcium salts were not given. The pressor action of pervanadate is indicated as well as are the effects of cadmium and chromic chlorides. Note the differences between the ions and their complexes as shown in Figure 13 especially in regard to chromous manganous ferrous nickelous zinc, and ferric iron which was inert in large doses (From Schroeder H. A. and Perry H. M. Jr. *J Lab & Clin Med* 46:416 1955)

TABLE XVIII

SIGNIFICANT EFFECTS ON DIASTOLIC BLOOD PRESSURE OF METAL CHELATES (15 MG) AND ION (0.6 MG) IN HYPERTENSIVE RATS

Me^{++}	Atomic No	$\log K_1$	$H_2MeEDTA$ (mm Hg)	$MeCl_2$ (mm Hg)
Na	11	1.66	—	—
Mg	12	8.69	—	—
Ca	20	10.59	-63	—
Cr	24	13.00	-51	—
Mn	25	13.47	-31	—
Fe	26	14.22	—	-40
Co	27	16.10	-33	(-21)
Zn	30	16.58	—	-29
Ni	28	18.45	(-22)	—
Cu	29	18.38	—	-28
$Fe^{+++}Na$		25.00	+33	—

$\log K_1$ is an index of the stability of the chelate the higher values being more stable. The figures were taken from Sequestrene a publication of the Alrose Chemical Co. Providence quoting Scharzenbach *et al*. That for chromous is not exactly known.

EDTA—ethylenediamine tetraacetate

effects were observed with three glutamic acid and two phenylethylamine complexes. Copper again comes under suspicion.

These same effects were observed in renal hypertensive dogs, by the use of BAL and hydralazine (Fig. 15). In renal hypertensive dogs BAL (5 mg per kg) injected intramuscularly produced definite but transient (2 to 5 hour) depression of blood pressure as did sodium thio glycolate intravenously. When BAL was injected with 1 hydrazinophthalazine a moderately active depressor substance, the effects were enhanced. Only four of these compounds were sufficiently studied to give to human beings. Cysteine caused no demonstrable alteration in the blood

tensive compounds not acting on nerves that is the ability to bind trace metals is not confined to this class of drugs. In fact most modern drugs have this ability. Their differences lie in their relative affinities for the metals in question their dispersing powers and their transport to other sites. The striking coincidence however of metal binding properties and effect lead to only one conclusion that one or more metals are bound and altered from metallo-enzyme sites and that abnormal trace metals may indeed be acting upon enzymatic mechanisms to produce hypertension. A consideration of how they may act will be discussed in following chapters.

THE EFFECT OF ANTIHYPERTENSIVE AGENTS ON NEPHROGENIC EFFECTOR SUBSTANCES

A method for screening antihypertensive agents involves the isolated rabbit aortic strip a spirally cut piece of smooth muscle which contracts when pressor substances are applied (120). Substances acting mainly on norepinephrine and other primary amines acting on more complex pressor substances and showing general inhibition of all types can be evaluated. While many agents tested cannot be applied to man their activities can be evaluated readily on isolated muscle and in the hypertensive animal. A substance which is nontoxic inhibits pherentasin and lowers the blood pressure of hypertensive rats while not affecting normotension is obviously of therapeutic interest.

Pherentasin Using the isolated rabbit aorta suspended in oxygenated Ringer's solution a number of these substances have been tested for their activities against pherentasin. The relative degrees of inhibition are indicated in Table VII. All of the *metal binding* agents are inhibitory. On the possibility that pherentasin may be an adrenergic agent a number of sympatholytic substances




FIG 15 Effect of various substances on the mean blood pressure of a renal hypertensive dog 035. The left renal artery was constricted in August 1949 causing moderate hypertension. *Upper* 1 Hydrazinophthalazine (5968) injected intravenously. Note the effect when given at less frequent intervals than daily blood pressure falling for 24 hours and then rising in 48. Only small doses were required. During the subsequent year mean blood pressure rose. *Lower* Cysteine intravenously caused only insignificant variations; sodium thiosglycolate more pronounced but transient ones. BAI intramuscularly alone and combined with intravenous cysteine similar depressions but BAL combined with 5968 produced marked responses. Both the immediate (2 to 6 hour) and late (24 hour) responses to these substances are shown. Only BAL and 5968 together produced significant depression for 24 hours. The dog's mean blood pressure consistently remained above 200 mm Hg for 5 months after this study when it was given 10 gm thiosemicarbazide by mouth and died of convulsions.

is not lowered or raised 2) renal plasma flow increases relatively more than peripheral blood flow 3) blood flow through other areas does not change 4) blood viscosity and volume are not altered and 5) there are no toxic manifestations Hydralazine does not fulfill all of these criteria and also causes late toxicity and some unpleasant side effects However it is probably the closest approximation available at the present time the others either being in

APRESOLINE BLOCKADE OF PHERENTASIN




FIG 16 At 0 minutes after a control period of 20 minutes 10 unit of pherentasin previously found active was injected intravenously into a rat with the response of systolic and diastolic pressure shown. At 10 minutes 10 mg of hydralazine (apresoline 5968) was injected intravenously resulting in an immediate fall of blood pressure. A subsequent injection of 20 units of pherentasin caused little response however 10 unit of angiotonin was pressor. At 35 minutes 50 mg of 5968 was injected the response to another unit of angiotonin 5 minutes later was not inhibited (From Perry H M Jr and Schroeder H A. *Am J M Sc* 228 396 1954)

TABLE XIX
ADRENERGIC BLOCKADE OF VASOACTIVE PEPTIDES
(RABBIT AORTIC STRIP)

Blocking Agent	Pherentasin	Hypertensin*	Serotonin	Norepinephrine
Regitine	0	±		
Dihydroergotamine	0	0	+	+
Iproniazid	sl	sl		
Cocaine	0	0		
Dibenamine	0	0	+	+
Pyribenzamine	0			
Atropine	0			
Amine oxidase	+	+	+	+
Tyrosinase	0	+	0	+

* Probably mainly hypertensin I

were also tested. None showed the characteristic alterations of pherentasin activity exhibited by primary amines (Table XIX). Pherentasin was actively inhibited by hydralazine in the intact rat (Fig. 16).

Renin and Angiotonin. On the isolated smooth muscle system, hydralazine in fairly high doses is antagonistic to angiotonin. In the intact animal this antagonism is not demonstrated by doses sufficient to inactivate pherentasin. A number of antihypertensive metal binding agents however inactivate angiotonin in the isolated system suggesting that a metal is essential for its activity.

Others. Hydralazine inactivates sustained pressor principle as does β mercaptopropionate. It also inactivates pressin.

CLINICAL IMPLICATIONS

A true antihypertensive drug is one which lowers elevated blood pressure to normal without affecting normal blood pressure, in the process of which 1) cardiac output

■ not lowered or raised 2) renal plasma flow increases relatively more than peripheral blood flow, 3) blood flow through other areas does not change 4) blood viscosity and volume are not altered and 5) there are no toxic manifestations Hydralazine does not fulfill all of these criteria and also causes late toxicity and some unpleasant side effects However it is probably the closest approximation available at the present time, the others either being in

APRESOLINE BLOCKADE OF PHERENTASIN




FIG 16 At 0 minutes after a control period of 20 minutes 10 unit of pherentasin previously found active was injected intravenously into a rat with the response of systolic and diastolic pressure shown. At 10 minutes 10 mg of hydralazine (apresoline 5968) was injected intravenously resulting in an immediate fall of blood pressure. A subsequent injection of 20 units of pherentasin caused little response however 10 unit of angiotonin was pressor. At 30 minutes 50 mg of 5968 was injected the response to another unit of angiotonin 5 minutes later was not inhibited. (From Perry H M Jr and Schroeder H A *Am J M Sc* 228 396 1954)

experimental stages, or showing excessive toxicities or only transient effects

Toxic effects appearing late are those of the development of a syndrome indistinguishable from disseminated lupus erythematosus, reversible when the agent is omitted (93, 184-187). This syndrome has been characterized by 1) normotension, 2) arthralgia or arthritis, and 3) appearance of elevated cephalin-cholesterol flocculation and thymol turbidity of serum. Continuation of the drug causes later manifestations which include anemia, leukopenia, splenomegaly, hepatomegaly, low plasma cholesterol, albuminuria, microscopic hematuria, azotemia, pleuritis, pulmonary lesions and the appearance of a positive LE test on peripheral blood. These dire events appear only when the drug is continued at full doses. The many bizarre findings of collagen diseases can occur. The syndrome has a seasonal incidence appearing mainly in warm weather. Coming on only after 5 months or more of administration of drug, it is similar to late toxicity from several other metal binding agents.

Since hydralazine is the only known drug which will produce disseminated lupus erythematosus in man and the dog (188), speculation as to its mode of action may help understanding of collagen diseases. For some time we were attracted to the hypothesis that this syndrome and perhaps disseminated lupus itself represented a state of depletion from the body of some material important in the health of ground substance. Loss of a trace metal or imbalance between essential and abnormal trace metals was considered, in view of hydralazine's known reactions. Feeding of several trace metals failed to influence the disease. The universal appearance of normotension or hypotension before symptoms appeared was in line with this hypothesis. On the other hand, definite hypersensitivity has been observed,

fever acute arthritis and prostration have occurred within a few hours of giving the drug or its analogues (185-189) both to patients recovering from hydralazine disease and to others never receiving the drug before. We have seen showers of L-E cells appear in one recovered person who had taken no drug for 2 years and was given small doses. In several other individuals reduction of doses has resulted in reversal of symptoms but not of all laboratory abnormalities. If the L-E phenomenon is one of hypersensitivity which is not known this explanation for the disease is tenable. The question is open but we suspect that its answer will be fruitful of information on hypersensitivity collagen disease and hypertension.

We do not know which substance is removed from the body by hydralazine or which enzyme system or group of systems is inactivated. The ability to produce this syndrome in man by a drug however suggests that lupus erythematosus itself is an enzymatic disturbance which might be affected by replacement therapy. A suggestion of what has been removed in the way of metals may be obtained from trace metal analysis of human urine when hydralazine was given and from cases of known hydralazine disease and known lupus erythematosus (Table XX). The abnormal urines are somewhat low in manganese somewhat high in tin and zinc. While these findings may not be pertinent to pathogenesis they deserve study. Blood copper levels were not reduced in this syndrome.

Of the other known functions of hydralazine carbonyl binding is the most logical to explain the toxicity. It is difficult however to conceive of carbonyl binding as leading to depletion. There was no diminution in total carbonyl or pyruvate in blood of patients treated with hydralazine. Its other function removal of sulphhydryl is also a possible but not probable cause of hydralazine

TABLE XX
URINARY TRACE METAL CONCENTRATIONS* IN DISSEMINATED LUPUS ERYTHEMATOSUS (111)

T ₁	V	C _r	Mn	Ni	Zn	Mo	Ag	Cd	Pb	Sn	Comments
Ch.	<0.05	0.6	5.2	Inter†	Inter	>50	0.36	1.4	120	38	Lupus
Ev	<0.05	—	—	5.7	180	21	0.29	1.8	15	5.0	Lupus
Sc.	4.0	0.41	0.36	Inter	175	4.4	0.46	3.0	1.1	3.0	Lupus
Mean±	1.37	0.5	2.78	3.75	177.5	23.1	0.37	2.07	45.4	15.3	
Dr	10	4.9	0.50	<5	175	6.1	0.58	6.0	170	6.8	Lupus
Ha.	3.6	1.3	1.9	<5	111.5	12	0.33	<0.3	5.3	17	Lupus
Mean	6.8	3.1	1.2	<5	131.3	9.0	0.46	3.15	87.65	11.9	
St	2.8	1.5	0.34	<5	159	2.4	2.0	70	0.90	8.8	Hydralazine Disease
Ba.	<0.05	0.11	12	<5	108	3.9	1.2	0.5	0.50	7.8	Hydralazine Disease
Mean	1.43	0.81	6.17	<5	133.5	3.1	1.6	35.2	0.70	8.3	
Normal											
Mean	<1.8	<0.63	<0.64	<2.8	<67	<14	0.80	<0.86	<5.7	<3.2	
Max.	15	2.2	1.0	37	135	29	1.4	4	28	5.6	
Mfn	<0.05	<0.5	<0.05	<0.05	<5	<0.5	0.23	<0.5	<0.05	<0.5	

*Results are expressed in parts per billion
 **Specimens supplied by Dr A C Corcoran.
 †Interference

disease. Its known antihistaminase activity and the relation of histamine to hypersensitivity is another possible explanation as is its affinity for pyridoxal.

Lest the reader refrain from using this potent agent when it is needed for the prolongation of life we can say that hydralazine disease occurs in less than 10 per cent of patients and then only when relatively large doses are given that it is readily detectable easily reversible and does no permanent harm if the drug is discontinued in time. There has been no mortality except in unwatched patients and the drug on the whole is hardly more toxic than many in continuous use for the control of chronic diseases. The method of use is discussed in Chapter VIII.

Chapter V

FACTORS INFLUENCING THE CONVERSION OF NEUROGENIC TO NEPHROGENIC HYPERTENSION

THE TRANSITION FROM INTERMITTENT TO PERMANENT VASOSPASM

IF THE VASOSPASM resulting from emotional reactions to stress were confined to the reversible phenomena seen in hyperreactors to pain the net effects upon the cardiovascular system would be less important than those resulting from exercise (Unfortunately at some stage *permanent vasospasm*, at first of slight degree then more and more pronounced gradually develops engrafted upon which are the repetitive reversible episodes of neurogenic vasospasm) The key to the understanding of the pathogenesis lies in this change of reversible to irreversible vasospasm therefore we may be allowed to theorize for purposes of orientation The curve of incidence of chronic hypertension in the general population plotted against age (showing a rapid increase in the fifth decade) is consistent with several theories Since all biologic phenomena can eventually be resolved in terms of physics and chemistry we should examine possible basic disturbances in that light The physical explanation—organically induced increase in vascular resistance from sclerosis of all vessels—does not fit the facts although the effects of increased intra arterial tension which both cause cardiac overwork

and which increase the rate of development of atherosclerosis are beginning to be appreciated. Of chemical explanations we look for some disturbance of some enzyme system concerned a) in the relaxation of smooth muscle b) the destruction of potential pressor substances, c) the reactivity of blood vessels or d) the metabolism of the kidney.

THEORY OF HABITUAL REPETITIVE STIMULI

One idea is that the trigger mechanism for emotional discharge to vasospasm becomes more sensitive as the years pass, lesser and lesser stimuli setting off the response. In other words, an habitual pattern of reaction is set up which becomes more and more active and eventually leads to organic renal vascular disease, thereby causing organic renal ischemia. This explanation begs the question and is inconsistent with the fact that demonstrable renal vascular disease may be absent in sustained hypertension.

THEORY OF DEPLETION OF VASCULAR SUBSTANCES

Another theory is concerned with the depletion of substances or the wearing out of the mechanisms which cause reversal of vasospasm, i.e. the relaxation of smooth muscle. In other words, repetitive stresses accelerate the aging process in smooth muscle, making it more reactive. There is no evidence for this theory, although as Szent Gyorgyi has pointed out (190), contraction of muscle involves loss of potential energy, relaxation a build up of energy (phosphate) in the contractile elements. Therefore, slight loss of some substance promoting the restoration of the energy for relaxation may occur with time, or possibly inhibition of the mechanisms of energy storage by accumulation of another substance. In that event, permanent vasospasm

would result from normally circulating vasoactive substances. This idea has no present basis of fact, although the ions calcium, magnesium sodium and potassium are intimately concerned in muscular contraction and relaxation and it is not impossible to believe that imbalances occur with age.

The irritability of muscle and presumably smooth muscle depends upon the ratio in extracellular fluids

$$\frac{\text{Na}^+ + \text{K}^+ + \text{OH}^-}{\text{Ca}^{++} + \text{Mg}^{++} + \text{H}^+}$$

When the concentration in the numerator is increased irritability increases when that in the denominator is increased irritability decreases. The extracellular concentrations under most conditions can affect intracellular ones. Therefore vascular smooth muscle may become more irritable and therefore contract more either with higher sodium and potassium levels, by interference or displacement of calcium or magnesium by another inactive element or by their depletion (192).

INTRARENAL ENZYMATIC MECHANISMS

If all nephrogenic hypertension (except azotemic) is dependent upon the same renal enzymatic alterations it is well to consider and search for reasons as to how this can come about. Hypertension has been produced experimentally in animals and resulted in man from a variety of methods of damaging the kidney most of them can be considered as producing ischemia. Hypertension has also been produced in dogs with no kidneys kept alive by hemodialysis, whether the mechanism is the same or not is unknown. Yet in man with permanent hypertension there

may be no vascular lesions no organic renal disease no organic renal ischemia but functional changes are found which are obviously dependent upon circulating vasoconstrictor substances provoking spasm. In the dog spasm is even present distal to renal arterial constriction (10) What is the reason?

To find the answer we must delve deeper into those mechanisms affected by ischemia in order to think of similar ones altered in the functional state. Something has happened to the kidneys of patients with sustained functional hypertension which may be similarly affected in organic renal ischemia. We look to altered enzymatic mechanisms to supply us with a common denominator. Because ischemia is related to oxygen tension and oxygen consumption oxidative mechanisms are the first to be considered. Is it possible therefore that some renal oxidative enzyme in man is reduced in function by both organic ischemia and an exogenous accumulating substance? If this were so a population might be exposed uniformly to this substance but only certain members predisposed to hypertension i.e. those who react to stress by vasospasm might develop permanent disease.

Pickering put forth this same idea that a whole population was contaminated but only certain persons developed the disease (Chapter II). This theory is the only one consistent with the known facts and which explains the virtual absence of the disease in many areas of the world. For it is likely that a proportion of all human beings react to stress by neurogenic discharges through the sympathetic nervous system.

There are two possibilities intimately related which should be explored in order to discover this basic disturbance. Both could explain this most important factor. One involves vitamin B₆ one trace metals.

Theory of Local Vitamin B₆ Deficiency Vitamin B₆ is a most prevalent coenzyme, causing reactions described before which are essential for life and health. Deficiency disease in man has been produced by desoxypyridoxine, a metabolic antagonist which may not compete with all the known functions of the vitamin, the principal lesions were of the skin and included cheilosis, stomatitis, papular eruptions and dandruff (191) similar to deficiency of other B vitamins or to zinc deficiency (181). Peripheral neuritis has also been produced by isoniazid which causes excretion of this vitamin. In monkeys loss of hair, weakness, weight loss, muscular wasting, microcytic anemia and skin lesions occur. Obviously we cannot look to generalized vitamin B₆ deficiency for explaining human hypertension, nor any other disease since most patients lack symptoms and appear in the best of health. In young rats however hypertension has been produced by desoxypyridoxine (193, 195). Since this coenzyme takes part in all amino acid metabolism, it is possible that a relative or marginal deficiency occurs in the tissues (or kidneys) of populations subject to hypertension, being a local deficiency, generalized lesions would not occur.

Is there a deficiency of vitamin B₆ in the American diet? Authorities differ in their opinions. The need for vitamin B₆ in man has been established but the daily requirement has not, being estimated as more than 10 and less than 50 mg (191). The vitamin is heat labile (196) and destroyed by light (197). It is destroyed or removed during the processing of foods, which includes canning and cooking (198, 199). Simple methods for its estimation, depending upon the growth of certain bacteria or yeasts, are considered as giving values too low (200) or too high (201) compared to rat growth curves. The answer is difficult to find.

The American diet composed as it is of many canned

and processed foods, may be marginal with respect to vitamin B₁₂ during certain seasons of the year, according to the best figures available (201-202). Furthermore all pregnant women appear to be somewhat deficient the growing fetus apparently removing the vitamin from the mother without causing skin lesions (203-205). Army combat rations were found deficient for monkeys and rats (206-207) and a brand of infant food was found deficient causing convulsions (208-209).

✓ As we have said there is obviously no generalized deficiency state which can be recognized in the American adult population. Marginal intakes however are possible especially during seasons of the year when the diet is composed largely of processed foods. Converting the values in foods described in the literature to include a daily diet we have found that the intake is barely adequate (202). About 0.2 mg per 100 Gm of food is necessary to promote the growth of rats. Not many foods contain this much when cooked and it was difficult to calculate a 2.0 mg intake in a sample hospital diet (202).

Why do not pronounced deficiency symptoms appear? Apparently this coenzyme has an affinity for systems where it is most needed for life and less for health. Its distribution in organs shows wide variations (201). Perhaps renal deficiency can exist without deficiencies elsewhere, perhaps overloading of one vitamin B₁₂ enzyme system by metabolic products can produce a state of local deficiency without it being manifest in other systems. The need for a coenzyme varies as the load placed upon the enzyme system as is so well known in the case of vitamin B₁₂ or thiamin. A third possibility is that specific antagonists accumulate with age.

✓ **Trace Metal Imbalance** The second theory concerns metalloenzymes. There are many in the kidney. If deficiency of a metal were produced that enzyme would be

TABLE XXI

URINARY EXCRETION OF TRACE METALS IN NORMOTENSIVE AND HYPERTENSIVE STATES (%/L) (111)

	Mn	Zn	Mo	V	Co	Pb	Cr	Vi	Se	As
Normotensive 15 cases	Mean Range	66.8 <5-135	14.0 <0.5-45	<0.6 <0.3-7.3	<1.1 <0.5-4	<3.75 <0.03-10.7	<0.64 <0.03-1.0	<2.78 <0.03-12	<3.23 <0.3-10.25	0.80 0.4-1.4
Untreated hypertensive 16 cases	Mean Range	34.11 31-355	10.63 2.1-26	1.95 <0.2-14.5	37.9 <0.5-3.0	5.83 <0.5-31	0.88 <0.05-4.4	3.33 <0.1-16.8	8.93 0.5-41	1.21 0.3-4.6
Untreated hypertensive 8 cases	Mean Range	62.6 5-205	7.59 3.8-15.5	2.86 0.4-14.5	41.7 <0.5-370	3.21 1.8-5.3	0.67 <0.05-3.1	3.00 1.1-6.75	5.47 0.5-10.5	1.44 0.3-4.6
Same treated	Mean Range	12.14 31.170	4.34 0.5-10.11	0.93 0.21-1.85	3.14 <0.5-13	3.97 0.8-11	0.71 <0.03-2.6	5.78 0.3-28.5	2.64 0.3-9	0.73 0.24-1.7
Hydralazine disease 2 cases	Mean Range	<5 108-159	2.4-3.9	0.11-1.5	0.5-70	<0.05-2.8	0.34-12	1.1-4.4	7.8-8.8	1.2-2.0
Disseminated lupus 5 cases	Mean Range	<5 87.5-180	18.2 4.4-750	1.80 0.5-4.9	2.5 0.3-6.0	3.54 <0.05-10	1.00 0.4-2.8	2.7 1.4-5.7	13.96 3.0-38	0.40 0.29-0.58

By ganglion cbl chloride and Hydralazine
From data of Perry and Schroeder

come inactive until the metal were replaced. There is no evidence at the present time that specific metal deficiencies exist in man with the possible exception of zinc in under nutrition. On the contrary, there are many trace metals in American tissues which perhaps are not only unnecessary but undesirable. The kidney is notable in this respect (Chapter VI).

(Because an undesirable metal can replace an essential one in an enzyme system and inactivate it *in vitro*, it is probable that such a consequence can occur *in vivo*.) In order to determine where to look we must examine the essential and the presumably abnormal trace metals in American human adult tissues and urine (Table XXI) compare them with metals found in infants to discover which accumulate with age and also compare the tissue content of people from areas not exposed to hypertension. This subject will be discussed in Chapter VI but examples can be considered here.

Cadmium was found in large quantities in adult American kidneys but not in infancy. This metal is nephrotoxic. An examination of the inhibitory effects of a number of trace metals upon DOPA decarboxylase and monamine oxidase revealed the following. Some inhibition was exhibited by all in high concentrations but at low (0.1 millimolar) only cadmium and mercury significantly inhibited enzymatic activity of DOPA decarboxylase both inhibited monamine oxidase to less extent (Table XXIII). Both are nephrotoxic and will displace zinc (p. 146).

(Any disease which is a function of aging may be influenced by the gradual accumulation in tissues of those trace metals which appear to show organ selectivity and poor excretion.) Any diseases appearing frequently as a function of Western Civilization which are virtually absent in uncivilized man may be influenced by accumula-

TABLE XVII
CHANGE IN SEVERAL METALS WITH AGE (P P M Ash)*

Decade Cases	Kidney					Lung			Liver				
	Ni	Zn	Cd	ΔZn-Cd	Pb	Sn	Al	Fe	Ti	Ni	Cd	Sn	Cr
0	5	1850	0	1850	13	151	77	0	0	0†	0	3‡	21
1	2	2050	160	1890	36	134	60	0	0	0	0	103	15
2	1	4700	1450	3250	68	53	440	82	14	0	190	66	21
3	4	5800	2750	3070	130	17	>1560	220	7	12	174	38	16
4	3	5100	2500	2600	115	37	>2400	>740	19	<33	167	124	16
5	3	6503	3500	2800	96	91	>2220	>660	22	0	186	33	14
6	6	7450	4200	3200	96	24	>2660	>910	10	<4	282	27	35
7+	4	6050	2850	3200	71	44	>3000	>900	10	37	385	36	17

* After Tipton (231)

† Present in only 1 stillborn

‡ Absent to trace in stillborn Present in 7 week old child only

Note: These values are indicative of concentration in wet weight of organ $\pm 10\%$. The remarkable constancy of the differences between zinc and cadmium suggests that as cadmium is accumulated displacing zinc from enzymes, more zinc enzymes are formed. If they were not this amount of cadmium would cause overt renal toxicity.

tion of those abnormal trace metals to which civilized man is exposed. Cardiovascular diseases associated with aging therefore may be influenced by accumulation of trace metals in kidney liver blood vessels adrenal or brain.

In Table XXII are shown evidences of accumulation of various trace metals or lack of it in American kidneys with age. Although the numbers in each decade are small the trends are definite for nickel titanium and cadmium, not so for tin. Zinc is accumulated in proportion to cadmium. One of these metals could be the culprit although we suspect cadmium because of its prevalence (see p. 146).

Other oxidative metalloenzymes in kidney (or elsewhere) might be affected by abnormal exogenous trace metals. Two pertaining to the problem of hypertension are listed in Table XXIII. (Any enzyme containing free sulphhydryl groups can be inactivated by metal binding thereon; thus metalloenzymes are not essential for inactivation by metals.) Direct evidence for their participation is lacking but they are shown to call attention to their role in nitrogen metabolism direct or indirect and to their metalloenzyme natures. Vanadium and cadmium have striking actions.

Theory of Electrolyte Imbalance. Small elevations in the serum sodium of hypertensive patients have been reported from time to time (210-211). Their significance is unclear. The hypertensive kidney is a salt losing kidney; no functional or morphological alterations in adrenal cortex have been demonstrated in the usual case. There is evidence however, that the sodium content of arterial walls may be increased causing enough swelling to increase peripheral resistance (212). There is also evidence that the sodium in the body affects vascular irritability in that the peripheral vessels become less sensitive in sodium depletion and more sensitive in sodium repletion and the administration of desoxycorticosterone ace

TABLE XXIII
EFFECT OF METAL IONS ON TWO ENZYME SYSTEMS (GUINEA PIG) (% ACTIVITY) (311)

Metal	Bound by Hydrate	DOPA Decarboxylase Millimolarity of Metal ion			Monamine Oxidase (Substrate tryptamine) Millimolarity of Metal ion		
		10	1	0.1	10	1	0.1
Mg ⁺⁺		103	—	—	94	99	96
Ti ⁺⁺⁺		24	82	—	87	101	103
V ⁺⁺⁺		52	92	94	100	100	99
V ⁺⁺⁺	+	11	99	113	135	137	110
V ⁺⁺⁺	+	7	100	99	256	154	108
Cr ⁺⁺⁺		96	—	—	127	106	99
Cr ⁺⁺⁺		34	100	—	90	102	104
Mn ⁺⁺⁺		26	77	86	110	111	106
Fe ⁺⁺	+	84	94	—	98	91	94
Fe ⁺⁺	+	70	100	—	106	103	102
Co ⁺⁺	+	32	106	105	106	104	103
Ni ⁺⁺	+	69	91	94	144	136	107
Cu ⁺⁺	+	33	100	—	110	107	105
Cu ⁺⁺	+	60	93	—	58	114	96
Zn ⁺⁺	+	8	13	91	18	110	101
Cd ⁺⁺	+	41	83	93	93	—	—
Hg ⁺⁺	+	2	9	89	86	82	94
VO ₂ ⁺⁺	+	—	6	86 (89)	1	64	106
Mg ⁺⁺ Na ₂ EDTA		93	105	101	127	100	97
Mg ⁺⁺ Na ₂ EDTA		104	110	—	127	116	93
Ca ⁺⁺		103	101	—	108	102	91
Mn ⁺⁺		106	107	—	126	109	103
Fe ⁺⁺		100	105	—	—	117	—
Na ⁺		95	94	—	125	115	101
Na ⁺	(24 hr)	102	—	—	—	—	—

Italicized figures represent 20% change. Note the specific effects of Cd Hg V Co (cf Table XIII p 88).
Those in parenthesis show dilutions by 10.

* Depressor in hypertensive rats as EDTA complex (Figs 13 and 14 pp 105 107)

tate. What change affecting sodium intake, loss or shift occurs in hypertension is not known. There is no correlation with salt intake in man, although moderately hypertensive rats choose to eat more. The alteration must be an esoteric one and may involve potassium and magnesium or possibly calcium as well.

Theory of Mechanical Renal Arterial Obstruction. In view of the above discussion it is highly possible that enzymatic alterations secondary to organic ischemia and those caused by one or more of the aforementioned factors may be similar. If so, partial obstruction of a renal artery by atherosclerotic plaques could provide the necessary mechanism for permanent hypertension just as well as could intrarenal enzymatic changes from trace metals or coenzyme deficiency. Such obstructive lesions exist and may be more common than realized (145). One can imagine a hypothetical case: a man with the ability to react to stress by vasospasm passes through his first five decades only with tachycardia or transient hypertension under the stimulus of an examination. In his fifth decade in our civilization he begins to develop overt atherosclerosis, plaques of which are deposited by chance or by dynamic design at the mouths of his renal arteries. He then develops hypertension caused by some organic renal ischemia and some neurogenic vasospasm. As the hypertension increases the rate of development of atherosclerosis, these plaques may become larger, leading to further renal ischemia and hypertension but without much intrarenal arterial sclerosis. He dies in his sixth or seventh decade usually of an atherosclerotic complication. This sequence of events may be very common and does not necessitate trace metal imbalance or other enzymatic disturbance unless a common disturbance influences both hypertension and atherosclerosis (Chapter VII). Further

TABLE XVIII
EFFECT OF METAL IONS ON TWO ENZYME SYSTEMS (GUINEA PIG) (% ACTIVITY) (311)

Metal	Bound by Hydrate	DOPA Decarboxylase Millimolarity of Metal ion			Monamine Oxidase (Substrate tryptamine) Millimolarity of Metal ion		
		10	1	0.1	10	1	0.1
Mg ⁺⁺		103	—	—	94	99	96
Ti ⁺⁺⁺		24	82	98	87	101	103
V ⁺⁺	+	52	92	103	100	101	99
V ⁺⁺⁺		11	99	113	185	118	110
V ⁺⁺⁺⁺	+	7	100	99	256	154	108
Cr ⁺⁺⁺	+	96	—	—	127	101	99
Cr ⁺⁺⁺		34	100	—	90	102	104
Mn ⁺⁺⁺	0	26	77	86	110	111	96
Fe ⁺⁺	+	84	94	—	98	91	106
Fe ⁺⁺⁺	+	70	100	—	106	103	94
Co ⁺⁺⁺	+	32	106	105	106	101	102
Ni ⁺⁺⁺	+	69	91	94	144	104	98
Ni ⁺⁺⁺	0	33	100	—	110	136	109
Cu ⁺	+	60	93	—	58	107	102
Cu ⁺⁺	+	8	13	91	114	114	96
Zn ⁺⁺	0	41	83	93	78	86	101
Cd ⁺⁺	0	2	9	89	93	—	86
Hg ⁺⁺	+	—	6	86 (89)	82	—	—
UO ₂ ⁺⁺	+	93	105	101	64	88	94
Me ⁺⁺ Na ₂ EDTA					127	100	106
Mg ⁺⁺ Na ₂ EDTA					—	98	97
Ca ⁺⁺		104	110	—	116	—	—
Mn ⁺⁺		103	101	—	127	102	92
Fe ⁺⁺		106	107	—	108	106	91
Na ₂		100	105	—	126	109	103
Na ₂		95	94	—	—	117	—
Na ₂	(24 hr)	102	—	—	125	115	101

Italicized figures represent 20% change. Note the specific effects of Cd Hg V Co (cf Table XIII p 88).
Those in parenthesis show dilutions by 10

• Depressor in hypertensive rats as EDTA complex (Figs 13 and 14 pp 105 107)

guish between these conditions and functional neurogenic vasospasm they can be presumed to react in the same way. Therefore in late stages arteriolar nephrosclerosis caused by the hypertension produces organic renal ischemia which sustains the hypertension. As discussed previously we probably cannot use this mechanism to account for middle stages of sustained hypertension because organic lesions are often not present.

Similarly the tubular part of the nephron may be unable to distinguish the difference between organic arterial and arteriolar narrowing from these causes or from intrarenal arterial obstruction by scars (pyelonephritis) and glomerular obstruction (nephritis and glomerulosclerosis). The locus of the mechanism reacting to renal ischemia may be postglomerular (tubular) or it may be in the juxta glomerular apparatus which lies around the afferent arteriole. In the latter case chronic glomerulonephritis might not be expected to cause hypertension until fairly widespread renal degeneration had occurred. This may be the usual situation.

Comment One can only guess at which factor operates in a given hypertensive patient. There may be several others not mentioned. The theory of vicious cycles or cybernetics is quite prominent in much of what has been said as it is in many pathologic states and normal metabolic pathways (which are far from vicious until disturbed). This mechanism which transforms intermittent neurogenic vasospasm into permanent nephrogenic and neurogenic hypertension, is the 'killer'. Therefore it becomes of foremost importance to understand it for treatment. If we could counteract this one mechanism and break the cycle perhaps hypertension would be a mild relatively nonfatal but interesting physiologic abnormality.

more, cholesterol emboli in the kidneys have occurred from plaques (213), associated with hypertension

The renal hemodynamic picture of hypertension in older persons is that of the major resistance being on the arterial side of the glomerulus (214) contrary to that seen in younger people where it is predominantly in the efferent arterioles. If the disease begins in the 50's and 60's such sequential events are likely pathogenetic features, although it is now impossible more than to guess which comes first. A vicious cycle of this sort involves the initiation of nephrogenic hypertension by local atherosclerosis and the progression of atherosclerosis by hypertension with the predisposing factor (neurogenic vasospasm) present, however, for the previous lifetime of the individual.

Sustained chronic hypertension causes arteriolar nephrosclerosis characterized in order of appearance by 1) thickening of the glomerular capsule 2) thickening of the glomerular intercapillary substance 3) thickening and hypertrophy of the walls of the arterioles 4) intimal thickening and 5) fibrosis and hyaline degeneration of the walls of arterioles and small arteries. In neurogenic hypertensive dogs these alterations take 2 to 4 years to develop (7). In man with chronic hypertension little or no changes are apparent in half of biopsies (159) while almost all show it at necropsy (2). When pheochromocytomata act as the neurogenic factor for long enough, arteriolar nephrosclerosis is the frequent result and nephrogenic hypertension may remain after removal of the tumor.


When arteries and arterioles are narrowed by permanent sclerotic changes blood flow to nephrons is obviously reduced at normal blood pressure levels. It matters little to a nephron whether its flow is cut down by a single aortic and renal arterial plaque or by organic narrowing of its afferent blood vessel. Perhaps its tubules cannot distin-

TABLE XXIV
VARIOUS EFFECTS OF PYRIDOXINE IN MAN WITH ESPECIAL REFERENCE TO ANTAGONISM TO METAL-BINDING AGENTS

Clinical Finding	Induced by Vital binding Drug	Relieved by Vitamin B ₆	No Reports	Remarks
Convulsions	Isoniazid	Yes	1	
Convulsions	Semicarbazide	Yes	1	
Peripheral Neuritis	Isoniazid	Partly	1	Local disorder
Leukopenia and agranulocytosis	Thiouracil	Yes	5	
	Sulfonamides	Yes	2	
Peripheral Neuritis	Arsenic	Yes	1	
Cheilosis Chemosia etc	EDTA	No	1	Zinc deficiency
Same	Desoxypyridoxine	Yes	2	
Same	Spontaneous	Yes	8	
Seborrheic Dermatitis	Desoxypyridoxine	Yes	2	
Same	Spontaneous	Yes	4	Applied locally

Vitamin B₆, Selected Annotated Bibliography 1954 Merck & Co

Can we bring some of these ideas together into one theory? In the case of enzymatic mechanisms, we can. For pyridoxal phosphate is believed to contain a metal necessary for activity chelated to the pyridoxal amino acid complex in the following manner (215)



We have demonstrated that cadmium and mercury can selectively inhibit at least one pyridoxal enzyme, probably by competing with the essential metal just as a number of strong metal binding agents also inhibit this same enzyme (Chapter IV) probably by removing the essential metal. Therefore, certain trace metals can be biochemically interrelated with certain pyridoxal enzymes. It is possible that not only the decarboxylases which produce the vasoactive and cerebroactive primary amines serotonin, tryptamine, tyramine, isoamylamine, dihydroxyphenyl ethylamine from amino acids but also transaminases may be inhibited by abnormal trace metals (Table XXIV).

CLINICAL IMPLICATIONS

The existence of organic narrowing of renal arteries and arterioles must be in mind during every attempt to reverse or control hypertension whether by drugs or surgery. No available therapeutic measure known will dilate renal arteries and arterioles more than they can dilate through smooth muscular relaxation; scar tissue will not

mechanisms are unknown but the clinical and laboratory evidence that adrenal steroids cause hypertension in certain cases is clear. The reader should remember, however, that there is no evidence that the adrenal cortex is over active in most cases of neurogenic or nephrogenic hypertension but that isolated instances in which it plays a definite and perhaps primary role are known.

Experimental Steroid Hypertension For many years it has been recognized that desoxycorticosterone (DOCA) a salt retaining hormone will cause hypertension in rats when added salt is given (216-217). Likewise a syndrome similar to toxemia of pregnancy can also be produced relieved or prevented by hydralazine (218). Feeding of salt alone in excessive quantities can produce rat hypertension (219); vascular lesions result. The amount of steroid and the amount of salt necessary to produce this disorder are far beyond physiologic limits. DOCA is pressor in renal hypertensive dogs (220) and hypertensive patients (221). Salt restriction apparently induces adrenal cortical hyperactivity (222).

Effect of Experimental Nephrogenic Hypertension on Adrenals Adrenal hypertrophy accompanies experimental nephrogenic hypertension (223). Furthermore rats with moderate hypertension voluntarily drink more saline than do normals or their paired severely hypertensive mates (224). This increased requirement for salt may be a reflection of the salt losing tendencies of ischemic kidneys already discussed in Chapter IV.

Relation of Adrenal Cortex to Medulla It may not be a coincidence that the adrenal medulla concerned with the release of epinephrine and the cortex concerned with sugar, salt and sex, are enclosed in the same gland. There is an intimate relationship between the two hormones acting on vascular smooth muscle. There may be a further

become more elastic This statement may not hold true however, for cholesterol filled atheromata, which probably can be partly absorbed under the proper conditions

Fortunately, the cases of severe hypertension which become azotemic when the blood pressure is lowered are rare When present azotemia may be worsened The existence of renal arterial constriction can make therapy difficult, however, intrarenal constriction beyond the obstruction probably can be quite readily opposed

The existence of organic narrowing of other major arteries to myocardium and brain must be in mind during every attempt to reverse or control hypertension, for a lowered peripheral pressure may cause ischemia beyond the obstruction These circumstances are fortunately uncommon

Because hydralazine and similar compounds appear to attack the factor converting intermittent into permanent vasospasm in time, this drug is indicated in all patients with sustained hypertension who are able to tolerate it without symptoms of sensitivity Whether or not it helps to restore a disturbed enzyme system to normal function, or merely makes abnormality more abnormal, is not known at this time Its reactions on DOPA decarboxylase suggest that amino acid decarboxylation would be suppressed by the kidney thus preventing the formation of amines its actions on monamine oxidase suggest that it can promote the destruction of amines its inhibition of pherentasin suggests that it specifically inactivates the one pressor substance found in the hypertensive state

ADRENOCORTICAL MECHANISMS

One possible factor which may influence the conversion of intermittent to sustained vasospasm lies in the adrenal cortex and in its influence on electrolyte balance The

readily when deprived of sodium conductance is restored by a number of quaternary ammonium compounds (229). Whether or not increased conductance occurs when there is an excess of intraneuronal sodium is not known. The decreased sensitivity and the sometimes lowered blood pressure seen when dietary salt is severely restricted may perhaps be explained on this basis.

These interactions between nerve transmission salt vasoconstrictor substances and steroids can explain some of the clinical findings which appear on the surface to be inexplicable. Normal vasomotor tone normal discharges of sympathetic fibres normal amounts of norepinephrine can produce generalized vasospasm when the vascular smooth muscle becomes hypersensitive through salt and steroids. Removal of salt or steroids may restore sensitivity to normal. Excessive vasomotor tone excessive discharges of sympathetic fibres excessive amounts of norepinephrine formed at nerve endings can produce a much greater degree of generalized vasospasm when the vascular smooth muscle becomes hypersensitive. Removal of salt or steroids restores sensitivity to normal but does no more than partly reduce the vasospasm to a lesser level. To achieve strict normality requires additional restoration of sympathetic activity to normal. When the vasospasm is in part caused by circulating humoral pressor substances restoration to a normal state is impossible unless these substances are inactivated.

Clinical Findings Many but not all patients with adrenal cortical adenomata or hyperplasia have hypertension. Other steroid producing tumors may also be associated with hypertension. Hypertension is uncommon but not unknown in virilizing tumors. We have seen it regress on surgical removal of the tumor. Cushing's syndrome is

more basic, relationship between salt retaining hormone and the transmission of nerve impulses along sympathetic fibres affected by sodium or potassium

1 The administration of DOCA increases the sensitivity of vascular smooth muscle to epinephrine and norepinephrine (38)

2 The vessels of the patient with Addison's disease show a relatively low reactivity to injected epinephrine and norepinephrine (225, 226)

3 Salt restriction decreases these sensitivities, salt repletion increases them

4 The hypertensive, but not the normotensive, individual responds to intravenous DOCA by a rise in blood pressure (221)

There are two possibilities to explain these findings The first is concerned with the smooth muscle fibre the second with unmyelinated sympathetic nerve fibres. Certain adrenal cortical steroids apparently act at the cellular level regulating the amount of sodium, potassium and possibly magnesium within the cell (227-228). At least there are rather profound alterations in cellular content of cations when salt retaining hormones are given or are formed in excess. In extracellular fluid there is apt to be hypernatremia, hypokalemia and alkalosis of variable degrees. If smooth muscle cells were so affected, the result might be hyperirritability of the fibres with excessive responses to vasoconstricting impulses either neurogenic or mediated through circulating pressor substances. Perhaps the intracellular edema found in the arteries of some hypertensive individuals (212) is on this basis.

Another theory involves the effect of sodium or potassium on nerve transmission through unmyelinated fibres. The fibres of primitive animals do not transmit impulses




FIG 1: Central obesity, menstrual irregularities, low sodium salt (<20 mEq/L) and hypertension. Rapid weight gain, mild hirsutism, easy bruisability and moderate diabetes were also present. This complex has been named the "endocrine hypertensive syndrome" for want of a more definitive word. The blood pressure was highly responsive to salt restriction (3-3c).

They may be recognized by the presence of central obesity and hypertension. In women, menstrual irregularities are common (Fig 17). The condition has been seen in families (3). Presumably their hypertension is influenced by an overproduction of aldosterone or other salt retaining hormones which decreases the sodium in sweat to low levels. We must hypothecate the chain of events in the

not invariably associated with hypertension primary aldosteronism, in which there is overproduction of salt retaining hormone, appears to be

The administration of cortisone and adrenocorticotrophic hormone (ACTH) is sometimes followed by hypertension. In such cases, we must assume that sensitivity of vascular smooth muscle increased because of the mild salt retaining side effects of these agents which are not of themselves primarily concerned with salt. In the presence of a normal or decreased sympathetic tone cortisone should be inactive in this respect. Hormones with lesser salt retaining qualities hydrocortisone, metacortandren etc are less active. DOCA, on the other hand, produces hypertension in a fair number of Addisonian patients treated with large amounts of salt.

"Therefore, the pressure raising activities of steroids and salt, according to this theory are not primary qualities residing in the substances themselves but depend principally upon the state of the neurogenic control of vasoactivity. If sympathetic tone is elevated, they elevate pressure. If sympathetic tone is low, they do not unless excessive hyperphysiologic amounts are given. Abnormal amounts of any hormone can cause profound derangements which would not occur with physiological replacement.

There is a group of patients now being better described which appears clinically to show excessive adrenocortical activity of two or three types of the hormones concerned with salt, sugar and sex. There are many clinical variations from the normal, extending from minor degrees to the borderline of full blown Cushing's syndrome. So far, all have had either adrenal cortical adenomata often small, or pituitary basophilism with adrenal hyperplasia.




FIG 17 Central obesity, men, menstrual irregularities, low sweat salt (<20 mEq/L) and hypertension. Rapid weight gain, mild hirsutism, easy bruisability and moderate diabetes were also present. This complex has been named the 'endocrine hypertensive syndrome' for want of a more definitive word. The blood pressure was highly responsive to salt restriction (3, 3c).

They may be recognized by the presence of central obesity and hypertension. In women, menstrual irregularities are common (Fig 17). The condition has been seen in families (3). Presumably their hypertension is influenced by an overproduction of aldosterone or other salt retaining hormones which decreases the sodium in sweat to low levels. We must hypothecate the chain of events in the

absence of exact hormonal measurements. A small adenoma forming only aldosterone will produce hypertension by polydipsia and alkalosis. One forming both aldosterone and hydrocortisone or cortisone like hormones will produce hypertension and central obesity with the resultant muscular weakness thin skin and possibly menstrual abnormalities. One forming both hormones plus androgens will induce in addition hirsutism an enlarged clitoris menstrual irregularities muscular hypertrophy maleness and the like. There can therefore be seven clinical types only four of which are associated with aldosterone and hypertension four with central obesity and four with androgenic overproduction. While the distinctions between cases are not as simple as outlined here since a single hormone may have the minor side effects of another this idea is worth considering from clinical grounds and can explain the presence or absence of these different clinical manifestations. In aldosteronism the tumor is probably derived from cells of the zona glomerulosa. The severity of the manifestations naturally depends upon the amounts of hormones produced in excess.

Hypertension and Hyperaldosteronism Recent studies have shown that there is a mild hyperaldosteronism in severe and malignant hypertensive patients as evidenced by the salt retaining properties of urinary extracts in adrenalectomized rats (230). If this is so it is possible that vascular hyperactivity is dependant upon a slight excess of this hormone. However taking into consideration all of the data concerning the adrenal cortex in hypertension this theory is hardly tenable.

The hypertensive kidney loses salt under a load and the more severe the hypertension in terms of nephrosclerosis the greater is the tendency to lose salt. Since salt de

pletion or some electrolyte abnormality may be the stimulus to the formation of aldosterone it is possible that the mild aldosteronism measured may be merely a reflection of this salt losing tendency which probably has its seat in the kidney. Slightly excessive production of aldosterone could be predicted from knowledge of chronic renal salt loss. Obviously this form of adrenal cortical hyperfunction would cause if a primary initiating factor salt retention by the kidney a phenomenon opposite to what is actually encountered.

CLINICAL IMPLICATIONS

Obviously patients with hypertension influenced by adrenal cortical overactivity should respond to restriction of salt by a lowered blood pressure. They do. The fact that severe salt restriction will not influence severe hypertension secondary to organic renal disease argues against the role of the adrenal in this state. Severe salt restriction can occasionally influence neurogenic hypertension probably because vascular reactivity to sympathetic discharges is decreased. But these results do not mean that all human hypertension is dependant upon steroids and salt. on the contrary these cases are in a minority. The reader must remember the simple fact that dietary salt restriction of severe degree causes overactivity of the adrenal cortex and that the usual hypertensive kidney is a salt losing kidney to an extent dependant upon the degree of renal damage or renal ischemia.

The clinician does well to recognize cases of aldosterone hypertension for treatment of them may differ radically from that of the usual case of neurogenic or nephrogenic hypertension. Although eventually arteriolar nephrosclerosis develops a lesion dependant only on diastolic hyper

tension from any cause, it seems slow to occur in these cases and is apt to be less severe than in other types (3, 4). Salt restriction, antiadrenal hormones and adrenalectomy are logical methods to use if diagnosis can be accurate. None of these measures is necessary nor justifiable in other types. Therefore their recognition becomes of practical significance. The measurements of sodium in sweat (5) or saliva and of specific steroids in urine or blood are specialized diagnostic procedures for such cases.

Chapter VI

TRACE METALS AND CARDIOVASCULAR DISEASE

INTRODUCTION

BECAUSE of the strong suggestion that trace metal imbalances may be involved in some of the chronic diseases to which the people of Western Civilization are exposed a chapter on this subject is in order. To be considered are the relations of metalloenzymes to the problem, the concentrations of essential trace metals in human tissues, the presence and amount of abnormal metals and from whence they may come, and the possibility of their interference with metalloenzymes to such an extent that they cause chronic diseases. Because this subject represents a new frontier in Medicine, vast gaps in knowledge exist but the pattern is clearing.

By trace metals we will consider only those present in small or relatively minute amounts and not discuss the bulk metals sodium, potassium, magnesium, and calcium, nor iron which has an intermediary position between ubiquitous elements and trace metals. All bulk metals probably take part in enzymatic reactions or in exchange mechanisms; trace metals are often confined to more specialized systems. If interference with one of the bulk metals occurred in the body, profound toxicity would result. For example, should all magnesium enzymes be inhibited, intermediary metabolism would cease, if calcium were displaced, muscular relaxation would cease. Partial

inhibition of some of these systems undoubtedly occurs in disease, but many can be recognized

There are many metalloenzymes in mammalian tissues but only five essential trace metals have been identified manganese cobalt, copper, zinc and molybdenum Deficiency of one of these trace metals in a metalloenzyme either by depletion or displacement by another more or less active metal can be expected to lead to a profound metabolic disturbance induced in a very basic and discrete level There is growing evidence that arterial hypertension and possibly atherosclerosis may be influenced by trace metal imbalances induced by exposure to and accumulation of abnormal trace metals resulting from products confined to Western Civilization

METALS CONCERNED IN METALLOENZYMES


For a metal to be reactive in oxidation reduction mechanisms it must contain at least two valence states which are fairly readily transposed The essential metals iron manganese cobalt and copper fit the requirement as do titanium vanadium, chromium and nickel of the first transitional group For a metal to chelate* readily a requirement for enzymatic activity (232), it should usually

* The definition of chelation and complex formation can best be given by quoting from Martell and Calvin (233) When a metal ion combines with an electron donor the resulting substance is said to be a complex or coordination compound If the substance which combines with the metal contains two or more donor groups so that one or more rings are formed the resulting structure is said to be a chelate compound or metal chelate and the donor is said to be a chelating agent The electron pair bonds formed between the electron accepting metal and the electron-donating complexing or chelating agent may be essentially ionic or essentially covalent depending on the metals and donor atoms involved Without further considering the nature of bonds simple examples of complex formation and chelation are represented schematically as follows

have a coordination number of 4 or 6 an index of the number of donors of the chelate with which the metal will combine. Thus magnesium aluminum vanadium chromic ion manganous and manganic ferrous and ferric, cobaltous and cobaltic nickelous and nickelic tin and lead have coordination numbers of 6 while zinc cupric cadmium mercury silver gold have one of 4 and molybdenum of 8. Those of titanium and scandium have not been determined (233). Some functional groupings which bind metals are carboxyl hydroxyl carbonyl amino (primary secondary tertiary cyclic tertiary) sulphhydryl thioether sulfonate and phosphonate (232).

Principles of Chelation The general rules regulating the stability of metal chelates according to Bailar (234) are as follows:

- 1 Ring structures involving metals and organic configurations have increased stability
- 2 Five membered rings in the absence of double bonding and six membered rings in its presence are the most stable
- 3 Fused rings that in configurations in which two or more rings have a common side have a greatly increased



where M represents a metal ion A represents a complexing agent and A—A represents a chelating agent.

stability, e.g., ethylenediamine tetraacetate (EDTA) is 50 times more stable than predictions would indicate

4 Maximum stability is achieved in the presence of a minimum charge. Thus inner salts are maximally stable.


5 Spatial factors are important. Thus primary amines are better than secondary amines which in turn are better than tertiary amines, probably because the methyl groups are cumbersome. Similarly water is better than alcohol which in turn is better than ether, methanol is better than ethanol, and *n* propanol is better than isopropanol. In addition each internal angle of a five membered ring should approximate 108° . If the ring involves an aromatic nucleus and its resultant obtuse external angle no chelate is formed.

6 The active groups involved in chelation are (1) fluorine and oxygen (2) nitrogen (3) sulfur carbon (CN carbonyl) phosphorus (as phosphene) and the halogens. The first group has maximum binding capacity for beryllium with a secondary one for vanadium. The second group has a maximum binding for cobalt and the third for palladium and copper. In addition both sulfur and oxygen bind metals centering around tin and antimony in the Periodic Table (Table XXV).

7 Transition metals are the most strongly bound because their inner shells are unfilled and allow a shifting of electrons to meet the optimum chelating requirements whereas other metals are much more rigid in the way they can accept or donate electrons.

The spatial type of chelate is also of interest (Table XXVI). Beryllium and boron, zinc, cadmium and mercury form tetrahedral complexes. Presumably the first two could resemble magnesium chelates, the last three each other. Copper, silver, gold and nickel form square complexes while all of the other essential metals save molybdenum

TABLE XV
AFFINITIES OF VARIOUS COMMON TRACE METALS FOR CHELATION BY DIFFERENT ACTIVE GROUPS



After Bailar (234)

TABLE XXVI
NORMAL AND ABNORMAL METALS IN CHELATES (233)

Coordination No	Tetrahedral	Square	Octahedral	Dodecahedral
4 4	Zn ⁺⁺ Cd ⁺⁺ Hg ⁺⁺	Cu ⁺⁺ Ag ⁺⁺ Au ⁺⁺⁺ Ni ⁺⁺		
6 6	Mg ⁺⁺ Be ⁺⁺ B ⁺⁺⁺			
6 6 6			Mn ⁺⁺⁺ Fe ⁺⁺ Co ⁺⁺ Co ⁺⁺⁺ Cr ⁺⁺⁺ Al ⁺⁺⁺ Pb ⁺⁺⁺⁺ Sn ⁺⁺⁺⁺	
8 8				Mo ⁺⁺⁺⁺ W ⁺⁺⁺⁺

See footnote p 193

form octahedral ones, as do chromium, aluminum, tin and lead. Thus possible interfering metals may be roughly grouped according to their chelate forms. Those of the first transitional group have the requisite outer shell unfilled, a measure of reactivity.

Trace Metals and Metalloenzymes In Table XXVII is a partial list of some of the enzyme systems believed to contain a trace metal as a prosthetic group. The list is by no means complete and undoubtedly will be expanded in the future as enzymes are purified. According to Williams (235) and Najjar (236) there are two types. In one a specific element and no other is firmly combined or chelated with the protein apoenzyme for enzymatic activity, other metals may inhibit activity. The second is relatively less specific in that two or more metal ions usually in the first transitional series can be interchanged and the metal is more or less dissociable from the protein. Some of the peptidases were thought to have only partial specificity until the work of Emil Smith (140) strongly

suggested that metal ions considered interchangeable such as magnesium manganese and cobalt are specific for enzyme activity and cannot be interchanged in the strict sense of the term

Certain metalloenzyme systems need organic coenzymes (or vitamins) for activity One possible example is pyridoxal phosphate which according to Snell requires a metal for the coenzyme to become activated (215) While the metal is not known model systems constructed without the apoenzyme suggest that either copper iron or aluminum could be the essential one (237) It is apparently so firmly bound that most metal binding agents will not remove it Other well known examples are riboflavin where flavin adenine nucleotide is intimately bound with the oxidation and reduction of iron and the copper flavinoid in acyl Coenzyme A-dehydrogenase Other members of the vitamin B group in some cases may require metals for activity magnesium with thiamine and molybdenum with flavin adenine nucleotide are examples

In general the active essential metals are divalent and in the first transitional group of the periodic table Copper is essential for phenolic and catecholic oxidation and for fat metabolism Manganese is required for peptide splitting and for carboxylation In view of the high concentrations of zinc in tissues and the very few zinc enzymes found carbonic anhydrase being the most prevalent it is possible that others exist The metallo-porphyrins are good examples of chelates heme the prosthetic group of hemoglobin has iron chelated to four methyl pyrrole rings the iron porphyrins of the cytochromes and myoglobin vitamin B₁₂ has cobalt chelated in a porphyrin structure and the porphyrin of chlorophyll chelates magnesium There are several metalloproteins known ceruloplasmin and hemocuprein contain copper mercaptalbumins ap-

parently transport zinc and copper by imidazole binding and gamma globulins contain various metals some possibly bound to sulfhydryl groups. The discovery of hexavalent molybdenum as essential not only drew attention to heavier metals but was also the first example of a high valency metal in an enzyme. Therefore, higher valency metals in the first transitional group are not excluded from essential functions (Ti, V, Cr) nor are heavier ones.

The practice of suspecting the presence of a trace metal in an enzyme system by attempting to inactivate it with metal binding agents (cyanide, sulfide azide, mercaptans, thiocyanate, ethylenediamine tetraacetate) may lead to false assumptions if the metal is more tightly bound to the enzyme than it can be to the binding agent. In the case of carbonic anhydrase, a known zinc metalloprotein, many strong chelating agents apparently fail to inhibit activity although some binding agents do (238). Inhibition by sulfanilamide may be the result of zinc binding. Strange to say, zinc itself is a potent inhibitor as are silver, gold, copper, mercury and vanadium. The kinetics of such reactions have not been described sufficiently to allow predictions as to different metals involved. Purification of an enzyme now is the only real proof.

POSSIBLE COMPETITIONS BETWEEN ABNORMAL AND ESSENTIAL TRACE METALS

The validity of the Periodic Table appears established for physics, geology, chemistry and metallurgy but until recently there has been little application of these disciplines to the biochemistry of disease. Substitution of one element of a periodic group for another, however, has been often demonstrated in specific mammalian tissues.

Substitution of One Element for Another In group II B, radium, barium, strontium, calcium and beryllium all

have an affinity for bone both strontium and beryllium can cause rickets and beryllium displaces magnesium on phosphatases inactivating them. Therefore all but magnesium are concentrated by one tissue. Similarly two anionic and all cationic elements in group VII have been shown to be concentrated by the thyroid: iodine, astatine, manganese, technetium and rhenium; those of the halide sub-group quite specifically (239-242). Likewise in group V A bismuth, antimony and arsenic are believed to displace phosphorus in phosphates. Gold, silver and copper of group I B have strong affinities for each other, as does cadmium for zinc in group II B. Complete separation of the two from ores is difficult and often too expensive for commercial purposes. Cadmium displaces zinc on human mercaptalbumin while lead does not, presumably because the former two ions bind the same molecular group (the 16 imidazole groups) while the latter binds at a different site. Cadmium therefore has a higher affinity than zinc for this protein. Similarly cupric ion is displaced from the sulphydryl groups of bovine serum albumin by metals in the following order of affinity: $Hg^{++} > Pb^{++} > Cd^{++} > Zn^{++}$ (243). Among the anions, fluorine, chlorine, bromine and iodine are biologically interrelated while selenium and tellurium of group VII A will displace sulfur in hair and nails, possibly in sulphydryl groups. In group I A, radio-rubidium is used to measure potassium space (244).

Metalloenzyme Inhibitions In spite of these obvious relationships in biological material, metalloenzyme competition by an extraneous metal has not been systematically studied. In Table XXVIII are shown examples of cases where an extraneous metal apparently displaces an active metallic prosthetic group. The list may be far from complete. At least two types of enzyme inhibition can occur

TABLE XXVIII
SOME EXAMPLES OF INHIBITION OF METALLOENZYMES BY METALS

Enzyme	Activator	Inhibitor	References	Remarks
Alkaline phosphatase*	Mg ⁺⁺	Be ⁺⁺ Cu ⁺⁺	298	Other inhibitors less effective
ATPase*	Ca ⁺⁺ Mg ⁺⁺	Be ⁺⁺ Cu ⁺⁺	298 299	
Arginase*	Mn ⁺⁺	Be ⁺⁺	267	
Carbonic anhydrase	Zn ⁺⁺	Cu ⁺⁺ Ag ⁺⁺ Au ⁺⁺	238	Other metals (Cd ⁺⁺) forming in soluble bicarbonates or phosphates may compete
		Zn ⁺⁺ Hg ⁺⁺ V ⁺⁺⁺		
Tyrosinase*	Cu ⁺⁺	Au ⁺⁺ Ag ⁺ Hg ⁺⁺	246	No other transition elements or Cd
Leucine aminopeptidase	Mn ⁺⁺	Cd ⁺⁺ Cu ⁺ Hg ⁺⁺ Pb ⁺⁺	300	
Carnosinase*	Zn ⁺⁺ or Mn ⁺⁺	Ca ⁺⁺ Cd ⁺⁺	301	
Xanthine oxidase	Mo ^{+vi}	Cu ⁺⁺ Hg ⁺⁺ Ag ⁺ Pb As	302	
Aldehyde oxidase	Mo ^{+vi}	As	303	
Glutamic transferase	Mn ⁺⁺	Cu ⁺⁺	301	Metal not established
Succinic dehydrogenase	Cu ⁺⁺ ?	Cd ⁺⁺	238	
Choline oxidase	?	Cd ⁺⁺	238	
Prolidase	Mn ⁺⁺	Co ⁺⁺ Ca ⁺⁺ Zn ⁺⁺	238	
Glycylglycine peptidase	Co ⁺⁺	Zn ⁺⁺	305	
Phosphoglucomutase	Mg ⁺⁺	Cu ⁺⁺ Ag ⁺ Hg ⁺⁺ Zn ⁺⁺ Pb ⁺⁺	306 238	

*Probably by peptic displacement. For other examples see Tables XXIII and XXVI.

One is when a heavy metal combines with sulphydryl groups to inactivate the enzyme. Mercury, copper and silver will inactivate many enzymes which do not contain a metal (245). Presumably the toxic effects of many heavy metals are due to this type of reaction. The second is when the essential metal is displaced by another often of the same periodic group. Lerner has offered good examples of both types of reactions in respect to tyrosinase essential for formation of melanin (246). Metals which compete with copper. Increased melanin pigmentation is frequently observed when heavy metals such as arsenic, bismuth, iron, gold, silver and mercury are deposited in the skin. Patients with hemochromatosis have relatively large amounts of iron and copper deposited in the skin. The most plausible explanation for these findings is that metals bind epidermal sulphydryl groups and thereby release inhibition of tyrosinase. The increased tyrosinase activity results in increased melanin formation. However, if sufficient quantities of the metals mercury, silver or gold are present they can replace the copper of tyrosinase to produce an inactive enzyme with resultant depigmentation. It is possible that the slight decrease in skin color produced by ammoniated mercury freckle creams is achieved in this manner. Six copper binding agents have caused depigmentation *in vivo* (247), most of them anti-thyroid drugs.

Essential metals such as copper, manganese, cobalt and zinc can interact to inhibit the metalloenzymes of each. Excess enzymatic activity by a presumably abnormal metal can also occur. For example, chromium causes increased synthesis of cholesterol and fatty acids by rat liver (248). Cadmium and cobalt enhance bacterial oxalacetic carboxylase, a manganous enzyme. Vanadyl ion enhances monamine oxidase (Table XXIII). Thus both stimulation and depression by abnormal metal are possible.

The effects of a series of metals on two enzymes possibly concerned in arterial hypertension are shown in Table XVIII. At the highest concentrations it is probable that inactivation of dihydroxyphenylalanine (DOPA) decarboxylase by metals was nonspecific or caused by sulphhydryl binding. At low concentrations the specific inhibition by cadmium and mercury may be the result of displacement of another essential metal. Since the coenzyme is pyridoxal probably with a metal displacement of the related essential metal is the most plausible explanation of the mechanism of inhibition. If so zinc may be the essential one. Obviously high concentrations of cadmium in the kidney might cause serious metabolic alterations in the decarboxylation of several amino acids.

If interference of a single metalloenzyme system can be caused by another competing and inactivating metal certain chronic diseases could ensue. As a theoretical example if the molybdenum in xanthine oxidase were replaced by another in the same periodic group for example, tungsten or chromium, and the enzyme so inhibited gout might be produced. There is no evidence whatsoever that gout is due to tungsten or chromium but this is a theoretical possibility. Interference by an extraneous metal such as chromium, with manganous ion in the Krebs cycle would interfere with carbohydrate metabolism. Any one of these reactions could have profound and lasting results if a sizeable part of the total activity of the enzyme in the body were inhibited.

Simple Chelating Compounds A great many organic compounds possess the ability to bind metals in more or less dissociable complexes. Many others form chelates in which two or more electron donors combine with the metal to produce one or more rings (233). The importance of chelation has long been appreciated in industry but only

lately in biology although the calcium citrate chelate is commonly used to prevent clotting of blood All metallo-enzyme reactions are believed to depend upon chelation

Each chelating compound differs widely in its affinity for different metals. In Table XXIX are shown the stability constants of a number of common oxygen and nitrogen chelators with divalent metals of the first transitional group and with cadmium. Ten of these compounds are present in biological fluids. In general an increase in tightness of structure is proportional to atomic number reaching a peak at copper (or nickel) and decreasing thereafter. This fundamental property of most chelating agents must be in mind whenever they are used, in effect this property means that a free ion having a higher stability constant with the chelator will displace a chelated metal with a lower constant. When the active groups are sulfur and other chelators the pattern of metallic affinity is different (Table XXV).

Metal Binding Simple metal binding is dependent either upon the tightness of the bond, the lack of dissociation of the dissolved salt, or upon the insolubility of the complex. Thus complexes may be formed between metal and ammonia, metal and sulfhydryl, metal and cyanide, or metal and hydroxide. The stability constants for transitional metal complexes in solution are usually lower than for chelates, although mercury has a fairly high affinity for CN , NH_3 , OH and pyridine. The common law relating the stabilities of chelates of the first transitional group and atomic numbers appears to operate in the case of simple complexes of OH , CN , NH_3 , and pyridine.

DRUGS AS CHELATING AGENTS

Most potent drugs may act through their abilities to chelate trace metals on metalloenzymes. Schubert states

(232) The action of many drugs probably can be explained, partly or wholly, by their possession of groupings capable of binding metals. The drug whether deleterious or helpful to the organism inhibits or activates a physiological function in which a metal is required. Inhibition or activation may come about in several ways:

1 The drug may chelate a metal ion needed for the activation or inhibition of an enzyme system and hence, indirectly necessary for survival.

2 The drug by its chelating action may facilitate the transport of a metal ion to its site of action, in some cases by the formation of a fit soluble metal chelate.

3 The chelating drugs may render available for metabolic purposes a metal ion which otherwise might remain in an inactive, insoluble form.

4 The metal chelate may be readily excreted, thus providing a means of detoxification.

Examples of drugs which may act through chelation by some of these actions are given below. Of further interest are the factors determining whether or not a metal chelating drug will be effective, since these same factors are responsible for chemical specificity in biological systems. Knowledge that metal chelation is the basis of a drug's action facilitates considerably the development of new drugs because it becomes possible to anticipate how the drug molecule can be modified to enhance its metal binding properties.

In the case of salicylic acid it is highly probable that metal chelation is important. This is shown by the fact that the *m* and *p* hydroxybenzoic acids which do not chelate are inactive as analgesic agents or against the fever and pain associated with rheumatic fever. It is not known which metal or metals are affected by salicylic acid, but it is known that the metals affected must belong to the

transition groups. Numerous derivatives of salicylic acid containing the o-carboxyl hydroxyl group are about as effective as salicylic acid although they differ in dosage required and side effects. It might be anticipated that physiologically cortisone would have some resemblance to salicylates as has been demonstrated experimentally. Terramycin and aureomycin reverse the Be inhibition of alkaline phosphatase through the formation of a complex ion with Be. He lists as examples salicylic acid, adrenalin, terramycin, aureomycin, a thiosemicarbazone and cortisone. Penicillin forms insoluble salts with heavy metals.

Many chelating agents are fungicidal, antiseptic or bactericidal (233). Thirteen of nineteen common organic chelators of one or more transitional metals are listed by Martell and Calvin as effective against growth of *B. subtilis* with seven against growth of *E. Coli*. Likewise 8-hydroxyquinoline of seven quinolines and 26 substituted quinolines of 33 are effective against the growth of *Clostridium welchii*, most of which inhibit *Streptococcus hemolyticus*, *Staphylococcus aureus* and *B. Coli*, less so *Proteus* and *Pseudomonas pyocyaneus*. Zinc and manganese appear to be bound although the other essential metals iron and cobalt may be involved. Apparently copper is not for copper reagents in general are inert. Few are effective against *pyocyaneus*, an *organism resistant* to most antibiotics. The fungicidal properties of the oxines so widely used in industry is believed to be the result of their chelation with zinc, an essential metal for growth. Therefore bactericidal and fungicidal activity of many antiseptics and antibiotics may be functions of metal binding or chelation.

The most popular and versatile of the recognized chelating drugs is ethylene diamine tetraacetate (EDTA, Sequestrene, Versene) stability constants for which are shown in

TABLE XXIX
THE LOGARITHM OF THE STABILITY CONSTANTS OF SOME METAL COMPLEXES*

Ligand	N	Mg	Ca	Mn	Fe	log K _N				
						Co	Ni	Cu	Zn	Cd
NH ₂ CH ₂ CH ₂ NH ₂ (En)	2	Small	Small	4.8	7.5	10.7	13.8	19.6	10.4	10.0
Histidine	2	—	—	7.7	—	13.8	—	18.6	12.8	—
N(CH ₂ CH ₂ NH ₂) (Tren)	1	—	—	5.8	8.8	12.8	14.8	18.8	14.6	12.3
CH ₂ NH(CH ₂ CH ₂ NH ₂)	—	—	—	—	—	—	—	—	—	—
CH ₂ NH(CH ₂ CH ₂ NH ₂) (Tren)	3	—	—	4.9	7.8	11.0	14.0	20.4	12.1	10.7
Glycine	2	4.5	1.4	6.6	8.0	8.9	11.1	15.4	9.7	8.6
Glycyl glycine	3	1.1	1.2	—	—	3.5	4.5	6.0	3.8	—
N(CH ₂ CO ₂ H) (Triac)	3	5.4	6.4	7.4	8.8	10.4	11.3	12.7	10.4	9.5
CH ₂ N(CH ₂ CO ₂ H)	—	—	—	—	—	—	—	—	—	—
CH ₂ N(CH ₂ CO ₂ H) (EDTA)	3	8.7	10.6	13.5	14.2	16.1	18.5	18.4	16.1	16.5
Oxalate	3	3.4	3.0	3.9	—	4.7	5.3	6.2	4.9	3.9
Tartrate	3	1.4	1.8	—	—	—	—	—	2.8	—
Salicylaldehyde 3 Sulphonic acid	2	—	—	—	—	5.6	6.6	9.3	5.4	—
Salicylaldehyde†	2	6.8	—	6.8	7.6	8.3	9.2	13.3	8.1	7.8
Acetyl acetone†	2	9.5	—	—	—	11.2	12.1	17.1	—	—
Polysphosphate (N=2)	7	3.2	3.0	2.5	3.0	3.0	3.0	5.5	2.5	—
Hydroxyl ion	3	2.6	1.1	2.8	3.2	3.6	3.8	6.5	4.7	3.0
Dipyridyl	3	—	—	—	16.5	—	—	17.8	—	10.5
ortho-Phenanthroline	3	—	—	—	21.5	—	—	—	17.0	15.2
Riboflavin	7	—	—	3.4	7.1	3.9	4.1	6.6	5.6	4.7
Folic Acid	7	—	—	6.0†	7.9	8.1	9.0	7.8	7.5	6.7

* After Williams (235)

† The measurement of these stability constants was made in a mixed dioxan/water solvent whereas the other measurements were all made in aqueous solution

Table XXIX In addition to the transitional metals many others have strong affinities lead (18.2) lanthanum (15.4) chromic (24.0) ferric (25.0) as well as beryllium vanadium titanium silver and many rare earths * Because EDTA is not metabolized (249) and apparently enters cells (250) it provides a means for removing soluble ions from the body in the order of their stability constants. If an abnormal trace metal is to be removed normal ones will accompany it according to the relative amounts and stability constants of each. Thus EDTA is not specific for lead for example a current popular use but will remove other ions with a higher constant such as copper and nickel and especially ferric iron. EDTA will be inactive however if the metals in the body are more tightly bound or chelated to protein than to the drug. This relative chelating capacity of a sequestering agent and a metal in the body follows certain definite laws and explains the ineffectiveness of EDTA for removing most metals.

An example of the effects of EDTA given intravenously to two patients is shown in Table XXX. Zinc was removed in sizeable quantities other metals less so or not at all. The high excretion of zinc in the patient with the nephrotic syndrome found before the drug was given is probably explained by the excessive proteinuria which carries combined zinc. There was no mobilization of lead while

EDTA makes a good chelating agent for clinical use for the following reasons: 1 The stability constants ($\log K_a$) for common but important loosely bound metals is low (Ba Sr Ca Mg = 7.76-10.96) 2 The constants for more tightly bound metals is moderate (Mn Fe⁺⁺ Co Cu Zn = 14.04-18.8) 3 The constants for several abnormal metals is high (Hg 21.8 V⁺⁺⁺ 25.9 Fe⁺⁺⁺ 23.1). Unfortunately several abnormal metals fall in the range of the essential ones (Pb 18.04 Al 16.15 Ni 18.6? Y 18.09 Cd 10.46) so that these cannot be removed without danger of essential metal deficiency notably zinc.

RENAL EXCRETION OF 13 METALS BEFORE DURING AND AFTER INTRAVENOUS EDTA

Date	¹⁹ EDTA gm	Urine Volume l	Urine Protein gm/l	Ti	V	Cr	Mn	Ni	Zn	Mo	Ag	Cd	Pb	Sn	F ¹⁹	Cu ⁶⁴
Normal Subjects																
Nephrosis																
11/3/54	0	1.55	—	<3.8	<0.03	<0.64	<9.7	<2.8	<67	<14	0.88	<0.86	<5.7	<3.2		
2/25/55	0	2.66	2.6	0.37	<1.0	0.14	<5.0	0.75	360	5.0	0.74	2.9	0.80	11	570	330
2/26/55	0	2.15	2.4	0.16	<1.0	<0.05	<5.0	1.8	170	3.6	0.59	1.3	3.4	22	560	—
2/27/55	0	1.80	2.2	0.88	<1.0	<0.05	<5.0	2.2	370	3.5	0.76	0.88	0.28	6.0	560	162
2/28/55	0	2.36	1.6	0.95	<1.0	<0.05	<5.0	2.2	240	3.2	0.54	2.5	0.60	14	660	230
Mean	0	2.24	2.2	0.89	<1.0	<0.07	<5.0	1.7	285	4.1	0.57	1.4	0.22	6.4	460	265
3/1/55	3	1.81	2.4	1.1	<1.0	0.11	21	2.4	1900	3.6	0.62	1.5	1.1	12	560	219
3/2/55	3	2.01	2.8	2.0	<1.0	0.35	12	4.0	1400	3.0	0.36	<0.5	0.27	2.5	1050	180
3/3/55	4	1.46	3.2	0.50	<1.0	7.3	15	16	2200	2.4	0.32	<0.5	0.07	2.2	1070	162
3/4/55	0	1.97	2.4	0.73	<1.0	0.12	8.5	2.4	1200	1.2	0.38	2.8	0.70	4.8	1930	187
Mean	2.5	1.81	2.7	1.1	<1.0	2.0	14	6.2	1675	2.2	0.37	4.0	0.04	3.4	1450	385
3/5/55	0	1.73	3.2	1.3	<1.0	<0.05	<5.0	3.0	640	<0.5	0.43	3.6	0.13	3.9	—	385
Normal Female																
10/6/55	39															
10/8/55	0															
10/11/55	0															
Mean																
10/16/55	3															
10/17/55	3															
10/18/55	3															
10/20/55	3															
Mean																

From data of Perry and Schroeder (181) The normal subjects were 15 laboratory workers Note the increase in the normal subjects in the amount of lead excreted in the urine after EDTA treatment. The high level of lead excretion in the normal subjects is due to the fact that they were all in the lead industry. The lead in the blood is obviously a deficiency Note also the fall in the normal women and the normal men after EDTA treatment. The lead in the blood is obviously a deficiency Note also the fall in the normal women and the normal men after EDTA treatment. The lead in the blood is obviously a deficiency Note also the fall in the normal women and the normal men after EDTA treatment.

The lead in the blood is obviously a deficiency Note also the fall in the normal women and the normal men after EDTA treatment. The lead in the blood is obviously a deficiency Note also the fall in the normal women and the normal men after EDTA treatment.

eight metals almost certainly present in a strongly bound form in their tissues did not change

BAL (2,3-dimercaptopropanol) a straight chain dithiol binds the following heavy metals in a chelate zinc chromium cadmium nickel, lead, antimony, arsenic, bismuth copper, mercury, gold (251) Substitution complexes on the sulphydryls are formed In the case of cadmium at least, these are dissociated in the kidney and may result in cadmium nephritis a reflection of the greater binding capacity of renal tissue for cadmium than BAL Citrate a chelating agent used for lead poisoning is metabolized by the body and is therefore relatively ineffective A list of some representative binding and chelating agents is shown in Table XXXI Their use in medicine is only beginning For example all antithyroid drugs have this common property suggesting their probable action

These considerations open up a wide field of thought on the mechanisms of disease and of drug actions Similar conclusions can be drawn when late toxic reactions of drugs are compared with structure The common denominator of the offending drugs appeared to be in chelation

Drug Reactions Late systemic reactions to drugs affect several organs and systems of which blood dyscrasias hepatitis and polyarteritis are the most serious (252) Most of the drugs causing fatal agranulocytosis as listed by Alexander (252) are metal binding agents (253-255) such as aminopyrine phenylbutazone antihistamines dinitrophenol Presidon procaine amide and Tapazole containing pyridines amines amides nitroso or sulphydryl groups (253) Their solubilities and specificities for heavy metals however are not known to our knowledge Nonfatal leucopenia has occurred with arsenical compounds gold salts thiouracils hydantoins salicylates sulfonamides streptomycin and thiosemicarbazone which can displace or bind

TABLE XXVI

SOME EXAMPLES OF CHELATING AND METAL-BINDING DRUGS (232 233 253)
(OTHER THAN ANTIHYPERTENSIVE AGENTS)

<i>Drugs Used To Remove Metals</i>	<i>Reference</i>
EDTA	233
BAL	251
Citric Acid	235
<i>Antithyroid Agents†</i>	294
Thiourea	247
Thiouracil	247
2 Mercaptoimidazole* (Tapazole)	253
2 Aminothiazole*	253
P Aminobenzoic acid*	253
Sulfonamides	233
L-5 vinyl 2 thio-oxazolidone	294
<i>Antibiotics†</i>	
Sulfonamides	233
Penicillin (and penicillamine)	253
Chloramphenicol*	253
Streptomycin*	253
Isoniazid	296
Thiosemicarbazone*	253
P Aminosalicyclic acid	233
<i>Analgesics and Antipyretics†</i>	
Aminopyrene	233
Antipyrine	253
Phenylbutazone*	253
Phenacetylurea*	253
Salicylic acid	233
<i>Miscellaneous†</i>	
Bis(diethylthiocarbamyl) disulfide (antabuse)	297
2 Acetyl amino 1 3 4 thiadiazole 5 sulfonamide (Diamox)	233
<i>Drugs Containing Specific Groups†</i>	232 233 234
Pyridine	
Thiol or Mercaptan	
Carbazide	
Diazine	
Thiazol	

* Contains metal binding groups affinities not known

† Drugs causing late toxic reactions

TABLE VXXI—(continued)

Nitrite	
Thiocyanate	
Pyrocatechol	
Quinaldine	
Hydantoin	
Hydrazine	
Chelating Chemicals *	
Phytic Acid	
2 ketogluconic acid	
Glycerophosphates	
Potassium gluconate	
Gallates	
Rubeanic acid and derivatives	
Guanidine carbonate	
Potassium ethyl xanthate	
Dimethyl glyoxime	
Uracil	
Oximes	
Diphenyl carbazide	
Diphenyl thiocarbazon	
Potassium thiocarbonate	
Cupferron	
Adipoin	
Some Reagents for Analysis of Metals	256
Zn Ferric cyanide	
8-hydroxyquinoline	
Quinaldinate	
Sn Dinitro-diphenylamine sulfoxide	
Toluene dithiol	
Ag P-dimethylamino-benzalrhodamine	
Ni γ benzil-dioxime	
Dithiooxalate	
Dithiol	
Mo Thiocyanate	
Cu Quinosol	
Pyridine thiocyanate	
Cd β -naphthoquinoline	
Thiourea	
Benzoin-oxime	

From chemical catalogues

trace metals. The properties of the few other drugs causing this disorder are not known. Even the more unusual cases of leucopenia are due to such metal binding agents as barbiturates, chloramphenicol, isoniazid, demerol, phenothiazines, novalgin, pamaquine, penicillin and phenurone, which appear to possess the requisite metal binding groups or to form insoluble metallic salts.

Alexander's list of drugs reported to cause aplastic anemia contains eight of the above agents, with the addition of such possible metal binding agents as quinacrine, hydralazine, mercurial diuretics (both mercury and amide are present in mercurhydrin), novurone and para-aminosalicylic acid. The drugs causing thrombocytopenic purpura include eleven of the above with the addition of sedormid, procaine, quinine and quinidine containing either similar groups or quinoline. In the case of quinine and quinidine the quinoline structure is not such as to have chelating properties, the requisite group being on the 4 position while 8-hydroxyquinoline is a strong chelating agent. Unless the ring structure is broken in the body to form quinolinic acid, the mechanism of action is probably not dependent upon chelation. Hepatitis has been caused by 17 of the above drugs and by acriflavine, cortisone and carbazone, all of which contain metal complexing or sequestering groups.

Aside from proteins and undefined extracts of plant and animal tissues, many of the same drugs appear in the list of causes of what Alexander calls the serum sickness pattern (252). Twenty-one of the above drugs are listed, with the addition of thiocyanate, ACTH (which may mobilize zinc and contain sulfhydryl), bismuth, two new antibiotics structurally unidentified and chlorpromazine, which obviously has metal binding properties when hydrolyzed. When a comparison is made with the substances

causing shock 13 new ones appear which do not have this property and 13 of the above are represented Bronchial asthma caused by 36 agents of which 19 are of plant or animal origin and unidentified structurally is caused by 14 containing possible metal complexing groups or metals A similar situation appears among the agents causing severe late toxic skin reactions such as eczema urticaria exanthemata exfoliative dermatitis bullous eruptions and the like Metals and binding agents appear frequently when the chemical structure is known

Curiously enough serious local and systemic reactions are rare or absent among the drugs not containing metal reactive groups or producing them only on extensive hydrolysis Sulfobromophthalein decholin paredrine ether boric acid Banthine menthol quotate diocaine chloral hydrate morphine opium codeine digitalis are examples On the other hand barbituric acid the basic constituent of many sedatives and a pyridine compound forms salts with metals Metal binding by sulfanilic acid is well known (233) The instability of hydantoin hydrolyzing to metal binding hydantoic acid the metal binding properties of pyridines nitroso groups (dinitrophenol is a good example) cyanides amine and sulphydryl groups semicarbazides dicarboxylic acids thiols and sulfur-containing structures appear to be related to many forms of drug sensitivity Therefore it is possible that trace metals may be involved in many reactions of sensitization and perhaps even in some forms of allergy BAL (2,3-dimercaptopropanol) for example is a potent contactant Although drug reactions vary widely in frequency such agents as dinitrophenol being very active and amines relatively inactive metalloenzyme disturbances cannot be excluded as causes It will be noted that the more metal binding groups on the soluble sulfonamides (pyridine thiazole succinate etc.) the more likely

the agent is to produce late generalized reactions. The interested reader can find many examples of this apparently general phenomenon by comparing structure (253), metal binding power (233) and ability to produce late reaction (252).

The author by no means wishes to imply that the phenomena of hypersensitivity, allergic and immune reactions, and anaphylactic shock are the result of trace metal chelation. The mechanisms of these reactions involving altered proteins have been studied extensively enough to exclude trace metals as being primarily responsible. Late toxic reactions to drugs, however, may well be caused either by metal imbalances or sensitivity. Thrombocytopenia induced by quinine is an example of the latter. Obviously the problem should be studied further from this viewpoint.

ESSENTIAL TRACE METALS IN MAN

To be essential for mammalian metabolism the trace metals under consideration should be able to form chelates and to be reactive. They should be demonstrable in human tissues both of infants and of adults. They should be found in sea water, for life began in the sea and in plants. They should demonstrate activity on enzyme mechanisms especially to accelerate reactions. We can apply these criteria to the metals actually found, examining the most logical ones (Table XXVII).

In Table XXVIII are shown the metals of interest found in sea water. In general those of highest concentration are more prevalent in plants and animal tissues. The relative composition of sea water however has probably changed since life began in the primitive ocean only those elements present when amphibians left the ocean

TABLE XXXII
TRACE METALS FOUND IN MAN AND THEIR PROBABLE ROLES

Essential	Possibly Essential	No Known Metabolic Function	Metabolic or Antimetabolic	Not Found in Animals
Cobalt	Aluminum	Barium	Bismuth	Antimony
Copper	Selenium	Boron	Cadmium	Arsenic
Iron	Vanadium	Cesium	Chromium	Beryllium
Manganese		Gallium	Gold	Thallium
Mercury		Lanthanum	Lead	
			Nickel	
Zinc			Silver	
		Tungsten	Titanium	

Those in italics may be implicated in chronic diseases especially cardiovascular because of their prevalence concentrations or known functions on enzyme systems.

and satisfying certain criteria for reactivity in enzyme mechanisms can be expected to have become essential for metabolism. We cannot say that living cells have learned to use new and less reactive elements in enzyme systems by a process of adaptation; the basic structures of atoms have not changed and life began by using the most suitable ones.

Because all food comes eventually from plants, an examination of the metallic content of plants is necessary. Local pastoral variations can be neglected. No metal can be expected to be essential for animals which does not occur in plants or in water. In Table XXXIII are the metals of interest in plants. Little aluminum, nickel, and no cadmium, tin, silver, gold, titanium, lead, or mercury is to be expected in animal tissues, while vanadium and the five known essential metals will be found. Obviously, if domestic animals or man show appreciable quantities of those which do not appear in plants, they must have come from unnatural sources.

To be classed as abnormal for our thesis, a metal

TABLE XXXIII
TRACE METALS IN SEA WATER %
(Also found in plants animals and man (256 257 231 254))

Seawater	Found in American Tissues			Essential for Mammals	Possible Contaminant	
	Essential for Plants	Infants	Adult's		Adult Urine	from Soil
Factor	X 10 ⁻					
Mg	13	1				
Sr	13	3				
B	45	4				
Rb	20	5				
Zn	50	6				
Fe	50	6				
Cu	20	6				
Al	5	5				
Pb	50	7				
Mn	40	7				
Ni	30	7				
Sn	30	7				
Co	10	7				
Mo	10	7				
Ti	<10	7				
V	50	8				
Hg	30	9				
Ag	n	8				
Au	40	10				
Cd	Trace					
Cr	Trace					

0 = Strong evidence against element

0 = Strong evidence against element being essential ? = Cannot be excluded at present
• After V. V. V. (255)

a) should be found in human tissues from some areas of the world and not from others b) should not be found in plants or wild animals c) should affect some metallo-enzymes d) preferably should not be in the tissues of young infants e) should be introduced by the habits of Western Civilization into foods or beverages as a result of processing transportation or manufacture and f) should be poorly excreted cumulative and preferably showing organ specificity

Concentrations of the Essential Trace Metals in Man
Although many analyses have been done by various methods for single or several elements in blood tissues and urine (254-257) the first extensive systematic investigation on the content of both essential and abnormal trace metals in human tissues was made by Tipton and her co workers. Using spark spectrographic methods with indium as an internal standard and densitometric photoelectric recording of plates Tipton analyzed 258 tissues from 24 persons dying suddenly in various areas of the United States for 18 metals (almost 4500 analyses) (231). A preliminary analysis of 42 autopsies from various places in this country showed similar but less quantitative results (258) while in a later series the findings were essentially the same (259).

In Table XXXIV are the mean concentrations in various tissues of the essential elements manganese cobalt copper zinc and molybdenum calculated roughly for total bodily amounts. Zinc is the most prevalent of the normal group in several times the concentration of any of the others. Essential cobalt was found in only five bodies sparsely scattered in small concentrations probably because of methodological limits and its presence in very minute quantities. These results appear comparable to those of Griffith *et al* for copper zinc and manganese on

the basis of dry tissue in a much larger series (260)

Some organs concentrate certain metals others do not Zinc was found in every organ in concentrations of 4.4 to 300 mg/Kg being far highest in prostate then muscle liver kidney and heart and lowest in adrenal bladder brain testis lung and intestine Copper was concentrated in brain liver and spleen being lowest in muscle adrenal aorta intestine and testis Manganese in much smaller amounts was concentrated especially in liver with pancreas lung spleen and thyroid following quite far behind lowest organs were heart muscle testis and aorta Three of these four metals were found in all 258 specimens examined Molybdenum was absent in only half of the samples of muscle and testis a third of those of pancreas thyroid and lung most prostates and all but one brain but was found in concentrations of more than 0.13 mg/Kg in all heart kidney and liver samples being by far the highest in liver In the concentrations detectable, molybdenum apparently is not essential for metabolism in all organs but three of the others may be

Sources and Turnover of Essential Metals All of the essential trace metals are found to a greater or less extent in plant and animal tissues (Table XXIV) derived from the soil Cobalt is probably the least concentrated Soils vary widely in their contents of trace elements and disorders due to deficiencies or excesses have been recognized in both plants and animals Semi-quantitative trace mineral analysis is a recognized practice in the evaluation of soils for farming The following was summarized from Momer Williams (256) and Marston (261)

Manganese The largest sources are in the following foods with above 30 mg/Kg oatmeal whole meal flour bran soy bean meal cocoa cloves chestnuts pepper maple sugar tea contains 150 to 900 mg/Kg With lesser con

TABLE XXXIV

CONCENTRATIONS AND CONTENTS OF ESSENTIAL TRACE METALS IN HUMAN TISSUES (WET WEIGHT) (231)

Organ	Height ^a Kg	Mn mg/Kg	Mn Total	Cu mg/Kg	Cu Total	Zn mg/Kg	Zn Total	Mo mg/Kg	Mo Total	Cot mg/Kg	Cot Total	No
Adrenal	0.02	4	0.003	1.7	0.03	35.3	0.3	0.18	0.004			17
Aorta	0.19			1.96		20.2		0.33				5
Bladder	0.02	0.25	0.05	3.40	0.68	16.6	3.3	0.12	0.02			4
Brain & Cord	2.1	0.40	0.8	10.6	21.0	16.8	21.4	(0.21)	0.44			7
Heart	0.3	0.1	0.03	4.09	1.2	49.2	15.0	0.23	0.06			23
Stomach & Intestine	2.0	0.32	0.64	3.0	6.0	23.2	46.4	0.15	0.3			11
Kidney	0.3	0.6	0.1	2.6	0.82	67.2	21	0.65	0.1			22
Liver	1.3	1.13	1.6	10.6	15.9	68.4	10.6	1.62	2.4	0.20	0.06	24
Lung	0.7	0.6	0.42	4.5	3.2	18.3	17.6	(0.18)	0.12	0.8	1.2	24
Muscle	28.0	0.14	3.92	1.53	42.9	70.0	196.0	(0.41)	11.5	0.24	6.75	23
Pancreas	0.1	0.74	0.07	3.0	0.3	41.0	4.1	(0.21)	0.02	0.2	0.02	22
Prostate	0.03	0.24	0.01	6.79	0.02	155.0	7.8	(0.36)	0.02			8
Spleen	0.2	0.5	0.1	8.7	1.74	22.3	4.4	(0.17)	0.03			24
Testis	0.02	0.19	0.004	2.3	0.04	13.8	0.27	(0.13)	0.02			13
Thyroid	0.03	0.48	0.013	3.5	0.1	36.6	1.1					9
skin	4.4											
Skeleton	19.0	0.41	4.92	4.6	55.2	43.8	525.6	0.27	3.18	0.3	3.6	
Adipose Tissue	7.8											
Other Tissue	7.8											
Sub Total known (mg.)			5.762		93.111		455.37		15.134		8.03	
Total with estimated skin and other soft tissue at mean value X 12 Kg (mg.)			50.68*		149.13		960.97		18.374		11.6	
Specimen 1 (lung metal)			0	0	0	0	0	56			234	

Fig 10 in parentheses indicate the same as relating in two of two examples: Mn Cu Zn w c p nt in every sample Mo was absent in on an la

* For 0.1 g man according to Fo to 1.5 (203)

† In only 5 of 24 bodies

may also be important in hemoglobin formation. A copper enzyme ceruloplasmin is found in concentrations of about 34 mg per 100 ml of serum. Several phenolic oxidases depend upon copper. Pigmentation may be related to the content in skin and hair follicles. Copper is quite well retained by the body with some dependency upon intake being slowly eliminated by way of the feces. Gallstones contain large amounts. No chronic copper poisoning has been described in human beings. Human milk is extremely low in content 0.04 mg/kg. As a rule American foods contain adequate amounts sometimes an excess since many insecticides and fungicides contain copper. The largest amounts 10 mg/kg or more are found in tea, coffee, cocoa, chocolates, nuts, liver, shell fish especially oysters, tomatoes and yeast. The least is found in milk, butter, cheese, refined sugar, honey, margarine, lard and suet.

Zinc This most prevalent of the trace metals in the human body is present in large quantities in most organs as seen in Table XXXIV. It is found in foods and is a requirement of plants, bacteria and fungi. Most modern fungicides are zinc chelating agents. Deficiency in soils causes diseases of both plants and animals although its prevalence makes animal diseases more uncommon. Foods with over 50 mg/kg are wheat germ, bran, oysters, beef livers, gelatin and dried eggs; those which contain the least amount are fruits, chestnuts, green vegetables and fish. Chronic poisoning in man is not known. There have been several outbreaks of supposedly acute poisoning from foods stored in zinc lined receptacles but the contamination of zinc by cadmium makes it questionable that zinc itself was the cause. Symptoms of zinc and cadmium poisoning are identical i.e. violent gastroenteritis and zinc poisoning is most difficult to produce in animals.

centrations are green vegetables, nuts, rice and barley of considerably less content are meats, legumes and many organ tissues. Dairy products and fish are low in manganese and coffee contains extremely little. It has been estimated that about half the intake of adults in Britain during the winter came from tea. The minimum daily requirement for man has been variously set at 4.0 to 10 mg, about 0.01 mg per day being excreted in the urine. In view of the small body pool, approximately 11 mg according to the method of analysis (Table XXXIV), this high requirement may reflect the poor absorption of manganese from the gastrointestinal tract. Large amounts may be given daily, up to 1.0 Gm per day of the citrate or glycerophosphate, without signs of toxicity and apparently without excessive absorption. While deficiency in man has not been described, a reasonable assumption that it might occur can be postulated, especially if conditioned by competing metals or affected by drugs. Toxicity from ingested manganese has not been described, although inhaled dust can cause Parkinsonian symptoms and occasionally cirrhosis of the liver.

Cobalt Present in vitamin B₁₂ as a porphyrin chelate, this element is essential for maturation of red blood cells but has no other known function in man. It is rapidly excreted both in urine and feces and apparently does not accumulate. It may not be readily absorbed in man. An excessive amount produces polycythemia in the rat, dog, frog, mouse, guinea pig and sheep. While the amounts in food are not well known, traces occur in vegetables, fruits and cereals, 0.5 mg/kg in legumes and as little as 0.003 mg/kg in white flour. In view of the small body pool, deficiency in man is possible but unproven. Cobalt is a vasodilator in man (262) and in the rat (183).

Copper An essential element in cell respiration, copper

high content of iron in their livers. Apparently the bacteria in the rumen synthesize vitamin B₁₂ when cobalt is present. High requirements are indicated by the large doses of the vitamin necessary to cure this disease. Horses and pigs raised in the same deficient areas are not affected as their requirements are lower. Bacterial synthesis in the colon, as occurs in man, apparently does not lead to absorption of this vitamin, therefore it must be ingested as such. Copper deficiency has been implicated in certain anemias in infancy but no known diseases in adults have been described. Anemia has been produced in laboratory animals along with a slow rate of growth, impaired absorption of ingested iron, impaired mobilization of iron from tissues, and impaired utilization of iron for hemoglobin synthesis have been found, as well as low cytochrome oxidase activity of the bone marrow. Cattle grazing on copper-deficient pastures show depigmented, abnormal hair, develop cachexia, anorexia, and anemia; their bones become fragile; reproduction and milk production is decreased and they frequently die of cardiac failure. Young animals may become ataxic. Sheep show defective keratinization and hypochromic anemia. Lambs born of copper-deficient ewes develop swayback and ataxic and paralytic diseases characterized by diffuse demyelination of the central nervous system. Depigmentation has been produced in many species. Excesses or deficiencies of other trace elements may influence the disorders in cattle and sheep, especially of cobalt and molybdenum. Molybdenum deficiency prevents fixation of nitrogen by soil bacteria but diseases in higher animals have not been discovered. Zinc deficiency causes hyperkeratosis in pigs (264), hyperkeratosis and keratinization of the esophagus in rats (265), sterility (266) and signs suggestive of ariboflavinosis with vascularization of the cornea and lesions at the mucocutane

Molybdenum The newest of the essential elements to be found necessary in human and animal metabolism molybdenum plus a flavin are necessary for the metabolism of xanthine to uric acid by xanthine oxidase and the oxidation of aldehydes by liver. It is essential for the fixation of nitrogen in the soil by nitrogen fixing bacteria. Molybdenum is present almost universally in fertile soils and in plant and animal tissues. Its toxicity resembles that of selenium poisoning; excesses in soils affect ruminants rather than horses and pigs, producing a disease characterized by chronic diarrhea called teart. Copper fed to animals prevents molybdenum poisoning. An examination of the periodic table indicates that molybdenum is unique in that it is next to the heaviest element essential for mammalian metabolism and occurs in the hexavalent form. Whether or not deficiencies occur in man is not known, the body pool is small.

Specific Metal Deficiencies (256, 261) * Actual deficiencies of some metals in man are not inconceivable, although no true deficiency (other than iron) has been described. Lack of manganese kills rabbits; deficiency in rats causes failure of male reproduction and a high mortality rate in the young. Hen's eggs do not hatch well, perosis or 'slipped tendon' with enlargement and malformation of the tibio metatarsal joint and arrested growth of long bones, possibly due to low bone phosphatase, is caused by deficiency of this element in growing chicks. Pigs and rabbits also show bone affections suggesting that it may be related to the growth or health of bone and joints.

Cobalt deficiency in soils causes enzootic marasmus or Bush Sickness in ruminants characterized by impaired growth, anorexia, weakness, emaciation and anemia with

* The reader is referred to Moore's recent critical and inclusive discussion of this subject (263)

TABLE XXV
CONCENTRATIONS AND CONTENTS OF ABNORMAL TRACE METALS WITH ORGAN SPECIFICITIES
(1.0-1.5% COT) (231)

[illegible]

Figures in parentheses indicate 1 month interval or at zero or more samples.

ous junctions. These signs are more like those of pyridoxine deficiency. It is doubtful that zinc deficiency ordinarily can be produced in man except on very low intakes or during excessive proteinuria, during which loss of protein bound zinc can occur. Some of the symptoms of beriberi have been thought to be manifestations of zinc deficiency caused by low intakes. The patient shown in Table XXX exhibited acute pyridoxine deficiency twice when EDTA was given intravenously (181) probably his excessive urinary loss of protein bound zinc added to the zincuretic effect of EDTA resulted in deficiency of the zinc chelated to some pyridoxal enzymes (Fig 20 p 231).

"ABNORMAL TRACE METALS IN MAN"

In Table XXXV are the concentrations and contents of the five presumably 'abnormal' trace metals showing some organ specificity. We observe the following. Aluminum was not found in three hearts but was in every other organ examined almost always in concentrations of over 1 mg/kg and in all but six in over 3 mg/kg. It was selectively concentrated in lung (perhaps by inhalation) with a third as much in aorta and a sixth or less in prostate, stomach, thyroid and adrenal. Lowest values were in kidney. Amounts were higher than those of any essential metal save zinc. Cadmium appeared in kidneys in very high concentrations, with liver, pancreas, thyroid containing a tenth as much. Titanium appeared in lung (perhaps by inhalation) with prostate a poor second and a relatively even distribution in the other organs. Lead appeared highest in liver, pancreas, spleen, kidney, adrenal and aorta, lowest in stomach, brain and bladder. The less frequently found boron appeared to be concentrated in some spleens. On the other hand little evidence of concentration in any one organ was found in the cases of the

ubiquitous elements tin nickel, chromium and silver (Table XXXVI)

The obvious conclusions are that relatively large amounts of cadmium are in American kidneys and aluminum and titanium in lungs while other metals are more or less evenly distributed. Furthermore there is weight for weight more of several abnormal metals in most organs than normal ones of high biological activity such as manganese copper and molybdenum. On the basis of mass alone these three tables show the following when the metals are arranged according to the periodic table. Silver is present in amounts equal to 2.2 per cent of copper, cadmium equal to 12 per cent of zinc (50 per cent in the kidney), chromium equal to 61 per cent of molybdenum (and is more prevalent), nickel equal to 140 per cent of cobalt while there is more titanium tin and lead than manganese molybdenum and cobalt and there is more aluminum than copper. Thus the order in decreasing amounts is Zn, Al, Cu, Cd, Pb, Ti, Sn, Mo, Ni, Co, Cr, Mn, Ag. II according to the present estimate (essential ones in italics). Traces of gallium were found in most lungs, of bismuth in 21 samples, of gold in 72 samples and of thallium in 6 samples.

In Tipton's second series of 24 autopsies from another (western) part of the United States (259) the findings were quite similar for the essential metals although there were somewhat less copper and zinc in most organs and molybdenum was largely confined to liver and kidney. Of those now considered abnormal cadmium appeared in liver and kidney in the same concentrations as in her first series but a large majority of other organs were lacking in this element. There was much less aluminum in all organs but lung (23 mg/Kg) and titanium was found in only a few bodies except for lung where its concentration

TABLE XXVI
CONCENTRATIONS AND CONTENTS OF "ABNORMAL TRACE METALS WITHOUT ORGAN SPECIFICITY
(WET WEIGHT) (231)

Organ	Cr mg/Kg	Total mg	Ni mg/Kg	Total mg	Sr mg/Kg	Total mg	Ag mg/Kg	Total mg
Adrenal	0.28	0.006	0.26	0.005	0.34	0.007	0.05	0.001
Aorta	0.01		0.20		0.42		0.07	
Bladder	0.42	0.08	0.28	0.06	0.19	0.04	0.07	0.01
Brain	0.36	0.76	(0.14)	0.29	(0.55)	1.16	0.04	0.08
Heart	(0.13)	0.04	(0.23)	0.07	0.36	0.11	(0.26)	0.08
Stomach & Intestine	0.18	0.36	(0.39)	0.78	0.48	0.96	(0.08)	0.16
Kidney	0.08	0.03	(0.22)	0.07	0.48	0.14	0.06	0.07
Liver	0.27	0.40	(0.32)	0.48	0.63	0.98	0.07	0.10
Lung	0.72	0.50	0.47	0.33	0.99	0.66	(0.15)	0.10
Muscle	(0.18)	3.04	(0.40)	11.2	(0.51)	14.3	(0.06)	1.68
Pancreas	0.20	0.02	(0.32)	0.03	(0.53)	0.05	(0.08)	0.008
Prostate	0.28	0.01	(0.48)	0.02	0.74	0.04	0.04	0.002
Spleen	0.63	0.13	(0.72)	0.14	(0.41)	0.08	(0.23)	0.05
Testis	0.39	0.008	(0.67)	0.01	0.22	0.004	(0.08)	0.002
Thyroid	0.42	0.01	(0.25)	0.008	1.0	0.008	0.03	0.0009
Skin								
Skeleton	0.32		0.27	4.44	0.53	6.36	0.085	1.02
Adipose Tissue								
Other Tissue								
Sub Total known (mg.)		7.394		11.738		18.561		2.294
Total with estimated skin and other soft tissue at mean value X12 kg (mg.)		11.234		16.178		24.921		3.314
Specimens lacking metal		8	62		24			33

Figures in parentheses indicate element ml ng in two o more sample

(256) There were 4 kidneys and livers 3 lungs 2 spleens and 1 aorta heart intestine and muscle In contradistinction to adult tissues kidneys and livers and lungs contained no titanium cadmium or tin Aluminum was not concentrated in lung although it occurred in amounts of 0.3-1.0 mg/kg in most tissues less than that of adults Titanium was found in only one body in intestine kidney and muscle Nickel occurred in one other kidney and liver tin was in both spleens and the sample of muscle and aorta On the other hand boron was in all tissues but one kidney and liver chromium and silver were ubiquitous in adult concentrations as was lead but in smaller amounts than in adults Organ specificity as determined by concentration was not found consistently *

In the bodies of 3 older infants and children (7 weeks 10 months and 2 years) there was no titanium Nickel in traces was in 1 kidney tin was found in all tissues as was lead while silver occurred in 7 of 12 specimens Cadmium was present in the 10 month-old kidney (0.65 mg/kg) and in the 2 year-old (2.75 mg/kg) but not in the 7 week old one The essential metals were found in distributions and concentrations similar to those of adults Manganese was if anything more concentrated zinc less so while copper was comparable showing an affinity for liver Molybdenum was in all livers while cobalt was present in only two

Within the limits of these observations, and in view of what is known the following further conclusions can be drawn 1 Titanium nickel and cadmium are not essential to infant life but accumulate with age 2 Aluminum chromium silver and lead either qualify as essential trace metals or pass through the placental membrane Obviously titanium nickel cadmium and tin do not so pass

Analyses of stillborn infants gave essentially similar results

was lower (2.8 mg/kg). Likewise lead was somewhat less frequent, being in all livers, kidneys, lungs, pancreases, bones, aortas and adrenals but missing in a few to many samples of other tissues. Chromium and silver were also absent in one or more samples of each tissue and were found in lower concentrations, while nickel was quite uncommon. Tin on the other hand, was widespread through most samples. There was less gallium, the same amount of bismuth and much less gold.

New elements added to the analysis were barium found in all samples of lung, bone, adrenal, aorta, gastrointestinal tract and thyroid and in most samples of the other organs; cesium in half the lungs (3.1 mg/kg); iron in all tissues in high concentrations especially spleen (280 mg/kg), lung (210 mg/kg) and liver (170 mg/kg); lanthanum in a third of spleens; strontium in every tissue (0.04-0.20 mg/kg) with much (20 mg/kg) in bone; and vanadium in two thirds of the lungs (0.27 mg/kg). No antimony, arsenic, beryllium, niobium, ruthenium, thallium or zirconium were found.

One can draw some tentative conclusions on Tipton's two series: the first obtained on autopsies from New York, Memphis and Chicago, the second from a Western city. 1. Minor regional differences in exposure or accumulation of some abnormal trace metals appear, especially as regards aluminum, titanium, chromium, silver, nickel and possibly lead. 2. Molybdenum is essential only for liver and kidney. 3. Chromium and nickel are probably not essential elements. These conclusions apply only to the concentrations detectable by the method.

Trace Metals in Infant Tissues We can gain some idea as to which metals are essential for life and which are not by examining the tissues of babies. Analyses of 2 St. Louis stillbirths and 2 babies living 12 hours were revealing.

Some of these metals accumulate with age in Americans others do not. In Table XXII Chapter V are shown examples. Obviously cadmium, titanium, nickel and tin in all tissues and aluminum in lung increase from little or none in infants to relatively higher concentrations at older ages. The striking examples are in cadmium and titanium.

Trace Metals in Tissues from Uncivilized People In order to ascertain more definitely what trace metals are essential and what are not, a small number of tissues from African natives in little contact with Western Civilization were obtained by Dr. Perry from Uganda and analyzed by Dr. Tipton (266). The ages ranged from 18 months to over 50 years; there were three under 10 and four over 40. None showed any evidence of atherosclerosis in the aorta or elsewhere; even fatty streaks were not seen. The causes of death were several; 6 patients died of acute infections. No age trends in essential metals were apparent as is the case with Americans. The interesting findings lay in the absence of those which might be guessed to be products of Western Civilization: cadmium (in only one kidney), nickel and tin, and the much smaller amounts of silver, lead, chromium and possibly titanium (Table XXXVII).

Conclusions Therefore it becomes apparent that nickel, chromium, cadmium, lead, silver and tin are not essential elements but results of civilization, a conclusion which could be drawn from the analyses of children's tissues only for cadmium, nickel and titanium. The possibility of these six elements found in American tissues being toxic must therefore be considered. Common sense excludes silver because of its low concentrations. In addition we cannot rule out the possible essential nature of aluminum, barium, strontium and for lung of vanadium and ti

MEAN CONCENTRATIONS OF ESSENTIAL AND NON-ESSENTIAL TRACE METALS IN AMERICAN AND AFRICAN TISSUES
(ANALYSES PERFORMED BY TIPTON *et al*)
(mg /Kg Wet Weight*)

Metal	Kidney	Africa	U S A	Liver	Africa	Long	U S A	Africa	Spleen	U S A	Africa	Americans	0-2 Years
No cases	10	24	24	1	2	24	24	6	1	2	24	7	7
Mn	0.39	0.43	0.36	0.57	1.13	0.76	0.49	0.58	0.19	0.27	0.52	0.13	2
Cu	0.26	2.76	2.0	4.47	10.6	5.7	2.8	4.49	1.4	1.7	4.67	1.3	22
Zn	24.5	67.2	48	65.3	68.6	48	39.5	18.3	17	33.8	22.3	21	2
Mo	0	0.63	0.33	0.55(1)	1.62	1.1	0	0.18(13)	0	0	0.17(17)	0	2
Al	5.95	1.80	0.67	5.77	2.55	0.7	28.8	30.8	23	4.88	3.34	2.2	4
Fe	0.64(1)	0.16	0.67(5)	1.6(2)	0.26(21)	0.5(2)	3.45	7.63	2.8	0	0.31	1.0(5)	0.55
Cr	0.037	0.09	0.04(1)	0.0	0.27	0.03(11)	0.04	0.72	0.14	0.009	0.63(23)	0.03(13)	0.89
Pb	0	0.22	0	0	0.32(13)	0.26(2)	0	0.47	0.33(8)	0	0.72(14)	0	0.33
Te	0	1.27	0.94	0.24	2.88	1.5	Te	1.21	0.63	0.27(1)	1.33	0.38	0.69
Ag	0	0.48	0.27	0	0.65	0.56	0	0.95	1.1	0	0.41(23)	0.27(19)	0.51
Bi	6.3(6)	0.06	0.02	0.015	0.07	0.03	Te	0.15(19)	0.02(19)	0	0.23(15)	0.06(14)	0.37
Cd	±2(2)	3.1	3.1	1.25(1)	0.61(3)	0.9(3)	0	0	1.1(11)	0	0.25(1)	0.36(2)	0.33
				0	3.60	3.3	0	1.73(20)	1.1(11)	0	1.96(6)	1.3(1)	0.12
													0

Differences considered significant from American adults are italicized.
Numbers in parentheses indicate specimens with metal (all specimens did not show L).
The African tissues were preserved in formal. The per cent ash was 3 to 5.1 mers greater than in f ash tissues (dehydration?) there fore increased the sensitivity of the method.
† Two patients had 18 and 19 mg /Kg Bi in kidney probably the result of treatment
‡ In older children only not in babies.
1 - Tipton's first series (231) 2 - second series (259)

tanium We can add to our list of possibly toxic metals bismuth and cesium

Are these extraneous elements biologically active or inert? Could one or more of these abnormal elements displace an essential metal and thus lead to metalloenzyme inhibition or combine with sulfhydryl enzymes and so inactivate them (Table XXVIII)? If so the possibility of inhibition causing dysfunction leading to disease is considerable

METALS OF POSSIBLE BIOLOGICAL SIGNIFICANCE IN THE FIRST TRANSITIONAL GROUP

It is interesting that the transitional and nearby metals in the periodic table are those with most biological activity an expression perhaps of their structures (267) Other than the known essential trace metals of the first transitional group four might serve in metalloenzymes but have at present no known function i.e. titanium vanadium chromium and nickel Vanadium is found in all of the animal phyla is concentrated from sea water by tunicates as an essential oxygen carrier (268) is required by *aspergillus niger* (269) is concentrated in certain mushrooms (270) was probably an oxygen carrier in petroleum forming animals and appears in concentrations of about 10 mg/kg in all plants dry weight (271) The case for it having a function in mammals is good While chromium stimulates plant growth is present in all vegetables in concentrations of 10 to 1000 γ /kg dry weight and is in many human tissues evidence for its essential nature is doubtful Nickel is probably not required by mammals although plants contain traces The role of titanium is not known although it is found in almost all human adult lungs Those concentrated in certain organs may be of more significance in metabolism or in causing diseases

TABLE XXVIII
EFFECT OF TRANSITIONAL METAL IONS ON HEPATIC METABOLISM IN THE RAT*

Atomic Number	Ti†	V	Cr†	Mn	Pb**	Co	Ni	Cu	Zn	Cd
Oxidation of phospholipid fatty acid	22	23	24	25	26	27	28	29	30	48
Dehydrogenation of PFA	0	+	0	—	0	—50%	0			
Oxidation of double bond in PFA		+								
Oxidation of cysteine to its sulfonic acid	—	+								
Synthesis of cholesterol from acetate	—	0	al	—						
Synthesis of fatty acids from acetate	0	—90%	al	—						
Human liver content American mg/kg	0	—40%	150**	125**	—60%	—	0			
Log K EDTA	0.26	0-10	0.27	1.13	—40%	0	0	0	0	0
Ratio hydralazine binding Cu=1.0	(1.6)	0	0.02	0.57	1.0	(0.8)	0.32	10.6	68.4	3.6
		0.3	0.1	0.3	0.1	0	0	4.47	65.3	0
							0.2	18.4	16.6	16.5
								1.0	0	0

Note: Metal binding agents CN, pyrophosphate, p-aminophenol and aminopyrine inhibited the liver enzyme of Bernheim & hydroxyquinoline depressed hepatic synthesis of cholesterol and fatty acids while EDTA enhanced it (375)

PFA = phospholipid fatty acid

* From Bernheim and Bernheim (272, 274, 275) and Curran (248)

† As dichromate or chromium potassium sulfate.

** As ferric.

‡ As pertitanate

§ As chromous

|| As ferrous

turated fatty acids were oxidized very slightly. Further more they showed that vanadium exhibited two effects: dehydrogenation to produce unsaturated fatty acids and oxidation of the double bond (Table XXVIII). The reaction was inhibited by the metal binding agents cyanide, pyrophosphate, fluoride, p-aminophenol and aminopyrine. Brain contained none of the enzyme, kidney little. When other metals were tested, manganese and to a less extent cobalt were found to inhibit the system, while nickel, iron, titanium and chromium had no effect (275). Manganese, cobalt and titanium inhibited the oxidation of cysteine to its sulfonic acid. Titanium in the form of sodium per titanate also inhibited hepatic oxidation of thioglycolic acid and ethyl mercaptan, but glutathione was not oxidized by this system (272).

Evidence for Vanadium Being an Essential Trace Metal

What evidence there is for vanadium being essential to mammalian metabolism is indirect but good. Aside from its use by ascidia which use it for oxidation-reduction reactions at a time when they are buried in mud, petroleum contains varying amounts of vanadium in a porphyrin form which has led to the hypothesis that animal organisms and not plants originated the formation of petroleum. It is found in mammalian tissues at a fairly good concentration, said to be 0.13 per cent dry weight, 12 mg/kg for invertebrates and 0.1 mg/kg dry tissue for vertebrates (268). While its occurrence may be a chance contamination, universal presence and three valence states (V^{III} , V^{IV} , V^{V}) with an ability to release energy similar to phosphorus make it likely that vanadium may be essential. Tipton found it only in the lung.

Vanadium is a powerful stimulant to monoamine oxidase (Table XXIII). Only cobalt of the others tested exhibited this property to much less degree. This phenomenon

than those widespread in smaller concentrations (chromium, tin, nickel) We can supply our six rules of thumb to each

Titanium There is no evidence that titanium is necessary for normal function. It can, however, act as an antimetabolite. Titanium inhibits the oxidation of cysteine to its sulfonic acid (as well as thioglycolic acid) (272) but does not affect cholesterol and lipid synthesis in the rat (248). The antimetabolic action of this substance could but does not necessarily implicate it in chronic disease. If involved, its only known effect is upon sulfur metabolism.

When a patient with moderate hypertension was treated with hydralazine in increasing doses at four hour intervals up to 600 mg per day the only change in the urinary excretion of 11 trace metals was in titanium. Taking the highest value of 4 control days this value was exceeded on 7 of 9 days of treatment on 5 it was twice as much or more on 2 6 times and on 1, 50 times greater. No other trace metal so moved the control value for vanadium and chromium were exceeded three times, of lead twice and of manganese once of nine days. Late results of hydralazine therapy on pairs of urine specimens before and after control of hypertension showed no essential changes in mean titanium excretion. The values doubled twice and fell markedly once. There were no significant changes in the urines of 5 patients with disseminated lupus (273).

Vanadium Bernheim and Bernheim have studied the oxidation of certain rat and guinea pig tissues as influenced by vanadium acetate or sodium metavanadate (274). They found that phospholipids were oxidized by the insoluble portion of liver proteins in the presence of vanadium. Brain and liver phospholipids and soy bean lecithin were good substrates for the vanadium enzyme system. The oxidation of many other substances were unaffected. Sa




FIG 18 The effect of certain transition metal salts on the incorporation of C^{14} -carboxyl labeled acetate into cholesterol and fatty acids by surviving rat liver (From Curran G L. *J Biol Chem* 210 765 1954)

adults and being ubiquitous in plants and animals (256) no role for chromium is known. It markedly stimulates the hepatic synthesis of cholesterol and fatty acid in rats. No other transition element save manganese had this property (Fig 18) (248). It did not affect decarboxylase and monamine oxidase.

Normal urine contained less than 0.05 to 1.03 γ/L (mean 0.46), hypertensive urine less than 0.05 to 4.4 γ/L (mean 0.88). Treatment did not change the means significantly (0.67 to 0.71 γ/L), nor did hydralazine or EDTA cause a consistent loss.

Chromium in liver could stimulate cholesterol and fatty acid synthesis in man. There is as much, however, in infants as in adults. Only by analyzing many more tissues from primitive areas can one determine whether or not chromium can qualify as an essential metal or if not play a part in chronic disease.

strongly suggests, but does not prove, that vanadium is an essential metallic component of monamine oxidase. Not until the enzyme is obtained pure and the metal identified can we say for certain that it is essential for amine oxidation.

The urinary output of vanadium in human beings is fairly constant, less than $0.63 \mu\text{g/L}$ (range less than 0.5 to 2.15). In hypertension, however, it was increased to three times normal values, $1.95 \mu\text{g/L}$ (range 0.4 to 14.5). Treatment appears to bring back the values toward normal (2.86 to $0.93 \mu\text{g/L}$). However, only five of our values were initially greater than the highest normal.

The pharmacological effects of vanadium have been extensively studied by Jackson (276). It is a unique element in that it causes vasoconstriction in rabbits. The older literature contains equivocal reports of its effects in syphilis, tuberculosis and skin diseases. Oral doses are well tolerated. In hypertensive states, giving sodium metavanadate by mouth sometimes caused transient reduction of blood pressure but also produced chills and fever. In rats it markedly depressed fatty acid and cholesterol synthesis by liver (248) (Fig. 18).

It is possible therefore that vanadium deficiency, either through lowered intake or exogenous abnormal metallic competitions, is one of the causes of the conversion of intermittent vasospasm into sustained vasospasm. Consistent with this theory are: 1. Stimulation of renal monamine oxidase only by V^{++} and V^{+++} , an enzyme which destroys norepinephrine and most other circulating vasoactive primary amines. 2. Reduction of pervanadate by hydralazine which also enhances monamine oxidase activity (277). Unfortunately vanadium was acutely pressor for hypertensive rats but may be depressor in dogs.

Chromium Although found in all lungs of infants and

rier while its absence in many adults suggests that it is not necessary after full growth

Aluminum is almost absent from plant tissues although it represents seven to eight per cent of the earth's crust (256). Animal tissues with the exceptions of lungs and liver are said to contain less than plants (0.7 to 1.5 mg/kg in the dog and 0.5 to 3.3 mg/kg in the rat) (278-279) although a former study showed considerable amounts in human beings (brain 2.5 heart 2.1 liver 0.8 kidney 1.0 and spleen 0.7 mg/kg) but less than were found by Tipton *et al*. Salts have been put into baking powders can be absorbed from cooking vessels and canning processes. A considerable amount of investigation 25 to 50 years ago indicated the lack of toxicity of aluminum which is fed in antacid preparations to patients. The large amount found in lungs probably comes from inhaled aluminum silicate from dust. Having only one valence state in spite of its prevalence in the earth it has not been shown to have any essential role in human metabolism although by our criteria it cannot be excluded as an essential trace metal.

Scandium and gallium are found in soils. The traces of gallium in human lungs probably have been inhaled since gallium is present in all aluminum minerals. Both are relatively unreactive compounds with only one valence state.

Comment If one were forced to choose a single trace metal to undo the harmful effects of degenerative cardiovascular diseases vanadium would be that choice for the following reasons:

1. Vanadium stimulates monamine oxidase thereby probably increasing the destruction of pressor vasoactive and cerebroactive amines and affecting hypertension thereby (Table XXIII).

Nickel While found in all plants and animals tissues in traces, it has no known function (256) It is almost certain that this element is not essential for mammalian growth and development There is frequent exposure in processed and manufactured foods especially hardened vegetable oils (Chapter VII) where it is used as a catalyst (containing 0.012 mg/Kg), and from corrosion of nickel vessels No increase was noticed in human tissues after the second decade until the seventh Therefore, although present in small amounts we cannot state whether or not it is doing harm, although it probably has little direct action It did not affect the enzyme systems of interest to this discussion and is usually inert in others

Normal concentrations in urine averaged 2.78 γ /L with a range of less than 0.05 to 12 γ /L Hypertensive urine contained twice as much, 5.53 γ /L with a range of less than 0.1 to 40 only a third however, contained more than the normal mean amount Hydralazine caused no essential changes, treatment did not alter the mean values significantly (3.99 to 5.78 γ /L) EDTA caused no apparent changes Nickel cannot at the present time be implicated in cardiovascular diseases Excessive exposure causes dermatitis or eczema

Elements of the Third Group There is no evidence that any of the elements in the third periodic group are essential for mammalian life Boron, however, appears to be essential for plant life occurring in most forms and is necessary for reproduction (256) Only traces are found in dairy products and flesh foods, since this element is fairly rapidly excreted In man however in large amounts it causes weight loss albuminuria and gastrointestinal disturbances Its presence in most tissues of stillborn infants means either that it is essential or that it is a contaminant in the mother easily transported across the placental bar

185) After treatment the mean value diminished from 5.47 to 2.64 γ/L . five of eight values declining. Hydralazine decreased the output to about a fourth as did EDTA. The possible role of tin is undetermined although its source lies in the products of Western Civilization i.e. tin plate traces dissolving in some tinned foods.

Silver Like tin silver is widespread occurring in every adult kidney and brain and in almost every other sample examined (225 of 258 specimens) (231). There was no tendency for accumulation with age and almost every young tissue contained it in adult concentrations (266). It was in all urine (0.8 γ/L . range 0.23-1.4). hypertensive urine contained little more than did normal (1.4 γ/L . range 0.3-4.6). Exposure to silver is constant in our society there is little or none in plants. Because of the small amounts found it is doubtful that enzymatic inhibition (on copper enzymes) if present is extensive enough to cause metabolic disorders.*

Lead There is lead in all human tissues at birth and during life. This toxic metal accumulates especially in bone and liver. As far as is known it is not an essential constituent of any living organism getting into food mainly from the use of its compounds on plants and from vessels in which food is manufactured transported or stored. Shell fish may absorb lead from sea water contaminated with drainage from factories and animals from sprayed plants. African tissues had little.

A knowledge of the coordination number of a metal the shape of its chelate and its periodic group allows a reasonably accurate if indirect method of predicting displacement of a known essential metal and inactivation of its enzyme. Conversely by inactivation studies unknown metals on metalloenzymes may be predicted (Table XXVI) cadmium and mercury displacing zinc gold silver nickel displacing copper tungsten displacing molybdenum. More basic chemical knowledge will lead to more accurate predictions.

2 Vanadium unsaturates fatty acids on phospholipids and oxidizes the double bond (274)

3 Vanadium depresses the synthesis of cholesterol and fatty acids (248)

4 Vanadium lessens the formation of atheromata in experimental animals (280)

If one were to choose a single abnormal trace metal as a contributing cause of hypertension, cadmium would be the choice for reasons discussed in Chapter IV

If one were to choose three abnormal trace metals as contributing causes of atherosclerosis, chromium cadmium and lead would be the choices Tin could not be excluded

METALS WITH POSSIBLE HARMFUL EFFECTS

With some certainty one can list the metals present in American human tissues which are contaminants and which may be potentially harmful, i.e.: silver cadmium tin, antimony arsenic gold and lead Of these, known toxicities are found in the cases of cadmium arsenic and lead large amounts of the others are less harmful but will produce diseases or disorders Just as in the cases of transitional metals those which are evenly distributed throughout all tissues (tin silver) are under less suspicion for causing disease than are those concentrated in specific organs with high metabolic activities (cadmium lead)

Tin There is no evidence that the metal is essential for life (256) It is not essential for plants Little is known of its action as an anti enzyme It was present in almost all human adult American tissues and in the spleens of infants, older children showed quantities comparable to those of adults The mean normal urinary concentration was 3.22 γ /L (range less than 0.5 to 10.0) the mean hypertensive concentration was 8.93 γ /L (range 0.9 to

cause pulmonary fibrosis (from inhalation) (282-285) renal damage (286) this toxic metal is under considerable suspicion as a cause of chronic disease. Of all the exogenous abnormal metals found in adult American tissues cadmium appears the most toxic. It is obviously cumulative. Supposedly 40 mg by inhalation can cause death in man which is strange since the total content of adult bodies is about 120 mg and the lethal dose in rabbits by injection is 3 mg/kg (LD_{50}) (81). Hepatic and renal lesions are prominent features of acute poisoning in rabbits and rats cardiac hypertrophy is universal (286). Proteinuria and renal lesions occur in exposed workers (287). There must be obvious differences between acute and chronic effects in man especially when this metal accumulates for a life time. The protein in the urine is not albumin since it appears on the heat test but is not precipitated by Esbach's reagent (287). Cadmium causes aminoaciduria in man (288) •

The source of the cadmium may lie in zinc for it is a constant contaminant of zinc ores. There is probably one per cent or more in the galvanizing grade (Prime Western) as indicated by the following specifications adopted in 1911 by the American Society for testing materials last

Cadmium causes increased excretion of the following amino acids in man exposed industrially: glycine, alanine, glutamine, tyrosine, lysine, histidine, methyl histidine. All of these except possibly lysine can act as donors of ammonia. Furthermore serine excretion was increased 9.5 and threonine 53 times. The amount of cadmium in the urine was in the same range 12-53 $\mu\text{g/L}$ (average 20 $\mu\text{g/L}$) as we have found for hypertensive individuals (308). Cadmium was unique among four heavy metals (U, Pb, Cd, Hg) studied by Clarkson and Kench (288) who believed that it specifically inhibited the renal tubular reabsorption of these amino acids. An alternative and to us preferable explanation lies in the specific inhibition of decarboxylases by cadmium thus preventing the first step of renal amino acid metabolism.

There is no toxic metal which has received such concerted attention as lead (84). It has been proposed, and discounted, as a cause of many chronic diseases, including hypertension and atherosclerosis. The predilection of American lead for adrenal, aorta, bone, kidney, liver, lung, pancreas, prostate and spleen, but not for brain, bladder, muscle and intestine, suggests that it might exert an anti-metabolic function. The much smaller amounts in infantile and African tissues with a tendency to accumulate with age places it under suspicion. There are however, no good ideas as to its effects on enzyme systems in ordinary concentrations, although lead poisoning affects the nervous system and blood. It is well known that exposure to lead in industry produces definite slow accumulation. Tetra-ethyl lead in gasoline is a fair source (84).

While we cannot implicate this toxic, accumulating metal in any chronic disease in our society we cannot discount it as a possible etiological factor. Workers in lead industries, however, either develop clinical manifestation or suffer from no noteworthy disorder. The earliest symptoms of sub-clinical lead intoxication are those referable to emotional stability: being irritability, moodiness, restlessness, excitability, common complaints in this period of history. Lead salts are vasoconstrictor in perfused dogs' legs and cause vascular smooth muscle to contract (281).

Cadmium The high renal concentrations of cadmium in American adults, its absence in infants and in African native tissues focuses suspicion on this metal as an etiological agent in chronic disease. Since cadmium can displace zinc on mercaptalbumin (243) is a highly potent inhibitor of sulphhydryl enzymes (of which Coenzyme A is an example) and at least one vitamin B₆ enzyme, can

are no good examples) we could expect on the basis of mass alone the following enzymatic inhibitions Renal 55 per cent hepatic 6 per cent pancreas 5 per cent thyroid 5 per cent adrenal 8 per cent aorta 5 per cent intestine 5 per cent brain 0 per cent Obviously a 5 per cent reduction of metabolic activity would probably be unmeasurable while a 50 per cent would manifest itself in disorder which could lead to disease

Renal decarboxylase is inhibited *in vitro* at a lower concentration of cadmium than that present in adult kidney Other enzymes known to be inhibited *in vitro* are leucine aminopeptidase carnosinase succinic dehydrogenase choline oxidase (Table XXXVIII) possibly through sulfhydryl binding If other metalloenzymes are specifically inhibited such as vitamin B₆ enzymes it is obvious that effects of low concentrations could be profound and in the case of vitamin B₆ result in a conditioned local deficiency

As in the case of zinc and lead cadmium can be dissolved in slightly acidic media Therefore foods and waters coming in contact with cadmium could become contaminated by traces There are three possible sources 1) Water is usually piped in American houses through galvanized zinc coated iron pipes If soft aerated in municipal water stations to contain carbon dioxide and chlorinated appreciable quantities of zinc lead and presumably cadmium could be dissolved from the galvanized coat If hard however insoluble carbonates are laid down on the coating protecting it from solution and corrosion Water softeners probably would not soften water enough to corrode zinc Chlorinated water even when hard takes up zinc.* 2) Carbonated beverages are acidic and will take up zinc lead and presumably cadmium from galvanized or zinc lined

* A probable source of abnormal trace metals in some soft and acid water areas is in the corrosion of hot water heaters

revised in 1949 The maximum impurities allowable are (per cent)

	Lead	Iron	Cadmium	Total Not Over
Special High Grade*	0.006	0.005	0.004	0.010
High Grade*	0.07	0.02	0.07	0.10
Intermediate	0.20	0.03	0.50	0.50
Brass Special*	0.60	0.03	0.50	1.00
Selected*	0.80	0.04	0.75	1.25
Prime Western	1.60	0.08	—	—

* It shall be free from aluminum

Since Prime Western zinc is the grade used largely in galvanizing and no limits for cadmium are provided, it is therefore probable that zinc coating so widely used in pipes and food processing and brass are likely sources of the cadmium found to accumulate in human tissues

Cadmium poisoning has been reported in human beings drinking acid beverages made in cadmium plated (yellow tinged) ice trays (289)

The high concentrations in adult human kidneys (331 mg/kg or about 10 mg of the metal) with secondary affinities for liver pancreas and thyroid and lesser amounts (± 1 mg/kg) in adrenal aorta stomach and intestines suggests that antimetabolic activity could be exerted especially in those organs of greatest import to essential functions Its absence in most hearts muscle tissue spleens and all brains is interesting indicating that proteins or enzymes in those areas do not chelate or bind this metal readily for cadmium is readily chelated by sulfur and nitrogen ligands (its affinity for EDTA, for example exceeds that of zinc cobalt ferrous iron and manganese) Its affinity for zinc suggests that it might interfere with zinc enzymes displacing the essential metal as it does on serum albumin (by displacement from indole groups) If zinc enzymes were inhibited by cadmium (although there

that zinc poisoning which does not occur in animals fed small amounts may be actually caused by contaminating cadmium

The source of cadmium which does not occur in plants is obviously in the products of Western Civilization *

Other Metals Analyses for other commonly occurring possibly toxic metals such as arsenic antimony and bismuth of group V A have revealed no striking accumulations in human tissues There may be as much as 0.3 parts per million of arsenic in man much of it in hair and nails derived from fish and sea foods or from contaminants of food Arsenic displaces phosphorus in essential phosphate mechanisms but the amounts are probably too small to cause functional disorders and habituation or tolerance develops Antimony can gain access to foods from enamels solders tin foil rubber and insecticides The normal amounts in human tissues are not known but presumably it also displaces phosphorus Bismuth was found by Tipton in only a few bodies in small amounts in liver and kidneys (12 of 18 cases) and is probably not to be considered of universal import Mercury appeared in a surprisingly large number of kidneys analyzed by Griffith *et al* from patients with congestive heart failure who had supposedly never received diuretics containing this metal (260)

Cardiovascular Implications Aluminum and strontium were present in all samples of American heart muscle These metals plus lead and tin were found in all aortas In kidney there was the additional metal cadmium in liver these five and silver In adrenals were the same six and

Preliminary single analyses of five bottled drinks revealed a carbonated water of a popular carbonated drink 11 a citrus drink 1 a grape juice 1.5 a whiskey 5.5 in parts per billion Three of these values are considerably higher than those of normal urine The grape juice contained relatively much nickel tin and lead.

containers in which they are piped, prepared or bottled Lemonade made in galvanized pails has produced acute gastroenteritis The widespread use of carbonated acidic drinks ("pop ") in this country is a possible source which has not been explored 3) Acidic foods prepared in zinc lined containers, especially vegetables, can absorb cadmium and lead

According to Monier Williams (256) zinc is taken up by the following ingested products presumably cadmium is also dissolved Chlorides in water, chlorinated water, carbonated water, oxygenated water (from brass) soft acid water (from brass), milk (during pasteurization) milk (from bottle caps), alcoholic, acid or saline liquids, especially wine, vinegar soup orangeade lemonade, beer molasses (from zinc coated vessels in sugar refineries), maple sugar, honey, chocolate and candy (wrapped in zinc foil) gelatin (from zinc coated vessels and wire netting on which it is dried) dried fruit (from drying trays), jam (from pans) Poisoning resembling that from cadmium has been reported from soda water, rain water (collected from galvanized roofs or stored in tanks) stewed apples (from galvanized iron vessels) root beer, cider Coffee is floated and dried on galvanized trays All galvanized iron vessels are suspects since electrolytic action between the iron and the zinc may be initiated by moist foods

Cadmium is widely used for washing machines electric cooker parts and refrigerator trays It is absorbed by weakly acidic foods, sugars (jam) wine tomatoes, fruit fruit juice ice cubes (from acidic water?) coffee cooked food gelatin and attacked by lactic succinic citric and tartaric acids Possible sources of contamination besides galvanized zinc and cadmium plated vessels, are solders, fruit insecticides The similarity of known sources of acute poisoning and those of zinc are remarkable and suggest

presence in large quantities and its lower affinity for some proteins than other metals with a higher EDTA metal stability constant. Of course excessive quantities of metals obey the law of mass action and can be partly removed minor quantities cannot until better chelators are developed for fairly specific purposes

What good will it do our patients if the abnormal metals are removed from their bodies? We do not know. The subject of metals and chronic diseases is barely beginning to be appreciated. Forbes *et al* say for example. It is conceivable that the continuous ingestion of infinitesimal amounts of these metallic elements present in natural foods leading to their very gradual accumulation in the tissues may contribute to the processes of senescence in proportion to the degree with which they are combined with tissue proteins (apoenzymes) and the extent to which they inhibit or distort enzyme action in such combinations (290). While this may be true it is more likely that many of the diseases common only to our Civilization may be caused by the nonessential metals contaminating our foods, as a result of our industrial habits. We may be pleasantly surprised at the therapeutic results of their removal. Scleroderma has already been completely relieved in at least one instance by EDTA (291).

A logical therapeutic regimen within the limits of present-day vision is a concerted effort at removal by relatively nonspecific chelators followed by replacement of essential metals so removed. Generalized deficiency states of the essential metals iron cobalt copper and molybdenum is probably unlikely under such a regimen. manganese and zinc may require replacement. Too much of an essential metal however probably can cause as much disorder as too little. When deficiencies are recognized they can be treated.

Local deficiency states caused by abnormal metal com

boron chromium gold and nickel Barium was found in all tortas Cardiovascular organs, except the heart, appear to have the ability of accumulating at least four abnormal metals Several are known antimetabolites for man or living organisms (Table XXXII)

Many of these metals are found in normal and hypertensive urine (308-310), cadmium and manganese being increased in the latter Specific enzyme inhibition has been demonstrated for several which may play a part in cardiovascular (311) and other chronic diseases (312)

CLINICAL IMPLICATIONS

At the present time, there are no known methods for removing from the human body one or more of these abnormal metals and leaving the essential ones Furthermore, the rules of chelation make such a procedure inconceivable Each metal probably has a different stability constant for different proteins and removal therefrom would require toxic amounts of very strong chelators which would complex or bind such essential metals as iron and magnesium The situation may be roughly analogous to that in argyria where silver is permanently deposited in the skin and cannot be removed by any known method

On the other hand certain metals might be eliminated from the body by the judicious use of chelators with specialized groups Thus aurointricarboxylic acid fairly selectively binds beryllium in a soluble lake reversing some of the actions of beryllium poisoning (232) A sulfur containing chelator might sequester cadmium although the affinity of this metal for renal tissue is high BAL giving up cadmium to kidney which it has displaced from other areas While such oxygen nitrogen containing chelators as EDTA and its relatives prefer copper and nickel to other elements in the first transitional group, in actual practice zinc is largely removed, probably because of its

Chapter VII

SOME MECHANISMS IN ATHEROSCLEROSIS

INTRODUCTION

ALTHOUGH atherosclerosis is usually a disease of Western Civilization it has been observed in nomads. To begin to understand its pathogenesis one must consider the influences which civilization may contribute and those which can lead to the disease in uncivilized people. A brief discussion in a monograph on hypertension is justifiable for hypertensive patients are prone to develop the disease, treated hypertensive patients die mainly of its effects (319). Hypertension accelerates its progress and there may be some basic factor common to both.

Atherosclerosis can occur without diastolic hypertension. Severe degrees of the disease in the aorta causing loss of elasticity produce systolic hypertension because the pipes are hard but do not of themselves cause elevated diastolic pressure. Contrariwise hypertension can persist without significant atherosclerosis especially in China (8, 313, 440).

In 1941 Snapper made some pertinent comments which are lately being appreciated (8). Another point which must be specially mentioned is the infrequency of arteriosclerosis in North China. The rarity of arteriosclerosis is proved by the scores of middle aged patients dying from all sorts of diseases showing hardly any sclerosis at autopsy. Extensive arteriosclerosis certainly does occur in North China but the thickened inelastic aorta with the widely

petition with metalloenzymes pose a more difficult problem of replacement, especially when the abnormal metal is more firmly complexed to enzyme than is the essential one. If a vitamin coenzyme is involved in the metalloprotein complex, it need be also replaced. Local enzymatic deficiencies have been postulated, for example, in the case of vitamin B₆ deficiency in the skin causing seborrheic dermatitis (292).

We may speculate on the results of such a therapeutic trial aimed at restoration of normal metallic balances. If the copper involved in the formation of melanin were partly displaced by an exogenous abnormal metal deposited in the skin, or were removed therefrom, the resultant grey hair and deficient tanning could be reverted to normal by removal of the offending metal and replacement of the copper. If the excessive cadmium, nickel, lead or titanium could be removed from human tissues, the part that one or more of these metals might play in hypertension, atherosclerosis, malignant tumors, arthritis, collagen diseases or allergic responses might be mitigated, none of these conditions can be excluded as not being influenced by abnormal trace metals. The field is wide and the frontier untrod.

Perhaps some day when these hypotheses are more firmly proven and specific metals strongly implicated in the causation of diseases, industry will prevent contact of foods with those metals shown to accumulate in American tissues such as nickel, cadmium, tin and lead. The subject would then enter the field of preventive medicine, rather than that of therapeutics where it now lies.

PATHOGENETIC FACTORS

According to Friedman *et al* (314) the following schema invokes the multiple etiological factors and illustrates the pathogenesis of atherosclerosis

$$\begin{array}{l} \text{Time} \times \begin{array}{l} \text{Intrinsic (?) } \\ \text{Intimal} \\ \text{Derangement} \end{array} \times \begin{array}{l} \text{Quantitative and} \\ \text{Qualitative Alter} \\ \text{ation of Plasma} \\ \text{Lipids Including} \\ \text{Cholesterol} \end{array} \times \text{Blood Pressure} = \text{Atherosclerosis} \end{array}$$

We will consider each of these factors separately

1 **Blood Pressure** Rarely does long standing diastolic hypertension in Caucasians exist beyond the age of 40 without atherosclerotic lesions being found in aorta major arteries or coronaries. Experimental hypertension is necessary to induce atherosclerosis in the rat a resistant animal and is desirable in the dog. Fat in serum can be made to infiltrate the walls of arteries under high pressure especially if the intima is injured (315). Even in normotensive persons lesions develop at the sites of changes of pressure such as the mouths of the renal arteries in the Circle of Willis and at the bifurcation of the aorta (316 317). Atherosclerotic gangrene seldom occurs in the arm but is frequent in the leg where the hydrostatic pressure of the blood in the upright position is added to the blood pressure (318). These lesions are believed to be the result of pressure causing deposition of insoluble cholesterol or its esters subintimally either by forcing them into the vessel walls or preventing their diffusion out after entrance via the vasa vasorum.

2 **Intimal Injury** Mechanical injury to the intima of dogs results in the formation of atheromata (320 322). It is difficult to understand how injury can occur at a normal pressure although acute hypertension in animals (323)

ulcerated intima so frequently found in autopsies in the Western part of the world, is decidedly rare here. This explains why the genuine angina pectoris syndrome, and also the picture of coronary thrombosis with myocardial infarction are only rarely encountered. During the past two years we saw three possible cases of this disease in the combined material of the common and private wards, the outpatient department, and the very busy emergency clinic of the hospital, although in every doubtful case repeated electrocardiograms with four leads are taken and scrutinized with utmost care. However in December 1940 one classical example of coronary thrombosis with typical findings at the autopsy was observed. The rarity of coronary thrombosis in North China is the more striking because the increase of the frequency of this affection in America and Europe is appalling. Even in diabetes mellitus extensive arteriosclerosis must be infrequent in North China because diabetic gangrene is as rare here as senile gangrene.

It is difficult to give an explanation of this characteristic feature of geographic pathology. One can, of course, fall back on the equanimity of the Chinese, but the differences in nutrition of Chinese and Westerners may give a better explanation. Arteriosclerosis begins as a fatty infiltration of the intima of the vessel walls. Quantitative and qualitative differences exist between the lipid content of the Chinese and the foreign diets as has been mentioned before. The Chinese diet contains only small amounts of cholesterol but considerable quantities of unsaturated acids especially of linoleic and linolenic acid. It is certain that the average cholesterol content of the blood of the Chinese is lower than that of Westerners and this gives perhaps an indication why the tendency to lipid infiltration of the vessel wall is so much smaller among the Chinese.

metal interference (with decarboxylases for example) that in liver by marginal concentration of vitamin B₆ excessive saturated fatty acid load and possibly metals. There is no evidence for a generalized deficiency state except for the high incidence of dandruff in the population believed by some to be dependent upon vitamin B₆ and fatty acid imbalance.

3 Trace Metals The synthesis of cholesterol and fatty acids by surviving rat liver can be influenced by metals of the first transitional group (Fig. 18). Chromium and manganese have a pronounced enhancing action, vanadium a depressant one (248). Vanadium also promotes unsaturation of phospholipid fatty acid and oxidation of the double bond opposed by manganese (Table XXXVIII). There is no evidence, however, that chromium is implicated in the hypertensive process. In American tissues hepatic chromium is much less concentrated than manganese, a known lipotropic agent (231-259) (Chapter VI). Many metals directly affect oxidation of unsaturated fatty acids *in vitro*. Hydrogenation to harden or saturate them is accomplished commercially mainly by copper and nickel; sizeable quantities enter the fat during processing (256). Cadmium, however, inhibits at least one vitamin B₆ enzyme, DOPA decarboxylase (Chapter V), although it does not affect hepatic synthesis of cholesterol in the rat (331). Obviously we need to know much more about the effects of abnormal metals on the enzymes concerned in fatty acid and steroid synthesis.

A significant series of experiments were done by Curran and Costello in rabbits (280). Hypercholesterolemia was induced by feeding cholesterol at the 3 per cent level for 4 weeks. On resumption of a normal diet, cholesterol levels usually fall slowly. Half the rabbits were fed vanadium as VOSO₄ (0.05 per cent) for 6 weeks. There were

and chronic hypertension in man will result in deposition of lipid in the high pressure areas. This process is hastened if lipid in blood is elevated (324).

Subintimal 'injury' from biochemical alterations in the mucopolysaccharides of collagenous tissue results from pyridoxine deficiency in the monkey (325, 326). The changes found resemble the earliest lesions of atherosclerosis (327-330). * It is possible, therefore, that a conditioned vitamin B₆ deficiency not only affects the enzymes concerned in protein metabolism resulting in hypertension (Chapter V) but also initiates the arterial lesions in which cholesterol is deposited.

It should be emphasized that the vitamin B₆ deficiency postulated in this discussion is a local, conditioned deficiency state and not a generalized one, and that it involves enzyme systems in kidney and liver but not necessarily in brain, blood-forming organs or skin. The complex Schiff base of pyridoxal and amino acids is a strong chelating agent, for example, and could form a stable chelate with several abnormal metals. *Generalized* deficiency of vitamin B₆ is accompanied by low blood pressure and skin manifestations similar to seborrheic dermatitis and ariboflavinosis. A *local* deficiency in kidney could be induced by marginal concentrations of vitamin B₆ and especially trace

* Rinehart and Greenberg state: Arteriosclerotic lesions develop regularly in the rhesus monkey subjected to prolonged pyridoxine deficiency. The initial lesion is characterized by the accumulation of a mucinous substance in the intima and to a less extent in the media of the arteries involved. This material exhibits the metachromatic staining property characteristic of mucopolysaccharides. Associated with the accumulation of this substance, cellular proliferation occurs and collagenous and elastic tissue fibers are formed. Studies of human arteriosclerosis indicate that similar sequences are seen in the evolution of the human disease. The morphologic features of the experimental vascular lesions and those occurring in man are similar. The possible role of pyridoxine deficiency in the etiology of human arteriosclerosis remains to be determined. (32)

examine the possibilities we can look at factors of suspicious import in hypertension which could conceivably influence the development of cholesterol-containing atherosclerotic plaques in arteries

There is no good evidence that the blood cholesterol is higher in American hypertensive than in normotensive people. Therefore the increase in the rate of progression of atherosclerosis in hypertension is probably largely due to intravascular filtration pressure causing deposition of lipids through the intima (319)

Hypertension and atherosclerosis however may be interrelated in a more fundamental fashion than by mechanical excessive filtration of cholesterol through intima by the high pressure when there are adequate cholesterol levels in blood. 1) A conditioned vitamin B₆ deficiency may involve both disorders. 2) abnormal trace metals may not only affect the hypertensive process but increase cholesterol synthesis. At this point the reader may wonder whether or not the author has an obsession with vitamin B₆ and its functions. Upon careful thinking in terms of enzymatic mechanisms this coenzyme continually obtrudes itself into possible schemata derived from experimental and clinical data both in hypertension and in fatty acid metabolism.

We must turn to epidemiologic data for evidence that there is no common denominator of these two diseases. Some atherosclerosis but no hypertension has been found in Alaskan Eskimau (332) the incidence may be smaller than in whites. Hypertension is extremely common in Hawaiian sugar plantation workers as is atherosclerosis but severe coronary sclerosis is less frequent than in Caucasians (333). Atherosclerosis is said to be prevalent in Kirghiz nomads as is contracted kidney (from hypertension?) (334). Snapper observed hypertension but little

no significant differences in hepatic cholesterol at the end of this time, but aortic and serum cholesterol values were about half the controls in the animals receiving vanadium. Likewise the livers of these rabbits incorporated C^{14} labeled acetate into cholesterol at a markedly reduced rate. Thus, both endogenous synthesis and aortic deposition of cholesterol were depressed considerably by vanadium.

Therefore, vanadium as a possible essential metal, manganese as a known one and chromium as an abnormal one can be implicated in cholesterol metabolism. As will be considered below, any metal interfering with renal enzymatic mechanisms also cannot be excluded as an indirect participant in vascular damage, initiating deposition of lipid in arteries.

SOME COMMON DENOMINATORS OF HYPERTENSION AND ATHEROSCLEROSIS

One anatomical common denominator between the two diseases lies in the location of the lesions. When involving the renal arteries or their mouths, reduced renal blood flow may result in diastolic hypertension of sufficient degree to restore flow to normal (Chapter IV). These lesions have been demonstrated frequently in hypertensive patients and confirmed by physiologic measurements. It is also possible that chronic hypertension may influence deposition of lesions in the smaller renal vascular areas which of themselves cause further hypertension on a renal ischemic basis. Thus will one vascular disease worsen another in a vicious circle.

There may be chemical common denominators which predispose human beings to both hypertension and atherosclerosis. This is no new idea, for many people have wondered about the relationship. The geographic and racial distributions of the two are often quite similar. To

is probable that local deficiency of vitamin B₆ due to the interference of its trace metal by an extraneous one could probably have the same result. The intimal injury in vitamin B₆ deficient monkeys is exactly like the earliest lesions of atherosclerosis.

Comment Some derangement common to both diseases may be present but atherosclerosis with which the American public is riddled is more frequent in the population than is hypertension. Therefore while atherosclerosis can and does occur without hypertension the contrary is unusual in our civilization but frequent in others. Both abnormal trace metals and local pyridoxal deficiency may be implicated

THE ROLE OF FAT AND OTHER LIPIDS

Let us review modern ideas on the pathogenesis of the lesions other than the factors already discussed. Most of the recent interest in the subject has centered on fats. Quite a case can be made for the role of cholesterol which is largely carried by lipoproteins as a strong link in the chain of reactions leading to the formation of plaques. The subject has had its ups and downs since 1914 but probably is here to stay. As Aschoff so aptly put it: "From plasma of low cholesterol content no deposition of lipoids will occur even though the mechanical conditions are favorable" (327).

Normal Cholesterol Levels in Blood What is the normal level of blood cholesterol? That is a difficult question to answer. The levels found in Europeans and especially Americans may not represent normal values but rather average values in a population subject to the disease. If so we should look elsewhere at healthy adults to determine our normal standards and thus our therapeutic aims in controlling and reversing the atherogenic tendencies of

atherosclerosis in poorer Chinese (8) sometimes the condition was malignant. Therefore, while the two diseases usually are found together in the same population, exceptions in both directions may exist. Coronary sclerosis however, is much more common in hypertensive than in normotensive people (335). Coronary sclerosis may be a different disease than aortic atherosclerosis or may be a different manifestation influenced by local cardiac factors. Likewise cerebral atherosclerosis may differ. Undoubtedly however, the underlying biochemical alterations are a common denominator. The epidemiological data does not prove the lack of association of the atherosclerosis seen in hypertensive states in Western countries but merely indicates that each condition can in some areas of the world, exist separately.

Experimental evidence, however, which points to a close association between the kidney and atherosclerosis is accumulating. Holman was the first to show that arteritis appeared in dogs fed butter only when the kidneys were damaged by uranium or mercury (336). Methods for producing experimental atherosclerosis have been developed which fit into Friedman's schema if kidney is substituted for blood pressure. Renal damage will produce atherosclerosis in rats and rabbits fed cholesterol (331, 332). Nephrectomy causes an increase in plasma cholesterol and low density lipoproteins especially when protein is fed (385). Unfortunately we have been unable to cause the disease by feeding rats and chicks stearate and any one of eleven metals.

One further factor which may be common to the two disorders is in pyridoxal deficiency. Olsen and Martindale were able to produce chronic hypertension in young rats by desoxypyridoxine, an antimetabolite for vitamin B₆ (194). While theirs was a generalized deficiency state, it

the populations with high values. Just because a disease is common does not make it or any one of its measurable parameters normal.

Considerable information comes from studies in other than Western countries (Table XXXIX). If these values for blood cholesterol be correct as there is little reason to doubt the normal range is 120 to 160 mg per cent higher values may be ascribed to dietary influences or their concomitants. That environment and an increasing standard of living may affect blood lipids was well shown by Toor *et al.* in their study of recent immigrants to Israel compared to immigrants living 20 years or more in that country (338) (Table XL).

In Table XLI are shown some wide variations in total cholesterol and other lipids in blood done by analytic methods which are considered quite accurate from various Western countries. The variations are unexplained. Page *et al.* tried to check the differences between their analyses done in New York (339) and Boyd's done in Ontario (340) they state: "our results for cholesterol determined in the presence of the other lipids are likely to be low rather than high. For the fact that our normal cholesterol values range so much higher than those of Boyd (in Ontario) and of Gardner and Gainsborough (in England) we therefore lack an explanation. We can find no source of error for our results and none is obvious for theirs." Since Boyd's normal subjects were taking the standard high fat diet customary in this country (340) it is possible that an environmental factor not present in England and Ontario but influencing levels in New York was operating.

Effect of Blood Levels of Total Cholesterol. Most investigators believe that coronary atherosclerosis does not occur to any appreciable extent when blood cholesterol is low. Furthermore some reversal of atheromata is in

TABLE XXXIX
SOME BLOOD CHOLESTEROL LEVELS IN HEALTHY MALE SUBJECTS

Location	Race	Mean Age	Mean mg %	Dietary Fat %	Method	Author
Calcutta	Hindu & Mohammedan*	—	140	—	Myers & Wardell (Whole blood)	Bose & De (1936) (378)
Calcutta	Indian	—	116	—	(Whole blood)	Boyd & Ray (1928) (379)
	Indian	—	140	—	(Blood)	Ghose (1933) (380)
E Arctic	Esquimo	—	141	High	(Blood)	Corcoran & Rabinowitch (1937) (381)
		—	203	35	(Blood)	Rodahl (1954) (332)
Alaska	Esquimo	21-38	149	<20	(Lieberman Burchard)	Walker & Arvidsson (1954) (382)
S Africa	Basuto	21-40	153	<20		
	Bantu	21-40	167	<20		
	Bantu Westernized	21-40	178	20-25		
	Europeans	21-30	206	30-35		
	Europeans	41-50	238	30-35	(Lieberman Burchard)	Keys <i>et al</i> (1954) (383)
	Laborers	45	210	27		
Spain		45	254	40?		
	Professional	45	231	20		
Naples		45	252	35		
London		45	247	40	(Blood)	Toor <i>et al</i> (1954) (338)
Minnesota		45	160	—		Page <i>et al</i> (1935) (339)
Israel	Yemenites	45-54	232	—		
New York		20-91				

NOTE: In another survey Bronte-Stewart *et al* showed that in the Cape Peninsula Africa cholesterol values done by the same method were Bantu 166.3 ± 47.2 Cape Colored 201.1 ± 54.8 and European 234.0 ± 52.9 mg per 100 ml serum (140)

* Twenty for women 76 men

TABLE XLI
VARIATIONS OF PLASMA CHOLESTEROL LEVELS IN WESTERN COUNTRIES*

Author	Location	Date	Total	Free	Phospholipids
Gardner and Gainsborough	England	1927	153 ♀ 169 ♂	54 50	
Man and Peters	Connecticut	1933	207 ♂		222
Boyd	Ontario	1935	177 ♂	52	185
Page <i>et al</i>	New York	1935	232 ♂	82	181
Peters and Man	Connecticut	1943	194	54	240
Gertler and Garm	New York	1950	224		299
Gubner and Ungerleider	New York	1949	211		
Keys	Minnesota	1949	218		
Kornerup	Denmark	1950	203	55	172
Block <i>et al</i>	Minnesota	1951	181		234
Perry and Schroeder (<i>in</i> petten <i>ive</i>)	St. Louis	1955	226		

NOTE: The earlier determinations were done by digitonide precipitation and the later usually by acetic anhydride which tends to give lower values (439)

From Page *et al* (339) and Katz and Stamler (356)

TABLE VI
COMPARISON OF SERUM LIPIDS CHOLESTEROL AND LIPID-PHOSPHORUS IN THE OLD AND NEW
YEMENITE IMMIGRANTS IN ISRAEL*

Age Group	Total Lipids mg %		Relative Difference %	Total cholesterol mg %		Relative Difference %	Lipid phosphorus mg %		Relative Difference %
	Old Immig	New Immig		Old Immig	New Immig		Old Immig	New Immig	
Men									
35-44	639	558	11	188	146	28	93	84	100
45-54	695	602	15	195	160	22	96	89	78
55-64	654	603	8	191	158	20	104	95	98
Women									
35-44	688	620	11	196	172	14	98	98	0
45-54	731	607	20	213	170	22	106	87	210
55-64	732	615	19	220	205	7	109	103	03

For the purpose of this Table values of all

For the purpose of this Table values of the new immigrants group were considered as 100%
 New Immigrants—living in Israel 3 to 5 years Old immigrants—living in Israel over 20 years
 * After Toor Agmon and Allalouf (338)

acid esters of cholesterol regardless of the length of the carbon chain melt at higher than body temperatures the lowest m for oleate (44.5°C) and linoleate (42°C) compare stearate (82.5°C) and palmitate (90°C) (348) Therefore variations in solubility and melting point may determine deposition of these esters in the lesions Solubilities of the cholesterol esters of β -lipoproteins believed to be of atherogenic importance (350) are not known

Since pyridoxal m concerned with hepatic desaturation of di and tri unsaturated fatty acids to tetra and hexa forms (349) this coenzyme could influence the type of ester Experiments in our laboratories however have failed to show that vitamin B_6 raises the iodine number of plasma lipids when given for a week or 10 days the tendency was for it to fall (Table XLII) Surprisingly enough the iodine numbers of blood lipids was found m be much higher in Chinese (8) than in American patients (Table XLIII) probably a reflection of their high unsaturated fatty acid diets

Other Lipid Substances We have not considered the phospholipids of plasma nor the chylomicrons containing neutral fat nor the lipoprotein fractions which carry cholesterol These are complicating parameters whose significance m unclear Their relations are shown in Table XLIV Keys has said At the present time (1951) it is entirely unjustified to attribute to G measurements any special virtues beyond that for simple cholesterol measurements for the prediction of atherosclerosis or the estimation of the activity of the atherosclerotic process (351) The type of lipoprotein its solubility and its physical characteristics however may have atherogenic properties These large molecules transport lipids and steroids in blood (352) Therefore an increase in β -lipoproteins may do something to the process directly or indirectly but at

ferred in patients dying of debilitating diseases (341) with depressed blood lipids. In the monkey, both vitamin B₆ deficiency and elevated blood cholesterol are necessary to induce atheromata, levels are higher in deficient than in normal monkeys fed cholesterol (324). Since not only cholesterol, but other suspended particles will filter through intact intima (342, 343), the blood level is the obvious factor in determining whether or not this sterol is deposited in the lesions. There is no evidence at present, however, to implicate vitamin B₆ in the synthesis of cholesterol.

The deposits in the aortic plaques are mainly esterified cholesterol (316, 344-347). Schoenheimer found that there was a steady increase with age of both free and cholesterol ester extractable from the aorta as atherosclerosis developed. The proportion of free cholesterol to bound cholesterol, however, was relatively constant (22.5 to 31.9 per cent) showing no age trend, while cholesterol ester calculated as oleate tripled at older ages with advanced lesions. In other words although the aortas contained more extractable fat, the cholesterol esters in atheromatous aortas were relatively greatly increased. Most of the esters were oleate, palmitate and stearate, with small amounts of unidentified unsaturated fatty acid esters. There was also a marked increase in aortic phosphorus and lecithin with atheromata and a decrease in free hexosamine (433).

The Nature of Cholesterol Esters Cholesterol is a very insoluble substance; how all of it is transported in blood is not known, but most is carried by lipoproteins. Esters of stearate, palmitate and oleate are found in human blood and tissues (348). Cholesterol linoleate is considerably more soluble and linolenate much more soluble than is the stearate ester. Solubility in tissues and tissue fluids may be of considerable importance. Although all fatty

acid esters of cholesterol regardless of the length of the carbon chain melt at higher than body temperatures the lowest is for oleate (44.5°C) and linoleate (42°C) compare stearate (82.5°C) and palmitate (90°C) (348) Therefore variations in solubility and melting point may determine deposition of these esters in the lesions Solubilities of the cholesterol esters of β -lipoproteins believed to be of atherogenic importance (350) are not known

Since pyridoxal is concerned with hepatic desaturation of di and tri unsaturated fatty acids to tetra and hexa forms (349) this coenzyme could influence the type of ester Experiments in our laboratories however have failed to show that vitamin B_6 raises the iodine number of plasma lipids when given for a week or 10 days the tendency was for it to fall (Table XLII) Surprisingly enough the iodine numbers of blood lipids was found to be much higher in Chinese (8) than in American patients (Table XLIII) probably a reflection of their high unsaturated fatty acid diets

Other Lipid Substances We have not considered the phospholipids of plasma nor the chylomicrons containing neutral fat nor the lipoprotein fractions which carry cholesterol These are complicating parameters whose significance is unclear Their relations are shown in Table XLIV Keys has said At the present time (1951) it is entirely unjustified to attribute to G measurements any special virtues beyond that for simple cholesterol measurements for the prediction of atherosclerosis or the estimation of the activity of the atherosclerotic process (351) The type of lipoprotein its solubility and its physical characteristics however may have atherogenic properties These large molecules transport lipids and steroids in blood (352) Therefore an increase in β -lipoproteins may do something to the process directly or indirectly but at

TABLE XLII
IODINE NUMBER OF SERUM LIPIDS BEFORE AND AFTER ORAL B₆*

Patient	Age	Sex	Iodine Number		Total Dose mg	Diagnosis
			Before Vitamin B ₆	After Vitamin B ₆		
T C	77	♂	87			
G E	76	♂	100	58	250	Myocardial infarction Parkinsonism atherosclerosis
C H	61	♂	54	45	300	Myeloid leukemia aortic stenosis atherosclerosis
B H	53	♀	60	56	250	Metastatic carcinoma atherosclerosis
L J	58	♂	53	59	150	Metastatic fibrosarcoma
R LeG	19	♀	83	70	300	Myocardial infarction atherosclerosis
M R	68	♀	42	37	250	Fracture spine accident
G S	74	♂	59	69	250	Atherosclerosis diabetes mild
G B	58	♂	33	67	250	Atherosclerosis Carcinoma of prostate
T B	74	♀	78	50	150	Hypertension atherosclerosis
M J	50	♂	126	77	350	Metastatic carcinoma of breast atherosclerosis
E K	64	♀	124	71	350	Pulmonary insufficiency and fibrosis atherosclerosis
F S	55	♂	71	34	350	Atherosclerosis lobar pneumonia convalescent
			62	55	300	Atherosclerosis hypertension
Mean	61		74	61		
S D			27	15		

From data of Perry Schwartz Hager and Schroeder
* Fifty mg pyridoxal HCl per day

TABLE XIII
IODINE NUMBERS OF SERUM LIPIDS WHITE PATIENTS

Patient	Age	Sex	Total Cholesterol mg/100 ml	I ₂ No	Atherosclerosis Diagnosed	
K	64	Q	96	71	+	Lobar pneumonia convalescent
P	65	Q	101	94	+	Pulmonary insufficiency bronchiectasis
M	59	Q	106	56	+	Rheumatic heart disease
I	54	Q	111	70	+	Myocardial infarction
S	58	Q	119	82	+	Myocardial infarction emphysema
L	67	Q	124	89	+	Essential hypertension
J	62	Q	131	63	+	Hyperthyroidism
D	68	Q	133	97	+	Metastatic carcinoma of stomach
R	49	Q	134	61	+	Inferior vena cava obstruction
S	67	Q	182	70	+	Cerebral thrombosis
N	50	Q	191	124	+	Pulmonary fibrosis and insufficiency
B	55	Q	206	61	+	Hypertension
M	58	Q	210	78	+	Hypertension
G	48	Q	231	88	+	Angina pectoris
S	74	Q	242	126	+	Metastatic carcinoma of breast
I	45	Q	550	73	+	Angina pectoris
T	60	Q	>500	162	+	Nephrotic syndrome
G	44	Q		102	+	Angiodysplasia nephrotic syndrome
J	43	Q		84	+	Cerebral thrombosis hypotension
T	53	Q		76	+	Vascular tumor of brain
B	54	Q		70	+	Hypertension aneurysm of Circle of Willis
M	65	Q		62	+	Chronic cystitis
C	71	Q		76	+	Diabetes Parkinsonism
H	70	Q		78	+	Carcinoma of prostate
V		Q				
W		Q				
Mean	60			81		

From data of Ferry, Schwartz, Hager and Schroeder

NOTE: The iodine number of human depot fat is 61 (348) and cholesterol is 65.8. The mean iodine number of fatty acids in plasma of normal Chinese is 156.6 (8).

TABLE XLIV

COMPARISON OF DESIGNATIONS OF LIPOPROTEINS SEPARATED BY VARIOUS TECHNIQUES*

Ultracentrifuge		Electrophoresis	Cohn Method Fraction 10	Barr Russ & Eder
Solvent Density				
1.063 (Gofman <i>et al.</i>)	1.21 (Lewis Green & Page)			
Symbol				
S_t	$-S_{12}$			
20-100+	>70			
10-20	40-70			
3-8	25-40	Beta Globulin	I III	C
1-3	20-25	Alpha-2		
	2-8	Alpha-1	IV V VI	A

Note that the use of a solvent density of 1.063 does not permit alpha 1 lipoprotein to undergo flotation. It is not certain which Cohn fraction contains the lipoprotein identified ultracentrifugally as alpha 2.

* From Furman (352)

best, these molecules are secondary invaders or carriers and probably are not as directly concerned with pathogenesis as is cholesterol and its synthesis. If the total amount of cholesterol to be carried were low there would be little or none to be deposited. The nature of the fatty acids in phospholipids also may be more important in atherogenesis than the total quantity. We must go deeper into first causes than a consideration of carrier components.

in the blood. What they are and what they are made of is of the greatest importance.

The lipoproteins carry steroid hormones, cholesterol and its esters, carotene or vitamin A α -tocopherol and acetal lipid (containing hydroxyl groups) (352, 353, 387). Most (75 per cent) of the free cholesterol in serum is in the β -lipoprotein fraction as is the esterified fraction (73 per cent) while less (55 per cent) of the phosphorus is in this fraction. Barr found somewhat lower values in β -lipoproteins (354, 355). Thus, increase in the cholesterol/phospholipid ratio, suspected to be of atherogenic significance, means in terms of lipoproteins that with relatively less phospholipid than cholesterol the β -lipoprotein fraction will be increased in the proportion of 1:1.55. Gofman finds that particles of the S_{10-20} classes have weight ratios of cholesterol to phospholipid as high as 1:1.3 (356).

Exogenous Cholesterol. There is no evidence that a diet containing reasonable amounts of cholesterol (up to 1.0 Gm per day or the equivalent of four eggs) influences the level of blood cholesterol (357). Feeding healthy volunteers (358) or patients (359) up to ten times that amount causes insignificant changes in plasma levels. * Actually at 200 mg per 100 ml blood there is about 8 Gm in circulation with an additional 3 to 4 Gm in liver and a considerable amount in other tissues. While exogenous cholesterol probably little affects plasma levels in man, the reverse, i.e. restricting the dietary intake to very low values, does decrease plasma levels since all dietary cholesterol is contained in fatty foods which therefore need

* It is possible to block some of the intestinal absorption of exogenous cholesterol by plant sterols such as sitosterol in large doses. The effect on plasma cholesterol, however, is either insignificant, or significant to a very minor degree.

TABLE XLIV

COMPARISON OF DESIGNATIONS OF LIPOPROTEINS SEPARATED BY VARIOUS TECHNIQUES*

<i>Ultracentrifuge</i>		<i>Electrophoresis</i>	<i>Cohn Method Fraction 10</i>	<i>Barr Russ & Eder</i>
<i>Solvent Density</i>				
1.063 (Gofman <i>et al</i>)	1.21 (Lewis Green & Page)			
<i>Symbol</i>				
S_f	$-S_{11}$			
20-100+	>70			
10-20	40-70			
3-8	25-40	Beta Globulin	I III	C
1-3	20-25	Alpha-2		
	2-8	Alpha-1	IV V VI	A

Note that the use of a solvent density of 1.063 does not permit alpha 1 lipoprotein to undergo flotation. It is not certain which Cohn fraction contains the lipoprotein identified ultracentrifugally as alpha 2.

* From Furman (352)

best these molecules are secondary invaders or carriers and probably are not as directly concerned with pathogenesis as is cholesterol and its synthesis. If the total amount of cholesterol to be carried were low there would be little or none to be deposited. The nature of the fatty acids in phospholipids also may be more important in atherogenesis than the total quantity. We must go deeper into first causes than a consideration of carrier components.

usually contain unsaturated fatty acids. This is not true of fish oils which must be largely unsaturated or short chain because of the low melting point essential for mobility of the animal at low temperatures. Actually fish fat contains several very long chain unsaturated fatty acids.

There are three habits largely common to the U.S.A. and some European countries which tend to raise the dietary intake of saturated fats (202, 348, 360): 1) Since 1920 animals fattened for slaughter have been fed high carbohydrate diets in order to lay down a hard fat. Meat from animals eating unsaturated vegetable fats is oily and housewives do not like to buy it; the melting point is low. 2) For many years vegetable fats (unsaturated) have been commercially hardened, often by a copper or nickel catalyst in order to provide shortenings or margarine which are solid at room temperatures. 3) The consumption of milk, butter and cheese has increased; milk fats contain shorter chain saturated fatty acids and are believed to be atherogenic (356).

Relation of Dietary Fats to Cholesterol. Why does an excessive intake of hard or saturated fats cause atherosclerosis? The following information is known:

1) Animals lay down in their tissues part of the fat ingested. This has been demonstrated in all mammals but man. Pigs fed very long chain high melting point fatty acids may crack in the cold. Unnatural fats (odd numbered carbon atoms or optical isomers of natural fats) can be recovered from the bodies of animals to which they are fed in amounts from 10 to 25 per cent (348).

2) Cholesterol esters can be formed of the type of fat in the diet. Thus stearic or even unnatural fatty acid esters of cholesterol can be recovered when a specific fat is fed (348).

3) The esters of cholesterol in blood usually contain

be severely restricted. In animals, however, especially rats, rabbits, monkeys and chickens, very high intakes (2 to 4 per cent of the diet) raise plasma levels markedly (356).

Type of Fat Ingested The weight of evidence at present is in favor of the idea that a diet high in fats of animal origin is atherogenic, while diets containing adequate but relatively smaller amounts of vegetable fat are not. Although there are many types of fat in both animal and vegetable sources, the number is somewhat limited by the digestibility of the fats with higher melting points. Natural fats contain an even number of carbon atoms and are usually found as triglycerides, the lengths of the chains vary from 4 to 24. Some are saturated, some contain one, two, three or four unsaturated ethylene linkages. Obviously an enormous number of possible combinations can occur; fortunately, in nature they do not (Table XLIV).

The melting points of the saturated fatty acids are directly proportional to the length of the carbon chain, short chain acids being liquid (348). Equal length unsaturated acids have lower melting points. Solubilities are directly related, the saturated acids being less soluble in water and alcohol. Furthermore, the specific gravities of saturated fatty acids are lower than their unsaturated relatives.

Insofar as is known, there is no difference between glyceryl tristearate obtained from animal sources and that derived from vegetable; the fatty acids are identical. Fully hydrogenated linolenic acid becomes stearic acid. What then are the differences? Unless vegetable oils contain some esoteric product which counteracts the atherogenic influence of animal fats, we must look to the composition of the fats themselves. In general, animal fats have more saturated fatty acids than vegetable fats, while the latter

usually contain unsaturated fatty acids. This is not true of fish oils which must be largely unsaturated or short chain because of the low melting point essential for mobility of the animal at low temperatures. Actually fish fat contains several very long chain unsaturated fatty acids.

There are three habits largely common to the U.S.A. and some European countries which tend to raise the dietary intake of saturated fats (202, 348, 360). 1) Since 1920 animals fattened for slaughter have been fed high carbohydrate diets in order to lay down a hard fat. Meat from animals eating unsaturated vegetable fats is oily and housewives do not like to buy it; the melting point is low. 2) For many years vegetable fats (unsaturated) have been commercially hardened, often by a copper or nickel catalyst in order to provide shortenings or margarine which are solid at room temperatures. 3) The consumption of milk, butter and cheese has increased; milk fats contain shorter chain saturated fatty acids and are believed to be atherogenic (356).

Relation of Dietary Fats to Cholesterol. Why does an excessive intake of hard or saturated fats cause atherosclerosis? The following information is known:

1) Animals lay down in their tissues part of the fat ingested. This has been demonstrated in all mammals but man. Pigs fed very long chain high melting point fatty acids may crack in the cold. Unnatural fats (odd numbered carbon atoms or optical isomers of natural fats) can be recovered from the bodies of animals to which they are fed in amounts from 10 to 25 per cent (348).

2) Cholesterol esters can be formed of the type of fat in the diet. Thus stearic or even unnatural fatty acid esters of cholesterol can be recovered when a specific fat is fed (348).

3) The esters of cholesterol in blood usually contain

TABLE XLV

COMPOSITIONS OF CORN COTTONSEED OLIVE OILS AND BUTTER*

	Corn	Cottonseed	Olive	Butter
Iodine number	103-129	90-110	79-90	26-38
Saturated acids (%)	12-18	21-32	9-19	30-43
Oleate	21-49	19-36	64-86	28-41
Linoleate	34-61	34-56	4-15	
Linolenate	0-2.9	0	0	0
Arachidonate	0	0	0	0
Squalene (mg %)	28	8	383	0
Ergosterol	+	+	0	+
Sitosterol	+	+	0	
Stigmasterol	+			
Rate of enzymic hydrolysis	1	2	3	
Tocopherol (mg %)	87-250	83-110	3-30	

* After Deuel (348) and Eckey (447) Contents vary with climate soil and seed

cholesterol has been shown to be squalene a hydrocarbon with six double bonds having the empirical formula $C_{30}H_{48}$ (362). Squalene is found in the unsaponifiable fraction of several but not all fish oils and only one plant oil olive oil (0.41-0.54 per cent). Other vegetable oils contain only very small amounts (peanut oil 0.07 per cent). Animals fed labelled squalene synthesize cholesterol 50 times as efficiently as when given labelled acetate (362). Squalene is not converted to fatty acids as is acetate. An other precursor of cholesterol is provitamin D₂ or 7-dehydrocholesterol widespread in foods but in small quantities.

Effect of Various Fats on Blood Cholesterol Levels in Man One can gain some information on the relationship of the type of fat ingested to the level of cholesterol in plasma by human experiments in which dietary fat was markedly increased (Table XLVI). If these results are valid an examination of the table points at once to specific dietary factors or the lack of them which alter cholesterol

TABLE XLVI
DIETARY FACTORS ALTERING PLASMA CHOLESTEROL IN MAN*

<i>Factors Causing Increased Levels</i>	<i>Factors Causing Decreased Levels</i>
High fat intake	Low fat intake (386)
Starvation	Scurvy
Low carbohydrate intake	Vegetable fat (Diabetics)
Vitamin B deficiency	Soy bean oil (446)
Vitamin B ₆ deficiency (monkey)	Sunflower seed oil (448)
Olive oil	Nuts (363 365)
Cottonseed oil	Corn oil (367 368)
Butter (368)	Brain extract (366)
No change caused by	
Obesity	
Cholesterol intake (357)	
(moderate)	

* After Deuel (360) and others

levels in man Vitamin B deficiency starvation low carbohydrate intake high fat intake olive and cottonseed oils and butter move cholesterol values in the same direction, up while specific factors appear among those reducing it Because corn and olive oils act oppositely we must look to differences in content of specific factors in these two fats

The outstanding difference appears in the linolenic content which is absent in olive and cottonseed oils* and is present to the amount of 0.6 per cent of corn oil This essential fatty acid is not found in butter unless it is fed to the cow it was present in one sample of American human fat and serum (348) (possibly influenced by diet) but was not found in one German (348) is in some lecithins and cannot be synthesized by the animal (Table

* Oils may vary in their atherogenic properties possibly because of variations in essential fatty acid (linolenate?) content (440) Olive oil consumed in Spain is usually adulterated with soy oil

XLVII) Arachidonic acid a normal component of animal tissues lecithins cephalin phosphatides and fats is an other essential fatty acid formed from linoleic probably by a vitamin B₆ enzyme system (349)

Therefore the factor in certain vegetable fats (and not others) which lowers blood cholesterol may not lie in the presence or absence of unsaturated fatty acids themselves

TABLE XLVII

ESSENTIAL FATTY ACID CONTENT OF SOME EDIBLE OILS (%)

Food	Linoleic	Linolenic	Production†
Linseed	15-43	40-53	2.2
Peanut	47-72	0	3.9
Sunflower	44-75	0.1	2.0
Sesame	40-48	0	1.5
Soy bean	52.0	2.3-11	3.8
Coconut	1-2	0	4.6
Animal fats	+	0	17.8
Rapeseed	12-16	7-10	3.3
Palm	6-11	0	3.3

* After Eckey (447) †Estimated World 1951 billions of lbs

but in the linolenic or other specific fatty acid content. The cholesterol lowering diets of Kinsell *et al* contain nuts in large amounts (363). The fat from some nuts especially walnuts contains linoleic and linolenic acids (348). In this respect Kinsell's diets (364-365) contained soybeans soy lecithins soy sauce corn oil and walnuts all containing linolenic acid while this fatty acid has not been found in peanuts almonds and cashew nuts (348). The hydrogenated oils in margarine Crisco and peanut butter as well as cottonseed peanut and olive oil which apparently do not contain linolenate were also given in spite of these fats at least two of which usually raise blood cholesterol it fell. Brain extract probably cephalin which

contains arachidonic acid also has been reported to lower cholesterol (366) The common denominator of the effects of these various conflicting data appears to be in the tri or tetraethenoid acids similar to linolenic and arachidonic (367-369) (Table XLVIII)

TABLE XLVIII
FOODS CONTAINING LINOLEIC LINOLENIC AND ARACHIDONIC ACIDS*

	<i>Linoleic</i> (C ₁₈ , 2 double bonds)	<i>Linolenic</i> (C ₁₈ , 3 double bonds)	<i>Arachidonic</i> (C ₂₀ , 4 double bonds)
Egg yolk lecithin	+	0†	+
Brain lecithin	0	0	+
Brain cephalin		0	+
Liver lecithin	0	0	+
Pig fat	+	0	2-1%
Butter fat	3-6-4-5%	7**	+
Fowl fat	21-3%	0	+
Fish	40±%	+	+
Soy bean lecithin	+	+	0
Phosphatidic acids	+	+	0
Walnut oil	73%	3-8%	0
Beechnut oil	38%	0-4-2-9%	0
Soy bean	52-0%	2-3%	0
Alfalfa	67-5%	20-8%	0

* After Deuel (348)

† Only when fed to hens

** Only when fed to cows

It is interesting that atherosclerosis is unusual in countries where soy beans are a staple article of diet. If these deductions are correct substances containing linolenic acid, either in fats or in phosphatides, should lower blood cholesterol*. The relationship between pyridoxal and the formation of linolenate will be discussed below.

* The practice of fasting by some religious groups during one day a week and the Lenten season may have logic in terms of essential fatty acid

Pyridoxal and Trace Metals The amount of vitamin B₆ in the diet has a definite influence on essential fatty acid metabolism in animals. Vitamin B₆ deficiency and essential fatty acid deficiency in rats resemble each other grossly and each factor will partly alleviate the other. There are however fundamental differences in enzymes in the two

TABLE XLIX

COMPARISON OF ESSENTIAL FATTY ACID AND PYRIDOXINE DEFICIENCIES IN RATS (384)

Function	Organ	Essential Fatty Acid	Pyridoxine
Respiration	Liver	Increased	
Cytochrome oxidase	Liver	Increased	Increased ±
Succinic oxidase	Liver	No Change	No Change
Phosphate esterification	Liver	Decreased	Decreased
Glutamic dehydrogenase	Liver	Decreased	Decreased
Butyric dehydrogenase	Liver	Decreased	No Change
Succinic dehydrogenase	Liver	Decreased	No Change
Glutamic decarboxylase	Brain	—	Decreased
Arachidonic synthesis	Carcass	Decreased	Decreased
Hexaenoic synthesis	Carcass	Decreased	Decreased
Octanoate oxidation	Carcass	—	Decreased

conditions (Table XLIX). Apparently vitamin B₆ is essential for desaturating partly unsaturated fatty acids such as linoleic further to synthesize arachidonic and in metabolizing linolenic to hexaenoic acids. Linoleic is a precursor of arachidonic and linolenic of the hexaenoic acids (349).

deficiency or saturated fatty acid excess Thus the members of the Russian Orthodox Church eat nothing of animal origin during Lent. Advent and on Wednesdays and Fridays and use oils high in linolenic acid. Roman Catholics by custom supply themselves with adequate essential fatty acids on Fridays and during Lent but do not restrict other animal fats. Mohammedans have strict dietary laws during Ramadan. In terms of deposition of lipid these religious habits probably do no harm in maintaining or restoring the integrity of the intima.

In deficiency of this coenzyme, liver fat becomes more saturated (370)

Snell believes that vitamin B₆ as a coenzyme contains a metal for activity (215) If so, the interrelationships are obvious although whether or not such a metalloenzyme acts in the fatty acid cycle is not known The only one of these enzymes containing a metal is acyl Co enzyme A de hydrogenase which uses copper

Some further information may be obtained by the use of metal binding and chelating agents in lowering blood cholesterol Calcium disodium ethylenediamine tetraacetate (EDTA) is a good cholesterolytic agent in man (Figs 20 21) sometimes lowering values to the Indian normal (180, 371, 372) In rabbits (373) and rats (374) fed cholesterol however, it raises blood levels above the controls and in rabbits but not in rats it prevents deposition of this lipid in the liver Because EDTA is not metabolized in the body and diffuses readily (250) its sparing effect on liver but not on blood levels must be related to removal of one or more trace metals EDTA also raises lipid synthesis by rat liver while another agent 8 hydroxquinoline lessens it (375) EDTA causes marked loss of subcutaneous and depot fat (376) suggesting that a metal is involved in fat metabolism and synthesis Hydralazine another metal binding agent also lowers cholesterol in man (180) (Fig 22)

Comment These indirect but quite suggestive data are provocative of thought when viewed in pathogenetic and therapeutic terms Obviously normal cholesterol levels are lower in some countries than in others usually in those less touched by Western Civilization If we could reduce our own to these normal values by interfering with the processes which raise them to abnormal levels

LT 44 NEPHROSIS.






FIG 20 Effects of oral hydralazine and intravenous EDTA on plasma cholesterol levels. L. F. 44 years of age was seen in October 1954 because of mild exertional dyspnea and ankle edema for six months. At 7 years of age he had Marie Strumpell arthritis and at 25 years of age migratory polyarthritis without urinary symptoms. Nephrosis was clinically evident and amyloidosis was proved by renal punch biopsy. To lower his plasma cholesterol hydralazine was begun without evident clinical improvement. In a further effort to lower his plasma cholesterol three courses of parenteral EDTA were given. On the sixth day of this first course of therapy slight inflammation of the mucous membranes and a magenta tongue were observed and he complained of soreness about his mouth and gums. By the final day cheilosis, chemosis, scrotal inflammation and pustular lesions over the face and trunk had appeared. Within a week the lesions had vanished and a second course of EDTA was begun. On the fourth day stomatitis reappeared and within 7 days the same syndrome was present again necessitating the discontinuation of therapy. The 3-day final course produced no such lesions, however fever immediately followed the dosage increase to 4 Gm. Cholesterol values for the second course were not plotted because such a low plasma level was attained that a laboratory error was suspected (303 mg per 100 ml on a single determination). The changes in cholesterol preceded clinical toxicity (From Perry H. M. Jr and Schroeder H. A. J. Chronic Dis. 2:520, 1955). Metal excretion in Table XXX, p. 160.

L S J 28 DIABETES



A M



M B



FIG 21 Effect of intravenous EDTA on plasma cholesterol The material was given as the calcium disodium chelate L S The patient's diabetes controlled on 45 units of insulin a day worsened to the point that it needed 55 units possibly a result of pancreatic loss of zinc (From Perry H M Jr and Schroeder H A J *Chronic Dis* 2 520 1955) A M Hydralazine given in small doses appeared to maintain the lower values achieved with EDTA M B The rebound in a month is obvious

we would expect little or no atherosclerosis especially of our coronary arteries

There appears to be something in certain but not all vegetable fats which lowers blood cholesterol markedly in man while animal fats hydrogenated vegetable fats and other vegetable fats with a lower iodine number raise plasma cholesterol. As a first guess this substance may be linolenate an essential fatty acid. If that is so Europeans and Americans may be suffering from a relative essential




FIG. 92 Effect of oral hydralazine on total fasting plasma cholesterol in 11⁰ hypertensive patients. Changes in cholesterol concentrations before and after hydralazine are plotted against the length of therapy. Each large dot indicates a patient with an initial cholesterol level of more than 215 mg per 100 ml plasma. Each small circle indicates a patient with lower initial values below 211 mg per 100 ml plasma (From Perry H. M. Jr., and Schroeder H. A. J. Chronic Dis 2:570 1955)

LS J 28 DIABETES





FIG 21 Effect of intravenous EDTA on plasma cholesterol The material was given as the calcium disodium chelate L S The patient's diabetes controlled on 45 units of insulin a day worsened to the point that it needed 55 units possibly a result of pancreatic loss of zinc (From Perry H M Jr and Schroeder, H A J Chronic Dis, 2 520 1955) A M Hydralazine given in small doses appeared to maintain the lower values achieved with EDTA M B The rebound in a month is obvious

Intimal Injury due to	Increased Saturated over Unsaturated	X Blood Pressure = Atherosclerosis
X a) Vitamin B deficiency	Fatty acid esters of	
b) Excessive hypertension	cholesterol lipo-	
c) Normal pressure differentials	proteins and phospho- lipids Increased synthesis or decreased destruction of cholesterol due to metals or fatty acid deficiency	

The nature of the vitamin B₆ deficiency and its possible relation to trace metals has already been discussed. The plasma lipids under consideration include a) Cholesterol esters which are said to be usually of unsaturated fatty acids although esters of equal length saturated fatty acids are lighter and more insoluble. Dietary excess of the latter could influence their nature. b) Lipoproteins or protein fatty acid complexes the nature of which are unknown. The saturated fatty acid esters should be lighter and more insoluble than their unsaturated counterparts. If so they should centrifuge more slowly (or float more rapidly). A lipoprotein with a specific flotation rate of S₁ 0 10 if its fatty acid became saturated should theoretically change to the S₁ 10 20 class unless rearrangement of the molecule took place. c) Phospholipids the fatty acid components of which depend partly perhaps on dietary intake but usually are formed of unsaturated fatty acids in functioning tissue (brain and liver).

Effect of Sex For some unknown reason premenopausal women are quite immune from coronary atherosclerosis. The disorder however becomes as frequent in women after the menopause as in men. Coronary occlusion in a normotensive menstruating woman was formerly extremely rare although cases are now appearing. The degree of aortic atherosclerosis however shows little sex

fatty acid deficiency There may be very little linolenic acid in the American diet Pyridoxal is concerned with the utilization of essential fatty acids and a deficiency of one may enhance a deficiency of the other Furthermore, trace metals can be involved since they affect fat synthesis and may be concerned in vitamin B₆ enzymes although their role is possibly of only secondary importance

The differential effects of metal chelating agents must be explained (Let us assume that in the livers of human beings there is a metal (chromium, for example) which stimulates the formation of cholesterol and fatty acids or a metal (copper for example) which depresses catabolism of lipids, in addition to the normal metal (manganese for example) EDTA because of its higher affinity for the abnormal metal removes it allowing synthesis to revert from an accelerated to a normal rate or catabolism to rise itself to normal In the animal fed cholesterol however there is no abnormal metal affecting synthesis therefore the normal one is removed In that event the synthesis of cholesterol in liver might be lowered or catabolism raised preventing accumulation of endogenous cholesterol in liver but allowing exogenous cholesterol to remain in the blood The latter would be the case if storage and synthesis were related The differential effects of EDTA and 8 hydroxyquinoline in the rat can be explained by different affinities of the two substances for metals the former being the stronger chelating agent That two antagonistic metals may influence an enzyme system is well known for actomyosin (Mg and Ca) and has been proposed by the Bernheims for lipid metabolism (Mn and V) (274)

These various factors can be substituted in Friedman's schema to include a more definitive but much more hypothetical one

fluctuations can occur (377) A persistently high level is atherogenic a momentary low level may not reflect the true state of affairs in terms of intimal exposure There are conflicting opinions and data but the opposing views can be resolved by realization that a) cholesterol levels fluctuate and unless consistently elevated values may be meaningless 2) when a patient is sick the levels fall 3) the full lesions of atherosclerosis develop only after prolonged constant or intermittent hypercholesterolemia

In this chapter we have spoken of trace metal imbalances conditioned vitamin B₆ deficiencies and essential fatty acid deficiencies We have emphasized that these deficiencies are relative conditioned and local to one or at most a few enzyme systems There is no practical way however of reversing vitamin B₆ deficiencies at the present time The administration of 50 mg of pyridoxal hydrochloride daily to many patients has not resulted in a detectable fall in blood cholesterol The administration of at least two trace metals cobalt and manganese in large daily doses have not caused clinical changes detectable by ordinary laboratory methods Only by chelating agents have we been able to affect blood levels favorably (180)

The several pathogenetic factors outlined by Friedman *et al* should be affected simultaneously if we are to expect cessation of the process or at the best reversal Whatever is making the intima injured so that plaques are formed should be opposed as an approximation pyridoxine in adequate doses is required until more is known The abnormally high cholesterol levels in blood should be reduced by dietary influences and chelating agents if possible Elevated diastolic pressure should be controlled at normotensive levels Under these conditions some reabsorption of plaques which are not too scarred might be expected

difference (355) These differences cannot be explained by gross differences in plasma lipids, cholesterol or phospholipids but lower concentrations of beta lipoproteins higher ones of alpha lipoproteins and lower atherogenic ultra centrifugal lipoproteins are found in women The administration of estrogens to men alters these values to those of healthy young women, while methyl testosterone acts in the opposite direction Estrogen shifts an appreciable amount of cholesterol carried by beta lipoproteins into alpha lipoproteins while testosterone does the opposite The same sex immunity to coronary disease is found in chickens Although estrogen is carried in blood by lipoproteins this phenomenon is unexplained on a mass action basis by the small amounts administered

Clearing Factor Heparin will clear lipemic serum both *in vivo* and *in vitro* (444) Apparently this anticoagulant alters the physicochemical structure of chylomicra so that they become soluble These large fat filled particles carry almost all dietary cholesterol The rates of clearing are faster in young women than in men and slower in the aged Their relations to atherosclerosis are not known

CLINICAL IMPLICATIONS

At present there are several available methods for lowering blood cholesterol in man Because the pathogenesis of atherosclerosis is a multivalent one the process must be attacked at different levels Obtaining a permanently lowered cholesterol level in blood might allow cessation of the deposition of cholesterol in plaques with probably some absorption in the presence of an altered gradient between plaque and plasma Practical methods will be discussed in Chapter IX

What the level is at any one instant of a lifetime of exposure to atherosclerosis is relatively unimportant Wide

3 Ischemia due to organic vascular disease which does not appear until the pressure is lowered is a clear and present hazard in actual practice it is rare

4 Diastolic normotension must be achieved and maintained whenever possible A compromise is hazardous merely modifies the disease promotes drug tolerance and does not allow eventual reduction of dosage

5 The use of any ganglionic blocking agent the action of which does not last for 24 hours requires that blood pressure be measured before each dose in order to prevent a) hypertension b) hypotension and c) to provide as constant a blood level as possible throughout the day and night Varying requirements and absorption necessitate varying dosages according to the prevailing levels of blood pressure

6 Arterial hypertension due to increased generalized vasospasm is a disorder or a disease The patient either has it or has not If he has severity varies widely from slight to marked Therapy should be applied when both patient and physician want to control the disease If therapy is not applied the responsibility rests on the physician that the disease is not doing or going to do harm

EVALUATION OF PATIENT FOR DRUG THERAPY

The first question to be answered is Has the patient hypertension? A diastolic pressure of 90 mm Hg or over (measured by the disappearance of Korotkoff sounds) is strongly suggestive in fact usually indicative of generalized vasospasm in the absence of tachycardia polycythemia or coarctation of the aorta When persistent it suggests chronic hypertension when relieved by relaxation it suggests the prehypertensive state

The second question is How severe or sustained is the

Chapter VIII

PRACTICAL METHODS FOR MODERN THERAPY OF HYPERTENSION

INTRODUCTION

ON THE BASIS of the various hypotheses and findings outlined in previous chapters and using the potent drugs discussed a practical method of controlling excessive vasospasm in man can be outlined and the therapeutic limits of a long term regimen can be predicted. While the use of this regimen requires care and precautionary measures, it is no more difficult in fact much less so than is the control of diabetes mellitus. Some simple but basic rules need be kept in mind, which any practitioner of medicine can follow. The results are often life saving in severe cases.

General Rules 1 Vasospasm alone is being treated. In no case are the results of atherosclerosis (coronary and cerebral arterial narrowing, the loss of aortic elasticity, renal arteriosclerosis) being reversed as far as we know, although there may be slow changes with time. Therefore the most striking results will be seen in cases where the effects of vasospasm are the greatest (hypertensive heart failure, cerebral edema), and the poorest in cases where the effects of atherosclerosis are the most advanced.

2 In all cases where two different factors are contributing to the generalized vasospasm, two differently acting drugs must be used. When only one factor is operating, only one drug is necessary. In severe hypertension two factors almost always are functioning.

primary organic renal diseases adrenal dysfunction or emotional crises

For a thorough work up evaluation of the cardiac status requires a study of the symptoms electrocardiographic tracing for left ventricular hypertrophy strain patterns or old myocardial infarction and roentgen or fluoroscopic examination of the heart In actual practice only signs of a previous coronary occlusion are important indications for cautious therapy but physicians are often gratified to watch enlarged hearts slowly become smaller and abnormal electrocardiographic tracings revert to normal under continuous therapy

Renal status is evaluated most easily by routine urinalysis and the intravenous injection of phenol red (PSP) with urine specimens obtained 15 30 and 60 minutes after injection The test is simple and reliable The bladder need not be emptied before the test although the first specimen may show a somewhat smaller amount of PSP* for unknown reasons (Reabsorption of PSP by bladder wall has not been ruled out) Adequate hydration is essential for accurate values The urinary concentration test is impractical on an outpatient basis owing to difficulties in restricting the amount of dietary water If the 15-minute PSP excretion is less than 10 to 15 per cent azotemia may be suspected

Retinoscopy is essential in all cases The appearance of exudative or hemorrhagic retinitis is often a poor prognostic sign making treatment mandatory The best method for grading fundal changes is that of Keith and Wagener

* In a series of 39 medical students paired for the test with bladder empty the 15-minute excretion was 30.5 per cent with bladder full, 30.9 per cent The normal values with bladder initially empty were 1 minutes 30.5 per cent 30 minutes 21.2 per cent 60 minutes 17.0 per cent with a total of 73.7 per cent

hypertension now? This can be answered only by repeated measurements of blood pressure sometimes complete bed rest is necessary to rule out emotionally induced vasospasm. The examining physician must be aware of the 'manometric reflex,' a psychosomatic response by vasospasm to the wrapping of the cuff about the arm (4). He also must keep in mind the wide spontaneous variations of blood pressure sometimes seen in hypertensive individuals (388-397, 36).

The third question is *How much harm, if any, is hypertension doing or has it done? This can be answered mainly by physical examinations and simple laboratory tests, bearing in mind the sharp division of what changes are atherosclerotic and what are the results of overwork and vasospasm. Systolic hypertension is not caused by vasospasm but by hard arteries or increased cardiac output, cerebral thrombosis and coronary occlusion are not directly hypertensive in origin.*

The fourth question is *How rapidly is it progressing? An accurate history and clinical judgment supplies the answer, often only after many examinations.*

Office Practice While partial answers to these questions can be obtained in office practice one can do better by a hospital work up (400).

The date of onset of hypertension should be determined if possible in order to get an idea of the rate of progression. The date of discovery may be less important. The effects of hypertension can be evaluated by inquiry into the cardiac status, dyspnea being the earliest symptom of insufficiency and renal status by polyuria and nocturia. The approach to the patient is divided into three parts: a) estimation of the rate of progression b) estimate of the present status in terms of secondary organic damage and c) inquiry into possible definite etiologic factors such as

- 5 External compression of the renal artery
 - a Tumors of the pedicle*
 - b Aneurysms*
- 6 Diminution of the calibre of the renal arteries
 - a Congenital malformations hypoplasia*
 - b Atherosclerosis, with atheroma of the main renal artery (common)*
- 7 Disorders of the urinary tract
 - a Obstructive disorders
 - (1) Lithiasis*
 - (2) Hydronephrosis (usually infected)*
 - (3) Pyonephrosis
 - (4) Congenital malformations*
 - (5) Prostatic hypertrophy*
 - (6) Uterine prolapse
 - (7) Pelvic tumors (fibromyomata)*
 - b Pyelonephritis (common)*
- 8 Venous obstruction
 - a External compression of renal vein
 - b Congestive heart failure*

The following intrarenal diseases must be considered

- 1 Inflammatory vascular lesions
 - a Disseminated lupus erythematosus*
 - b Polyarteritis nodosa*
 - c Syphilis
 - d Thromboangitis obliterans
- 2 Inflammatory renal lesions
 - a Glomerulonephritis*

The following endocrine diseases can influence hypertension

- 1 Hypophyseal tumors and hyperfunction*
- 2 Adrenal cortical and medullary tumors and hyperplasia*

(389), in simplest terms it means Grade I, spasm, Grade II, spasm and sclerosis Grade III, spasm and hemorrhage and/or exudate, Grade IV, spasm, hemorrhage and/or exudate plus papilledema Cases between grades are naturally encountered

The lability of the blood pressure can be tested by giving tetra ethylammonium chloride (Etamon) intravenously, thus blocking sympathetic ganglia This drug is not to be given in states of renal insufficiency excreted by the kidney, it may be retained and the patient may suffer from postural hypotension for several hours

Intravenous pyelography and repeated cultures of the urine are essential for revealing the presence of chronic pyelonephritis if active low grade infection is present Estimation of the numbers of bacteria per ml of urine (colony count) is of more value than merely finding organisms

The following renal conditions usually discovered by pyelography or aortic arteriography, can influence hypertension unfavorably by adding a renal factor to a neurogenic one The list was modified from that of Braun Menendez *et al* (148, 393, 394)

- 1 Reduction of renal parenchyma
 - a Polycystic kidneys*
 - b Renal tumors (rare)
 - c Hydatid cyst of kidney (rare)
 - d Traumatic lesions*
 - e Hypoplasia*
- 2 Perinephritis, healed*
- 3 Complete obstruction of main artery or branch*
 - a Thrombosis and atheromata of the renal artery*
 - b Emboli to the renal artery clot or cholesterol*
- 4 Intermittent occlusion of the renal artery
 - a Renal ptosis*

* Personally observed

EVALUATION OF GENERALIZED VASOSPASM IN HYPERTENSIVE STATES

It is of little more than academic interest what the underlying pathogenetic factors in a state of severe hypertension may be except when chronic pyelonephritis can be treated with antibiotics (often with little success) or recurrences of glomerulonephritis prevented by antibiotics designed to abort upper respiratory tract infections. It also matters little what the type of renal disease contributing to the vasospasm may be pyelonephritis glomerulonephritis secondary arteriolar nephrosclerosis or even polycystic disease. What do matter are the relative influences of neurogenic nephrogenic or adrenocortical factors in causing the vasospasm for the relative amounts of different drugs required will differ according to the amount of renal ischemia present. Therefore it is a good plan to group cases according to several stages of the disease dependent upon the amount of vasospasm one finds and its lability.

The degree of lability of the vasospasm is the factor which determines these stages. Complications such as cerebral vascular accident and coronary arterial occlusion can occur in any stage mild severe or normotensive as they are caused not directly by vasospasm but by an associated disease atherosclerosis. The fact that this other disease can be influenced by the severity of the hypertension i.e. the vasospasm has little to do with therapeutic measures aimed at vasospasm. Therefore classifications based partly upon atherosclerotic damage are valid for purposes other than the choice of drugs or procedures such as prognostic implications and for surgical risk. One would not use the most potent drugs in a patient with hemiplegia or congestive heart failure who exhibited severe atherosclerosis and mild hypertension one would use them however in a patient with severe but asymptomatic

- 3 Ovarian tumors*
- 4 Toxemia of pregnancy*
- 5 Testicular tumors with hyperfunction*

The following nervous lesions can contribute to hypertension

- 1 Certain tumors of brain*
- 2 Anxiety states*
- 3 Expanding inflammatory lesions*
- 4 Cerebral vascular lesions*

Hospital Patients For further evaluation, the patient should be examined in hospital both for the purpose of determining the lability of blood pressure and for initiating treatment with ganglionic blocking agents. Blood pressure is measured every 4 hours by the nurses and is charted. The sodium amytal release test is performed (0.2 Gm sodium amytal given each hour for 3 hours, blood pressure being measured hourly during the night). The ability of the kidneys to concentrate urine also can be measured by giving the patient a dry diet and no fluids for 12, 18 or 24 hours; the last specimen shows the maximal specific gravity corrected for proteinuria or glycosuria.

The obvious disorders causing true or false hypertension must be ruled out before starting therapy. Pheochromocytoma is a rare disease requiring a high index of suspicion; it can be suspected by using phentolamine (Regitine) intravenously without prior sedation. Regitine can cause acute hypotension and renal shut down in azotemic states. Measurement of catechol amines in urine either by bioassay (390) or chemical determination, is a specialized procedure done only in a few medical centers. Coarctation of the aorta is unusual; palpation of the femoral arteries or abdominal aorta will usually show its presence as will roentgenograms of the rib cage.

Serious secondary atherosclerotic complications may or may not be present if so about 30 to 40 per cent may be dead in 3 years. The ocular fundi are Grade I or II renal function is normal or nearly normal and the blood pressure is roughly 180/100 to 220/120 mm Hg during rest in bed. Reserpine plus fairly large doses of hydralazine (300 to 400 mg per day) will control about half of these cases eventually the remainder require the addition of ganglionic blockade. With time individuals in this stage uniformly exhibit reversal of the process and marked reduction of dosage in 2 to 3 years a majority can be maintained on reserpine alone and a few will be in a complete but probably temporary remission.

Stage III is made up of individuals with Grade II to III (Keith Wagener) ocular fundi with or without occasional hemorrhagic and exudative lesions with severe generalized vasospasm and hypertension not relieved by heavy sedation (sodium amytal). Renal function is adequate but usually reduced. Serious atherosclerotic complications may or may not be present. The blood pressure is usually 200/120 to 270/160 mm during rest in bed. In this stage which usually carries a poor prognosis (40 per cent dead in 3 years) ganglionic blockade plus adequate doses of hydralazine (500 mg or more per day) are essential for control. Reserpine may or may not be added mainly for its sedative action in smoothing out variations in blood pressure caused apparently by emotional lability in the presence of incomplete and irregular ganglionic blockade. Therapeutic results are good 95 per cent surviving 5 years with considerable eventual reduction in dosages in most.

Stage IV corresponds to Perera's accelerated phase or what is more commonly called the malignant stage. For therapeutic purposes it can be divided into three sub-

1) matic diastolic hypertension and retinitis without serious cardiovascular damage having yet occurred

We define normotension as levels below 140/90 mm Hg. It is at this diastolic level that vasospasm becomes slightly excessive. Definitions based on higher diastolic levels in older age groups pay lip service to the prevalence of the disease, avoiding realities. Actually in the absence of vasospasm the diastolic pressure falls slightly as atherosclerosis develops while the systolic rises.

Prehypertensive The blood pressure is slightly above 140 mm systolic or 90 mm Hg diastolic at times but falls with relaxation. There are no signs of secondary damage. Chronic pyelonephritis or hydronephrosis, however, may be found in young individuals (391).

Stage I comprises patients with elevated levels of blood pressure during a physician's examination but normal or lower levels part of the time corresponding to early stages of Perera's uncomplicated asymptomatic phase (392). Admission to hospital and frequent measurements by nurses combined with diagnostic procedures lower them to normal, often dramatically (400). Renal function is excellent and there are no findings suggestive of secondary damage. Emotional tension is present and continuous. Reserpine will effectively control about half of these cases in the remainder small doses of hydralazine (75 to 200 mg per day) may be necessary. We do not advocate the use of protoveratrine or available blocking agents in these individuals, for their irregularity and intermittency of action may cause hypotensive symptoms. A very long acting ganglionic blocking agent however should be effective.

Stage II comprises patients with elevated levels of blood pressure at all times except under heavy sedation (sodium amytal). It corresponds partly to Perera's symptomatic uncomplicated phase and partly to his complicated phase.

more theoretical benefits of dividing the dose or of using slowly absorbed increments such as are dispensed in some modern capsules than there is in dividing the dose of digitalis. It has been our practice to use 1.0 mg. per day for 1 month reducing it then to 0.5 mg. and further reducing it to 0.25 or 0.1 mg. slowly if excessive sedation appeared. It is such a mild anti-hypertensive drug in most cases that it should not be depended upon if signs of cardiovascular damage are present. Its many side effects are listed in Chapter III, nasal congestion being the most prominent and paranoid depression with suicidal tendencies the most dangerous. This latter side effect places it among the agents indirectly hazardous to life; the self-satisfaction of a physician using it in severe and malignant stages who is afraid to employ more potent measures also makes it less directly hazardous. At the first sign of increasing nervousness, anxiety, insomnia, emotional tension and agitation it should be discontinued for agitated paranoid depression may develop (70-72). In our experience reserpine is not a very valuable agent for hypertension except as a curious kind of sedative with many side effects (Fig. 24).


Reduction in dosage will often alleviate the usual depressive effects of the agent and may reduce the number of nightmares, but nasal stuffiness can be most annoying. Epistaxis induced by the drug usually necessitates discontinuation. The time-tested sedatives are the only alternatives to replace reserpine if it cannot be used.

We have seen four patients whose severe hypertension was cured for several months in that all drugs but reserpine were slowly discontinued during 2 to 3 years. In one an ulcer developed in two inactive ulcers became active, one having a massive hemorrhage and perforation into the pancreas requiring partial gastrectomy in the fourth


stages (a) early, in which hemorrhagic and exudative retinitis is present but not marked (Grade III to IV) and renal function is reduced but adequate, (b) severe, in which retinitis is advanced (Grade IV) and renal function is borderline, and (c) azotemic in which nitrogen retention has occurred. The diastolic pressure is usually 130 mm or more and fixed and albuminuria is usually present. Each sub stage carries a different prognosis, 3 year survivals of treated patients being roughly 100 per cent for (a), 80 per cent for (b) and 50 per cent for (c) without frank uremia. Ganglionic blockade plus adequate doses of hydralazine (500 to 1000 mg per day) are essential for reversal of the stage. In general control of hypertension is easier to achieve and is more even than with patients in Stage III, reduction of dosage is the rule after 12 to 18 months except in azotemic individuals. The systolic pressure can usually be maintained at or near former diastolic levels.

SPECIFIC USE OF DRUGS

Use of Reserpine Reserpine is given in one dose a day usually at night (Fig 23). Since the effect of this drug is cumulative (although the drug itself is not), there are no



YOHIMBINE



RESERPINE

FIG 23 Chemical structures of Yohimbine and Reserpine according to Schlittler *et al* (442)

more theoretical benefits of dividing the dose or of using slowly absorbed increments such as are dispensed in some modern capsules than there is in dividing the dose of digitalis. It has been our practice to use 1.0 mg. per day for 1 month, reducing it then to 0.5 mg. and further reducing it to 0.25 or 0.1 mg. slowly if excessive sedation appeared. It is such a mild anti-hypertensive drug in most cases that it should not be depended upon if signs of cardiovascular damage are present. Its many side effects are listed in Chapter III, nasal congestion being the most prominent and paranoid depression with suicidal tendencies the most dangerous. This latter side effect places it among the agents indirectly hazardous to life; the self-satisfaction of a physician using it in severe and malignant stages who is afraid to employ more potent measures also makes it less directly hazardous. At the first sign of increasing nervousness, anxiety, insomnia, emotional tension and agitation it should be discontinued, for agitated paranoid depression may develop (70-72). In our experience reserpine is not a very valuable agent for hypertension except as a curious kind of sedative with many side effects (Fig 24).

Reduction in dosage will often alleviate the usual depressive effects of the agent and may reduce the number of nightmares, but nasal stuffiness can be most annoying. Epistaxis induced by the drug usually necessitates discontinuation. The time-tested sedatives are the only alternatives to replace reserpine if it cannot be used.

We have seen four patients whose severe hypertension was cured for several months in that all drugs but reserpine were slowly discontinued during 2 to 3 years. In one an ulcer developed in two inactive ulcers became active, one having a massive hemorrhage and perforation into the pancreas requiring partial gastrectomy in the fourth


serious mucous colitis and proctitis with ulceration and bleeding appeared and remained. Because reserpine produces relative parasympathetic overactivity it may be contraindicated in such individuals * and complications such as these must be watched for.

Use of Protoveratrine. One can begin this agent in doses of 0.2 mg three times a day increasing by 0.2 mg per dose until nausea or vomiting appears (395). The dose causing nausea is then reduced by 0.1 or 0.2 mg and the others gradually increased to the point of nausea. The emetic effect appears within an hour after the dose often sooner. Wide swings of blood pressure occur with a rise at night. This agent cannot be given effectively every 4 hours as tolerance soon develops only to disappear with a few hours rest. To be completely effective

These developments stimulate speculation. If psychosomatic influences are blocked in one somatic nervous pathway the sympathetic perhaps excessive outflow through the other the parasympathetic, has led to gastrointestinal disorders. The patient is determined to develop a psychosomatic disease when we do not allow him (or usually her) to have one kind he gets another. Reserpine may thus be an accessory etiologic agent.

been on treatment for 2 years with a fair response his pretreatment levels ranging between 200 and 250 systolic and 130 and 150 mm. Hg diastolic. Congestive heart failure had disappeared without drugs or dietary restrictions. Note the decreased intake of hexamethonium chloride required when reserpine was added the average level of blood pressure appeared to rise at end of the period. G.C. same in a 54-year-old man with severe aortic atherosclerosis who after 1 year achieved only a fair response from initial levels of 205 to 240 systolic and 120 to 140 mm. Hg diastolic. He preferred to maintain his blood pressure at levels higher than normal and to vary his dose of hydralazine his diastolic pressure was only slightly elevated. Note the reduction in average daily dosage of both agents without change in blood pressure when reserpine 10 mg a day was added. Control had been previously increased on two occasions by adequate doses (From Schroeder H. A. *Am J Med* 17:540 1954.)

DB of 43. HYPERTENSION FOR 40 YEARS



G C P




FIG 24 Effect of added reserpine II B mean weekly blood pressure levels (each 35 measurements) and average daily doses of hydralazine (5968) and hexamethonium chloride (C₆) as affected by reserpine (Serpasil) 10 mg per day in a patient with severe benign hypertension previously suffering from congestive heart failure He had

to judge accurately the effective dose of a ganglionic blocking agent without knowing the level of blood pressure. It is most difficult to give increasing doses to maximal effect without overdosage unless the patient is under careful supervision of blood pressure and symptoms. Therefore it is our practice to begin ganglionic blockade by drugs in the hospital not only for convenience sake but also to achieve greatest benefit. We know of only one way to give oral ganglionic blocking agents effectively (Fig 26)

1 Blood pressure is measured by competent nurses every 4 hours day and night and charted

2 Initial dose is given every 4 hours if the blood pressure is above a chosen level usually 140 mm systolic. It is not given if the blood pressure is below that level. Slightly higher orist levels are used in the cases of atherosclerotic or azotemic patients 150 to 170 mm Hg. Initial doses which are usually safe to give to patients with severe hypertension are: Hexamethonium chloride 125 mg, Pentolinium tartrate 20 mg, Chlorisondamine 10 mg, Mecamylamine 2.5 mg

3 If the desired normotension is not achieved each dose is raised by increments amounting to the initial dose daily until 4 or 5 days have passed. Thus each dose given every 4 hours will be: Hexamethonium chloride 500 to 750 mg, Pentolinium tartrate 150 to 200 mg, Chlorisondamine 50 to 75 mg, Mecamylamine 15 to 20 mg. By this time intermittent normotension should have been achieved. (In order to change intermittency to more even control hydralazine must be added at this point (Fig 27)) Each dip in systolic pressure gives the physician confidence in the lowest levels tolerable without cardiovascular accident.

4 Doses are then given on a sliding scale dependant on the level of blood pressure. If normotension is desired

protoveratrine must usually be supplemented by hydralazine (Fig 25)

Use of Ganglionic Blocking Agents It is impossible




FIG 25 Example of poor initial control of blood pressure by insufficient doses and excellent control later in a patient with malignant hypertension and renal insufficiency who also suffered from partial asymptomatic duodenal obstruction. Hypertension of 10 years duration had become severe and grade IV ocular fundi had developed. She had suffered a minor apoplectic stroke. Hexamethonium chloride induced intermittent subtotal obstruction and vomiting and was poorly tolerated after 2 months. After the initial excellent response a grade of only a fair response was achieved on large doses of hydralazine. 1 year later blood pressure slowly returned to control levels. The addition of protoveratrine caused a sharp decline to lower levels. The later addition of reserpine (serpasil) produced normotension. Each point represents the average of 150 measurements. Elevated nonprotein nitrogen in her blood of 40 mg per cent (Somogyi zinc method) had fallen to 16 mg per cent, an abnormal electrocardiogram had become normal and her ocular fundi had cleared. In our experience the effect of these two additional agents in severe stages is unusual. This case is illustrative of the point that control of hypertension is possible in almost all cases. (From Schroeder H. A. *Am J Med*, 17:540, 1951)

to judge accurately the effective dose of a ganglionic blocking agent without knowing the level of blood pressure. It is most difficult to give increasing doses to maximal effect without overdosage unless the patient is under careful supervision of blood pressure and symptoms. Therefore it is our practice to begin ganglionic blockade by drugs in the hospital not only for convenience sake but also to achieve greatest benefit. We know of only one way to give oral ganglionic blocking agents effectively (Fig 26)


1 Blood pressure is measured by competent nurses every 4 hours day and night and charted

2 Initial dose is given every 4 hours if the blood pressure is above a chosen level usually 140 mm systolic. It is not given if the blood pressure is below that level. Slightly higher initial levels are used in the cases of atherosclerotic or azotemic patients 150 to 170 mm Hg. Initial doses which are usually safe to give to patients with severe hypertension are Hexamethonium chloride 125 mg, Pentolinium tartrate 20 mg, Chlorisondamine 10 mg, Mecamylamine 2.5 mg

3 If the desired normotension is not achieved each dose is raised by increments amounting to the initial dose daily until 4 or 5 days have passed. Thus each dose given every 4 hours will be Hexamethonium chloride 500 to 750 mg, Pentolinium tartrate 150 to 200 mg, Chlorisondamine 50 to 75 mg, Mecamylamine 15 to 20 mg. By this time intermittent normotension should have been achieved. (In order to change intermittency to more even control hydralazine must be added at this point (Fig 27).) Each dip in systolic pressure gives the physician confidence in the lowest levels tolerable without cardiovascular accident.

4 Doses are then given on a sliding scale dependant on the level of blood pressure. If normotension is desired

H J 61 MALIGNANT HYPERTENSION.



H O 60 MALIGNANT HYPERTENSION




FIG 26

the full dose is given if the systolic pressure is over 140 mm half the dose if between 140 and 130 mm one fourth the dose if 130 and 120 mm and none if 120 or below. Higher or lower levels 10 mm apart are used in atherosclerotic and azotemic patients perhaps 150 140 and 130 or 160 150 and 140 depending upon where the diastolic pressure has settled or whether the azotemia has lessened or worsened. Measurements are then made with the patient seated in order to take advantage of some postural hypo-

MB # 43 NEUROGENIC HYPERTENSION





FIG. 26 Examples of adequate control of blood pressure by giving adequate doses of ganglionic blocking agents (hatched area pentolinum bitartrate C_2) and hydralazine (solid black area 5968). In the case of H J in hospital control was poor at first until doses were raised sufficiently to achieve normotension. Each point represents the mean of six measurements. Diastolic normotension was achieved. H O₂. Note increase in blocking agent required to maintain normotension in August. Hexamethonium chloride (C_3) was used at first in hospital. M B Note automatically decreasing doses when blocking drug was given on a sliding scale. Each point is mean of 35



E D 48 SEVERE BENIGN HYPERTENSION




FIG 27 Examples of failure of control of hypertension by ganglionic blockade (pentolinium C_5) alone E D Although normotension was achieved in hospital patient died of malignant hypertension in May 1955 Hydralazine should have been added to achieve control T P Hydralazine (5968) was discontinued because of late toxicity Although malignant hypertension was relieved and did not recur ganglionic blockade with hexamethonium chloride (C_6) failed to maintain diastolic normotension High systolic pressures were necessary because of postural hypertension resulting from drug and surgical sympathectomy Each point is the mean of 150 measurements


tension Standing pressures are avoided The night dose is omitted leaving eight hours of uninterrupted sleep

5 Parasympatholysis should be treated A nightly laxative and magnesium citrate if the bowels have not moved by mid morning will usually promote a daily evacuation It is important to prevent distension of the intestines (404)

Precautionary measures against obstruction of a hollow viscus already partially obstructed should be taken Abdominal scars prostatic hypertrophy, frequent rhinitis, are warning signs of possible trouble from this source They are usually less severe than the disease being treated When the drugs cannot be tolerated protoveratrine can be substituted with good results Surgical sympathectomy, of course does not carry this hazard Prostatic obstruction may require surgery

Use of Hydralazine This drug is given almost always in conjunction with either ganglionic blockade (Fig 28) or another milder agent acting on nerves (423) Because of initial side reactions mainly attributable to its antihistaminase action which are lessened with nerve acting drugs it is begun at doses of 25 mg every 4 hours raising the dose to 50 75 and 100 mg every 4 hours on 3 successive days It is given with the blocking agent Thus 500 mg a day is the usual dose in severe hypertension we have had to give as much as 10 Gm for short intervals These large doses may cause hydralazine disease in 10 per cent of patients after 6 months In general larger doses are given for greater nephrogenic components to the vasospasm smaller doses when the neurogenic component is large It is unreliable when used alone (189 396)

High fever aching and malaise appearing during the first few weeks of administration of hydralazine requires discontinuation or marked reduction of dosage Fortunately such sensitive individuals are rare Angina pectoris



E D # 48 SEVERE BENIGN HYPERTENSION.





FIG 27 Examples of failure of control of hypertension by ganglionic blockade (pentolinium C_5) alone E D Although normotension was achieved in hospital patient died of malignant hypertension in May 1955 Hydralazine should have been added to achieve control T P Hydralazine (5968) was discontinued because of late toxicity Although malignant hypertension was relieved and did not recur ganglionic blockade with hexamethonium chloride (C_6) failed to maintain diastolic normotension High systolic pressures were necessary because of postural hypertension resulting from drug and surgical sympathectomy Each point is the mean of 150 measurements

can be made worse (or relieved) by hydralazine. A compromise partial control of hypertension by neurogenically acting drugs plus perhaps restriction of dietary sodium may provide some measure of vascular safety which while not ideal may lengthen life. In our experience patients with severe hypertension are rarely intolerant to this agent when it is first given.

Hydralazine disease appearing after 0 to 24 months of ingestion of fairly large doses necessitates two courses. Stopping the offending agent entirely results in return of hypertension. In these patients the mortality rate from hypertensive causes is 10 per cent. Large doses of ganglionic and hypothalamic blocking agents with or without protoveratrine usually fail to control the hypertension adequately. Wide swings from high to low levels take place daily. This situation is about the most difficult to meet in therapy and we have no solution. Low salt diets or thiocyanate might be used. Sodium azide has been valueless (Fig 29). Closely related analogues of hydralazine have caused recurrences of the disease and chemically less related ones have been relatively worthless.

Hazards of severe restriction of dietary salt are well known. The nephrosclerotic kidney is a salt losing kidney to some extent and hyponatremia with renal failure (the low salt syndrome) can be induced by limiting the intake to a point less than obligatory urinary losses. Borderline renal function predisposes to this usually fatal condition (397-399) (Fig 30).

The second choice involves marked reduction of the dose and the possible addition of cortisone until symptoms subside. The disease resembles in part a phenomenon of depletion. By small doses blood pressure can be controlled although L.E. preparations may remain positive. The disease remains in a subclinical lupoid stage and



A.K. 49 SEVERE BENIGN HYPERTENSION.




FIG 28 Example of effect of pentapyrrolidinium bitartrate (hatched area) as compared with that of hexamethonium chloride in malignant hypertension quite resistant to the latter. Upper Curve The patient suffered from Leriche's syndrome proven by previous operation which probably extended a year later to involve the right renal artery as shown by contrast aortograms. Each point is the average of six measurements made at four hour intervals during his hospital stay (Dec and Jan) and of five measurements as an out patient (a representative month Feb to March is shown). Large doses of hydralazine have been required. While the result can be considered only fair the patient worked full time on a railroad section gang without symptoms and his grade IV ocular fundi cleared. He died of uremia 2 years later. Lower Curve Poor control of blood pressure in a patient taking adequate doses of hexamethonium chloride and insufficient doses of hydralazine after two years of good control. Each point is the average of 35 measurements. Pentapyrrolidinium bitartrate apparently altered a poor response into a good one. Such is not always the case.

creased the patient and his record are evaluated if relative normotension is not consistent and the fluctuations of pressure much less marked the dose of one or the other agent is adjusted upward until it is maintained. Maximal (but unusual) single doses of hydralazine can be as high as 200 mg of hexamethonium chloride 10 Gm of pentolinium bitartrate 300 mg or more of chlorisondamine 100 mg and of metamylamine 20 mg.

Before discharge measurement of blood pressure with the patient seated causes the amount of ganglionic block





FIG 29 Examples of hydralazine (collagen) disease with special reference to blood pressure and difficulty of achieving control without hydralazine (See also Fig 27) H D Control of systolic normotension was impossible by ganglionic blockade when hydralazine (5968) was stopped. Sodium azide (NaN_3) had no demonstrable effect. I W Note stroke normotension when hydralazine disease was once established. A sulfur containing pyridazine (13050) did not affect blood pressure nor did sodium azide W II represents the second choice that of continuing hydralazine in very much smaller doses. L-E cells appeared and disappeared several times in blood while this was done but normotension was maintained. Each point represents the mean of 5 35 or 150 measurements depending upon the time scale.

the patient's situation be potentially precarious. Discovery of a substitute for hydralazine which will not cause this phenomenon is the only solution to the problem (Fig 29).

Combined Therapy with Ganglionic Blockade and Hydralazine Hydralazine is given regardless of the level of blood pressure when the two agents are used together. It disappears rapidly from the blood. At the end of the four day period during which the dose was progressively in-

WG 54 SEVERE BENIGN HYPERTENSION



IW 93 MALIGNANT HYPERTENSION




FIG 29

ing agent automatically to adjust itself as postural effects occur. The usual result of omission of the night dose is a rise in the morning resting or basal pressure. The patient is taught to take his own blood pressure five times a day before each dose and record it on special charts. He is instructed on the actions of the drugs and their side effects. He leaves the hospital on the same schedule which was designed to prevent both hypertension and hypotension. By keeping a daily record trends can be observed which are invaluable for efficient therapy. In our clinic we examine a patient one month after discharge from hospital and then at 3 to 6-month intervals if he is doing well. Patients seldom complain of the inconvenience which takes about 15 minutes a day but they do object to the cost of the drugs.

Treatment of Crises In hypertensive crises (pulmonary edema, cerebral edema, toxemia of pregnancy) requiring parenteral administration, two lines 20 mm apart are drawn across the graphic chart at the level at which systolic pressure is to be maintained. After initial lowering of blood pressure by a small dose of a blocking agent, blood pressure is measured every hour and a subcutaneous injection of the full effective dose given if it is above the upper line, half the dose if between the lines, and none if below the bottom line. Changes in total dosage must be made often. The second day the two lines are drawn 20 mm lower. Thus a patient with encephalopathy (wet brain) may have his pressure reduced from 300 mm Hg to 220 to 200 mm the first day, 200 to 180 mm the second day, and 180 to 160 mm the third day. Usually oral medication becomes possible long before this time. The pressure must be reduced more drastically when there is pulmonary edema. We prefer parenteral ganglionic blocking agents to parenteral hydralazine because of their shorter




FIG 30 A woman aged 56 had rapidly progressive hypertensive vascular disease without retention of nitrogen but with diminution of renal function. When she was given a diet containing 0.5 Gm of salt (rice diet) oliguria developed 14 days later. This development was rapid and the patient complained of nervousness, apathy, loss of appetite and weakness. Her intake of fluids remained high in spite of the obvious overhydration which was developing. Plasma chlorides were low as was sodium and an attempt to reverse the oliguria by the use of intravenous hypertonic saline solution was to no avail. She died of uremia (From Schroeder H A. *JAMA*, 141:117 1949).




FIG 31 Medication and vital signs during hospitalization of a 52-year-old white male with malignant hypertension and pre-treatment azotemia. The upper bar graph indicates the daily dose of autonomic blocking agent. The open bars represent oral pentolinium tartrate (po C_2). The cross hatched bars represent parenteral pentolinium tartrate (im C_2) and the solid bars represent parenteral hexamethonium chloride (im C_2). The potency of oral pentolinium tartrate approximates that of intramuscular hexamethonium chloride however the scale for intramuscular pentolinium tartrate has been expanded to allow for its greater effect. The lower bar graph indicates oral hydralazine intake per day. Daily blood pressure averages are shown each value being the mean of at least 6 and often as many as 24 readings taken with the patient in a sitting position. The stippled area to the left indicates the pre-treatment range of blood pressure. The line graph at the bottom of the figure is a schematic representation of the vital signs. The solid line shows the temperature in degrees centigrade which was below 37.5 except for three bouts of pyrexia. The dotted line shows the pulse in beats per minute which was always below 80 except for two episodes of tachycardia. The figures indicate tachypnea with any daily average values above 30 breaths per minute being noted. The word failure denotes the three periods of cardiac decompensation. Note the very high doses necessary once escape has occurred. Patient died (From Perry H. M. Jr., O'Neal R. M. and Thomas W. A. *Am J Med* in Press 1957).

actions with less tendency to produce prolonged hypotension. In cerebral edema it may be necessary to avoid cerebral ischemia, as indicated by increasing coma by reducing cerebrospinal fluid pressure.

Tolerance to the Action of Drugs No tolerance seems to develop when both types of drugs are used correctly and continuously. On the other hand, tolerance is common when therapy is intermittent, an unexplained phenomenon. In the larger sense it resembles bacterial resistance to antibiotics given in less than therapeutic amounts.

One of the most difficult situations to meet is in the patient whose blood pressure has been lowered successfully, only to have the drugs discontinued because of undue alarm at side effects or the consequences of normotension (mental depression, malaise, lassitude, weakness). The hypertension which recurs immediately is much more resistant to therapy and requires much larger doses of drugs after a few days than it did initially, sometimes it seems impossible to treat (Fig. 31). We have encountered no resistance in fresh untreated cases; the secret of successful therapy is continuous therapeutic pressure. While we cannot account for this phenomenon, it is commonly observed and hazardous to the patient. Many lives have been lost by nervous and erratic therapy (Fig. 32).

Changes Occurring with Time If the dose of the ganglionic blocking agent automatically falls to negligible quantities (in 6 to 18 months) by reason of sustained normotension, the dose of hydralazine is then reduced to four times a day, three times a day, twice a day and finally halved at 2 to 6 month intervals. Reduction in dosage is made very slowly (Fig. 33). The amount of reserpine is halved in a month or two if drowsiness appears and then halved again until symptoms disappear (406).

What to Do If a Patient Is Not Doing Well The pa-




FIG 31 Medication and vital signs during hospitalization of a 52 year-old white male with malignant hypertension and pre treatment azotemia. The upper bar graph indicates the daily dose of autonomic blocking agent. The open bars represent oral pentolinium tartrate (po C_2). The cross-hatched bars represent parenteral pentolinium tartrate (im C_2) and the solid bars represent parenteral hexamethonium chloride (im C_2). The potency of oral pentolinium tartrate approximates that of intramuscular hexamethonium chloride however the scale for intramuscular pentolinium tartrate has been expanded to allow for its greater effect. The lower bar graph indicates oral hydralazine intake per day. Daily blood pressure averages are shown each value being the mean of at least 6 and often as many as 24 readings taken with the patient in a sitting position. The shaded area to the left indicates the pre-treatment range of blood pressure. The line graph at the bottom of the figure is a schematic representation of the vital signs. The solid line shows the temperature in degrees centigrade which was below $37^\circ C$ except for three bouts of pyrexia. The dotted line shows the pulse in beats per minute which was always below 80 except for two episodes of tachycardia. The figures indicate tachypnea with any daily average values above 30 breaths per minute being noted. The word failure denotes the three periods of cardiac decompensation. Note the very high doses necessary once escape has occurred. Patient died. (From Perry H. M. Jr., O'Neal R. M. and Thomas W. A. *Am J Med* in Press, 1957.)




FIG 32 Example of logic of using both ganglionic blockade and hydralazine (5968). Neither drug was effective alone in large doses. Hexamethonium (C_6), pentolinium (C_5) or hydralazine* failed to alter course of malignant hypertension until combined therapy was begun when relative normotension was achieved. These records were made in hospital and all readings are shown. Obviously in this azotemic patient (NPN 76) with heart failure death would have been the outcome had only one drug been used or had both been given in inadequate doses.

tients who do least well on combined therapy are usually men in the sixth decade with atherosclerosis, and not, as might be expected, those in malignant stages. Certain individuals, however, because of a too early reduction in dosage or because of a dosage schedule sufficient for the hospital but insufficient for the stresses of active living continually show hypertensive levels reaching as high as 180 or even 200 mm Hg systolic during one of the five measurements a day. Several choices are open: a) The dose of one agent is increased for a month. If not successful, the dose of the other agent is increased. b) Protoveratrine in amounts sufficient to cause nausea is begun. c) Dietary salt is re-

stricted moderately d) The patient is readmitted to the hospital and restabilized e) Pheochromocytoma is suspected in patients whose blood pressures fluctuate widely and cannot be controlled Reduction in dosage is not possible for those who keep themselves moderately hypertensive even after 3 years Those who do best are those who attain and maintain normotension (Fig 33) (406)

JG # 34




FIG 33 Blood pressure and oral medication for a 34 year-old white male with malignant stage of hypertension The range of pre treatment blood pressure is indicated by cross-hatching The bar graphs indicate the drug intake the open area representing hydralazine the dotted hexamethonium (C_6) and the solid pentolinium (C_5) Note that the scale is different for the two methonium compounds since the second is approximately five times more potent than the first. (From Perry H M Jr and Schroeder H A. *Circulation* 23 528 1956)

RESULTS EXPECTED

Since this monograph is not primarily concerned with a report on the results of therapy, only a brief resume of what can be expected with adequate therapy can be given. The long term effects have been published (401-403 93 168 405 419). In general, those which could be predicted from an understanding of the disease occur, several unexpected and unpredicted effects appeared as well.

1 a) Heart failure due to left ventricular strain which accounts for over 50 per cent of the death rate is virtually




FIG 34 One of the first four patients to receive ganglionic blockade (hexamethonium C_6) and hydralazine (5968). Severe left and moderate right sided heart failure disappeared in three days, grade IV fundi regressed, digitalis was discontinued and salt was added to her diet (in November 1951). She subsequently became sloppy in her habits, omitted her drugs from time to time, began to complain of dyspnea and hemorrhages reappeared in the ocular fundi. Hypertension was later controlled on larger doses of drugs and she remained symptom free. From being invalided, she has been able to work full time in her own restaurant for five years as long as she keeps her blood pressure down.

abolished this within a few days. Salt can be added to the diet in from 2 to 6 months time. Also in a few weeks digitalis can be eliminated (Fig. 34). Only a rare individual continues to require digitalis and dietary restriction of salt. We presume that these patients suffer from myocardial fibrosis due to atherosclerosis. Heart failure with only a moderate hypertension and much coronary arterial disease however is only moderately affected.

1 b) Abnormal electrocardiographic patterns indicative of left ventricular strain revert to normal within several months. Patterns suggestive of left ventricular hypertrophy revert to normal in some but not in all cases. This may take 1 to 4 years. Enlarged hearts often but not always become smaller in roentgenograms. Time 1 to 5 years (406).

2 a) A few weeks after the start of therapy the progression of renal damage due to arteriolar nephrosclerosis is halted. Unpredicted was a gradual return of depressed renal function in many but not all cases. This occurs in from 1 to 4 years (405).

2 b) In from 1 to 5 weeks albuminuria diminishes or disappears. When caused by pre-existing organic renal disease it remains at lessened quantities.

2 c) In azotemic individuals nitrogen retention remains static or diminishes unless initial values are over about 60 mg per 100 ml of nonprotein nitrogen in the blood (Somogyi zinc precipitate corresponding to 75 to 90 mg per cent by the phosphotungstic acid precipitate method). Time weeks or months. In those with higher values azotemia usually but not always progresses to uremia rarely however we have seen relatively acute elevations to 130 to 160 mg per cent return to much lower levels. This may occur after 3 weeks or more (Fig. 35-36).

2 d) Ocular fundi revert to normal. Hemorrhages are

RESULTS EXPECTED

Since this monograph is not primarily concerned with a report on the results of therapy only a brief resume of what can be expected with adequate therapy can be given. The long term effects have been published (401-403 93, 168, 405-419). In general those which could be predicted from an understanding of the disease occur, several unexpected and unpredicted effects appeared as well.

1 a) Heart failure due to left ventricular strain, which accounts for over 50 per cent of the death rate, is virtually




FIG 34 One of the first four patients to receive ganglionic blockade (hexamethonium C_6) and hydralazine (5968). Severe left and moderate right sided heart failure disappeared in three days grade IV fundi regressed digitalis was discontinued and salt was added to her diet (in November 1951). She subsequently became sloppy in her habits omitted her drugs from time to time began to complain of dyspnea and hemorrhages reappeared in the ocular fundi. Hypertension was later controlled on larger doses of drugs and she remained symptom free. From being invalided she has been able to work full time in her own restaurant for five years as long as she keeps her blood pressure down.




FIG 111 Medication blood pressure and nitrogen retention during hospitalization. The solid bars represent oral hydralazine (5968). The cross hatched bars represent parenteral and the open bars oral hexamethonium chloride (C_6). The parenteral dose has been multiplied by 10 in order partially to compensate for the much greater efficacy of this route of administration. Each of the points on the blood pressure curve is the average of at least six and initially as many as 24 determinations. All were made with the patient supine. Note that azotemia is shown in terms of blood urea nitrogen rather than total nonprotein nitrogen.

Except for life long enuresis this 18-year-old white male was entirely well until 3 days before he entered the hospital. His mother had died with polycystic kidneys. Pyrexia and malaise were the initial symptoms followed by lethargy, emesis, disorientation and coma. Physical examination revealed in addition papilledema, hemorrhagic retinitis, minimal cardiomegaly and a pre-systolic gallop. Roentgenologic examination suggested polycystic kidneys and 3 plus albuminuria was found. After returning home the patient did very well. He was working when last seen in July 1955 at which time his physical examination including fundoscopic examination was normal. His urine contained no protein. His antihypertensive regimen called for a maximum dose of 750 mg oral hexamethonium chloride and a constant dose of 100 mg of hydralazine every four hours. His sitting blood pressure at home averaged 160/80 mm. Hg. (From Perry H. M. Jr and Schroeder H. A. *Circulation* 14:105 1956.)




FIG 35 Medication blood pressure and nitrogen retention during hospitalization. The solid bars represent oral hydralazine. The open bars represent oral mecamylamine (Inversine Sharp & Dohme). Each of the points on blood pressure curve is the average of at least six and initially as many as 24 determinations. All were made with the patient supine. In addition to the medication shown 513 mg of intramuscular hexamethonium chloride were administered on November 22 without any effect on the blood pressure.

Except for probable pyelonephritis 10 years previously followed by the discovery of high blood pressure this 45 year-old Negro police man was essentially asymptomatic until 3 months before he entered Barnes Hospital. His initial complaints were progressive asthenia and increasingly frequent periods of syncope associated with vertigo and amblyopia. Urinary frequency and dyspnea appeared somewhat later finally nausea and vomiting became frequent. There was hemorrhagic retinitis with bilateral papilledema and cardiomegaly. Although cardiomegaly was present the lung fields were clear to percussion and auscultation and there was no edema. There was cylindruria and 3 plus albuminuria only 100 ml of blood contained 10 gm of hemoglobin. Both electrocardiograms and roentgenograms of the chest indicated left ventricular enlargement. The decrease in azotemia and blood pressure following the institution of oral mecamylamine and hydralazine therapy is indicated in the graph. This man was discharged from the hospital with a regular diet without digitalis and with no symptoms except amblyopia referable to his hypertension or to his therapy returning to work 3 weeks later (From Perry H M Jr and Schroeder H A. *Circulation* 14 105 1956).

absorbed in 2 to 6 weeks soft cotton wool exudates disappear in 1 to 4 weeks papilledema slowly regresses in 4 to 12 weeks and hard waxy exudates and scars shrink to nothing in 1 to 3 years

3 a) Atherosclerotic complications are less frequent In from 1 to 6 weeks angina pectoris usually disappears although rarely it becomes initially worse

3 b) The incidence of coronary occlusion appears somewhat lower (after 3 to 5 years) although this disease ac




FIG 57 Two directions of progress in azotemia and malignant hypertension Upper The condition of G. B. a 54 year-old man has been static or improving slowly and he has been able to return to full occupation Control of blood pressure has been deliberately only fair in order to avoid further azotemia which has varied from 48 to 70 mg per cent NPN (mean 59) Middle That of M. C. has remained fairly static or improved slightly weight and health have increased Lower That of L. T. a 48 year-old man improved at first but azotemia later rapidly progressed to death. Pyelonephritis was found at autopsy the kidneys together weighed 105 Gm.

G B # 52 MALIGNANT HYPERTENSION




FIG 37

272 →

absorbed in 2 to 6 weeks soft cotton wool exudates disappear in 1 to 4 weeks papilledema slowly regresses in 4 to 12 weeks and hard waxy exudates and scars shrink to nothing in 1 to 3 years

3 a) Atherosclerotic complications are less frequent In from 1 to 6 weeks angina pectoris usually disappears although rarely it becomes initially worse

3 b) The incidence of coronary occlusion appears somewhat lower (after 3 to 5 years) although this disease ac




FIG 37 Two directions of progress in azotemia and malignant hypertension. Upper The condition of G. B., a 54-year-old man has been static or improving slowly and he has been able to return to full occupation. Control of blood pressure has been deliberately only fair in order to avoid further azotemia which has varied from 48 to 72 mg per cent NPN (mean 59). Middle That of M. C. has remained fairly static or improved slightly; weight and health have increased. Lower That of L. T., a 48-year-old man, improved at first but azotemia later rapidly progressed to death. Pyelonephritis was found at autopsy; the kidneys together weighed 105 Gm.

counts for a major part of the mortality in treated patients

3 c) In 3 to 5 years the incidence of cerebral hemorrhage is markedly lessened in those patients who have suffered one attack

3 d) Also in 3 to 5 years the incidence of cerebral thrombosis is considerably lowered, but by no means abolished

4 a) In patients for whom treatment is considered mandatory, continuation causes increased life expectancy while discontinuation results in early death (Fig 37)

4 b) When a patient has survived 6 months of therapy, his chances of surviving 5 years are excellent

Surgery This monograph is not the place to discuss the pros and cons of surgical sympathectomy, an operation which has definitely altered the outcome and prolonged the life of many patients (420, 421). In our experience drugs faithfully taken and properly administered have been of considerably greater value than surgical sympathectomy for the following reasons: 1 Cases too far advanced for surgery and unoperable cases with azotemia can often be salvaged. 2 All patients can be treated regardless of the stage or degree of vascular damage. 3 Failures after surgical sympathectomy can be salvaged when hypertension has recurred and become severe. 4 The mortality rates of the most severe cases is considerably less than those following operation.

In actual practice no patient should be denied the choice of drugs or surgical operation when hypertension is doing harm. When a patient is unwilling or unable to take drugs regularly surgery should be urged in suitable cases. We must remember however that surgical sympathectomy even the subtotal variety can never block as many nerves as does adequate ganglionic blockade. Therefore, in cases resistant to ganglionic blockade surgical intervention can be expected to fail; contrariwise cases re-

sponding well to ganglionic blockade alone can be expected to respond to surgery even though the usual lumbodorsal sympathectomy only removes 50 to 60 per cent of the nerves. Operation therefore does not become the method of choice when medical measures fail for the opposite holds true i.e. drugs will work when surgery has failed. The one advantage of surgical over chemical sympathectomy is the lack of bother to the patient when the result is successful.

According to the data of White (421) when cardiovascular complications occur in hypertensive patients the mortality is high. Left ventricular weakness and failure cerebrovascular accidents angina pectoris and myocardial infarctions cause a 3 year mortality rate of 82 per cent and a 10 year mortality rate of 96 per cent with a mean survival time of 4.1 years. Surgical sympathectomy alters the 3 year rate to 24 per cent and the 10 year rate to 50 per cent with a mean survival time of 6.1 years for the deceased.

TABLE I

MORTALITY RATES AT FOUR YEARS OF PATIENTS SUBJECTED TO SURGICAL SYMPATHECTOMY USUAL MEDICAL MEASURES AND CHEMOTHERAPY (PER CENT)

Smithwick Group	Smithwick's Series (420) Age 38-47		White's Series (421) Age 30-60		Author's Series Age 34-76 Chemotherapy	
	Medical	Surgical	Medical	Surgical	Stopped	Continued
I	10	3			—	0
II	33	12			32	1
III	58	19	III	24	38	3
IV	87	52			100	20
Azotemia	(100)	†	(100)	†	100	45

* Most patients were 40-60

† Not suitable for operation because of high operative mortality

patients. Chemotherapy properly maintained definitely decreases the mortality rate in 4 years to a point well below these figures (Table L)

Nephrectomy also can alter the course of hypertension when 1) unilateral renal disease is present 2) hypertension is early and not far advanced, and 3) the function of the opposite kidney is excellent. When the hypertension has produced arteriolar nephrosclerosis in the good kidney removal of the offending one will naturally not result in 'cure'. Cases favorable for nephrectomy are rare.*

Bilateral adrenalectomy is indicated only in cases exhibiting evidences of adrenal cortical hyperfunction. Better diagnostic methods for overproduction of specific steroids may allow better selection for surgical therapy.

* When any surgical operations are indicated patients long treated by drugs will usually respond by strict normotension without drugs for one to two weeks after which hypertension will recur. This phenomenon has also been seen after severe infections, gastro-enteritis and trauma. Apparently the ability of the peripheral vessels to respond to trauma is altered by these drugs for some days.

Chapter IX

A PRELIMINARY APPROACH TO THE TREATMENT OF ATHEROSCLEROSIS

OBVIOUSLY, control of a patient's hypertension will do no more than relieve cardiac strain prevent further nephrosclerosis prevent cerebral hemorrhage and relieve angina pectoris. Theoretically it will slow that part of the rate of progression of atherosclerosis which is dependant upon an elevated blood pressure. Since atherosclerosis is probably reversible (443) at least in so far as cholesterol-containing plaques are concerned (and possibly calcification (422)) treatment of the whole patient and his diseases becomes essential for prolongation of a life potentially shortened by cardiovascular damage. Therefore an outline of the method we have used is given here. The method involves practical measures based on theoretical approaches of most promise. Since it is most difficult to measure alterations in this disorder for the better or worse until massive accidents occur only time will tell if the results are favorable.

The serial measurement of lipoprotein fractions in blood is a procedure confined to the larger specialized centers. Total plasma cholesterol however is readily measured in most hospital laboratories. Based upon the assumption that lowered plasma cholesterol will in part prevent deposition of esters in plaques one can attempt to lower these values by using some of the influences discussed in Chapter VII.

✓ The method is based upon three influences 1) removal of some trace-metals, 2) a diet low in animal fats but containing adequate vegetable fats, particularly linolenate, and 3) the provision of an adequate amount of pyridoxine. For it is the possible effect of these biochemically and metabolically interrelated substances which can contribute to the disease (446)

METHOD

I Diet As discussed in Chapter VII, the most important factor in the development of atherosclerosis probably lies

TABLE LI

LIST OF FOODS TO BE AVOIDED AS HAVING A HIGH SATURATED LOW UNSATURATED FATTY ACID CONTENT (348)

<i>Food</i>	<i>Reason for Avoidance</i>
Fats	
Coconut	Short chain saturated
Margarine	Hydrogenated vegetable oils
Palm	Short chain saturated
Cocoa	Short chain saturated
Hydrogenated vegetable oils and frying fats	Long chain saturated
Lard tallow	Long chain saturated
Butter cream cheese whole milk	Short chain saturated
Hydrogenated peanut butter	Long chain saturated
Proteins	
Pork and pork products	Mainly saturated
Fat meats*	Mainly saturated
Sweetbreads	Not investigated
Domestic goose and duck	Fattened not investigated
Processed meats of all kinds	Contain much fat
Hamburgers	Contain much fat

NOTE The Pure Food and Drug Administration requires that all processed foods be labeled correctly. The labels should be read and those foods containing 'hydrogenated shortening' hydrogenated vegetable shortenings or pure meat products should be avoided.

* The fat meats are beef rib roast, corned beef and tongue, lamb loin and shoulder, and mutton.

in the kind of fat in the American and European diet. From 30 to 40 per cent of the caloric intake comes from fat mainly of animal origin. The purpose of the diet therefore is to restrict animal fat and hydrogenated vegetable oils and to provide an adequate intake of unsaturated vegetable fats containing linolenic acid. The basic rules are

- A No obvious fat of animal origin should be eaten. Modern methods of fattening cattle for slaughter make a saturated body fat.
- B No hydrogenated vegetable oils should be used since hydrogenation saturates an unsaturated fatty acid (Table LI).
- C Natural fat of vegetable origin containing the higher unsaturated fatty acids can be eaten in amounts as large as practicable since these contain the essential unsaturated fatty acids linolenic and linoleic.
- D In general reduce the fat content of the diet to about 20 per cent of the caloric intake.

The most available sources of essential fatty acids are in soy bean and corn oil with the following iodine numbers

	<i>Iodine No</i>	<i>Remarks</i>
Soy bean oil	190	Contains 11% linolenate
Corn oil	115	Contains 0.5% linolenate
Cottonseed oil	105	Contains no linolenate
Sesame oil	103	Contains no linolenate
Peanut oil	85	Atherogenic in animals

In order to obtain enough protein without animal fats the following are recommended

All kinds of fish and shellfish. Fish oils have a high iodine number.

Poultry and game avoiding the fat (except domestic goose and duck). Chicken fat is high in linoleate.

Lean beef lamb and veal. Most animal fat is low in

linoleate and linolenate There is fat in muscle fibres of cattle force fed on corn before slaughtering

Legumes, such as peas, beans, lima beans soy beans and its products Their fats are largely unsaturated
Skim milk and fat free buttermilk Butter cheese, cream and whole milk contain principally short-chain saturated fatty acids, butter raises plasma cholesterol

Cereals

Some breads use hydrogenated vegetable oils for shortening

Eggs Yolks are fatty Fry or scramble in soy bean oil

Meat soups only if all fat is skimmed off at icebox temperature

Most canned soups contain butter, cream or fat

Salad dressings made of soy bean oil

All nuts, especially walnuts Seed oils contain unsaturated fatty acids

Curd cottage cheese and other fat free cheeses

The two vegetable oils should be used for shortening

Deep frying should be done only in corn or preferably soy bean oil

II Vitamins The second point of attack lies in the daily use of pyridoxine or pyridoxal, deficiency of which has caused the early lesions of atherosclerosis in animals and which is low in many processed foods About 5 to 10 mg per day is more than adequate

III Trace Metals Excessive amounts of certain trace metals in American human tissues may be concerned in cholesterol formation or the metabolism of fats One tablet, 0.5 Gm., of Calcium Versenate (EDTA) twice a day, or another similar compound, may chelate and remove these metals In some people, this substance alone will lower the cholesterol level in blood (Table LII)

Calcium If calcium deposits are demonstrable in blood

TABLE LII

CHANGE IN PLASMA CHOLESTEROL WITH ORAL EDTA (1.0 Gm /Day)

Patient	Sex	Age	Control (mg %)	Chol (mg %)	Interval (weeks)	Major Diagnosis
W. H.	♂	55	293	-154	20	Angina pectoris
B. McD.	♂	55	278	-150	35	Peripheral vascular disease
I. E.	♀	70	276	- 40	4	Arterial hypertension
E. B.	♂	55	253	- 58	16	Coronary occlusion, convalescent
G. H.	♂	45	252	- 36	25	Angina pectoris
H. S.	♀	49	237	- 37	14	Arterial hypertension
E. S.	♂	77	223	- 74	3	Arterial hypertension
E. S.	♂	48	210	+ 18	44	Angina pectoris
H. D.	♂	63	189	- 49	8	Angina pectoris
R. S.	♂	54	177	- 38	12	Angina pectoris
J. B.	♀	55	178	+ 14	4	Arterial hypertension
Men			233	- 53		

vessels and symptoms or signs are present the method of Clarke, Clarke and Mosher for removing metastatic calcium may be used (422). Trisodium EDTA, 5.0 Gm in 500 ml 5 per cent glucose solution is slowly infused intravenously over 2 to 6 hours. The patient is taught to slow the infusion at the appearance of unusual symptoms. Strangely enough hypocalcemic tetany does not appear under these precautions. Ionized calcium salts and calcium chelated to proteins and peptides at a weaker stability constant than 10⁻⁶ (Log K_2 EDTA) are probably removed; the strongly chelated calcium in bone is probably not.

An injection is given daily for 5 days. 2 days are allowed for rest and the 5-day course repeated. After a month or more for evaluation of symptoms a second 10 Gm is administered.

RESULTS EXPECTED

In Table LII are shown changes in blood cholesterol levels using calcium disodium ethylenediamine tetraacetate (Calcium Versenate) in doses of 1.0 Gm per day. In Table LIII are shown the changes produced by this agent.

TABLE LIII
EFFECT OF REGIMEN ON PLASMA CHOLESTEROL (mg %)

Patient	Age Sex	Pre treatment			4 Mo	Range After 3 Mo	No Samples	Diagnosis and Remarks
		Range	Mean	No Samples				
H Sch.	49 ♂	237	244	1	146	146-172	12	Normal
E Su.	70 ♀	276	278	1	151	216-227	12	Atherosclerosis
C Cru	62 ♂	260	300	3	236	112-237	9	Hypertension
S Mat	61 ♀	207	240	2	146	190-234	6	Hypertension
K Sch	59 ♂	200	217	4	120	117-154	8	Hypertension
G Net.	43 ♂	213	234	4	178	159-197	7	Hypertension
D Blu	49 ♂	219	295	4	179	176-204	6	Hypertension
U Boa	55 ♂	233	272	4	153	137-272	6	Hypertension and Atherosclerosis
B McD	52 ♂	204	278	2	145	105-156	8	Peripheral Vascular Disease
C Grt	57 ♂	210	253	3	206	171-201	6	Hypertension and Leriche's Syndrome
A Han	60 ♀	174	207	3	168	171-200	5	Mild Hypertension
E Frl	69 ♀	217	231	2	128	161-196	3	Hypertension
W Shr	49 ♂	228	249	2	119	119-232	4	Angina Pectoris
M Bro	72 ♀	276	276	4	237	172 184	3	Atherosclerosis
L Bat	62 ♀	256	300	3	183	241-250	7	Atherosclerosis
R. She	55 ♂	162	176	5	121	114-140	8	Mild Hypertension
D Lik.	56 ♀	481	624	6	377	366-422	11	Xanthomatosis
A Bla.	48 ♂	162	259	4	216	287	4	Hypertension
G Hir	46 ♂	338	262	3	181	298-321	1	Angina Pectoris
R Ber	53 ♀	299	323	1	279	298-321	4	Hypercholesterolemia
Mean			258		181	200		

with diet and vitamin B₆ added. In general the cholesterol changes are downward although in some cases they are resistant to all three forms of therapy. Some depressed values did not rise when EDTA was discontinued, an expected result if trace metals were being removed.

All patients with angina pectoris were relieved of attacks of pain either completely or partly in that they occurred less than once a month. No electrocardiographic changes in the direction of normal were observed. No signs of hepatocellular damage developed.

Comment. While untried for periods long enough to evaluate these results on the disease, there is little doubt that cholesterol values can become quite low by this form of treatment. Changes in the degree of atherosclerosis are difficult to measure, but rough estimates of improvement in the disease can be estimated, especially when it has advanced far enough to give local ischemic symptoms. In the coronary arteries, relief of angina pectoris, if it is real and not imaginary, suggests resorption of plaques. In the aorta, lessening of the widened pulse pressure suggests a return of aortic elasticity. In the legs, relief of claudication indicates improvement in blood flow. In the cerebral area, abolition of minor paraesthesias and paralytic episodes indicates reabsorption of plaques. Some changes may be expected in time, except for a return of aortic elasticity.

Therefore, if degenerative cardiovascular disease is to be treated, as many predisposing parameters as possible must be altered favorably. Today these lie in blood pressure, the health of vascular intima and the lipid esters of cholesterol.

Chapter X

SUMMARY AND INTERPRETATIONS

NATURE is not prodigal with biologic functions other than those for reproduction. Metabolic processes may have one or two alternate routes but Nature does not provide dozens of methods by which defenses of a single function are maintained, by which digestion and combustion of a single substance proceeds, or by which homeostasis is maintained. When an alternate pathway such as an anaerobic one, is substituted for an oxidation, malignant growth may result. It is proper, therefore to look at the many and complex mechanisms which Man in his erratic searchings has partly uncovered and try to unify them toward simplicity in an imitation of Nature. To do this we must depend upon evidence, in part factual and in part theoretical, delving into chemical causes.

Psychosomatic While the psyche may affect the soma, the reverse is also true. Realization that some areas of cerebral function may depend upon the valence of nitrogen in certain configurations, that one primary amine mediates one area of the brain and another can affect another and that the anatomic chemistry of phospholipids may influence healthy function, has opened up a wide field of investigation into the causes of mental derangements.

The psychic manifestations of arterial hypertension, when not due to organic cerebral vascular disease, are best explained by the effects of primary amines produced by intermittently or permanently ischemic kidneys. These

manifestations include emotional tension anxiety, excessive drive nervousness and the diencephalic blush. The blush is induced by histamine and resembles that seen with excessive quantities of circulating serotonin. Tension nervousness anxiety result in some individuals from epinephrine isoamylamine tyramine and those synthetic or natural methylated analogues which inhibit cerebral monamine oxidase (ephedrine amphetamine etc.) thus preventing oxidative deamination of naturally occurring substances.

From the huge amounts of tranquilizers sold the American public one might believe that chemically mediated nervous disorders were almost a national disorder. That many individuals might be so affected could be inferred from the abnormal trace metal content of American tissues. If one interfered with vanadium or monamine oxidase or there was deficiency of vanadium primary amines could be implicated as causes of a widespread cerebral disorder.

Hereditary The ability to react to stress by vasospasm is an hereditary trait apparently transmitted as a Mendelian dominant.

Neurogenic The sympathetic nervous system is over active most likely because of increased cortico-hypothalamic activity. The posterior hypothalamus for which serotonin has a predilection is apparently stimulated more than is the anterior the chemical mediator of which is not known. Cortico-hypothalamic activity is increased as a result of somatically formed primary amines. Neurogenic vasospasm causes neurogenic renal ischemia.

Renal Renal disturbances dependent upon ischemia produce humoral vasoconstrictor substances. Trace metals both normal and abnormal are involved. Two metabolic pathways may be considered.

✓ I Anatomic causes of ischemia usually depend upon intrarenal parenchymal disease, atherosclerotic narrowing of renal arteries, or arterial and arteriolar nephrosclerosis secondary to hypertension. When the ability to react to stress by vasospasm is combined in one individual with organic renal ischemia, hypertension becomes permanent. The first two renal disorders are anatomic accidents; the last is caused by hypertension.

Anatomic or intermittent functional ischemia produces enzymatic disturbances in the kidney. The expected biochemical alterations resulting are

- ✓ A Reduction of oxidative deamination of amino acids capable of anaerobic decarboxylation. The results in the kidney
 - a) Less urinary ammonia formed per mol of bicarbonate (theoretical). Ammonia from glutamine however would continue to be formed anaerobically.
 - b) A change of pH in the cortex to the acid direction (found).
 - c) Substitution of sodium for ammonia in order to maintain acid base balance in tubule (theoretical but logically inferred).

The urinary results

- a) Urinary NH_3 /acid ratio reduced (found)
- b) Acid urine (usually found)
- c) Sodium loss (found)

The expected remote results

- a) More primary amines in blood (found)
- b) Release of renin (found in acute states)
- c) Stimulation of the adrenal cortex to production of aldosterone in an attempt to prevent excessive sodium loss (found). Animals (and human beings) might therefore eat a little more salt in order to compensate (found in rats).

- II Renin is released possibly because of the acidity secondary to the lessened formation of ammonia (renin is extracted from kidney only at acid pH) This postulate is unproven and not too sound but we have no better one Renin comes from the superficial areas of the cortex of the kidney which becomes markedly acid when the renal artery is constricted Adjustments take place with time—several weeks

Result

- a) Hypertensin (angiotonin) is formed in blood at first through the physical release of renin (found)
- b) With time renin itself is no longer released into blood but continues to act *in situ* (not proven but renin disappears from blood) Perhaps renin is slowly modified into a somewhat different proteolytic enzyme
- c) Hypertensin I or its analogue formed in kidney is active on blood vessels becomes activated either
1) through decarboxylation leaving an active terminal NH_2 , the decarboxylase being in blood and kidney or 2) through action of a specific peptidase splitting off one or two amino acids and leaving a terminal $-\text{NH}_2$. In this latter event the peptidase would necessarily be a manganous enzyme The second pathway is the more logical one as peptidases are known and peptide decarboxylases are not Ordinarily in the absence of renal ischemia the small amounts of renin released into the renal venous blood form hypertensin which is inactivated both in kidney and in blood In renal ischemia the shift of locus of catabolism of hypertensin is from kidney to peripheral vasculature (theoretical but monamine oxidase acts on both hypertensin and pherentasin both peptides and it probably occurs in smooth muscle of blood vessels)

- d) Pherentasin is actually human hypertensin II, the amino acid content of which could be expected to differ from that obtained from bovine, horse, or hog globulin (unproven but very likely)

✓ II Enzymatic disturbances somewhat different from those resulting from organic renal ischemia may be caused by the accumulation of abnormal trace metals, notably cadmium. Cadmium is a nephrotoxic substance. Mercury and cadmium are the only metals which can readily displace zinc on a specific chelate being in the same periodic group, having the same coordination number and making the same shaped complex. The expected results on renal acid base equilibrium

- A Inhibition of carbonic anhydrase by displacement of zinc (probable but not proven)

1 More acid in urine

2 More base needed to neutralize acid i.e. ammonia or sodium

- B Inhibition of decarboxylases by displacement of zinc on pyridoxal enzymes causing a local vitamin B₆ deficiency (one decarboxylase known to be inhibited. Zinc displacement logical but unproven)

1 Less decarboxylation of amino acids other than glutamine

2 Less primary amines formed

3 Less ammonia available for urine

4 Sodium wastage

- C Inhibition of transaminase a pyridoxal enzyme which probably contains a metal (unproven but possible)

1 Less transamination from glycine, aspartic, glutamic and other amino acids as a source of urinary ammonia (transamination not proven to be a source of urinary ammonia)

2 Sodium wastage

D Aminoaciduria (found) either because of process II or interference with tubular reabsorption by inhibition of a carrier metalloenzyme probably containing zinc

The net results would be cortical acidity less urinary ammonia and sodium wastage the same as those found in organic renal ischemia but appearing by somewhat different routes. Primary amines in blood, however, would not be elevated (Fig 38)

(If cortical acidity is the stimulus for the action of renin, hypertensin I would be formed *in situ* and released into renal venous blood where it would be converted to hypertensin II (phorontasin) by action of a specific manganous peptidase. Thus both organic renal ischemia and cadmium can cause the same end results. Naturally renal ischemia accompanying neurogenic or phorontasin vasoconstriction would call into action pathway I.)

Therefore trace metals can be involved in the hypothetical peptidase probably manganous which converts hypertensin I to hypertensin II in monamine oxidase which inactivates it in the decarboxylases and amine oxidases which are concerned in the hypertensive state and even in tyrosinase (copper) which can inactivate norepinephrine, epinephrine, hydroxytyramine and tyramine.)

Therapeutic Note: Drugs or procedures which block sympathetic nerve impulses will counteract only the neurogenic portion of hypertension. Drugs or procedures which a) act to dilate vascular smooth muscle, b) increase renal plasma flow, or c) inactivate hypertensin II or phorontasin will counteract the reprogenic portion of hypertension. All known inactivators are metal binding or chelating agents :

The actions of hydralazine are fourfold ✓

- d) Pherentasin is actually human hypertensin II, the amino acid content of which could be expected to differ from that obtained from bovine horse, or hog globulin (unproven but very likely)

✓ II Enzymatic disturbances somewhat different from those resulting from organic renal ischemia may be caused by the accumulation of abnormal trace metals, notably cadmium. Cadmium is a nephrotoxic substance. Mercury and cadmium are the only metals which can readily displace zinc on a specific chelate being in the same periodic group, having the same coordination number and making the same shaped complex. The expected results on renal acid base equilibrium

- A Inhibition of carbonic anhydrase by displacement of zinc (probable but not proven)

- 1 More acid in urine
- 2 More base needed to neutralize acid, i.e., ammonia or sodium

- B Inhibition of decarboxylases by displacement of zinc on pyridoxal enzymes causing a local vitamin B₆ deficiency (one decarboxylase known to be inhibited. Zinc displacement logical but unproven)

- 1 Less decarboxylation of amino acids other than glutamine
- 2 Less primary amines formed
- 3 Less ammonia available for urine
- 4 Sodium wastage

- C Inhibition of transaminase a pyridoxal enzyme which probably contains a metal (unproven but possible)

- 1 Less transamination from glycine aspartic, glutamic and other amino acids as a source of urinary ammonia (transamination not proven to be a source of urinary ammonia)
- 2 Sodium wastage

1 Decarboxylase inhibition with the result that renal amino acid metabolism is further suppressed and therefore less primary amine is formed

2 Monamine oxidase stimulation with the result that those primary amines which are formed are oxidized more readily These include pherentasin or hypertensin II

3 Hypertensin and pherentasin are both directly inactivated either through carbonyl linkage or what is more probable removal of a chelated trace metal necessary for the integrity of the peptides


4 Constricted vascular smooth muscle is dilated no matter what causes the constriction by some unknown process which could be dependent either upon carbonyl or sulphhydryl binding or upon metal chelation

In addition histaminase is inhibited a reaction common to many hydrazides

Adrenocortical Renal sodium wastage (or need as in heart failure) probably causes adrenal cortical production of aldosterone (theoretical but logical) This steroid probably sensitizes blood vessels to circulating vasoactive amines and sympathetic discharges through intracellular sodium potassium alterations (proven only for DOCA) Most cases of hypertension exhibit secondary aldosteronism because of renal sodium wastage

Primary aldosteronism by sensitizing vascular smooth muscle to normally circulating vasoactive amines and normal sympathetic tone can produce a moderate degree of hypertension with normal renal plasma flow Cases of this nature are not unusual This type of hypertension while benign can slowly develop into a more serious variety with congestive heart failure the usual end result

Therapeutic Note While dietary salt restriction may induce enough sodium loss to negate the sensitizing effect of cortical steroids and salt on blood vessels it stimulates



The reactions in italics have been demonstrated Transamination to α ketoglutarate from other amino acids has not been shown for the sake of simplicity

Fig 38 Proposed intermediary metabolism in ischemic and cadmium loaded kidney

② Cholesterol has a predilection for making unsaturated fatty acid esters. When insufficient unsaturated fatty acids are available for esterification saturated fatty acids are used. These esters are quite insoluble and probably have lower specific gravities. Possibly breakdown metabolism or excretion of cholesterol is more easily accomplished when esters are unsaturated than when made of saturated long chain fatty acids.

These two ideas are highly speculative. The mechanism of lowering plasma cholesterol by essential fatty acids is not understood.

Factors which may influence the deposition of cholesterol esters in sub-intimal spaces are

C Physical—Intra arterial pressure and changes of pressure (turbulence) at bifurcations of major vessels (Found)

D Metabolic—Pyridoxal deficiency causes sub-intimal lesions identical microscopically to pre atherosclerotic lesions observed in animals and man (Found)

a) Pyridoxal is necessary for the integrity of the mucopolysaccharides of sub-intimal ground substance (Inferred)

b) Pyridoxal affects fatty acid metabolism by promoting the synthesis of essential fatty acids from less unsaturated ones (Found)

c) Experimental pyridoxal deficiency and essential acid deficiency are quite similar in signs differing only in a few basic enzymatic disturbances (Found). Vitamin B₆ will partly relieve essential fatty acid deficiency. Essential fatty acids will partly relieve vitamin B₆ deficiency.

The biochemical interrelationships of three of these influences are

1. Pyridoxal usually requires a metal for enzymatic activity. One abnormal metal (cadmium) can inhibit a pyridoxal metalloenzyme.

the adrenal zona glomerulosa to overactivity. The result is secondary hyperaldosteronism with salt depletion.

Atherosclerosis Treated hypertensive patients no longer die of heart failure or renal failure when treated soon enough. They die of the effects of atherosclerosis. In order to prolong life, both blood pressure and blood lipids must be reduced.

Factors which may affect cholesterol synthesis or degradation and therefore atherosclerosis are -

A Trace Metals 1) Chromium increases hepatic synthesis (in rats). Vanadium depresses hepatic synthesis. Manganese may be the normal metallic mediator of synthesis.

2) EDTA lowers cholesterol levels in man moderately or markedly, almost surely by chelation and removal of a metal from an hepatic enzyme concerned in synthesis or catabolism.

B Essential Fatty Acids Fats containing linolenic acid (and possibly arachidonic acid) lower plasma cholesterol in man even when given in excessive quantities. Fats not containing linolenic acid raise plasma cholesterol. The mechanisms are not known but two can be hypothesized.

(1) Squalene is a probable precursor of cholesterol. Squalene ($C_{30}H_{50}$) can be considered as a highly unsaturated C_{30} hydrocarbon chain with 6 extra methyl side groups and double bonds at the 2, 6, 10, 14, 18 and 22 positions or 4 carbon atoms apart. Linolenic acid (C_{18}) has double bonds at 9, 12, 15 positions and arachidonic acid at 5, 8, 11, 14 positions or 3 carbon atoms apart. It would be impossible to use any combination of ethylene groups from these two acids in the structure of squalene. Degradation to acetate and subsequent synthesis would be required. No one knows much about this matter, except that squalene markedly accelerates synthesis of cholesterol.

application of therapy present and to come Rapid improvements are expected

① Reduce blood pressure of hypertensive patients to a mean level of 140/90 mm Hg (or as low as tolerable) and keep it there indefinitely Two drugs are usually necessary given frequently regularly and carefully one should act on nerves and the other on vascular smooth muscle

② Lower plasma cholesterol to 120 to 160 mg per 100 ml (or about the same levels in mg per cent as systolic pressure is in mm Hg) This can be accomplished slowly in some individuals and soon will be in most by

a) Metal chelation probably removing from liver an abnormal trace metal affecting synthesis Chelation and removal of metastatic calcium in blood vessels can probably be accomplished when desirable

b) Diet based on Less total fat to about 20 per cent of caloric intake Less animal fat especially saturated fatty acids General dairy products and pork are avoided Adequate linolenic acid (probably 0.5 Gm per day is enough) oleic and arachidonic

c) Enough pyridoxine or pyridoxal Probably 5 mg per day is more than adequate This coenzyme is given for logical but untested reasons

It is a long step from a lowered cholesterol to absorption of plaques but the assumption is reasonable

There are enough ideas now under experimental observation to strengthen the belief that atherosclerosis is a reversible disease at least in so far as the fatty and calcific deposits are concerned Arterial hypertension in man can be controlled indefinitely and sometimes reversed Application of therapy to both diseases in the same individual may be expected to reverse in part the lethal and disabling effects of each

2 Pyridoxal affects unsaturated acid synthesis by promoting further desaturation to essential fatty acids (linoleic to arachidonic linolenic to hexaenoic)

3 Pyridoxal lowers plasma cholesterol in monkeys deficient of this coenzyme and fed cholesterol ✓

4 Metals affect synthesis of cholesterol and fatty acids

5 Removal of unknown metals lowers plasma cholesterol in man

6 Feeding essential fatty acids lowers plasma cholesterol in man

An hypothetical schema to include these influences is seen in Figure 39




FIG 39 Hypothetical interactions of metals, essential fatty acids and pyridoxal

Therapeutic Note Thus it would appear that therapeutic tools are now available to control or treat cardiovascular renal diseases quite specifically. While these tools represent first approximations, they are powerful enough and practical enough to be effective in any individual who wants to be treated and is willing to give the time and energy to do so. Since cardiovascular renal diseases account for over half the American death rate, considerable increase in our national longevity can be expected from wide

application of therapy present and to come. Rapid improvements are expected.

① Reduce blood pressure of hypertensive patients to a mean level of 140/90 mm Hg (or as low as tolerable) and keep it there indefinitely. Two drugs are usually necessary given frequently, regularly and carefully: one should act on nerves and the other on vascular smooth muscle.

② Lower plasma cholesterol to 120 to 160 mg per 100 ml. (or about the same levels in mg per cent as systolic pressure is in mm Hg!). This can be accomplished slowly in some individuals and soon will be in most by

a) Metal chelation probably removing from liver an abnormal trace metal affecting synthesis. Chelation and removal of metastatic calcium in blood vessels can probably be accomplished when desirable.

b) Diet based on Less total fat to about 20 per cent of caloric intake. Less animal fat especially saturated fatty acids. Several dairy products and pork are avoided. Adequate linolenic acid (probably 0.5 Gm per day is enough) and arachidonic.

c) Enough pyridoxine or pyridoxal. Probably 5 mg per day is more than adequate. This coenzyme is given for logical but untested reasons.

It is a long step from a lowered cholesterol to absorption of plaques but the assumption is reasonable.

There are enough ideas now under experimental observation to strengthen the belief that atherosclerosis is a reversible disease at least in so far as the fatty and calcific deposits are concerned. Arterial hypertension in man can be controlled indefinitely and sometimes reversed. Application of therapy to both diseases in the same individual may be expected to reverse in part the lethal and disabling effects of each.

This book has attempted to give an orientation from biochemical abnormalities to clinical findings and specific therapy as the only satisfactory way to explain a disease and its control. As usual in scientific medicine, much more needs to be known than is known but the directions for research are clear.

BIBLIOGRAPHY

- 1 SCHROEDER, H. A. The evidence that essential hypertension is not a single disease entity in *A Symposium on Essential Hypertension* Boston Commonwealth of Massachusetts 1953 pp 123-156
- 1b SCHROEDER, H. A. Generalized vasospasm and arterial hypertension in *Signs and Symptoms* 3rd Ed. edited by C. M. MacBryde Philadelphia Lippincott 1957
- 1c SCHROEDER, H. A. Arterial hypertension. Veterans Administration Technical Bulletin TB 10-59 November 1949
- 2 MORITZ, A. R., AND OLDT, M. K. Arteriolar sclerosis in hypertensive and nonhypertensive individuals *Am J Path* 13:69 1937
- 3 SCHROEDER, H. A. AND DAVIES, D. F. Studies on essential hypertension V An endocrine hypertensive syndrome. *Ann Int Med* 40:516 1954
- 3b SCHROEDER, H. A., DAVIES, D. F. AND CLARK, H. E. A syndrome of hypertension obesity menstrual irregularities and evidence of adrenal cortical hyperfunction. *J Lab & Clin Med* 34:1746 1949
- 3c DAVIES, D. F. AND CLARK, H. E. A hypertensive syndrome with relative adrenal cortical overactivity *Circulation* 2:481 1950
- 4 SCHROEDER, H. A. *Hypertensive Diseases—Causes and Control* Philadelphia Lea & Febiger 1955
- 5 PERRY, H. M. JR., O'NEAL, R. M., AND THOMAS, W. A. Pulmonary disease following chronic chemical ganglionic blockade A clinical and pathologic study *Am J Med* 22:37 1957
- 6 GOLDBLATT, H. *The Renal Origin of Hypertension* Springfield Thomas 1948
- 7 DAMMIN, G. J., GOLDMAN, M. L., SCHROEDER, H. A., AND PACE, M. D. Arterial hypertension in dogs II The effects of neurogenic hypertension with a study of periodic renal biopsies over a seven year period *Lab Investigation* 3:72 1956
- 7b GOLDMAN, M. L., SCHROEDER, H. A., AND DAMMIN, G. J. Renal changes in experimental hypertension. *Am J Med* 14:751 1953
- 7c DAMMIN, G. J., GOLDMAN, M. L., SCHROEDER, H. A., AND PACE, M. D. The effects of prolonged experimental hypertension in the dog with a study of periodic renal biopsies over a seven year period *Am J Path* 31:587 1955
- 8 SNAPPER, I. *Chinese Lessons to Western Medicine* New York, Interscience 1941
- 9 WILLIAMS, A. H. AND SCHROEDER, H. A. The systolic arterial pressure gradient as a measure of local peripheral resistance. *Am J Physiol* 156:132 1918

- 10 WILLIAMS A H AND SCHROEDER H A Regional vasomotor tone in normotensive and hypertensive dogs *Circulation* 4706 1951
- 11 COMENS P AND SCHROEDER H A Brachial systolic arterial pressure gradient in man *Am J Physiol* in press 1957
- 12 CHILD E G Observations on the pathological changes following experimental hypertension produced by constriction of the renal artery *J Exper Med*, 67 521 1938
- 13 HOPKINS E L JASON R S AND HAWTHORNE E W Effect of arterial pressure level on site of development of arteriolar necrosis in dogs with malignant hypertension *Federation Proc* 1596 1956
- 14 WINTERNITZ M C MILLOV E, WATERS L L AND KATZENSTEIN R Studies on the relation of the kidney to cardiovascular disease *Yale J Biol & Med* 12:623 1910
- 15 LEVY R L HILLMAN C C STROUD W D AND WHITE P D Transient hypertension Its significance in terms of later development of sustained hypertension and cardiovascular renal disease *J.A.M.A.*, 126 829 1941
- 16 LEVY R L WHITE P D STROUD W D AND HILLMAN C C Transient tachycardia Prognostic significance alone and in association with transient hypertension *J.A.M.A.* 129 585 1945
- 17 LEVY R L WHITE P D STROUD W D AND HILLMAN C C Transient hypertension The relative prognostic importance of various systolic and diastolic levels. *J.A.M.A.* 128 1039 1945
- 18 LEVY R L WHITE P D, STROUD W D AND HILLMAN C C Overweight Its prognostic significance in relation to hypertension and cardiovascular renal disease *J.A.M.A.* 1319:1 1946
- 19 HINES E A Jr Range of normal blood pressure and subsequent development of hypertension A follow up study of 1,522 patients *J.A.M.A.* 115:271 1910
- 20 HINES E A Jr The significance of vascular hyperreaction as measured by the cold pressor tests *Am Heart J* 19 408 1940
- 21 SCHROEDER H A AND GOLDMAN M L Arterial hypertension in dogs I Methods *Circulation* 5 730 1952
- 22 ZONDER S G Inhibiting influence of essential hypertension on malignant growth and rheumatoid arthritis *Acta med Scandinav* 152:231 1955
- 23 HINES E A Jr Hereditary factor and subsequent development of hypertension *Proc Staff Meet Mayo Clin* 15 145 1940
- 24 PICKERING G W *High Blood Pressure* New York Grune & Stratton 1955
- 25 THOMAS C B, AND HIRSCHHORN B The familial occurrence of hypertension and coronary artery disease with observations concerning obesity and diabetes *Ann Int Med* 42:90 1955
- 26 GRESSEL G C SHORE F O, SASLOW G DuBOIS P H AND

- SCHROEDER H A.. Personality factors in arterial hypertension
J.A.M.A 140:265 1919
- 27 BOGER, C. A. AGERMAN N W., COHN A. E., SCHROEDER, H A.,
AND STERLE, J M.. *Personality in Arterial Hypertension* (Psychosomatic Medicine Monographs) New York, Robert Brunner 1913
- 28 PICKERING C W.. The genetic factor in essential hypertension *Ann
Int Med* 43:457 1955
- 29 SCHROEDER H A. "Essential" hypertension A concept of its
Mechanism *Am J M Sc* 204:734 1942
- 30 SCHROEDER H A.. The pathogenesis of hypertension *Am J Med
10* 189 1951
- 31 SCHROEDER H A., AND STERLE J M. Studies on "essential" hyper-
tension I. Classification *Arch Int Med* 64:927 1939
- 32 BAYS, R. P., AND SCRIMSHAW N S. Facts and fallacies regarding the
blood pressure of different regional and racial groups. *Circulation*
8:685 1953
- 33 WILLIAMS, A. W.. Heart disease in the native population of Uganda.
Part IV Hypertensive heart disease *East African M J.* 21:328
1944
- 34 COHEN B M. Arterial hypertension among Indians of the south
western United States *Am J M Sc.* 225:505 1953
- 35 WILLIAMS A. W. BALL, J D. AND DAVIES J N P. Endomyocardial
fibrosis in Africa Its diagnosis distribution and nature *Tr Roy
Soc. Trop Med & Hyg* 48:290 1954
- 36 JANeway T C. *The Clinical Study of Blood Pressure* New York
Appleton 1904
- 37 SCHROEDER, H A., AND MENHARD E. M. Spontaneous variations of
blood pressure in hypertensive and normotensive individuals
Am Heart J. 51:577 1956
- 38 RAAN W. *Hormonal and Neurogenic Cardiovascular Disorders*
Baltimore Williams & Wilkins 1953
- 39 GUNTER, R., SILVERSTONE F., AND UNCLESLEDER, H E. Range of blood
pressure in hypertension. *J.A.M.A* 130:32, 1946
- 40 SMITHWICK, R. H., AND ROBERTSON E W. The phenomenon of
hyperactivity Definition *Angiology* 2:143 1951
- 41 REISER, M., AND FRANKS E. B. JR. The nature of the cold pressor
test and its significance in relation to neurogenic and humoral
mechanisms in hypertension *J Clin Investigation* 27:155 1948
- 42 HILF W R. *Die Regulierung des Blutkreislaufs* Leipzig G Thieme
1930
- 43 HETMANE C., NOWAK J G., AND SAMAN A. Sur l'action vasomo-
trice reflexe centrale et périphérique de l'acide carbonique de
l'azotémie et de l'asphyxie *Compt rend Soc biol Paris* 117:248
1934.

- 44 GELLHORN E AND LAMBERT E H *The Vasomotor System in Anoxia and Asphyxia Urbana III* Univ Illinois Press 1939
- 45 LYONS R II MOE G K NELIGH R II HOOBLER S W CAMPBELL, K N BERRY, R L AND RENNICK B R The effects of blockade of the autonomic ganglia in man with tetraethylammonium *Am J M Sc* 213 315 1947
- 46 FREEMAN N II AND JEFFERS W J Effect of progressive sympathectomy on hypertension produced by increased intracranial pressure *Am J Physiol* 128 662 1940
- 47 DIXON W E AND HELLER II Experimentelle Hypertonie durch Erhöhung des intrakraniellen Druckes *Arch exper Path u Pharmacol* 166 265 1932
- 48 NOWAK J G AND WALKER J J Experimental studies concerning the nature of hypertension *New England J Med* 220 269 1939
- 49 FISHBACK H R DUTRA F P AND MACCAMY E T Production of chronic hypertension in dogs by progressive ligation of arteries supplying the head *J Lab & Clin Med* 28 1187 1943
- 50 TAYLOR R D AND PAGE I H Production of prolonged arterial hypertension in dogs by chronic stimulation of the nervous system *Circulation* 3 551 1951
- 51 VON EULER U S AND HELLNER S Excretion of noradrenaline and hydroxytyramine in urine *Acta physiol scandinav* 22 161 1951
- 51b VON EULER U S HELLNER S AND PURKHOLD A Excretion of noradrenaline adrenaline in urine in hypertension *Scandinavian J Clin & Lab Invest* 6 34 1954
- 52 DOYLE A E AND SMIRK F H The neurogenic component in hypertension *Circulation* 12 543 1955
- 53 STARLING E H The physiologic factors in hyperpiesia *Brit M J* II 1163 1925
- 54 FAERIS E J YEAKEL E H AND MEDOFF H S Development of hypertension in emotional gray Norway rats after air blasting *Am J Physiol* 144 331 1945
- 55 WALTER C W AND PIJOAN M J Persistent hypertension due to hypothalamic injury *Surgery* 1 282 1937
- 56 McLEAN P D FLYNN J P AND KIM C Experiments Bearing on the Role of Limbic System in Cardiovascular Function Conditioning and Reserpine Studies *Proc Council For High Blood Pressure Research Am Heart A* New York 1955
- 56b BROCA P Anatomie Comparée des Circonvolutions Cérébrales Le grand lobe limbique et la scissure limbique dans la Série de Mammifères *Rev Anthropol Ser 2* 1 395 498 1878
- 56c RAAE W Central vasomotor irritability (contribution to the problem of essential hypertension) *Arch Int Med* 47 727 1931
- 56d BAILEY P AND SWEET W H Effects on respiration blood pressure

- and gastric motility of stimulation of orbital surface of frontal lobe *J Neurophysiol.*, 3:76 1940
- 56c. POOL, J. L. The visceral brain of man. *J Neurosurg.*, 11:45 1954
- MANN, P. J. G. AND QUASTEL, J. H. Benzedrine (β-phenylisopropyl amine) and brain metabolism. *Biochem J.*, 34:414 1940
- FELLOWS, E. J., AND BERNHEIM, F. The effect of a number of aryl kylamines on the oxidation of tyramine by amine oxidase. *J Pharmacol & Exper Therap* 100:94 1950
- TOMAN, J. E. P., AND DAVIS, J. ■ The effects of drugs upon the electrical activity of the brain *Pharmacol Rev.*, 1:425 1949
- BRODIE, B. B., FLETCHER, A., AND SHORE, P. A. Evidence that serotonin has a role in brain function *Science* 124:968 1955
- 60b. UDENFRIEND, S., WEISSBACH, H., AND BOGDANSKI, D. F., Biochemical findings relating to serotonin action. *Ann New York Acad Sc.*, 66 Art 3 1956
61. SJOERDSTRA, A. WEISSBACH, H. AND UDENFRIEND, S. A clinical physiologic and biochemical study of patients with malignant carcinoid (argenteofibroma) *Am J Med.*, 20:590 1956
62. SCHROEDER, H. A., AND GOLDMAN, M. L., A test for the presence of the hypertensive diencephalic syndrome using histamine. *Am J Med* 6:169 1949
- PAGE, I. H. Serotonin (>hydroxytryptamine) *Physiol Rev.*, 34:363 1954
- BORDLEY, J. III. AND BAKER, B. M. Jr. A consideration of arteriosclerosis of the cerebral vessels and the pathogenesis of hypertension *Bull Johns Hopkins Hosp* 39:229 1926
- FLETCHER, A. SHORE, P. A. AND BRODIE, B. B. Serotonin release as a possible mechanism of reserpine action. *Science* 122:374 1955
- 65b. SHORE, P. A. Role of brain serotonin in reserpine action. *Ann New York Acad Sc* 66 Art. 3 1956
66. SHORE, P. A. SILVER, S. L., AND BRODIE, B. B., Interaction of reserpine serotonin and lysergic acid diethylamide in brain *Science* 122:284 1955
67. SELLING, L. S. AND SELLING, P. H. Clinical study of a new tranquilizing drug *J.A.M.A* 157 1594 1955
- HERSHKANTZ, L., AND WILSON, W. A., Jr. The effects of reserpine on emotional behavior of normal and brain-operated monkeys *Ann New York Acad Sc.*, 61:96 1955
69. SCHROEDER, H. A. Hypertensive vascular disease. Therapy with modern drugs and its limits *J Chronic Dis* 1:497 1955
70. SCHROEDER, H. A., AND PERRY, H. M. Jr. Psychosis apparently produced by reserpine. *J.A.M.A* 159:839 1955
- 70b. MILLER, J. C. PRYOR, W. W., GIBSON, J. E., AND ORGAIN, E. S.

- Depression and anxiety occurring during rauwolfia therapy
J.A.M.A. 159 836 1955
- 70c. ACHOR R W P HANSON N O AND GIFFORD R W JR Hyper-
tension treated with rauwolfia serpentina (whole root) and with
reserpine *J.A.M.A.* 159 841 1955
- 71 CLARK C T WEISSBACH H AND UNGENFRIED S 5 hydroxytrypt-
ophan decarboxylase Preparation and properties *J Biol Chem*,
210 139 1954
- 72 BEILER J M AND MARTIN G J Inhibition of 5 hydroxytryptophan
decarboxylase *J Biol Chem* 211 39 1954
- 72b BUXTON J AND SINCLAIR, H M Pyridoxal phosphate as a coenzyme
of 5 hydroxytryptophan decarboxylase *Biochem J* 62 27 1956
- 73 BENDITT E P AND ROWLEY H A Antagonism of 5 hydroxytrypt-
amine by chlorpromazine *Science* 123 24 1956
- 74 ZELLER W W., GRAFFAGNINO P N CULLEY C F AND RIETMAN
H H Use of chlorpromazine and reserpine in the treatment of
emotional disorders *J.A.M.A.*, 160 179 1956
- 75 BORRIS J C Study of effect of miltown (2 methyl 2 n propyl 1,3
propanediol dicarbamate) on psychiatric states *J.A.M.A.* 157 1596
1955
- 76 HEYMANS C. Experimental arterial hypertension *New England J*
Med 219 154 1938
- 77 VOLHARD F (a) Über die Pathogenese des roten (essentiellen)
arteriellen Hochdruckes und der malignen Sklerose Schweiz. med
Wchnschr 78 1189 1948 (b) On the pathogenesis of red (essential)
arterial hypertension and of malignant nephrosclerosis *Stanford*
M Bull., 6 18 1948
- 78 ABREU B E. RICHARDS A B ALEXANDER W M AND WEAVER L C.
Cardiovascular and emetic properties of veratrum alkaloids *Fed*
eration Proc 12-297 1953 13 397 1954
- 78b SCHNEIDER J A *Central Action of Anti Hypertensive Drugs* Proc.
Council For High Blood Pressure Research Am Heart A New
York 1955
- 79 MEILMAN E AND KRAVER O Clinical studies on veratrum alkaloids
Circulation 6-212 1952
- 79b MEILMAN E AND KRAVER O Clinical studies on the pure veratrum
alkaloids protoveratrine and veratridine *J Clin Investigation*
28 798 1949
- 79c. DAWES G S Studies on veratrum alkaloids VII Receptor areas in
the coronary arteries and elsewhere as revealed by the use of
veratridine *J Pharmacol & Exper Therap* 89-325 1947
- 80 HOOBLER S W., CORLEY R. W KATZA T G AND LOYKE, H F
Treatment of hypertension with oral protoveratrine *Ann Int*
Med., 37 465 1952

- 81 McCUBRY J W., GREEN J H., AND PAGE, I H. Baroreceptor function in chronic renal hypertension *Circulation Res.*, 4:205 1956
- 82 OGDEN E. The relation of the nervous system to acute and chronic experimental hypertension in *Factors Regulating Blood Pressure Transactions of the First Conference* ed by Zweifach B W., and Shorr E., New York Macy 1947 p 12.
- 83 ZAWOJSKI E. J. BAKER J E., BRUNSCHWIG L. W., PATLSON S F., AND SHERNER, A.. Gastrointestinal secretion and absorption of 3 methyl aminoisocamphane hydrochloride (mecamylamine) *Federation Proc* 13:205 1956
- 84 GOODMAN L. S. AND GILMAN A. *The Pharmacological Basis of Therapeutics* 2nd Ed New York, Macmillan, 1955
- 85 FURCHGOTT R. F., AND BHADRAKUM S. Reactions of strips of rabbit aorta to epinephrine isopropylarterenol sodium nitrate and other drugs *J Pharmacol & Exper Therap* 103:129 1953
- 85b FURCHGOTT R. F. The pharmacology of vascular smooth muscle *Pharmacol Rev* 7:185 1955
- 86 BING R. J. AND ZUCKER, M. B. Renal hypertension produced by amino acid. *J Exper Med.*, 74:230 1941
- 87 HOLTE P. CHRISTEN K. AND WALTER, K. Über die Spezifität der Aminosäuredecarboxylasen. *Ztschr physiol Chem.*, 262:111 1959
- 88 BLASCHO H., RICHTER, D., AND SCHLOSSMANN H. The oxidation of adrenalin and other amines *Biochem J* 31:2187 1937
- 89 KOHN H. I. Tyramine oxidase *Biochem J* 31:1693 1937
- 90 STOCK C. C., AND SCHROEDER, H. A.. Pressor substances in arterial hypertension. Activity and amine content of crude extracts of blood. *Am J Physiol* 160:409 1950
- 91 SCHROEDER H. A. AND OLSEN H. S. Pressor substances in arterial hypertension. II. Demonstration of pherentazin a vasoactive material procured from blood *J Exper Med* 93:545 1950
- 92 COUNCIL ON PHARMACY AND CHEMISTRY. Blood dyscrasias associated with chlorpromazine therapy *J.A.M.A.* 160:287 1956
- 93 MORROW J. D., SCHROEDER, H. A., AND PERRY H. M., JR. Studies on the control of hypertension by Hyphex. II. Toxic reactions and side effects *Circulation* 8:329 1953
- 94 MORRISON B. Parenteral hexamethonium in hypertension. *Brit M J* 1:1291 1953
- 95 BALST A. A. AND FERRIS F. B. Varying patterns of blood pressure response to autonomic blockade. Implications concerning the interplay of neurogenic and humoral factors in control of vascular tone. *Proc. Annual Meeting Council For High Blood Pressure Research, Am Heart A.*, Nov 1955
- 96 OLSEN H. S., AND SCHROEDER, H. A.. Oxygen tension and pH of the

- renal cortex in acute ischemia and chronic hypertension. *Am J Physiol*, 163 181 1950
- 97 SCHROEDER H A AND STEELE J M The behavior of renal blood flow after partial constriction of the renal artery *J Exper Med* 72-707 1910
- 98 CANNON W B AND ROSENBLUETH A *The Supersensitivity of Degenerated Structures* (Experimental Biology Monographs) New York Macmillan 1919
- 99 BRAUN MENÉNDEZ E FASCIOLO J C LELOIR L F AND MUÑOZ J M The substance causing renal hypertension *J Physiol* 98 283 1940
- 99b PAGE I H, AND HELMER O M A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator *J Exper Med* 71-29 1940
- 100 SHORR E Participation of hepatorenal vasotropic factors in experimental hypertension *Am J Med* 4-120 1918
- 101 CORCORAN A C KOHLSTAEDT K G AND PAGE, I H Changes of arterial blood pressure and renal hemodynamics by injection of angiotonin in human beings *Proc Soc Exper Biol & Med*, 46 244 1941
- 102 KATZ L N Hemodynamics of the circulation in hypertension in *Factors Regulating Blood Pressure* Transactions of the Third Conference ed by Zweifach B W and Shorr E New York Macy 1919 p III
- 103 SHORR, E Comparative study of experimental renal and human essential hypertension with respect to the participation of the hepatorenal vasoactive factors ven and vdm in *Factors Regulating Blood Pressure* Transactions of the Fourth Conference ed by Zweifach B W and Shorr E New York Macy 1950 p 165
- 104 OLSEN N S Oxidation by normotensive and hypertensive tissues *Federation Proc*, 10-99 1951
- 105 RASKA S B The metabolism of the ischemic kidney I The respiratory and the oxidase activity of the ischemic kidney *J Exper Med* 74-75 1913
- 106 GARGILL W H AND HICKHAM J B The oxygen consumption of the normal and the diseased human kidney *J Clin Investigation* 28 526 1949
- 107 REUBI F C AND SCHROEDER H A Can vascular shunting be induced in the kidney by vasoactive drugs? *J Clin Investigation*, 28 114 1919
- 108 SCHROEDER, H A Personal observations
- 109 THOMPSON J E SILVA T F KINSEY D AND SMITHWICK R H The effect of acute salt loads on the urinary sodium output of normotensive and hypertensive patients before and after surgery *Circulation* 10-912 1954

- 109b Ex J The influence of heavy hydration on the renal function in normal and hypertensive man *Scandinav J Clin & Lab Invest.*, 7-Suppl 19 pp 177 1955
- 109c. FRIEDMAN S M., HARDWICK D F AND HINKE, J A M.. The effect of pitressin on sodium tolerance in experimental hypertension *Circulation Res* 3:490 1955
- 109d FRIEDMAN S M HINKE J A M., AND HARDWICK D F Sodium tolerance in experimental hypertension *Circulation Res* 3:297 1955
- 110 FARNSWORTH E B Renal reabsorption of chloride and phosphate in normal subjects and in patients with essential arterial hypertension *J Clin Investigation* 25:897 1946
- 110b. GREEN D M., JOHNSON A D BRIDGES W C. AND LEHMANN J H Stages of salt exchange in essential hypertension *Circulation* 9 416 1954
- 110c. COTTER P T HOOBLER S W AND WELLES J M.. Effects of a sodium chloride load on renal hemodynamics and electrolyte excretion in essential hypertension *J Clin Investigation* 35:698 1956
- 111 PERRY H M Jr AND SCHROEDER, H A Personal observations from our laboratories
- 112 SCHROEDER, H A AND OLSEN N S Humoral pressor substances and their relation to arterial hypertension *Am Chemical Soc. "Advances in Chemistry Series" No 2 Chemical Factors in Hypertension* May 1950
- 112b GOLDMAN M L KASS J P FUTCHER, P H AND SCHROEDER H A The transfusion of arterial hypertensive and normotensive blood into hypertensive subjects *Am J M Sc* 217:637 1949
- 112c. OLSEN N S SCHROEDER, H A AND MENTHARD E M Effect of certain amines on the blood pressure of normotensive and hypertensive rats *Proc Soc Exper Biol & Med* 74:581 1950
- 113 CROLLMAN A The Pathogenesis of Experimental and Clinical Hypertensive Cardiovascular Disease *Proc Council For High Blood Pressure Research* Am Heart A. New York 1953
- 114 EDVICK, E. F JR. AND OLSEN N S Urine amine levels in normotensive and hypertensive subjects *Federation Proc* 9:36 1950
- 115 DAVIES H F WOLFE, K. M AND PERRY H M Jr Studies on primary amines II Their natural occurrence in urine of normotensive and hypertensive subjects *J Lab & Clin Med* 43:620 1954
- 116 CROXATTO H AND CROXATTO R. Inhibitory action of amineoxidase and tyrosinase upon vasoconstrictor effect of hypertensin. *Proc Soc Exper Biol & Med* 48:392 1941
- 117 SCHROEDER, H A. The effect of a preparation of amine oxidase on experimental hypertension *Science* 97:306 1942.
- 118 REUBI F C. AND FUTCHER, F H The effects of histamine on renal

- function in hypertensive and normotensive subjects *J Clin Investigation* 28 440 1949
- 119 SCIALES O Kidney enzymes and essential hypertension in *Advances in Enzymology* Vol 7 F F Nord ed New York Interscience 1947 (pp 513 556)
- 120 SCHROEDER H A PERRY H M JR DENNIS E G AND MAHONEY, L. E Pressor substances in arterial hypertension V Chemical and pharmacological characteristics of pherentasin. *J Exper Med* 102 319 1955
- 120b SCHROEDER H A AND PERRY H M JR Characteristics of a long acting vasoconstrictor procured from human hypertensive blood *Federation Proc* 14 134 1955
- 120c SCHROEDER H A AND PERRY H M JR Inactivation of pherentasin by antihypertensive drugs *Circulation* 12 772 1955
- 121 OLSEN N S SCHROEDER H A AND MENHARD E M Pressor substances in arterial hypertension III Chemical studies on pherentasin *J Exper Med* 92 561 1950
- 122 DAVIES D F OLSEN N S, AND SCHROEDER H A Pressor substances in arterial hypertension IV Quantitative and qualitative studies of pherentasin *Circulation* 5 380 1952
- 123 SCHROEDER H A OLSEN N S AND GOLDMAN M L Pressor substances in human hypertensive blood in *Factors Regulating Blood Pressure* Transactions of the Second Conference New York Macy 1948 pp 118 130
- 124 SCHROEDER H A AND STOCK C C On the pressor activity of extracts of hypertensive blood *J Clin Investigation* 21 627 1942
- 125 MARSHALL, J., AND WAKERLIN G E Purification and possible histochemical localization of renin *Federation Proc* 8 106 1949
- 126 BARCROFT H AND KONZETT H On the actions of nor adrenaline adrenaline and isopropyl noradrenaline on the arterial blood pressure heart rate and muscle blood flow in man *J Physiol* 110 194 1949
- 127 GOLDENBERG M PINES K L BALDWIN H F GREENE H G AND ROH C E The hemodynamic response of man to nor epinephrine and epinephrine and its relation to the problem of hypertension *Am J Med* 5 742 1948
- 128 DEXTER L FRANK H A HAYNES F W AND ALTSCHULE M D Traumatic shock VI The effect of hemorrhagic shock on the concentration of renin and hypertensinogen in the plasma in unanesthetized dogs *J Clin Investigation* 22 847 1943
- 129 DEXTER L Mechanisms of human hypertension *Am J Med* 4 219 1948
- 130 DEXTER L AND HAYNES F W Relation of renin to human hypertension with particular reference to eclampsia preeclampsia and

- acute glomerulonephritis *Proc Soc Exper Biol & Med* 33:288 1914
- 131 MERRILL, A J MORRISON J L., AND BRANNON E. S. Concentration of renin in renal venous blood in patients with chronic heart failure. *Am J Med* 1:468 1916.
- 132 SHIPLEY R E., HELMER O M. AND KOHLSTADT K G.. The presence in blood of a principle which elicits a sustained pressor response in nephrectomized animals *Am J Physiol* 149:703 1947
- 133 DAVIES D F., WOLFE K. M., AND PERRY H M., JR.. Studies on primary amines I Methods. *J Lab & Clin Med* 41:802 1953
- 134 DAVIES D F WOLFE, K. M., PERRY H M., JR., SCHROEDER H A., AND MENTMANN E. M. Chemical characteristics of pressor amines extracted from urine. *Federation Proc.* 12:467 1953
- 134b DAVIES H F MILLER, H. AND SCHROEDER H A.. Association between primary amines and pressor substances in urine *Am J Med* 11:210 1951
- 135 PERRY H M JR AND GOLDBSTEIN G. Studies on primary amines III. Limiting and optimum conditions for quantitative determination by the ninhydrin method *J Lab & Clin Med* 45:963 1955
- 136 WAKELIN G E. AND JOHNSON C. A. Reductions in blood pressures of renal hypertensive dogs by hog renin *Proc Soc Exper Biol & Med* 46:104 1941
- 137 FRANK M H GRAHAM L., AND WAKELIN G E. Treatment and prophylaxis of experimental hypertension in monkeys with renins and anurenins *Federation Proc* 15:66 1956
- 138 SKELLS L. T. JR., MARSH W H., KAHN J R., AND SHUMWAY N P.. The existence of two forms of hypertension. *J Exper Med* 99:275 1954
- 138b HELMER, O M. Use of rabbit aortic strips to biologically differentiate two forms of angiotonin. *Federation Proc* 15:273 1956
- 138c. BUMPS F M., AND SCHWARTZ H J. Evidence for existence of pressor and oxytocic active peptides in angiotonin preparations *Federation Proc* 15:226 1956
- 139 SKELLS L. T., JR. MARSH W H. KAHN J R. AND SHUMWAY N P. Amino acid composition and electrophoretic properties of hypertensin I. *J Exper Med* 107:435 1955
- 140 SMITH E. L. Aspects of the Specificity and Mode of Action of Some Peptidases in *Enzymes and Enzyme Systems* Edsall J T., ed Cambridge Harvard 1951
- 141 SKELLS, L. T. JR., KAHN J R. AND SHUMWAY N P. The purification of hypertensin II *J Exper Med.* 103:301 1956
- 141b. SKELLS L. T. JR. KAHN J R., AND SHUMWAY N P.. The preparation and function of the hypertension-converting enzyme *J Exper Med* 103:295 1956

- function in hypertensive and normotensive subjects *J Clin Investigation* 28:440 1949
- 119 SCHIALES O Kidney enzymes and essential hypertension in *Advances in Enzymology* Vol 7 F F Nord ed New York Interscience 1947 (pp 513-556)
- 120 SCHROEDER H A PERRY H M JR DENNIS E G AND MAHONEY L E Pressor substances in arterial hypertension V Chemical and pharmacological characteristics of pherentasin *J Exper Med* 102:319 1953
- 120b SCHROEDER H A AND PERRY H M JR Characteristics of a long acting vasoconstrictor procured from human hypertensive blood *Federation Proc* 14:134 1955
- 120c SCHROEDER H A AND PERRY H M JR Inactivation of pherentasin by antihypertensive drugs *Circulation* 12:772 1955
- 121 OLSEN N S SCHROEDER H A AND MENHARD E M Pressor substances in arterial hypertension III Chemical studies on pherentasin *J Exper Med* 92:561 1950
- 122 DAVIES D F OLSEN N S AND SCHROEDER H A Pressor substances in arterial hypertension IV Quantitative and qualitative studies of pherentasin *Circulation* 5:380 1952
- 123 SCHROEDER H A OLSEN N S AND GOLDMAN M L Pressor substances in human hypertensive blood in *Factors Regulating Blood Pressure* Transactions of the Second Conference New York Macy 1948 pp 118-130
- 124 SCHROEDER H A AND STOCK C G On the pressor activity of extracts of hypertensive blood *J Clin Investigation* 21:627 1942
- 125 MARSHALL J AND WAKERLIN G E Purification and possible histochemical localization of renin *Federation Proc* 8:106 1949
- 126 BACROFT H AND KOVZETZ H On the actions of nor adrenaline, adrenaline and isopropyl nor adrenaline on the arterial blood pressure, heart rate and muscle blood flow in man *J Physiol* 110:194 1949
- 127 GOLDENBERG M PINES K L BALDWIN H F GREENE D G AND ROSS C E The hemodynamic response of man to nor epinephrine and epinephrine and its relation to the problem of hypertension *Am J Med* 5:742 1948
- 128 DEXTER L FRANK H A HAYNES F W AND ALTSCHULE M D Traumatic shock VI The effect of hemorrhagic shock on the concentration of renin and hypertensinogen in the plasma in unanesthetized dogs *J Clin Investigation* 22:847 1943
- 129 DEXTER L Mechanisms of human hypertension *Am J Med* 4:279 1948
- 130 DEXTER L AND HAYNES F W Relation of renin to human hypertension with particular reference to eclampsia, preeclampsia and

- 158 YULE, C. L. Obstructive lesions of the main renal artery in relation to hypertension. *Am J M Sc* 67:394 1944
- 159 CASTLEMAN B and SMITHWICK R. H. The relation of vascular disease in the hypertensive state *New England J Med* 239:732, 1948
- 160 WILSON C. AND BYROM F. B. Renal changes in malignant hypertension. *Lancet* 1 196 1939
- 161 SCHROEDER H. A. Arterial hypertension in rats I. Methods *J Exper Med* 75:513 1942
- 162 SCHROEDER H. A., AND NEUMANN C. Arterial hypertension in rats. II. Effects on the kidneys. *J Exper Med* 75:527 1942
- 163 SPITZNAGEL, J. K., AND SCHROEDER, H. A. Experimental pyelonephritis and hypertension in rats *Proc Soc Exper Biol & Med.* 77:762 1951
- 164 FLAHERTY J. AND DUCKY H. F. Effects of removal of "ischemic" kidney in rabbits with unilateral renal hypertension as compared to unilateral nephrectomy in normal rabbits. *Am J Physiol* 158:438 1949
- 165 SCHROEDER, H. A., AND GOLDMAN M. L. Arterial hypertension in dogs. I Methods *Circulation* 5:730 1952
- 166 SMITH H. W. Hypertension and urologic disease *Am J Med* 4:404 1948
- 167 SCHROEDER, H. A. AND FISH G. W. Studies on "essential" hypertension. III. The effect of nephrectomy upon hypertension associated with organic renal disease *Am J M Sc* 199:601 1940
- 168 PERRY H. M., JR. AND SCHROEDER, H. A. Studies on the control of hypertension by Hyphex. III Pharmacological and chemical observations on 1-hydranophthalazine *Am J M Sc* 228:396 1954
- 168b PERRY H. M. JR., AND SCHROEDER, H. A. The chemistry and pharmacology of 1-hydranophthalazine *Am J Med* 16:606 1954
- 168c PERRY H. M. JR. AND SCHROEDER, H. A. Pharmacology of hydralazine. *Proc. Second World Congress of Cardiology and Am Heart A* 19:4 p 442
- 169 JONCLAIN H. M. Pyridoxal phosphate as coenzyme of histaminase. *Biochem J* 51:1 1952.
- 170 BIEHL, J. E. AND VILTER, R. W. Effect of isoniazid on vitamin B₆ metabolism its possible significance in producing isoniazid neuropathy *Proc Soc Exper Biol & Med* 85:339 1954
- 171 SCHULZ, W. Inhibition of diaminoxidase (histaminase) *Experientia* 8:230 1952.
- 172 GROSS F. SCHULZ, W. TAYLOR J. AND MEYER, R. Inhibition of

- 142 PEART W S The isolation of a hypertensin *Biochem J* 61:50 1956
- 142b ELLIOTT H F AND PEART W S Amino acid sequence in a hypertensin *Nature* 177:527 1956
- 143 SAPHIR O and TAYLOR B Pyelonephritis lenta *Ann Int Med* 36:1017 1952
- 143b BROD J *Chronická Pyelonefritis* Praha Statní Zdravotnické Nakladatelství 1955
- 144 BELL E T *Renal Diseases* 2nd Ed Philadelphia Lea & Febiger 1950
- 145 BLACKMAN S S JR Arteriosclerosis and partial obstruction of the main renal arteries in association with essential hypertension in man *Bull Johns Hopkins Hosp* 61:355 1939
- 146 OPPENHEIMER H S KLEMPERER P AND MOSKOWITZ L Evidence for the Goldblatt mechanism of hypertension in human pathology *Tr A Am Physicians* 54:69 1939
- 147 KAHN J R AND LAIPPLY T C Frequency of bilateral renal disease in persistent hypertension *Am J M Sc* 203:807 1917
- 148 BRAUN MENÉNDEZ E FASCIOLA J C LEROIR L F MUNOZ J M AND TAQUINI A C translated by L Dexter *Renal Hypertension* Springfield Thomas 1946
- 149 GOLDBLATT H Experimental hypertension induced by renal ischemia The Harvey Lectures *Bull New York Acad Med* 14:523 1938
- 150 LEITER L Unusual hypertensive renal disease 1 Occlusion of renal arteries (Goldblatt hypertension) 2 Anomalies of urinary tract *JAMA* 111:507 1938
- 151 FREEMAN G AND HARTLEY G JR Hypertension in a patient with a solitary ischemic kidney *JAMA* 111:1159 1938
- 152 STEWART C F Arteriosclerosis of the renal artery orifices with severe hypertension *JAMA* 114:2099 1940
- 153 SAPHIR O AND BALLINGER J Hypertension (Goldblatt) and unilateral malignant nephrosclerosis *Arch Int Med* 66:541 1940
- 154 LAAS E Die Wirkung einer Nierenarterienverlegung auf Niere und Blutdruck *Virchows Arch path Anat* 305:638 1940
- 155 RICHARDSON G O Atherosclerosis of main renal arteries in essential hypertension *J Path & Bact* 55:33 1943
- 156 FRIEDMAN H MOSKOWITZ L AND MARRAS J Unilateral renal disease and renal vascular changes in relation to hypertension in man *J Urol* 48:5 1942
- 157 LISA J R ECKSTEIN D AND SOLOMON C Relationship between arteriosclerosis of the renal artery and hypertension Analysis of 100 necropsies *Am J M Sc* 205:701 1943

- Rheumatic and febrile syndrome during prolonged hydralazine treatment. *J.A.M.A.* 154:23 1954
- 185 PERRY H M JR AND SCHROEDER H A. Syndrome simulating collagen disease caused by hydralazine (Apretoline) *J.A.M.A.*, 154 6:0 1954
- 186 COMENS P., AND SCHROEDER H A. The L. E. cell as a manifestation of delayed hydralazine intoxication *J.A.M.A.*, 160 1154 1956
- 187 SHACKMAN N H SWILLER A. L. AND MORRISON M. Syndrome simulating acute disseminated lupus erythematosus Appearance after hydralazine (Apretoline) therapy *J.A.M.A.*, 155 1492 1954
- 188 COMENS P. Experimental hydralazine disease and its similarity to disseminated lupus erythematosus *J Lab & Clin Med.*, 47 414 1956
- 189 SCHROEDER H A. The effect of 1 hydrazinophthalazine in hypertension *Circulation* 5:28 1952
- 190 SZENT GYORGI A. The Contraction Cycle and Its Regulation *Proc. Annual Meeting For High Blood Pressure Research Am Heart A.*, 1954
- 191 VILTER, R. W., MUELLER, J F GLAZER, H S., JARROLD T., ABRAHAM J THOMPSON C., AND HAWKINS, V R. The effect of vitamin B deficiency induced by desoxypyridoxine in human beings *J Lab & Clin Med.*, 42:335 1953
- 192 SINGH S I AND SINGH L. The action of calcium on blood vessels and its relation to hypertension. *Proc Indian Acad Sc.*, 42 191 1955
- 193b SINGH S I AND SINGH L. The action of sodium and potassium on blood vessels and its relation to hypertension. *Proc Indian Acad Sc* 42 172 1955
- 195 OLSEN N S., AND MARTINDALE, W E. Hypertension and pyridoxine deficiency in the rat. *J Clin Investigation* 31:632 1952
- 195b OLSEN N S., AND MARTINDALE W E. Relation of pyridoxine deficiency and hypertension in the rat. *Federation Proc* 11 115 1952
- 194 OLSEN N S AND MARTINDALE, W E. Studies on chronic vitamin B₆ deficiency in the rat. I. Changes in the intact animal *J Nutrition* 33 317 1954.
- 195 OLSEN N S AND MARTINDALE, W E. Studies on chronic vitamin B₆ deficiency in the rat. II. Changes in tissue metabolism *J Nutrition* 33 329 1954
- 196 HARRIS S. A. Chemistry of vitamin B₆. IV Reactions in solutions at elevated temperatures *J Am Chem Soc* 63 5563 1941
- 197 GYOCSEY P. Investigations on the vitamin B₆ complex. III The inactivation of lactoflavin and vitamin B₆ by visible light. *Biochem J.*, 29:767 1955

diaminoxidase (histaminase) by phthalazine derivatives *Experientia* 8 2294 1952

- 173 SOLLMANN T *A Manual of Pharmacology* 7th Ed Philadelphia Saunders 1948
- 173b OLSEN N S Inhibitory effect of thiocyanate upon oxidations mediated by liver and kidney *Arch Biochem* 26:269 1950
- 174 PAGE I H CORCORAN A C DUSTAN H P AND KOFFANIT T Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients *Circulation* 11 188 1955
- 175 BLACK, M M ZWEIFACH B W AND SPEER F H Comparison of hypotensive action of sodium azide in normotensive and hypertensive patients *Proc Soc Exper Biol & Med*, 85 11 1954
- 176 MODELL W GOLD H AND CATTELL MCK Clinical uses of 2,3-dimercaptopropanol (BAL) IV Pharmacologic observations of BAL by intramuscular injection in man *J Clin Investigation* 25:480 1946
- 177 SULZBERGER M B BAER R L AND KANOF A Clinical uses of 2,3 dimercaptopropanol (BAL) III Studies on the toxicity of BAL on percutaneous and parenteral administration *J Clin Investigation* 25:474 1946
- 178 CARLETON A B PETERS R A STOCKEN L A THOMPSON R, H S AND WILLIAMS D I Clinical uses of 2,3-dimercaptopropanol (BAL) VI The treatment of complications of arsenic therapy with BAL (British Anti Lewinite) *J Clin Investigation* 25:497 1946
- 179 GILMAN A L PHILLIPS F S ALLEN R. P AND KOELLE, E S The treatment of acute cadmium intoxication in rabbits with 2,3 dimercaptopropanol *J Pharmacol & Exper Therap* 87:85 1946
- 180 PERRY H M JR AND SCHROEDER H A Depression of cholesterol levels in human plasma following ethylenediamine tetraacetate and hydralazine *J Chronic Dis* 2 520 1955
- 181 PERRY H M JR AND SCHROEDER H A Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetraacetate *Am J Med*, 22 168 1957
- 182 SCHROEDER H A MENTHARD E M AND PERRY H M Jr. The antihypertensive properties of some mercaptans and other sulfur containing compounds. *J Lab & Clin Med* 45:431, 1955
- 182b SCHROEDER H A The antihypertensive influence of certain sulfhydryl compounds *Science*, 114 441 1951
- 183 SCHROEDER H A, MENTHARD E. M AND PERRY H M Jr. Anti hypertensive effects of metal binding agents *J Lab & Clin Med* 46:416 1955
- 184 DUSTAN H P TAYLOR R. D CORCORAN A C AND PAGE I A

tous embolization with emphasis on an etiology of renal hypertension *Am J Med* 20:366 1956

- 214 CONCORAN A. C. TAYLOR, R. D., AND PAGE, I. H.. Functional patterns in renal disease *Ann Int Med* 28:560 1948
- 215 SNELL, E. E.. Summary of known metabolic functions of nicotinic acid riboflavin and vitamin B₆ *Physiol Rev* 33:309 1953
- 216 SELYE, H.. The role of the adrenal cortex in the pathogenesis of experimental hypertension in *Hypertension a Symposium* edited by Bell E. T. Minneapolis Univ Minnesota Press 1951 pp 119-132.
- 217 BRAUN MENÉNDEZ E.. The mechanism of hypertension due to desoxycorticosterone in *Hypertension a Symposium* edited by Bell E. T. Minneapolis Univ Minnesota Press 1951 pp 133-146
- 218 MASSON G. M. C. LEWIS L. A. CONCORAN A. C. AND PAGE I. H. Desoxycorticosterone in rabbits. Simulation of rabbit "toxemia of pregnancy" *J Clin Endocrinol* 13:500 1953
- 218a RENZI A. A. AND GAUNT R.. Effect of Apresoline (1-hydrazinophthalazine) on the experimental eclampsia like syndrome and on related aspects of water metabolism *Federation Proc.* 13:360 1953
- 218c RENZI A. A. AND GAUNT R. Apresoline (1-hydrazinophthalazine) in the experimental eclampsia like syndrome and related aspects of water metabolism *Am J Physiol* 175:313 1953
- 218d GAUNT R. ANTONCHAK N. MILLER G. J. AND RENZI A. A. Effect of reserpine (serpasil) and hydralazine (apresoline) on experimental steroid hypertension. *Am J Physiol* 187:63 1953
- 219 SAPIRSTEIN L. A. BRANDT W. L. AND DARY D. R. Production of hypertension in the rat by substituting hypertonic sodium chloride solutions for drinking water *Proc Soc Exper Biol & Med* 73:87 1950
- 220 GOLDMAN M. L. KRIS J. H. SCHROEDER H. A. AND DAVIES D. F. The relation of the kidney to the acute pressor action of desoxy corticosterone *Am J M Sc* 222:257 1951
- 221 GOLDMAN M. L. AND SCHROEDER, H. A. The immediate pressor effect of desoxycorticosterone acetate *Science* 107:272 1948
- 221b GOLDMAN M. L. AND SCHROEDER, H. A. Immediate pressor effect of desoxycorticosterone acetate in arterial hypertension. *Am J Med* 5:33 1948
- 222 GOLDMAN M. L. KONZOVIT H. AND SCHROEDER, H. A. The response of the adrenal cortex of the rat to dietary salt restriction and replacement. *Endocrinology* 38:57 1956
- 222b SCHROEDER H. A. Edema in *Signs and Symptoms* edited by C. M. MacBryde Philadelphia Lippincott 1951

- 198 HOCHBERG M MELNICK, D AND OSER B L On the stability of pyridoxine *J Biol Chem* 155 129 1944
- 199 IVES M POLLARD A E ELVERJEM C A AND STRONG F M The nutritive value of canned foods XVII Pyridoxine biotin and folic acid *J Nutrition*, 32 347, 1946
- 200 TOMARELLI R. M SPENCE E. H AND BERNHART F W The biological availability of vitamin B₆ of heated milks *Agric and Food Chem* 3 338 1945
- 200b DAY, P L AND DINNING J S Vitamin E Deficiency in the Young Rhesus Monkey Resume of Communications Third International Congress of Biochemistry 1955 p 116
- 201 Studies on the Vitamin Content of Tissues II The B Vitamin Content of Foods Austin University of Texas Pub 4237 1942
- 202 SCHROEDER H A Is atherosclerosis a conditioned pyridoxal deficiency? *J Chronic Dis* 2:28 1955
- 203 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B₆ metabolism in pregnancy *J Lab & Clin Med* 40 550 1952
- 204 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B₆ metabolism in pregnancy II The influence of various amounts of pyridoxine hydrochloride upon the abnormal tryptophane load test in pregnant women *J Lab & Clin Med* 42:98 1953
- 205 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B₆ metabolism in pregnancy III Abnormal vitamin B₆ load test *Am J Obst & Gynec* 66 1207 1953
- 206 REGISTER U D LEWIS U J RUEGAMER W R AND ELVERJEM C A Studies on the nutritional adequacy of army combat rations *J Nutrition* 10:281 1950
- 207 TAPPAN D V AND ELVERJEM C A Observations on the nutrition of rhesus monkeys receiving highly processed rations *J Nutrition* 51 469 1953
- 208 MOLONY C J AND PARMELEE A H : Convulsions in young infants as a result of pyridoxine (vitamin B₆) deficiency *J.A.M.A.*, 154 405 1954
- 209 COURVIN H H : Convulsive seizures in infants with pyridoxine deficient diet *J.A.M.A* 154 406 1954
- 210 HOLLEY H L ELLIOTT H C JR AND HOLLAND C M JR Serum sodium values in essential hypertension *Proc Soc Exper Biol & Med* 77 561 1951
- 211 JOHNSON L L SHAW C W GALEN W P AND HOLLEY H L Cerebrospinal fluid sodium values in essential hypertension *J Lab & Clin Med* 41 287 1953
212. TOBIAN L JR AND BINION J Tissue cations and water in arterial hypertension *Circulation* 5:754 1952
- 213 HANDLER F E : Clinical and pathologic significance of arterioma

234. BAKER, J. *Chemistry of Coordinate Compounds* New York Reinhold, 1956
- 235 WILLIAMS R. P. J. Metal ions in biological systems *Biol Rev.* 25 331 1953
- 236 NAJJAR, V. The role of metal ions in enzyme systems in *Phosphorus Metabolism* Vol. I McElroy W D and Glass B., editors Baltimore Johns Hopkins Press 1951 pp 500 520
- 237 METZLER, D. E., ISAWA, M. AND SWELL, E. E. A general mechanism for vitamin B₁₂-catalyzed reactions *J Am Chem Soc* 76 648 1954
- 238 VALLEE, B. L. Zinc and metallo-enzymes in *Advances in Protein Chemistry* Vol. X. New York Interscience 1955
- 239 HAMILTON J. G. AND SOLEY M. H.. Comparison of metabolism of iodine and of element 83 (eka iodine) *Proc Nat Acad Sc* 6483 1940
- 240 BAUMAN E. J., ZIMMER, W., OSHRY E., AND SEMLIN S. M. Behavior of thyroid toward elements of seventh periodic group rhenium. *Proc Soc Exper Biol & Med* 72 502 1949
- 241 BAUMAN E. J. SEARLE N. Z., YALOW A. A. STICKEL E. AND SEMLIN S. M. Behavior of thyroid toward elements of seventh periodic group technetium *Federation Proc* 11 184 1952
- *42 RAY T. W. AND DRYGACH L. J. Storage of manganese by thyroid Effect on oxygen consumption of guinea pig *Proc Soc Exper Biol & Med.* 51 228 1942
- 243 GURD F. R. N. The specificity of metal protein interactions in *Ion Transport Across Membranes* edited by H. T. Clarke New York Acad Press 1954
- 244 RAY C. T. THREEFOOT S., AND BURCH G. E. A study of the use of Rb⁸⁶ as a tracer for measurement of Rb⁸⁶ and K⁴⁰ space and mass in intact man with and without congestive heart failure *J Clin Investigation* 33 9, 7 1954
- 245 COLOWICK, S. P. AND KAPLAN H. D. *Methods in Enzymology* Vol. I New York Acad Press 1955
- 246 LEVNER, A. B. Metabolism of phenylalanine and tyrosine in *Advances in Enzymology* Vol. III Nord F. F. editor New York Interscience 1953 pp 73 124
- 247 LEVNER, A. B., AND FITZPATRICK, T. B.. Biochemistry of melanin formation *Physiol Rev.* 30-91 1950
- 48 CURRAN C. L. Effect of certain transition group elements on hepatic synthesis of cholesterol in the rat. *J Biol Chem* 210 763 1954
- *49 FOREMAN H. YER, M. AND MAGER M. The metabolism of C¹⁴-labelled ethylenediaminetetraacetic acid in the rat. *J Biol Chem* 203 1045 1953

- 222c SCHROEDER H A Studies on congestive circulatory failure III The relation of edema to urinary chlorides *Circulation* 2481 1950
- 222d SCHROEDER H A Low salt diets and arterial hypertension *Am J Med* 4578 1948
- 222e FUTCHER P H AND SCHROEDER H A Studies on congestive heart failure II Impaired renal excretion of sodium chloride *Am J M Sc* 20452 1942
- 223 OLSEN N S Chemical changes in experimental renal hypertension *Am J Physiol* 164448 1950
- 224 LANDIS E AND ABRAMS M I Salt choices by hypertensive rats in *Factors Regulating Blood Pressure* Transactions of the First Conference edited by Zweifach B W and Shorr ■ New York Macy 1947 p 68
- 225 ROWNTREE L G AND SNELL A M *A Clinical Study of Addison's Disease* Philadelphia Saunders 1931
- 226 RAMEY E R GOLDSTEIN M S AND LEVINE R Action of nor epinephrine and adrenal cortical steroids on blood pressure and work performance of adrenalectomized dogs *Am J Physiol* 163450 1951
- 227 DAVIS A K BASS A C AND OVERMAN R R Comparative effects of cortisone and DCA on ionic balance and fluid volumes of normal and adrenalectomized dogs *Am J Physiol* 166493 1951
- 228 GAUDINO M AND LEVITT M F Influence of the adrenal cortex on body water distribution and renal function *J Clin Investigation* 281487 1949
- 229 LORENTE DE NO R On the effect of certain quaternary ammonium ions upon frog nerve Parts I & II *J Cell & Comp Physiol* (Supplement) 33 July 1949
- 230 GENEST J LENIZUX G DAVIGNON A KOIW E NOWACZYNSKI W AND STEYERMARK P Human arterial hypertension A state of mild chronic hyperaldosteronism? *Science* 123503 1956
- 231 TIPTON I H STEINER E L FOLAND W D MUELLER J AND STANLEY M Spectrographic analysis of the tissues from autopsies of twenty four instantaneous deaths Oak Ridge National Laboratory Report C F 541266 Dec 10 1954
- 232 SCHUBERT J Interactions of metals with small molecules in relation to metal protein complexes in *Chemical Specificity in Biological Interactions* edited by Gurd F R N New York Acad Press 1954
- 233 MARTELL A E AND CALVIN M *Chemistry of the Metal Chelate Compounds* New York Prentice Hall 1952

- 251 LEHNINGER, A. L. Role of metal ions in enzyme systems *Physiol Rev.* 30 393 1950
- 252 BERTRAND D. Distribution of vanadium among the invertebrates and vertebrates *Bull Soc chim biol* 25:35 1943
- 253 BERTRAND D. Vanadium as an essential trace element for *Aspergillus niger* *Ann Inst Pasteur* 63:226 1942.
- 254 BERTRAND D. Vanadium in fungi, especially *Aspergillus*. *Bull Soc chim biol* 31 194 1943
- 255 BERTRAND D. Distribution of vanadium in plants. *Compt rend Acad sc.* 212 11 0 1941
- 256 BERNHEIM F. AND BERNHEIM M. L. C. The effect of titanium on the oxidation of sulphydryl groups by various tissues. *J Biol Chem* 127:69, 1939
- 257 PERRY H. M., JR. SCHROEDER H. A., AND PERRY B. F., Abnormally high urinary cadmium and manganese in hypertensive patients *Proc Soc Exper Biol & Med* 1957 (in press)
- 258 BERNHEIM F., AND BERNHEIM M. L. C. The action of vanadium on the oxidation of phospholipids by certain tissues *J Biol Chem* 127 353 1939
- 259 BERNHEIM F., AND BERNHEIM M. L. C., Note on the action of manganese and some other metals on the oxidation of certain substances by liver *J Biol Chem.* 123:79 1939
- 260 JACKSON D. E. The pharmacologic actions of vanadium *J Pharmacol & Exper Therap* 3 477 1912
- 261 PERRY H. M., JR. TESTERBAUM S. AND SCHWARTZ F. L. Effects of antihypertensive agents on amino acid decarboxylation and amine oxidation *Federation Proc* 14 113 1955
- 262 MYERS V. C. AND MCEL J. W. The influence of the administration of aluminum upon the aluminum content of the tissues and upon the growth and reproduction of rats *J Biol Chem* 78:605 1973
- 263 MYERS V. C., AND MCEL, J. W. The aluminum content of human autopsy tissue *J Biol Chem* 78:625 1973
- 264 MYERS V. C., AND MORRISON D. B., The influence of the administration of aluminum content of the tissues of the dog *J Biol Chem.* 78:615 1973
- 265 CURRAN G. L., AND COSTELLO R. L. Reduction of excess cholesterol in the rabbit aorta by inhibition of endogenous cholesterol synthesis *J Exper Med* 103 49 1956
- 266 SINGH S. I., AND SINGH I. The action of lead on unstriated muscle and blood vessels and its relation to hypertension *Proc Indian Acad Sc* 42:62 1956
- 267 BARRATT H. M., IRWIN D. A., AND SEMMONS F., Studies on the

- 250 FOREMAN H AND TRUJILLO T T The metabolism of C¹⁴ labeled ethylenediaminetetra acetic acid in human beings *J Lab & Clin Med* 43 566 1954
- 251 STOCKEN L A AND THOMPSON R H S Reactions of british anti lewisite with arsenic and other metals in living systems *Physiol Rev* 29 168 1949
- 252 ALEXANDER H L *Reactions with Drug Therapy* Philadelphia Saunders 1955
- 253 *The Merck Index of Chemicals and Drugs* 6th Ed Rahway NJ Merck & Co 1952
- 254 *Bibliography of the Literature on the Minor Elements and Their Relation to Plant and Animal Nutrition* 4th Ed Vols I II III. New York Chilean Nitrate Educational Bureau Inc. 1948
- 255 VINOGRADOV A P *The Elementary Chemical Composition of Marine Organisms* Memoir 2 Sears Foundation For Marine Research New Haven Yale 1953
- 256 MONIER WILLIAMS G W *Trace Elements in Food* New York, Wiley 1949
- 257 MITCHELL M L The spectrographic analysis of soils plants and related materials Commonwealth Bureau of Soil Science Tech Com 44 Harpenden England 1948
- 258 TIPTON I H FOLAND W D BOBB F C AND MCCORKLE, W C Spectrographic determination of trace elements in human tissues Oak Ridge National Laboratory Report C F 53 84 March 11 1953
- 259 TIPTON I H COOK M J STEINER R S FOLAND W D BOWMAN D K AND McDANIEL, K K Spectrographic analysis of tissues for trace elements Oak Ridge National Laboratory Report C F 56 3 00 March 12 1956
- 260 GRIFFITH C G BUTT E M AND WALKER J The inorganic element content of certain human tissues *Ann Int Med* 41 501 1954
- 261 MARSTON H R Cobalt copper and molybdenum in the nutrition of animals and plants *Physiol Rev* 32 66 1952
- 262 LEGOFF J M Cobalt as a vasodilator *J Pharmacol & Exper Therap* 38 1 1930
- 263 MOORE C V A Iron and the essential trace elements in *Modern Nutrition in Health and Disease* edited by M G Wohl and R S Goodhart Philadelphia Lea & Febiger 1955 pp 220 255
- 264 TUCKER H F AND SALMOV W B Parakeratosis or zinc deficiency disease in the pig *Proc Soc Exper Biol & Med* 88 613 1955
- 265 HOVE E ELVEHJEM C A AND HART E B Physiology of zinc in nutrition of rat *Am J Physiol* 119 768 1937
- 266 TIPTON I H Personal communication

- 7 DOMAR, G. FREIDA A., AND LINDBERGH H. A method for quantitative determination of tetraethylthiuram disulphide (antiabuse abstunyl) and its reduced form diethylthiocarbamic acid as found in excreta *Acta chem scandinau* 3 1441 1949
- 98 DuBois K. P., COCHRAN K. W., AND MAZUR, M. Inhibition of phosphatases by beryllium and antagonism of the inhibition by manganese. *Science* 110 470 1949
- 99 BOWEN W. J., AND KERWIN T. D. A study of the effects of ethylene diaminetetraacetic acid on myosin adenosinetriphosphatase *J Biol Chem.* 211:237 1954
- 00 SMITH E. L., AND SPACKMAN D. H. Leucine amino-peptidase. V. Activation, specificity and mechanism of action *J Biol Chem.* 212:771 1955
- 01 HANSEN H. T., AND SMITH E. L. Carnosinase. An enzyme of swine kidney *J Biol Chem.* 179:789 1949
02. WEINAND H. AND MITCHELL, W. Ueber den Mechanismus der Oxydationsvorgänge XXIX. *Liebigs Ann Chem.* 494 156 1932.
- 03 MARLER, H. R., MACKENZIE, B., GAZEN D. E., AND BOCK R. M. Studies on metalloflavoproteins III. Aldehyde oxidase. A molybdo-flavoprotein *J Biol Chem* 210 465 1954
04. WALLACH H.. Certain aspects of intermediary metabolism of glutamine asparagine and glutathione in *Advances in Enzymology* Vol. 18 Nord, F. F., editor New York Interscience 1952 pp 37 315
- 05 SMITH E. L. The specificity of certain peptidases in *Advances in Enzymology* Vol. 12 Nord F. F., editor New York, Interscience 1951 pp 191 207
- 06 SMITH E. L. The glycylglycine dipeptidases of skeletal muscle and human uterus. *J Biol Chem* 173:571 1948
- 07 VALLEE B. L. AND ALTSCHULE, M. D.. Zinc in the mammalian organism with particular reference to carbonic anhydrase *Physiol Rev* 29:3,0 1949
- 08 PERAY H. M. JR., SCHROEDER, H. A., AND FREDERICKSON A. F.. Urinary trace metals from normal and treated and untreated hypertensive patients *J Lab & Clin Med* 44:907 1954
- 09 PERAY H. M. JR. AND SCHROEDER, H. A. Concentration of trace metals in urine of treated and untreated hypertensive patients compared with normal subjects *J Lab & Clin Med* 46:936 1955
- 10 PERAY H. M. JR., AND SCHROEDER, H. A. Comparison of the concentration of several trace metals in the urine of treated and untreated malignant hypertensive patients as compared with normal individuals *Circulation* 1 738 1955

- toxicity of inhaled cadmium I The acute toxicity of cadmium oxide by inhalation *J Indust Hyg & Toxicol* 29:279 1947
- 283 BARRETT H M AND CARD B L Studies on the toxicity of inhaled cadmium II The acute lethal dose of cadmium oxide for man *J Indust Hyg & Toxicol* 29:286 1947
- 284 PATERSON J C Studies on the toxicity of inhaled cadmium III The pathology of cadmium smoke poisoning in man and in experimental animals *J Indust Hyg & Toxicol* 29:294 1947
- 285 HARRISON H E BUYTING H ORDWAY N A AND ALBRINK W S The effects and treatment of inhalation of cadmium chloride aerosols in the dog *J Indust Hyg & Toxicol* 29:302 1947
- 286 WILSON R H DeEDS F AND COX A J JR Effects of continued cadmium feeding *J Pharmacol & Exper Therap* 71:222 1941
- 287 FRIBERG L Proteinuria and kidney injury among workmen exposed to cadmium and nickel dust *J Indust Hyg & Toxicol* 30:52 1948
- 287b FRIBERG L Health hazards in the manufacture of alkaline accumulators with special reference to chronic cadmium poisoning *Acta med scandinav* 240 Supplement pp 7-124 1950
- 288 CLARKSON T W AND KENCH J E Urinary excretion of amino acids by men absorbing heavy metals *Biochem J* 52:361 1956
- 289 FRANT S AND KLEEMAN I Cadmium food poisoning *JAMA* 117:86 1941
- 290 FORBES R M COOPER A R AND MITCHELL H H On the occurrence of beryllium boron cobalt and mercury in human tissues *J Biol Chem* 209:857 1954
- 291 KLEIN R AND HARRIS S B Treatment of scleroderma sclerodactylia and calcinosis by chelation (EDTA) *Am J Med*, 19:798 1955
- 292 SCHREINER A W SLINGER W HAWKINS V R AND VILTER R W Seborrheic dermatitis a local metabolic defect involving pyridoxine *J Lab & Clin Med*, 38:948 1951
- 293 FORBES R M COOPER, A R AND MITCHELL, H H The composition of the adult human body as determined by chemical analysis *J Biol Chem* 203:359 1953
- 294 PITT RIVERS R Mode of action of antithyroid compounds. *Physiol Rev*, 30:194 1950
- 295 CALVIN M KLOTZ I M SMITH E L DAVIS N C., ADAMS E AND SPACKMAN D H *The Mechanism of Enzyme Actions* Mc Elroy W D and Glass B editors Baltimore John Hopkins Press 1954 pp 221-320
- 296 LEWIN E. AND HIRSCH J G Studies on the stability of isoniazid *Am Rev Tuberc*, 71:732 1955

- relationship to human arteriosclerosis *Arch Path* 20:81 123 253-304 1935
- 374 GREENBERG L. D., AND RYERHART J. F. Plasma cholesterol levels of cholesterol fed control and pyridoxine deficient monkeys *Proc Soc Exper Biol & Med.* 76, 80 1951
- 375b. RYERHART J. F., AND GREENBERG L. D., Arteriosclerotic lesions in pyridoxine-deficient monkeys *Am J Path.* 25 481 1949
- 375 RYERHART J. F. AND GREENBERG L. D. Pathogenesis of experimental arteriosclerosis in pyridoxine deficiency With notes on similarities to human arteriosclerosis *Arch Path.* 11 12 1951
- 376 MURPHY C. W., AND EMERSON C. A. Arteriosclerosis in pyridoxine-deficient monkeys and dogs *Federation Proc* 15:526 1956.
- 377 ASCHOFF L. *Lectures on Pathology* New York Hoeber 1954 p 131
- 378 MORAY K. Z. AND MORAY, R. H. Morphologic and histochemical studies on the development and progression of arteriosclerosis *Circulation* 1 484 1950
- 379 STONE J. P. MCGILL, H. C. JR., CARTER O. R., AND HOLMAN R. L. Natural history of aortic atherosclerosis, ages 1 to 40 *Federation Proc.* 15 535 1956
- 380 ANDRUS S. B. MANN G. V. FILLION L. C., AND STARR, F. J. Early histologic changes in experimental atherosclerosis. *Federation Proc* 15:342 1956
- 381 CURRAN G. L., AND CLUTE, O. L. Effect of cations on cholesterol synthesis by surviving rat liver *J Biol Chem* 212:13 1953
- 382 ROOSKE, K. Studies on the Blood and Blood Pressure in the Eskimo and the Significance of Ketosis under Arctic Conditions *Norsk Polarvitenskabeligt Skrift Nr 102 Oslo 1954*
- 383 LASSER N. ■ Stress and the aging circulation *Am Pract & Digest Treatment* 6 1681 1955
- 384 KICZYNSKI B., Pathologische-geographische Untersuchungen in der Kurzeschlagungsartigen Seeppe. *Klin Wchnschr* 4 39 1923
- 385 CLAWSON B. J. The heart in essential hypertension in *Hypertension A Symposium* edited by Bell E. T. Minneapolis Univ Minnesota Press 1951 pp 39-53
- 385b. GOLDSTEIN F. JENSEN B. K. WALSHOW J. M. AND DUNCAN C. G. The relationship between hypertension and coronary occlusion *Ann Int Med* 44 446 1956
- 386 HOLMAN R. L. Necrotizing arteritis in dogs produced by a combination of high fat diet experimental renal insufficiency in *Factors Regulating Blood Pressure Transactions of the Fourth Conference* ed. by Zweiback B. W., and Short E. New York, Macy 1950 p 150
- FILLION L. C., ANDRUS S. B., MANN G. V., AND STARR F. J. Experimental atherosclerosis in the rat. *Federation Proc* 15 550 1956

- 311 SCHROEDER H A AND PERRY H M JR. Essential and abnormal trace metals in cardiovascular diseases in *Proceedings of the Annual Meeting Council For High Blood Pressure Research American Heart A.*, 1955
- 312 SCHROEDER H A Trace metals and chronic diseases in *Advances in Internal Medicine* edited by Dock W and Snapper I Chicago Yr Bk Pub 1956 Vol VIII pp 259-299
- 313 PERRY H M JR. Personal communication
- 314 FRIEDMAN M ROSEMAN R H AND BYERS S O Deranged cholesterol metabolism and its possible relationship to human atherosclerosis A review *J Gerontol* 10:60 1955
- 315 DE SUTO NAGY G I AND WATERS L L The effect of altered lipid metabolism on experimental lesions of the coronary arteries. *Circulation* 4:468, 1951
- 316 COWDREY E V. *Arteriosclerosis* New York Macmillan 1933
- 317 KATZ L N Studies on experimental atherosclerosis and hypertension in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 174
- 318 WILENS S L Orthostatic influences on the distribution of atheromatous lesions in the cerebral and other arteries *Arch Int Med* 82:431 1948
- 319 CORCORAN A C PAGE I H DUSTAN H P AND LEWIS L A Atherosclerotic complications of hypertensive disease Relation to therapeutic response and to serum protein and to lipoprotein concentrations preliminary report *Cleveland Clin Quart* 23:115 1956
- 319b Dock, W Blood flow blood pressure and intimal thickness as factors in localizing atheroma formation in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 129
- 320 ANITSCHKOW N Experimental arteriosclerosis in animals in *Arteriosclerosis* Cowdrey E V New York Macmillan 1933 pp 271-322
- 321 WISLER R W ALLEN R F MOY R H AND BRADFORD W L Role of arterial and renal injury in production of atheromatous lesions in coronary arteries of the rat under various dietary conditions *Federation Proc* 15:539 1956
- 322 WAKERLIN G E MOSS W G NEVILLE J B AND BOURQUE J E. Effect of experimental renal hypertension on experimental cholesterol atherosclerosis in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 193
- 323 DUFF G L Experimental cholesterol arteriosclerosis and its re

- ships in human plasma atherosclerosis and related conditions.
Am J Med 11 480 1951
- 355 BARR, D D Influence of sex and sex hormones upon the development of atherosclerosis and upon the lipoproteins of plasma *J Chronic Dis* 1:63 1955
- 356 KATZ, L. N., AND STAMLER, J *Experimental Atherosclerosis* Springfield, Thomas 1953
- 357 KEYS A The physiology of the individual as an approach to a more quantitative biology of man. *Federation Proc.* 8 523 1949
- 358 KEYS A ANDERSON J T., MICKELSEN O Serum cholesterol in men in basal and nonbasal states *Science* 123:29 1956
- 358b LEE T M., KARYVAKIS E., AND IVY A. C. Absorption of dietary cholesterol in man *Federation Proc* 15 120 1956
- 359 TURNER, K. B. AND STEINER, A A long term study of the variation of serum cholesterol in man. *J Clin Investigation* 18 45 1939
- 360 DEUEL, H. J JR. *The Lipids* Vol 2 New York Interscience 1955
- 361 AFTERGOOD L., ALFEN SLATER, R. B., AND DEUEL, H. J., JR. Comparative effect of cottonseed oil and lard on cholesterol metabolism in the rat. *Federation Proc* 15:541 1956
- 362 LANGDON R. G III Some aspects of cholesterol metabolism related to atherosclerosis in *Fat Metabolism* edited by Najjar V A Baltimore Johns Hopkins Press 1954 pp 162 181
- 363 KINSELL, L. W MICHAELS G H COCHRAN G C., PARTRIDGE J W., JAFFE J J AND BALCH H E. Effect of vegetable fat on hypercholesterolemia and hyperphospholipidemia. *J Am Diabetes A.* 3 113 1954
- 364 KINSELL, L. W Personal communication
- 365 FRISKEY R. W., MICHAELS G H AND KINSELL, L. W Observations regarding the effects of unsaturated fats *Circulation* 11 492 1955
- 366 JONES R. J AND REISS H K. The hypocholesteremic effect of a hot alcoholic extract of brain in hypercholesteremic patients. *Circulation* 12 496 1955
- 367 ANDREWS E. H., JR. TAALAS T. T., HIRSCH J., AND INSULL, W., JR. Effects of dietary fats on the serum lipides of human subjects *J Clin Investigation* 34:918 1955
- 368 BEVERIDGE, J. M. R., CONNELL, W. F AND MAYR, C. Further studies on dietary factors affecting plasma lipid levels in humans. *Circulation* 12 499 1955
- 369 PETERSON D. W., NICHOLS C. W., JR., PEEK, N. F AND CHAIKOFF I. L. Depression of plasma cholesterol in human subjects consuming butter containing soy sterols. *Federation Proc* 15:569 1956
- 370 TULFULE, P. G., AND PATWARDHAN V. N. The effect of fat and

- 338 TOOR M AGMOY J AND ALLALOUF D Changes of serum total lipids total cholesterol and lipid phosphorus in Jewish yemenite immigrants after 20 years in Israel *Bull Res Council Israel* 4 202 1954
- 339 PAGE I H KIRK E LEWIS W H JR THOMPSON W R AND VAN SLYKE D D Plasma lipids of normal men at different ages *J Biol Chem* 111 613 1935
- 340 BOYD E M Diurnal variations in plasma lipids *J Biol Chem* 110 61 1935
- 341 WILEMS S L Bearing of general nutritional state on atherosclerosis *Arch Int Med* 79 129 1917
- 342 HUEPER W C Experimental studies in cardiovascular pathology thesaurosis and atheromatosis produced in dogs by repeated intravenous injection of sodium cellulose glycollate *Am J Path* 21 1021 1945
- 343 HUEPER W C Atheromatosis in dogs following repeated intravenous injections of hydroxy ethyl cellulose *Arch Path* 41 139 1946
- 344 WINDAUS A Über den Gehalt normaler und atheromatöser Aorten an Cholesterin und Cholesterinestern *Ztschr physiol Chem* 67 174 1910
- 345 SCHÖNHEIMER R Zur Chemie der gesunden und der atherosklerotischen Aorta Über die quantitativen Verhältnisse des Cholesterins und der Cholesterinester *Ztschr physiol Chem* 160 61 1926
- 346 LEARY T Crystalline ester cholesterol and atherosclerosis *Arch Path* 47 1 1949
- 347 MORRISON L M AND JOHNSON K H Cholesterol content of coronary arteries and blood in acute coronary artery thrombosis *Am Heart J* 39 31 1950
- 348 DEUEL H J JR The Lipids Vol 1 New York Interscience 1931
- 349 WITTEN P W AND HOLMAN R T Polyethenoid fatty acid metabolism VI Effect of pyridoxine on essential fatty acid conversions *Arch Biochem & Biophys* 41 266 1952
- 350 COFMAN J W Lipoproteins and atherosclerosis in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 48
- 351 KEYS A Giant Molecules and Cholesterol in Relation to Atherosclerosis *Bull Johns Hopkins Hosp* 38 473 1951
- 352 FURMAN R H Atherosclerosis and lipoproteins *South M J* 48 6 1955
- 353 HACK M H Some properties of human serum lipoproteins *Proc Soc Exper Biol & Med* 91 92 1956
- 354 BARR D F RUSS E M AND EDER H A Protein lipid relation

- cholesterol changes in nephrectomized dogs maintained by peritoneal dialysis *Federation Proc.* 15 118 1956
- 386 ANDERSON J T., TAYLOR H L. AND KEYS A. Serum cholesterol in subjects on reducing diets high and low in fat. *Federation Proc.* 15 540 1956
- 387 KATSKY V. L., CORNWELL, H. G., AND O'NEIL J. L. Vitamin A carotenoids and plasma lipoproteins *Federation Proc.* 15 115 1956
- 388 SCHROEDER, H. A. Rapid spontaneous variations in blood pressure *Federation Proc.* 8 1 1949
- 389 WAGNER, H. P., AND KATZ N. M. Diffuse arteriolar disease with hypertension and the associated retinal lesions. *Medicine* 18 317 1939
- 390 HILSON E. H. Estimation of catechol amines in urine by means of a rabbit aortic strip as an aid to the diagnosis of pheochromocytoma *J Lab & Clin Med* 46 871 1955
- 391 SCHROEDER H. A. Studies on essential hypertension IV Early arterial hypertension *Am J M Sc* 204 62 1942.
- 392 PERAZA, G. A. Hypertensive vascular disease: Therapeutic principles and objectives *J Chronic Dis* 1 472 1955
- 393 SCHROEDER H. A. STEELE, J. M. Studies in "essential" hypertension II The association of hypertension with organic renal disease *Arch Int Med* 68 261 1911
- 394 SCHROEDER, H. A. AND STEELE, J. M. Abnormalities of the urinary tract in "essential" hypertension. *Proc Soc Exper Biol & Med* 39 107 1938
- 395 GROPPER, A. L., SUTHERN S. AND HEDRICK, J. T. Effects on essential hypertension of veratrid A new derivative of *veratrum viride* *Arch Int Med* 87 789 1951
- 396 SCHROEDER, H. A. Hydralazine (Apresoline) in the control of severe hypertension *Practitioner* 173 195 1954
- 397 SCHROEDER, H. A. Renal failure associated with low extracellular sodium chloride The low salt syndrome *J.A.M.A.*, 141 117 1949
- 398 SCHROEDER H. A. GOLDMAN M. L. FUTCHER, P. H., AND HUNTER, W. Low sodium chloride diets in hypertension. *J.A.M.A.*, 140 4, 8 1949
- 399 SCHROEDER H. A. FUTCHER P. H., AND GOLDMAN M. L. The effects of the "rice diet" upon the blood pressure of hypertensive individuals *Ann Int Med* 30 715 1949
- 400 SCHROEDER H. A. AND PERRY H. M. JR. Errors in the evaluation of hypertension *Am Heart J.* 51 716 1956
- 401 SCHROEDER, H. A. The effect of 1 hydrazinophthalazine and hexamethonium on hypertension *J Lab & Clin Med* 38 919 1951
- 402 SCHROEDER, H. A. Control of hypertension by hexamethonium and

pyridoxine deficiencies on rat liver dehydrogenases *Arch Biochem & Biophys* 39 450 1952

- 371 SCHROEDER H A AND PERRY H M JR. Cholesterol lowering action of metal binding agents in man *Circulation*, 12 494 1955
- 372 PERRY H M JR AND SCHROEDER H A The effect of two metal binding agents on plasma cholesterol in man *Circulation* 12 759 1955
- 373 UHL, H S M BROWN H H ZLATIS A ZACK B MYERS G B AND BOYLE A J Effect of ethylenediamine tetraacetic acid on cholesterol metabolism in rabbits Preliminary report on effect of parenteral and oral administration of disodium and calcium salts *Am J Clin Path* 23 1226 1953
- 374 ROSENMAN R H AND SMITH M L The effect of certain chelating substances (EDTA) upon cholesterol metabolism in the rat *J Clin Investigation* 35 11 1956
- 375 CURRAN G L Metal chelating agents and hepatic cholesterol synthesis *Proc Soc Exper Biol & Med* 88 101 1955
- 376 RUBIN M MARTELL A E AND BERSWORTH F C *The Biological Actions of the Versenes* Framingham Mass Versenes Inc. 1954
- 377 WILKINSON C F JR. JACKSON R S BOZIAN R C BENJAMIN M R LEVERE A H CRAFT G AND DAVIDSON N W II Clinical experience with sitosterols *Tr New York Acad Sc* 18 119 1955
- 378 BOSE J P AND DE U N Cholesteremia in normal and diabetic Indian subjects *Indian J M Research* 24 489 1936
- 379 BOYD T C AND RAY A C Notes on cholesterol content of Indian blood in health and leprosy *Indian J M Research* 15 643 1928
- 380 GHOSH A C Cholesterol content of blood in Indians and its significance in jaundice *Indian J M Research* 20 883 1933
- 381 CORCORAN A C AND RABINOWITCH I M A study of the blood lipoids and blood protein in Canadian Eastern Arctic Eskimos *Biochem J* 31 343 1937
- 382 WALKER A R F AND ARVIDSSON U B Fat intake serum cholesterol concentration and atherosclerosis in the South African bantu Part I Low fat intake and the age trend of serum cholesterol concentration in the South African bantu *J Clin Investigation* 33 1358 1954
- 383 KEYS A VIVANCO F RODRIGUEZ MINON J L KEYS M H AND MENDOZA H C Studies on the diet body fatness and serum cholesterol in Madrid Spain *Metabolism* 3 195 1954
- 384 *Vitamin B₁₂—Selected Annotated Bibliography* Rahway N J Merck & Co Inc. 1954
- 385 LEWIS L A KOLFF W J AND PAGE I H Serum lipoprotein and

- cholesterol changes in nephrectomized dogs maintained by peritoneal dialysis *Federation Proc.* 15 118 1956
- 386 ANDERSON J T., TAYLOR H L. AND KEYS A Serum cholesterol in subjects on reducing diets high and low in fat. *Federation Proc* 15:512 1956
- 387 KATSKY N L., CORNWELL, D G., AND O'NELEY J L. Vitamin A carotenoids and plasma lipoproteins *Federation Proc* 15 113 1956
- 388 SCHROEDER, H A. Rapid spontaneous variations in blood pressure *Federation Proc* 8 1 1949
- 389 WAGENER, H P AND KEITH N M. Diffuse arteriolar disease with hypertension and the associated retinal lesions *Medicine* 18:317 1949
- 390 HELMER, O M Estimation of catechol amines in urine by means of a rabbit aortic strip as an aid to the diagnosis of pheochromocytoma *J Lab & Clin Med* 46:871 1955
- 391 SCHROEDER, H A Studies on essential hypertension IV Early arterial hypertension *Am J M Sc.*, 204:67 1942.
- 392 PERERA G A Hypertensive vascular disease: Therapeutic principles and objectives *J Chronic Dis.*, 1 472 1952
- 393 SCHROEDER H A STEELE, J M Studies in "essential" hypertension II. The association of hypertension with organic renal disease *Arch Int Med* 68:261 1941
- 394 SCHROEDER, H A., AND STEELE, J M Abnormalities of the urinary tract in essential hypertension *Proc Soc Exper Biol & Med.*, 39 107 1938
- 395 GROPPER, A L SIKTSHIN S AND HEDRICK J T Effects on essential hypertension of veratoid A new derivative of *veratrum viride* *Arch Int Med* 87:789 1951
- 396 SCHROEDER, H A Hydralazine (Apretoline) in the control of severe hypertension *Practitioner* 173 192 1954
- 397 SCHROEDER H A Renal failure associated with low extracellular sodium chloride The low salt syndrome *J.A.M.A.*, 141 117 1949
- 398 SCHROEDER H A., GOLDMAN M L, FUTCHER, P H AND HUYTER M Low sodium chloride diets in hypertension *J.A.M.A* 140 458 1949
- 399 SCHROEDER, H A FUTCHER, P H AND GOLDMAN M L The effects of the rice diet upon the blood pressure of hypertensive individuals *Ann Int Med* 30:713 1949
- 400 SCHROEDER H A AND PERKY H M., JR. Errors in the evaluation of hypertension *Am Heart J* 51:776 1956
- 401 SCHROEDER, H A The effect of 1 hydrazinophthalazine and hexamethonium on hypertension *J Lab & Clin Med* 38:949 1951
- 402 SCHROEDER, H A. Control of hypertension by hexamethonium and

- I hydrazinophthalazine Preliminary observations *Arch Int Med* 89 523 1952
- 403 SCHROEDER H A MORROW J D AND PERRY H M JR Studies on the control of hypertension by Hyphex I Effects on blood pressure *Circulation* 8 672 1953
- 404 PERRY H M JR SCHROEDER H A AND MORROW J D Studies on the control of hypertension by Hyphex IV Levels of the agents in urine and blood *Am J M Sc* 228 403 1954
- 405 SCHROEDER H A MORROW J D, AND PERRY H M JR Studies on the control of hypertension by Hyphex V Effects on the course of the malignant stage *Circulation* 10 321 1954
- 406 PERRY H M JR AND SCHROEDER H A Studies on the control of hypertension VI Some evidence for reversal of the process during hexamethonium and hydralazine therapy *Circulation* 13 528 1956
- 407 PERRY H M JR AND SCHROEDER H A Studies on the control of hypertension VII Effects of ganglionic blockade combined with hydralazine on the malignant stage complicated by renal azotemia *Circulation* 14 105 1956
- 408 SCHROEDER H A Hypertension in *Current Therapy* edited by Conn H F Philadelphia Saunders 1952 pp 162 167
- 409 SCHROEDER H A MORROW J D AND PERRY H M, JR. Medical control of hypertension by Hyphex *Proc A.M.A Scientific Session* June 1953
- 410 SCHROEDER H A Hypertension in *Current Therapy* edited by Conn H F Philadelphia Saunders 1954 pp 187 196
- 411 SCHROEDER H A The treatment of arterial hypertension Veterans Administration Technical Bulletin TB 10 102 1954
- 412 SCHROEDER H A AND PERRY H M JR Hexamethonium chloride and I hydrazinophthalazine (Hyphex) in malignant hypertension *Am J Med*, 16 607 1954
- 413 SCHROEDER H A AND PERRY H M JR. Medical management of hypertension *Proc Second World Congress of Cardiology and Am Heart A* 1954 p 89
- 414 SCHROEDER H A Why not control hypertension by drugs? *Clin Research Proc* 3 1 1955
- 415 PERRY H M, JR. AND SCHROEDER H A The use of pentolinium tartrate with and without hydralazine in the treatment of severe human hypertension *New England J Med* 252 1057 1955
- 416 PERRY H M JR AND SCHROEDER H A Studies on the control of hypertension VIII Effects on the course of the benign stage In preparation
- 417 PERRY H M JR AND SCHROEDER H A Evidence for reversal of

- the hypertensive process when blood pressure is controlled by drugs. *Circulation* 12:759 1955
418. SCHROEDER, H. A. AND PERRY H. M., JR. Clinical Conference: The treatment of hypertension with modern drugs. *Circulation* 13:98 1956
 419. SCHROEDER, H. A. Management of arterial hypertension. *Am J Med*, 17:540 1954
 420. SMITHWICK, R. H. BUSH R. W., KINSEY D., AND WHITELAW G. F. Hypertension and associated cardiovascular disease. *JAMA*, 160 1023 1956
 421. WHITE, P. D. Severe hypertension—study of one hundred patients with cardiovascular complications. *JAMA* 160 1077 1956
 422. CLARKE, N. E., CLARKE, C. N., AND MONIER, R. E. The "in vivo" dissolution of metastatic calcium. An approach to atherosclerosis. *Am J M Sc* 229 142 1955
 423. LEE, R. E., SELIGMAN, A. M., CORSELL, D., FULTON L. A. AND CLARK, M. A. Reserpine-hydralazine combination therapy of hypertensive disease with hydralazine in doses generally below the "toxic range." *Ann Int Med*, 44 456 1956
 424. MEIER, R. Apizone and related imidazolines. *Ann New York Acad Sc* 50 1161 1950
 425. WILKINSON, E. L., BACKMAN H., AND HECHT H. H. Cardiovascular and renal adjustments to a hypotensive agent (1-hydrazinophthalazine). *J Clin Investigation* 31:872 1952.
 426. REURI H. C. Renal hyperemia induced in man by a new phthalazine derivative. *Proc Soc Exper Biol & Med* 73 10th 1950
 427. MARAS P. A., REYNOLDS, P. C., AND BRADLEY S. R. Hemodynamic effects of 1-hydrazinophthalazine in the dog, with special reference to circulating splanchnic blood volume. *Am J Physiol*, 183 144 1955
 428. PICK, R., STAMMER, J. ROSSARD S. AND KATZ L. N. Inhibition of coronary atheromatosis in cholesterol fed chicks receiving estrogens. *Circulation* 4 468 1951
 429. PICK, R., STAMMER, J., ROSSARD S., AND KATZ L. N. Estrogen induced regression of coronary atherosclerosis in cholesterol fed chicks. *Circulation* 6:838 1952
 430. RYAN, A. U. AND DIMITROFF S. P. The incidence and severity of atherosclerosis in estrogen treated males and in females with a hypocarcinogenic or a hyperestrogenic state. *Circulation* 9 533 1954
 431. WILKINS S. L. The reorption of arterial atheromatous deposits in waring disease. *Am J Path*, 23:93 1947
 432. MEISTER, A. Metabolism of glutamine. *Physiol Rev*, 36 103 1956

- 433 NOBLE N L BOUCEK R J LAO K T AND PARTIN H C Hexosamine concentration in normal and atheromatous human aortic connective tissue *Federation Proc* 15 463 1956
- 434 MCGLOTHY D H OLSEN N S AND FIELD L A pressor material produced by the action of pepsin on casein *J Biol Chem* 210 299 1956
- 435 POFENOE E A AND DU VIGNEAUD V A partial sequence of amino acids in performic acid-oxidized vasopressin *J Biol Chem* 206 353 1954
- 436 MEIER R TRIPOD J AND BRUNI C Änderung der blutdrucksenken den Wirkung von Apresolin und Nepresol durch Reaktion mit Serumbestandteilen *Arch exper Path u Pharmacol* 273 338 1954
- 437 SCHULER W AND MEIER R Releasing action of metals on the hydrazine inhibited enzymatic oxidation of cadaverine *Arch Exper Path*, 223 169 1954
- 438 TRIPOD J AND MEIER R Détermination et classification pharmacodynamique de l'action vasculaire périphérique de l'Apresoline du Nepresol et du Serpasil *Arch internat pharmacodyn* 99 101 1954
- 439 SAIFER A AND KAMMERER O F Photometric determination of total cholesterol in plasma or serum by a modified Liebermann Burchard reaction *J Biol Chem* 164 657 1946
- 440 BRONTE STEWART B KEYS A AND BROCK J F Serum cholesterol diet and coronary heart disease An interracial survey in the Cape Peninsula *Lancet* 2 1103 1955
- 441 OFFENHEIM F Review of one hundred autopsies of Shanghai *Chinese Chinese M J* 39 1067 1924
- 442 SCHLITTLER E MACPHILLAMY H B DORFMAN L FURLLENMEIER A HUERNER C F, LUCAS R, MUELLER J M SCHWYZER R AND ST ANDRE A F Chemistry of rauwolfia alkaloids including reserpine *Ann New York Acad Sc* 59 1 1954
- 443 KATZ L N Current trends in atherosclerosis research. *Circulation Research* 4 123 1956
- 444 BRADON J H AND HAVEL R J *In vivo* effect of anti heparin agents on serum lipids and lipoproteins *Am J Physiol* 177 128 1954
- 445 ORDYKE, D F., AND OTT W H Influence of source of cholesterol grade of cottonseed oil and breed on experimental avian atherosclerosis *Proc Soc Exper Biol & Med* 85 414 1954
- 446 SCHROEDER H A A practical method for the reduction of plasma cholesterol in man *J Chronic Dis* 4 461 1956
- 447 ECKEY E W *Vegetable Fats and Oils* New York Reinhold 1954
- 448 BRONTE STEWART B ANTONIS A EALES L AND BROCK J F Effects of feeding different fats on serum cholesterol level *Lancet* 1 521 1956

INDEX

A

α -globulins ■ 76-77

from beef 76

from hogs 76

from horses, 16

in liver 69

Abdominal

aorta 244

lymphosarcoma 61

scars 257

Abnormal

hair in cattle 175

trace metals in man 116-185 206

Abraham J 311

Abrams M L, 314

Abreu B E., 302

Absence of kidneys 60

Acetate 8, 9^o 208 224 225 292
294

Acetal lipid 221

Acetaldehyde 8, ■

Acetic acid 224

Acetoacetic acid, 224

Acetyl mercaptan 99

Acetyl acetone 138

Acetylamine 169

Acetyl choline (quaternary ammonium compound) 40-41

Aching 257

Achor R W P 302

Acid

content in urine 59 286 288

esters of cholesterol 217

foods 198

renal cortex, 58-59

Ackerman N W 299

Actinavine 164

ACTH 164

Actomyosin 149

Acute infections 70 183

Acute nephritis 10

Actions of adrenergic blocking agents in man table on 48

Actomyosin 231

Acute vasospastic states 77

Acyl Co-enzyme A dehydrogenase
147 148 230

copper flavinoid in 167

Adams E., 318

Addison's disease 134 196

Adenoma in adrenal cortex 11

Adipoin 163

Adipose tissue trace metals in
estimate of 170-171

Adrenalin 157

Adrenals 4 6-7 11 40 49-50 109-
110 125 132 140 170-171 176-
183 194 196-197 199 224 241
243 276 286 291 292

aluminum in 176-183

barium in 180

cadmium in 196

cholesterol in 224

cortex 11 49-50 109-110 125
132 140 243 276 291 292

adenoma in 11

in hypertension 138

overactivity of 139

relation of to medulla 133-135

hyperfunction 276

mechanisms 132 140

clinical findings of 135

steroids 133-134

- as cause of hypertension 133
 as result 136-139 291
 tumors 243
 zona glomerulosa 292
 dysfunction 241
 effect of experimental nephro-
 genic hypertension on 133
 hyperplasia 136
 lead in 176-183 194
 medulla 40ⁿ
 trace metals in 125 170-171 176-
 183 194 196
 Adrenalectomy 198 140 276
 bilateral 276
 Adrenalectomized rats urinary ex-
 tracts in 188
 Adrenocortical factor summary
 291 292
 Adrenocorticotrophic hormone
 (ACTH) 136
 Adrenergic agent 109
 Adrenergic blocking agents com-
 ment on 49 50
 Adrenergic blockade of vasoactive
 peptides (rabbit aortic strip)
 110
 Aerated water metals in 197
 Aerobic metabolism 50
 Africa
 hypertension in 25
 natives 182 185 194
 tissues metals in 194
 Aftergood L. 323
 Agitated depressive psychosis 34
 Agmon J 214 322
 Ag P-dimethylamino-benzalrhoda-
 mine 163
 Agranulocytes 131 161
 Ahrens E H Jr 323
 α ketoglutaric carboxylase 148
 Alanine 63 76 195
 Alaskan esquimaux lipids of 209
 Albumin 6-7 112 190 195 248
 269-271
 Albuminuria 112 190 248 269-
 271
 Alcohol 144 149 198 222
 Aldehyde 77 149 152
 oxidase 152
 Aldosterone 136-139 286 291 292
 Aldosteronism 136
 Alexander H L 161 164 316
 Alexander W M 302
 Albrink W S 318
 Allen Slater R B 323
 Aliphatic compounds 103
 Alkaline 149 152 157
 phosphatase 152 157
 Alkalosis 134-138
 Allalouf D 214 322
 Allen R P 310 320
 Allergy 166 202
 Alpha lipoproteins 236
 Alrose Chemical Co 106
 Altshuler M B 306 319
 Aluminum 63 105 143 146-147
 167 176-183 191 199
 in adrenals 176-183
 in animal tissues 191
 in aorta 176-183
 in brain 191
 in heart 176-183 191 199
 in kidney 191
 in liver 191
 in lungs 176-183 191
 in plant tissues 191
 in prostate 176 183
 in spleen 191
 in stomach 176-183
 in thyroid 176-183
 phenylalanine complex 105
 toxicity of 191
 Amblyopia 270
 α mercaptopropionic acid 111
 American Indians hypertension
 among 25
 American Negroes hypertension
 among 25

- Amine oxidase—see Monamine oxidase
- Amino acids, 313^o 960 6^o 7^o 74-
 7 87 9^o III 99 110 1^o 132
 143-144 134 161 162 167 167
 183 19^o 197 206 224 286-290
 decarboxylation of III 15^o 283
 by kidney 84
 deamination of 313^o 59 6^o 12
 14 94 110 188
 theory of, 62 72
 in vasoactive peptides chart on
 76
 metabolism 6^o 224
 renal tubular reabsorption of 19^o
 Aminoaciduria cadmium 19^o 249
 Amino- α mercaptobenzoethiazole 99
 Amino grouping (primary second-
 ary tertiary cyclic tertiary) 145
 Aminoguanidine HCO₂ 87 9^o
 Aminopeptidase 197
 Aminopyrine 161 16^o 187
 Aminoethiazole 162
 Ammonia 97 103 13^o 153 155
 286-299
 in urine 288-289
 Ammoniated mercury freckle cream
 action of 153
 Ammonium
 chloride 97
 compounds 13^o
 nitrogen 103
 Amphetamine (Benzedrine) 31 6^o
 29^o
 Amyloidosis 219 231 2^o 0
 Androgens 138
 Androgenic overproduction 138
 Anaerobic decarboxylation 37 III
 50 62 286
 Anaesthetized rats 9^o-109
 effect of intravenous sulphhydryl
 compounds on the diastolic
 pressures of 98
 effect of intravenous EDTA on
 diastolic blood pressure of
 96-109
 Anaesthesia peripheral vasoconstric-
 tion under 38
 Analgesic agents 156-162
 Analysis of metals 163
 some reagents for 163
 Anaphylactic shock 166
 Anatomical causes of renal ischemia
 78-82
 Anatomical chemistry of phospholip-
 ids 284
 Anderson J T. 3.3 325
 Andrus S B 321
 Anemia 93 11^o 164 1.4 173
 aplastic 164
 hypochromic, 173
 in infancy 173
 Aneurysms 243
 Angina pectoris, 204 219 257 273
 27^o 277 281 283
 syndrome 204
 Angiotensin (constrictor peptide)
 58 66-67 III 74 9^o 110
 Animals
 atherosclerosis in 280
 ataxic 17^o
 blood protein obtained from
 1273
 fat 233 278-279 29^o
 tissues
 aluminum in 191
 nickel in 190
 Anionic elements 131
 Antichkov N. 320
 Ankle edema 231
 Anorexia 174 175
 Anolyte (perchloric acid) 43
 Antidrenal hormones 110
 Antibiotics 6^o 16^o 164 243 254
 bacterial resistance to 54
 Anticoagulant 236
 Antidiuretic properties 2
 Antiemetic action 35

- Antimetabolites 186 200
 Antihistamines 87 161
 Antihypertensive tranquilizing drugs 36-38 69 74 82 109
 comment on 36-38
 Anti Lewisite British (BAL) 93
 Antipyrine 162
 Antipyretics 162
 Antiseptic chelating agents 157
 Anti thyroid drugs 94 153 161 162
 Antituberculous hydrazides 91
 Antimony 144 151 161 167 180
 192 199
 in animals 199
 in insecticides 199
 in rubber 199
 in solders 199
 in tin foil 199
 Antonchak N 313
 Anuria 51
 Anxiety 20 31 66 244 249 285
 Apathy 262
 Aplastic anemia 164
 Apoplexy 5 11 252
 Apoplectic stroke 252
 Apotransaminase 59
 Appendix malignant carcinoid of serotonin in 32
 Appetite loss of 262
 Apresoline blockade of pherentasin 111
 Arachidonic acid 226 229 292 294
 foods containing 228
 synthesis 229
 Ariboflavinosis 175 206
 Arginine 63 74 76 148 149 152
 Arginine ATP transphorylase 149
 Argyria 200
 Army combat rations B₆ in 121
 Arsenic 85 131 151 153 161 167
 180 192 199
 in the skin 153
 compounds 161
 Arterenone 92
 Arterial
 blood primary amines in 59 69
 constriction 119
 disease organic
 extra renal 79 81
 intra renal 81
 hypertension 3 11 18 25 81 147
 284 285
 basic or constitutional factors
 of 18 25
 case histories of 4 11
 environment and heredity in
 20 25
 in dogs 84
 in rats 84
 psychic manifestations of cause
 of 284 285
 seen as sign of disturbed hemo-
 dynamics 3
 lesions 206
 mash 87 92
 obstruction 212
 thrombosis 53
 walls sodium content of 125
 Arteries
 cholesterol in 209
 coronary 25 204 209 210 213
 235 236 269
 hardening of 210
 hyalin degeneration of 128
 lipids in 206 208 213 214 216-
 217 230 234 236
 of the brain structure of 16
 retina 15-16
 Arterolar
 nephrosclerosis 7 11 13 128 129
 139 245 269 276 286
 sequence of development of 13
 spasm 6
 Arterioles
 hyalinization of 12
 thickening of 128
 Arteritis in dogs from fat 210

groups of patients as regards the clinical course the prognosis the survival rate and the incidence of coronary vascular accidents

SCHITTLE Concerning Dr HOONER's question on the heparin treatment of hypercholesterolemia I think that heparin has its indication only in cases with essential hyperlipaemia and in cases with very massive and very severe disturbances of fat metabolism. We could not find any good effects in cases with hypercholesteronaemia and with those of a *familial* type. I think this is very important to know. We administered 100 mg as a depot for one week over a period of one year. When not using a depot preparation we administered twice a week between 100 and 200 mg of heparin which is below the effective dose for coagulation. But if I may repeat we only saw good results in this small number of cases with essential hyperlipaemia.

With regard to the question of Dr HOOD we intend to reduce our diets from 3000 calories to 2300 and we give higher caloric diets only for persons who are working hard. If we apply diets with 2300 calories we allow about 40 g (cc) of oil 20 g of fats and 20 to 30 g of hidden fats in the food. It is worthwhile to reduce diets and to reduce weight in patients with coronary attacks.

To Dr COTTER We do not know very much about the metabolism of high unsaturated fatty acids in correspondance to the saturated ones. I do not believe that there is a strict antagonism between these acids. According to American investigators it is correct that the unsaturated fatty acids do enhance the excretion of bile acids but one does not know in which way these substances are affected. And I think it is impossible to use a diet — your second question — which contains only unsaturated fatty acids. It is impossible at least in Western Europe. Nobody will eat it and I am sure in America it is the same. There are only small groups of phrenetic dietetic sects who use these diets.

Now the third point the prognostic value of cholesterol and lipoproteins. I think that the diagnostic value of lipoproteins and cholesterol in cardio vascular disease in coronary disease is very slight but not their pathogenetic significance. I think it is true that high values of lipoproteins and cholesterol are harmful to the vessels.

COTTER I agree with you

Closing remarks

By

F. C. HALL

Gentlemen now that our meeting draws to its close allow me first of all to say how much I have appreciated your kind collaboration. The pleasant atmosphere of this symposium which each of you has helped personally to create has I feel been particularly conducive to a free and frank exchange of views. Speaking for myself I have derived a great deal from the debates of ours and my reaction has been one of both humility and admiration. Humility in face of the immense and complex problem with which we have been dealing and admiration for the splendid work which is everywhere being undertaken with faith, conscientiousness, determination and critical judgment.

While taking part in these discussions over the past few days I have been struck once again by the number of pitfalls awaiting us whenever we try to tackle a problem as vast as that of hypertension. Since no doubt all of you at some time or other will have fallen into one of these traps perhaps you will permit me to mention a few.

To begin with there are the difficulties of method. There are for example when we endeavour to determine adrenal hormone concentrations in the urine or in the blood. The discussion which followed the papers by Dr. GEYER and Dr. SCHWARTZ struck me as being very instructive in this connection. The same reservations have to be made when analysing renin or hypertenin. It would be a good thing if in future when confronted with diverging results authors were to carefully compare their techniques and try to discover why their findings do not tally before proceeding to interpret their results.

Another pitfall consists in seeing only one detailed facet of a problem without considering it in relation to the whole. Modern investigations are of such complexity that one is often compelled to concentrate on one particular aspect of a question. Where the results obtained prove interesting one is tempted to exaggerate their intrinsic importance instead of trying to integrate them into the overall picture.

Often it is difficult to determine the causal connections between two phenomena observed at one and the same time as for example in the case of hyperaldosteronuria and hypertension or arteriolar necrosis and malignant hypertension. That the problem of arteriolar necrosis now seems to have been partly solved is due to the fact that it is possible to reproduce this lesion in animals by raising their blood pressure and to prevent its development in hypertensive patients by means of anti hypertensive therapy. On the other hand there is nothing to prove that essential hypertension is due to hyperaldosteronism. In the absence of experimental proof and clinical arguments, it might equally well be supposed that the hyperaldosteronuria is secondary to the rise in blood pressure.

I am quite convinced of the importance of experimental proofs in arriving at a correct interpretation of a given set of clinical facts but it should not be forgotten that phenomena observed or provoked in the rat the rabbit or the dog cannot always be translated to human pathology. Dr Gross has rightly emphasized how easy it is to produce hypertension in rats. On the other hand we all know how comparatively unsusceptible dogs are to arteriosclerosis. Thus the fact that a hypertensive dog shows very little tendency to nephro-angiosclerosis does not mean to say that in man the vascular lesions encountered are not partly due to elevated blood pressure. Again the fact that rats treated with salt and corticosteroids develop hypertension and nephrosclerosis is no proof that essential hypertension in man is caused by an adrenal disorder.

However tempting it is wrong to interpret a chronic metabolic or haemodynamic upset on the basis of short term experiments. An experiment by its very nature is of limited duration. Now the effects of a drug may be quite different depending on whether the results are determined immediately after a single intravenous injection or after months of continuous treatment. We have seen this in connection with the action of hypotensive agents on renal function and during the discussion following the paper by Dr FREIS. Though it is true that chlorothiazide begins by reducing the cardiac output it ultimately leads to a decrease in peripheral resistance.

Finally another grave danger to be guarded against is that of considering an hypothesis as an established fact. Science would hardly be conceivable without hypotheses. Every research worker has to fall back on them once he is in possession of a certain number of experimental findings since only by forming an hypothesis can he obtain some idea as to the logical direction in which concentrate his efforts. Nevertheless every hypothesis must be abandoned as soon as it no longer tallies with the objective findings. The survival

of a mistaken hypothesis constitutes a severe handicap to scientific research. As for faulty hypotheses that have been set up as dogmas suffice it to say that they doom all effort to frustration.

These few remarks of mine are so obvious that they no doubt strike you as superfluous. I should now like to turn to a few points which the past few days' discussions have perhaps helped to clarify.

I was particularly pleased that Dr PICKERING and Dr PLATT had an opportunity of giving us their points of view. Without wishing to repeat the arguments you have already heard, I have the impression that in the end there was some measure of reconciliation between diverging conceptions and that at any rate several misunderstandings were cleared up. Dr PICKERING admitted that his hypothesis was open to certain criticisms and in so doing indicated that he was prepared to take account of them. Perhaps Dr PLATT is right in suggesting that the mathematical method of analysis employed is not entirely satisfactory. Moreover Dr PICKERING agreed that a large number of different populations might be involved rather than one homogeneous population.

The vexed question of salt, the adrenals and hypertension gave rise to an extensive exchange of views. There is hardly any disagreement on the whole as to the fact that hyperaldosteronism may possibly accompany essential hypertension. But opinions differ concerning the interpretation of this sign and the importance to be attached to it. My own feeling is that it is probably a secondary phenomenon and does not indicate the presence of a basic adrenal disorder. The same applies to the hypernatremia occurring in hypertension of every aetiology. However the discussion did bring to light various unsuspected correlations between the activity of the adrenals and that of the renin-hypertensin system. Unfortunately the whole question is complicated by the uncertainties involved in the techniques used. I am sure that the specialists will have derived great profit from this colloquium and that they now have a better idea than they did a week ago as to the direction in which to pursue their studies and the snags they must steer clear of.

The papers read by Dr BECHGAARD and Dr MILLIEZ gave rise to a most useful discussion on the definition of malignant hypertension. It was discovered in fact that there was no absolute clinical criterion of diagnosis and that each speaker had his own ideas on the subject. While we all ascribe major importance to the presence of high blood pressure side by side with Grade IV retinopathy, some of us pointed out that papilloedema might be absent

in certain patients in whom other signs and symptoms (deterioration in general condition massive albuminuria) indicated a diagnosis of malignancy By contrast Grade IV retinopathy may exceptionally be encountered in patients in whom the blood pressure is only moderately elevated

On the other hand there was unanimous agreement on the necessity of administering vigorous hypotensive treatment in all cases of severe or malignant hypertension although Dr WILSON stressed the shortcomings of such treatment from the theoretical standpoint We were all impressed by Dr SCHROEDER's results which have been largely confirmed by other authors However it appeared that one problem — that of arteriosclerosis — has yet to be solved From the work undertaken by Dr PAGE and his team it is evident that certain patients with malignant hypertension treated with apparent success by means of hypotensive agents succumb to vascular complications of the atheromatous type or subintimal fibroplasia Nor does it seem that hypotensive therapy has any significant influence on the slow progression of benign nephro angiosclerosis

As to the choice of and indications for the various antihypertensive drugs it is generally agreed that the saluretics and guanethidine constitute the major acquisition of recent years The mode of action of chlorothiazide still does not seem to have been definitely elucidated Darenthin (bretylum tosylate) has disappointed most of those who have used it Nevertheless we have good reason to be satisfied with the progress achieved by pharmacologists during the last 10 years That is why I should like to endorse the optimistic views expressed by Dr PLUMER and to conclude these remarks by quoting his statement to the effect that The hope for further life enhancing drug therapy seems bright indeed

Gentlemen it is time for us to part I sincerely hope we shall have an opportunity of meeting again in the not too distant future and of resuming our discussions where we have now left off

The editors acknowledge with gratitude the valuable assistance of Mr H D PHILIPS M A Dr W HATZINGER Miss S R NALOFFI Miss E PFEIFER and Miss U STURZENEGGER

Last of authors

- Arnold O II 350
 Bartorelli, C 33 30'
 Bechgaard P 193 235
 Biron P 176
 Bloch R 14
 Bock, H. D 15 185
 Brod, J 51 59 173 160 235 301
 Cottet J 381 385
 Cottier P T 66 90 174 195
 Dahl, L. H. 53 85 86 87 160 185
 352
 Dustan H 354
 Ferrero C 196 350
 Freis F D 67 19 19 193 194
 197 300 353
 Genest J J 6 160 16 163 164
 165 166 167 296
 Govaerts P 49 33
 Grollman A 46 48 177 123 168
 193
 Gross F 9 121 172 15 163 165
 192 301
 Hamburger J 236
 Hilden, T 89 237 61 706 347 352
 Hoobler M W 55 56 59 194 195
 0 98 300 301 347 348 350
 351 352 381
 Hood M 87 19 301 749 351 350
 Imhof P 347 354 381
 Iowa M 175
 Lauwers P 7 0
 Mach R 5 8
- Milhez I 14 271 349
 Muller A F 159 160 161 163 164
 Nowaczynski W 16
 Page I H J 238 296 354
 Peart, W 5 47 48, 11 152 153
 155 160 161 164 165 299 352
 Perry H M 35 57
 Pickering C W 50 4, 48 52 153
 232 352
 Platt R 39 50 59 34 350
 Plummer A J 196 350
 Reubens C 11 4, 46 48 50 53 8,
 125 159 160 161 165 163 16,
 166 192 194 231 237 238 290
 38 301 305 306 31 347 348
 350 351 357 353
 Rey L. I 14
 Samareq I 14
 Sandor T 16
 Sarre H 50 194 196 35 33 348
 Schettler G 195 560 382
 Schmid A 194
 Schroeder H A 46 83 90 16 163
 193 33 239 19 302 50 351
 352
 Schwartz J 11 161 162 163 167
 351
 Steinmann, B 350
 Taquni, A C 48 52 56 58 150
 Tcherdakoff P 14
 Warner J 147
 Wilson C 49 171 127 123 165 165
 234 259

Subject index

- Acetyl β methylcholine 10
- ACTH 14 167
- Adrenal cortex and hypertension 122
 - cortical hormones see Corticoids
 - function influence on experimental hypertension 90
 - insufficiency and renin content of the kidney 99
- Adrenalectomy 13 147 342 349 351
 - blood pressure levels before and after 344
 - cerebrovascular accidents 345
 - substitution therapy 344
 - survival rates 343
- Adrenaline 10 13 19,
 - effect on aldosterone excretion 130
 - effect on 17 hydroxycorticoid excretion 130
- Adrenergic blockade 241
- Albuminuria 210
- Aldactone 280
- Aldosterone 14 15 122
 - in Addison's disease 104
 - catabolism 11
 - effect on blood volume 160
 - excretion 127 128 136 148/149 150
 - overdose 93
 - secretion 76 104 132 150
 - — and heart failure 160
 - — and liver cirrhosis 160
- Aldosteronism primary 10 91 103
- Amino oxidase inhibitors 280
- Angina pectoris 367 370
- Angiotensin 16 52 97 123 120 161 190
 - biological activity 26
 - effect on aldosterone excretion 136 163
 - 17 hydroxycorticoid excretion 136
 - renal function 112
 - structure 26
 - System and salt metabolism 112
- Antidiuretic hormone 171
- Antinatriuresis 76 79
- Anticomm 25
- Aortography 13 23
- Aprasoline see also Hydralazine 192 196
- Arginine 26
- Arterial disease classification 300
- Arteriosclerosis 46 48 360
 - connection with blood pressure level 361
 - and diabetes mellitus 362 360
 - and diet 363 380
 - and gout 360
 - and hypothyroidism 360
 - and obesity 360
 - pathogenesis 363
 - prophylaxis 363
 - therapy 366
 - unsaturated fatty acids 364 360
- Atropine 266
- Benzhydroflumethiazide 272
- Benzothiadiazine see also Chlorothiazide 17
- Blood distribution 5
 - local need 0
 - pressure arterial and tissue perfusion 3
 - — regulatory mechanisms 2 8
 - — systolic frequency distribution 199
- Bradykinin 110
- Bretium see also Darenthin 204 261 277
 - comparison with ganglionic blockers 262 267
 - dosage 261
 - and guanethidine 204 261
 - side effects 263 266
 - tolerance to 264
- Carotid sinus mechanism 8
- Cerebrotonin 3 7
- Chemoreceptors 10
- Chlorisondamine 242 279 300
- Chlorothiazide see also Saluretics 08 79 173 179 200 272 284 300

- Chlorothiazide body weight loss 183
 — cardiac output 14 184
 — effect on blood pressure response 183
 — haematocrit 183
 — haemodynamic effects 196 206
 — heart rate 183
 — mechanism of action 197 214
 — peripheral resistance 14 184
 — plasma volume changes 174 183 250
 — renal function 318
 — side effects 74
 — sodium balance 183
 Cholesterol phosphate quotient 74
 Circulation, theory of by Pao 3
 Clearance methods 317
 Cold pressor test 13
 Compound D urinary excretion 17 131
 Conn's syndrome see also Hyperaldosteronism primary differential diagnosis 103
 Cortisone see DCA
 Corticoid overdosage and renal content of the kidney 98
 Corticoids in hypertension 93
 Corticosterone 14
 Cortisol action on sodium excretion 133
 — urinary excretion 17 131
 Cortison 14 16 34
 — action on sodium excretion 88 133
 — urinary excretion 17 131
 Darenthum see also Brevithum 99 301
 DCA 1 19 57
 — overdosage 93
 14 andro tene 11 3 el 3 17 done 13
 Depot thromboxide 33
 Desoxycorticosterone acetate see DCA
 Dextran 184 186 193
 Diuretics mercurial 183 187
 — sulfonamide 33
 DMPP 1
 F cold see Chlorisondamine
 Electrolytes arterial wall 188
 — tissue 171
 Filiparin 33
 F motion and blood pressure 13
 — and renal function 193
 Epinephrine see Adrenaline
 Ergotoxin 41
 Elixirex see Hydrochlorothiazide
 Ethinyl oestradiol 368
 Ethicholanolone urinary excretion 17 131 16
 Extracellular fluid volume 171 181 193
 Flumethiazide 72
 Fluorohydrocortisone 19
 Ganglionic blockade 24
 — — survival rates 307
 — blockers renal function 313
 Glomerular filtration rate see Renal function
 Glucose 6-phosphate dehydrogenase 103 108
 Guanethidine 2 288 296 301 330
 — action on catecholamines 33
 — and bretylium 34 81
 — clinical results 34
 — combined therapy 303
 — comparison with ganglionic blockers 63 67
 — dosage 34 30
 — intravenous 237
 — oedema formation 296 301
 Guanethidine pharmacology 249 296
 — side effects 233 236
 — tolerance to 296
 Headache 94 218
 Heparin 34 330 382
 Hexamethonium 14 168 169 242 307 309
 — toxicity 314
 — pneumonia 336
 Histamine 10 113 110
 Howard test 24 69
 HT see Serotonin
 Hydralazine see also 1pre-oline 9
 14 79 169 244 22 23 26 99 333
 — antagonism 243
 — effect on vascular smooth muscle 302
 — and renal function 318
 — side effects and toxicity 23 301 313
 — therapy survival rates 307
 Hydration and excretion 87

- Hydrochlorothiazide see also Salur-
etics 108 194 195 196 205
266 272 284 350
— body weight loss 194
— and hypokalaemia 306
Hydrocortisone see Cortisol
5-Hydroxytryptamine see Serotonin
Hyperaldosteronism differential di-
agnosis 153
— primary 94 281
Hyperaldosteronuria in hypertension
147 150
— in pregnancy 163
Hypercholesteronaemia 356 364 381
Hypertatriuresis 77 87 90
— extrarenal factors 74
— renal factors 75
Hypertensin see Angiotensin
Hypertension adrenal regeneration
14 94 97 100
— — — and renin content of the
kidney 99
— and age 33 45
— and aldosterone 15
— and aortic sclerosis 362
— and arteriolar disease 304
— and arteriosclerosis 300
— arteriosclerotic 360
— and atheromatous complica-
tions 100
— benign see also Essential
— — and age 200
— — classification 202
— — dyspnoea on exertion 200
— — encephalopathy 206
— — natural history of 198
— — and obesity 210
— — and sex 208
— — symptoms 204
— — vertigo 200
— cardiovascular participation 11
— coronary artery sclerosis 362
— diabetes mellitus 362
— endocrine participation 13
— environment 63
— essential see also Benign 47
— — and adrenocortical function
126
— — and conditioned reflexes 51
— — and electrolyte excretion 66
— — frequency 40 200
— — mechanism of 190
— — mortality 209
— — nature of 39
Hypertension essential patho-
genesis 156
— — prognosis 201 207
— — renal haemodynamics 66
— — — and sodium excretion
72
— — and salt intake 53
— — therapy and renal function
317
— experimental and adrenocortical
function 92
— — and renal pressure mechanisms
92
— — and sodium retention 107
— and heart failure 76 320
— and hypercholesteremia 306
— inheritance 30 50 63
— and kidney disease 319
— malignant 206
— — aetiology 226
— — and age 215
— — clinical findings 214 220
— — de novo 216
— — differential diagnosis 231
— — experimental 233
— — hereditary 219
— — histological findings 214 226
— — kidney changes 220
— — natural course of 214
— — onset 216
— — past history 219
— — precipitating factors 217
— — prodromal signs 218
— — and sex 216
— — weight loss 218
— mechanism groups of 2
— mosaic theory 1
— neurogenic participation 7
— pathogenesis 49
— pulmonary 51
— racial factors 84
— renal and adrenals 18
— — experimental 20 94 121
— and renal function 68 317
— — participation 17
— — and renin content of the
kidney 100
— — vascular origin 23
— and salt ingestion 57
— subintimal fibroplasia of renal
arteries 308 350
— systolic 47
— therapy 270 283

- Hypertension therapy: EX G 440
 — — nitro₂en retention 330
 — — and renal function 317 341
 — — resistance to 357
 — — and salturesics 343
 — — surgical 337
 — — survival rates 307
 — — and vascular diseases 344
 Hyponatraemia 146 253
 Hypophysectomy and hypertension 14
 Hypotension 259
 — — and arteriosclerosis 367
 Hypotensive drugs, pharmacology 240
 Hypothalamus 10
 Imelin see Guanethidine
 Juxta glomerular cells and renin content of the kidney 142
 Kidney, artificial 21
 — — enzymatic activities 103
 — — and hypertension 70
 — — renin content 38
 — — transplantation 19 236
 Lipaemia clearing 34
 Lipid metabolism, pharmacological effects on 30
 Lipotabil 374
 Mavren 349
 Mecamylamine 9 213 29 248
 — — 93 709
 — — side effects and toxicity 290 314
 NLR 2 359 381
 M₁ cardiac degeneration 210
 A triuretic factor 156
 Neo-nephrium: effect on aldosterone excretion 136
 — — on 17 hydroxycorticoid excretion 136
 Nephrectomy 14 15 71 3
 Nephrosclerosis, malignant 14
 Nefresol 244
 Nifedipine 42
 Nifedipine acid and arteriosclerosis 3 2 380
 — — and fibrinolysis 344
 — — side effects 32
 Nocturn 218
 Noradrenaline 3 10 11 1 13 166
 — — 193
 — — effect on aldosterone excretion 136
 — — on 17 hydroxycorticoid excretion 136
 — — on renal function 114 116
 Norepinephrine see Noradrenaline
 Oestrogens 367
 — — side effects 365
 PAH clearance see Renal function
 Papilloedema 14
 Paralysis 196
 Pimpridine 243
 Pindolol 243
 Prolactin 243 2 2 2 3 309 340
 Phenobarbital 146
 Phentolamine 241 297
 Phenyl-ethyl acetic acid 371
 — — side effects 341
 Pheochromocytoma, diagnostic test 241
 Phosphatides 374
 Phthalazine 176
 Plasma electrolytes in essential hypertension 71
 Polyene acids 364
 Potassium intake and hypertension 84
 Pregnane-3 α -20-one ratio
 — — urinary 127 130 166
 — — urinary excretion 17 130 162
 Premarin 369 369
 Pressor mechanism, extrarenal 40
 — — renal 97
 Progesterone effect on hypertension 134 167
 Protocollinase 293
 Rauwolfia see also Reserpine Serpaal
 — — and renal function 414
 Regimine see Phentolamine
 Renin: function in treated and untreated hypertension 342
 — — insufficiency 210
 — — vascular disease 44
 Renin 16 18 49 114 113 116 119
 — — 123 146 152
 — — aldosterone relationship 107 121
 — — angiotensin system 97
 — — physiological significance 103
 — — relation to adrenal cortex 104

Renin content of the kidney 98
 — — rapid variations 106
 — — relation to height of blood pressure 102
 Renotrophin 22
Reserpine see also *Serpasil* *Rauwolfia*
 79 244 246 272 275 286 300
 — central action 10
 — combination with chlorothiazide 274
 — mechanism of action 246
 — oedema formation 301
 Resistance peripheral 4 51
 — renal 105
 Ritalin 266

Salivary glands in experimental hypertension 103 108
 Salt appetite 56
 — consumption estimation 54
 — excretion 83
 — intake 53 83
 — load effect on excretion 67 71
 — metabolism relation to angiotensin system 112
 — need 53
 — overdosage 93
 — restriction therapeutic aspects 108

Saluretics see also *Chlorothiazide*
Hydrochlorothiazide
 — combination with antihypertensive agents 286
 — hypokalaemia 288 293
 — and impairment of renal function 290
 — mechanism of hypotensive action 179
 — metabolic disturbances 289
 — physiological considerations 292
 — potassium balance 284 293
 — side effects and toxic reactions 175 288
 — sodium balance 284
 — therapy with 283
 Serotonin 3 11 12 113
Serpasil see *Rauwolfia* *Reserpine*
 Sex hormones and arteriosclerosis 367
 Singoserp 248
 β Sitosterol 371

Sodium excretion 77 100 157
 159 196

Sodium intake and aldosterone secretion 163
 — ion importance for renin content of the kidney 101
 — load 172
 — — and renal function 91
 — metabolism 105 170
 — nitroprusside 272
 — restriction 168 172 175 193

Spironolactone 280

Steroids urinary 126

Surface active substances and arteriosclerosis 374

Sympathectomy 80 332

— blood pressure levels before and after 336
 — cerebral changes 341
 — contra indications 342
 — ECG 338
 — eyeground findings after 337
 — indications 297 341 348
 — psychic changes 341
 — and renal function 338
 — renal biopsy 338
 — side effects 340
 — size of heart 338
 — subjective condition 339
 — survival rates 334

Syringopine 248

Testosterone 368

Tetra ethylammonium chloride 1242

Thyroid principles active and arteriosclerosis 366

— — contra indication 367

Toxaemia of pregnancy and hypertension 208

Trimethaphen 272

Trisopon 367

Veratrum 244

Vitamin A + E + B₆ and arteriosclerosis 369

Water excretion in essential hypertension 66

Water load effect on excretion 71

Xolumbino 241

Zona glomerulosa adrenal and aldosterone secretion 104 142 143

